66th ASH Annual Meeting: Author Index B

Baaij, L.

600 - Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia – a Study on Behalf of the Chronic Malignancies Working Party of the EBMT
4733 - Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study

Baaij, III, L.

2379 - Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis from the Worldwide Network for Blood and Marrow Transplantation Global Study

Baaklini, S.

740 - A Single Cell Atlas of Follicular Lymphoma across Clinical Stages Defines Tumor B Cell Archetypes, Immune Microenvironment Heterogeneity and Novel Cell States Associated with High-Risk FL
1597 - Single-Cell Atlas of Diffuse Large B-Cell Lymphoma Reveals Integrated Malignant B Cell and Tumor Microenvironment Characteristics Associated with Clinical Response

Baali, I.

4106 - Uncovering the HOXA9 Translational Regulatory Complex That Promotes AML Leukemic Stem Cells

Baar, W.

603 - Innovative Model for Creation and Use of Co-Developed Pain Management Plans for Patients with Sickle Cell Disease

Baardemans, T.

2042 - CTLA-4-Based Activation Inducible Costimulatory Receptors Endow CAR-T Cells with Safe, Tumor-Restricted, Multi-Targeting and Increased Persistence

Baassiri, A.

1815 - MISTRG6kit^W41: Enhanced Engraftment in a Cytokine Humanized Patient-Derived Xenotransplantation Mouse Model

Baba, Y.

3123.3 - Trial in Progress: Phase 1/2 Study of Cereblon-Modulating Agent Golcadomide (BMS-986369/CC-99282) in Relapsed or Refractory (R/R) T-Cell Lymphomas (TCLs) (GOLSEEK-3)

Babačić, H.

4370 - Plasma Proteomics Differentiates between Patients with B-Cell Lymphomas

Babaha, F.

3959 - A Therapeutic siRNA Targeting Plasminogen Acts As a Long-Lasting Antifibrinolytic in Nonhuman Primates

Babbar, S.

11 - PORT-77, a Novel and Potent Inhibitor of ABCG2, Protects Against Skin Photo Toxicity and Liver Damage in a Mouse Model of Erythropoietic Protoporphyria (EPP)

Babel, H.

1994 - Exposure-Response (ER) and Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Optimal Step-up Dose (SUD) Selection to Improve Cytokine Release Syndrome (CRS) Safety Profile of Abbv-383 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Baber, R.

1877 - The Differences between Ide-Cel and Cilta-Cel in Relapsed Myeloma at Single Cell Resolution

Babich, S.

2242 - Stroke Training, Research, and Education Toward Capacity with Hydroxyurea (STRETCH)

Babiker, S.

2237 - Utilising Patient-Reported Experience Measures to Drive Healthcare Improvements: The Application of Validated PREM Survey Tools in a Haemoglobinopathy Network in South London
2517 - Barriers and Enablers to Hydroxyurea Adherence in Children and Adolescents with Sickle Cell Disease in Jos, Nigeria

Babinec, C.

919 - CD30.CAR-T Cells Co-Expressing the CCR4 Chemokine Receptor in Relapsed/Refractory Hodgkin Lymphoma
3468 - Phase 1 Trial of CD30-Directed, CCR4 Co-Expressing Chimeric Antigen Receptor T-Cells in Patients with CD30⁺ Cutaneous T-Cell Lymphomas Refractory to Brentuximab Vedotin

Babol-Pokora, K.

1587 - Rare Candidate Variants for Germline Predisposition to Childhood Lymphomas: Go Beyond Aberrations in DNA Repair Genes

Babu, A.

4881 - Low Risk of Relapse and Favorable Survival after Allogeneic Transplantation with Fludarabine and Melphalan Conditioning for Measurable Residual Acute Myeloid Leukemia

Babu, D.

1073 - Establishing a Patient-Derived Immortalized Erythroid Progenitor Cell Model to Investigate Disease Mechanisms and Lentiviral Gene Therapy Vector in Congenital Dyserythropoietic Anemia Type II

Babu Jagadeesh Reddy, P.

4163 - Preclinical Proof-of-Concept of an mRNA-Based T Cell Engager Targeting BCMA, FcRH5, and GPRC5D for the Treatment of Multiple Myeloma

Babu, K.

1222 - Body Mass Index As a Determinant of Clinical Outcomes in Disseminated Intravascular Coagulation: Observations from the National Inpatient Sample
4011 - Racial Disparities in the Management of Deep Vein Thrombosis: A Nationwide Hospitalization Study
4245 - Epidemiology, Outcomes, and Healthcare Utilization in Acute Myeloid Leukemia: A Study Using the National Inpatient Sample - 2021
4844 - Demographic Characteristics, Incidence and Outcomes of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients Undergoing CAR T-Cell Therapy: An Analysis of the National Inpatient Sample (NIS) - 2021
5023 - Unveiling the Impact of Anemia of Chronic Disease: A Comprehensive Analysis of Mortality, Length of Stay, and Hospitalization Costs Using the NIS 2021 Database

Babu, M.

59 - A Randomised Comparison of CPX-351 Versus Standard Daunorubicin and Cytarabine Plus Fractionated Gemtuzumab Ozogamicin in Older Adults with AML without Adverse Risk Cytogenetics: Results of the NCRI AML18 Trial

Babushok, D. V.

2134.1 - Trial in Progress: Cureaa - a Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia, Blood and Marrow Transplant Clinical Trials Network (BMT CTN) #2207

Bacac, M.

2990 - Evaluation of Anti-Tumor Activity and Impact on T Cell Activation of Glofitamab in Combination with Gemcitabine and Oxaliplatin (Glofit-GemOx)

Bacal, N.

2294 - Multicentric Standardization of Minimal/Measurable Residual Disease in Acute Myeloid Leukemia Using Multiparametric Flow Cytometry – a Brazilian Society of Bone Marrow Transplantation (SBTMO) Project

Baccelli, I.

636 - CD127-Directed Immunotherapy with Lusvertikimab Outperforms Imatinib in Preclinical ABL-Class-Fusion-Positive BCP-ALL

Bacchetta, R.

3525 - T-allo10 Immunotherapy Results in Enhanced Early Immune Reconstitution and Reduced GvHD with Excellent Clinical Outcomes Post Αβ-Depleted HSCT in Pediatric and Young Adult Hematologic Malignancy Patients

Bacchiarri, F.

4619 - Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study

Bacchus, S.

3728 - Duration of Therapy in Patients with Waldenström Macroglobulinemia Undergoing Dose Reductions of First-Line Ibrutinib: A Real-World Analysis

Bach, E.

1877 - The Differences between Ide-Cel and Cilta-Cel in Relapsed Myeloma at Single Cell Resolution
2094 - Cellular Composition and Clinical Factors Influencing Manufacturing Outcomes for Anti-BCMA CAR T Cell Therapy in a Large Real-World Cohort of Relapsed/Refractory Multiple Myeloma

Bachanova, V.

72 - Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study
523 - Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above
570 - Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma
3409 - Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL
3765 - Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium
4200 - NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival
4215 - Divergent CD4+ T-Cell Fates Govern Relapse and Remission in B-Cell Acute Lymphoblastic Leukemia
4503 - CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium
4434.3 - A Phase II Study of Pembrolizumab+ BEAM before Autologous Stem Cell Transplant (ASCT) Followed By Pembrolizumab Maintenance in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma

Bachar Lustig, E.

3401 - Overcoming NK Cell-Mediated Allograft Rejection By Anti-3^rd Party Central Memory Veto CD8 T Cells through Down-Regulation of the Activating Receptor DNAM-1 on Alloreactive NK Cells

Bachas, C.

2483 - Alterations in the Immune Phenotype of Adaptive Immune Cells in Sickle Cell Disease: A Conventional and Computational Flow Cytometry Analysis
3527 - Dynamics of Immune Reconstitution in Adults with Sickle Cell Disease Undergoing Nonmyeloablative Matched Sibling Donor Stem Cell Transplantation: A Conventional and Computational Analysis
4329 - Leukemic Phenotype Determines Prognostic Relevance of Limit of Quantification for Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia

Bacher, U.

114 - Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma
3383 - Idecabtagene Vicleucel (ide-cel) Shows Similar Efficacy and Toxicity in Patients with Multiple Myeloma Aged 70 and Older Compared to Younger Patients: A Multicenter Cohort Study
3818 - Outcomes of Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Multicenter Real-World Analysis
4759 - Efficacy of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma and Prior Central Nervous System Manifestation: A Retrospective Real-World Analysis

Bachiashvili, K.

878 - TGF-β1-SMAD2 Axis Regulates Hematopoiesis and β-Globin Gene Expression Via Super-Enhancer Associated Chromatin Reorganization
2808 - Effect of Lumbar Puncture Timing on Neurotoxicity with Blinatumomab Therapy in a Real-World Cohort of Acute Lymphoblastic Leukemia (ALL)
2900 - Superior Survival with Intensive Chemotherapy, Compared to Hypomethylating Agent + Venetoclax, in Patients with Intermediate/Adverse Risk Acute Myeloid Leukemia Unable to Proceed to Transplant

Bachier Rodriguez, L.

3501 - Intensive Conditioning with Fludarabine Plus Melphalan Versus Total Body Irradiation Prior to Haploidentical Transplant and Post-Transplant Cyclophosphamide
3528 - Safety and Efficacy of Ibrutinib Added to Rituximab-Based Primary Therapy of Chronic Graft-Versus-Host-Disease

Bachier-Rodriguez, L.

1450 - Improved Outcomes of Adult Patients with Philadelphia-like Acute Lymphoblastic Leukemia (Ph-Like ALL) Treated within an Integrated Leukemia/Transplant Program with Incorporation of Pediatric Inspired Regimens and Early Allogeneic Transplant
1522 - Comparison of FLAG-Idarubicin to FLAG-Idarubicin Plus Venetoclax for Treatment of Newly Diagnosed AML in Patients Eligible for Intensive Induction. Analysis of 200 Consecutive Patients Treated at a Single Center
2363 - Prophylactic Corticosteroids Allow Safe Outpatient Administration of Axicabtagene Ciloleucel with Comparable Toxicities to Other CAR-T Therapies in Large Cell Lymphoma
4912 - Extracorporeal Photopheresis (ECP) in the Era of New Chronic Graft-Versus-Disease (GVHD) Therapies
4913 - The Degree of HLA-DPB1 Mismatch Predicted By Evolutionary Divergence Scoring Informs the Risk of Chronic Graft-Versus-Host Disease after Haploidentical Transplantation with Post-Transplant Cyclophosphamide
4948 - High HLA Evolutionary Divergence in Donor HLA-B Locus Impacts Transplant Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide

Bachiller, M.

1613 - Patient-Derived Follicular Lymphoma Tumoroids: A Tool to Recapitulate Biological Features of Low and High-Grade Lymphoma

Bachiller, M.

333 - CD70 Deregulation in Follicular Lymphoma at Diagnosis Is Associated with Relapse and Opens New Avenues for Dual CD19-CD70 CAR-T Therapy

Bachireddy, P.

1007 - Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML
1047 - A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
4783 - Clinical Response after Allogeneic CAR T Cell Therapy Is Linked to Expansion of Identical CD8+ Effector-like T Cell Clones
4265.2 - A Multi-Site Break through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (Trial In Progress)

Bachmann, N.

1381 - S227928: A Novel Anti-CD74 ADC with MCL-1 Inhibitor Payload for the Treatment of Acute Myeloid Leukemia (AML) and Other Hematologic Malignancies

Bachner, C.

2774 - Selective SMARCA2 Degradation Promotes Leukemic Differentiation and Synergizes with CDK9 Inhibition to Potently Induce Death in Pre-Clinical Models of Acute Myeloid Leukemia

Bachu, R.

254 - Application of Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) Following BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (MM)
4713 - Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)

Bachurski, D.

367 - Targeting Lymphoma Associated Myeloid-Monocytic Cells through CSF1R Blockade Enhances CAR-T Cell Response in Aggressive B Cell Lymphoma

Bachy, E.

67 - Rapcabtagene Autoleucel (YTB323) in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Phase II Trial Clinical Update
864 - 5-Year Follow-up Analysis from ZUMA-5: A Phase 2 Trial of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
865 - Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study
869 - Longer Follow-up of Golcadomide (GOLCA), a Cereblon E3 Ligase Modulator (CELMoD™) Agent ± Rituximab (RTX), in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
979 - Prospective, Multicentric, Phase II Randomized Controlled Trial Comparing the Efficacy and Toxicity of Methotrexate to Cyclophosphamide in Large Granular Lymphocyte Leukemia: A French National Study (NCT01976182)
1726 - Primary Results of the Health-Related Quality of Life (HRQoL) and Tolerability Assessments from the Phase I/II NP30179 Study of Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
2079 - Myeloid Neoplasia after CD19 Directed CAR-T Cells : Cumulative Incidence, Risk Factors and Outcome
3034 - Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update
3129 - A Real-World Weighted Comparison of Tisagenlecleucel and Axicabtagene Ciloleucel CAR T Cells in Relapsed or Refractory Diffuse Large B Cell Lymphoma Aged 75 Years and Older : A Lysa Study from the Descar-T Registry
4342 - Prediction of Clinical Response By Phased Variants in Circulating Tumor DNA (ctDNA) in the VALENTINE-PTCL01 Trial of Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)
4479 - Valemetostat Monotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma: Primary Results of the Phase 2 Valym Study from the Lysa
4502 - Efficacy and Safety of Odronextamab in Rare Subtypes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL): Data from a Dedicated Cohort of Other B-NHLs in the ELM-2 Study
4505 - Health-Related Quality of Life after Axi-Cel As a Second-Line Therapy in Patients with High-Risk Relapsed/Refractory Large B-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Results of the Alycante Phase II Trial

Bacigalupo, A.

245 - Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition
2186 - Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Retrospective Multicenter Analysis on 285 Procedures Performed between 2000 and 2020

Backeljauw, P.

544 - Growth and Puberty in African Children with Sickle Cell Anemia Treated with Hydroxyurea

Backhaus, D.

2158 - CT-Based Muscle Quality and Visceral Obesity Prior to Allogeneic Hematopoietic Stem Cell Transplantation Is of Prognostic Relevance in Patients with Acute Myeloid Leukemia
4334 - Measurable Residual Disease Detection of IDH1 or IDH2 Mutations Post but Not Prior to Allogeneic Hematopoietic Stem Cell Transplantation Show High Prognostic Relevance in Patients with Acute Myeloid Leukemia

Bacon, L.

399 - Hematopoietic Stem Cell Transplantation in Hepatosplenic T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Badalamenti, B.

415 - Path of Differentiation Distinctly Influences Macrophage Identity

Badaoui, B.

226 - Flow MRD Monitoring Combining Laip/Dfn and CD34+CD38- LSCs Is a Strong Predictor of Outcome in Adult AML Independently of the ELN-2022 Risk: First Results from the Multicentric Acute Leukemia French Intergroup MRD Flow Network

Badar, T.

244 - TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance
440 - Prevalence and Clinical Features of Non-Myeloid Neoplasms in Patients with DDX41 Mutant Germline Predisposition Syndrome
447 - Impact of Time from Diagnosis to Treatment on Outcomes of Adults with AML Treated with HMA and Venetoclax: A US-Based, Multi-Center, Real-World, Retrospective Analysis from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
664 - Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database
1250 - Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase Therapy
1425 - Clinical and Molecular Characterization of TP53-Mutant Acute Lymphoblastic Leukemia
1487 - Leukemia Physician’s Perspective on Transplant in Patients with TP53 Mutated Acute Myeloid Leukemia
1489 - Association between Body Mass Index and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax
1823 - Venetoclax in Combination with Hypomethylating Agent (HMA) Compared to HMA Alone Improves Response but Not Survival in TP53-mutated High-Risk Myelodysplastic Syndrome: Real-World Mayo Clinic Series
2426 - Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium
2771 - Preclinical Evaluation of Stx-0712, a CCR2 Cytotoxicity Targeting Chimera (CCR2-CyTAC) for the Treatment of Chronic Myelomonocytic Leukemia
2801 - Clinical Characteristics and Outcomes of Mixed Phenotype Acute Leukemia (MPAL): A Large Multi-Center Retrospective Study
2852 - Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
3183 - Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41^MT Germline Predisposition Syndrome
3206 - Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome – a Multicenter Retrospective Analysis
3213 - Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms
3218 - PPM1D Somatic Mutations in Myeloid Neoplasms: Clinical Profile, Clonal Characteristics and Impact of Concurrent Somatic TP53 Mutations
3219 - Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database
4184 - The Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
4247 - Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
5174 - Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium

Badawy, S. M.

795 - Pediatric Autoimmune Hemolytic Anemia Is Associated with a High Incidence of an Underlying Immune Disorder and High Mortality Rate
1186 - Variation in Diagnostic Evaluation Patterns for Pediatric Evans Syndrome: Survey Results from the Pediatric ITP Consortium of North America (ICON)
- Sickle Cell Disease

Badbaran, A.

2073 - CD19-Directed CAR T Cell Therapy in 4 Patients with Refractory Multiple Sclerosis
3547 - Early Tapering of Immunosuppression in MRD Positive Myelofibrosis Patients Induces Molecular Response and Excellent Outcome after Hematopoietic Stem Cell Transplantation
3571 - Impact of TP53 Mutation on Outcome after Allogeneic Stem Cell Transplantation for Patients with MDS/AML Not in Complete Remission

Badell, I.

3463 - Alloreactive Vs IL15 Ex Vivo Stimulated Natural Killer Cells As Adoptive Cell Therapy in Haploidentical Transplantation for Pediatric Acute Leukemia: A Phase I/II Clinical Trial

Baden, D.

3818 - Outcomes of Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Multicenter Real-World Analysis

Baden, L. R.

3500 - BK Virus Reactivation and Disease after Allogeneic Hematopoietic-Cell Transplantation: A Natural History Study
4866 - Expression of HLA-B*35 Is Associated with an Increased Risk of CMV Viremia and Clinically Significant CMV Infection in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation
4885 - Early CMV Viral Load Burden Predicts Late Clinically Significant CMV Infections in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation

Bader, A.

2524 - Illuminating the Functional Architecture of iPSC-Derived Neutrophil Granulocytes with Split Fluorescent Proteins

Bader, G. D.

2724 - The Exportin, CSE1L, Regulates Ribosome Biogenesis and Is a Selective Dependency in Childhood and Young Adult Acute Myeloid Leukemia

Bader, P.

3540 - Total Body Irradiation Versus Chemotherapy Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphoblastic Leukemia Patients Aged 2 to 4 Years: A Retrospective Study of the EBMT Pediatric Diseases Working Party
3563 - Addition of Anti-T-Lymphocyte-Globuline As Graft Versus Host Disease Prophylaxis for Matched Unrelated Donors Equalizes Outcomes with Matched Sibling Donors: Results from the AML SCT-BFM 2007 Trial
4864 - Comparative Results of Pediatric Patients with ALL Receiving Either of Two Different Types of Human Anti-T Lymphocyte Globulin Prior to Hematopoietic Stem Cell Transplantation: Findings from the International Prospective Forum Study
5079 - Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Outcomes in Leukocyte Adhesion Deficiency Type -I

Bader, P.

3548 - Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia: Results of the AML BFM Study Group

Bader-Meunier, B.

1117 - Autoimmune and Inflammatory Diseases in Children with Sickle Cell Disease: A French Multicenter Observational Study on Diagnostic and Therapeutic Issues

Badia, V.

2387 - Longitudinal Trajectories of Patient-Reported Outcomes Among Older Adults with Multiple Myeloma (MM) Following Autologous Stem Cell Transplantation (ASCT)
3767 - Decisional Regret Among Older Adults with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation

Badikyan, M.

2870 - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results

Badillo, M.

3038 - Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma

Bado, K.

- Grassroots Network Lunch

Badoux, X. C.

1869 - Consistently High 5.5-Year Progression-Free Survival (PFS) Rates in Patients with and without Bulky Baseline Lymphadenopathy ≥5 Cm Are Associated with High Undetectable Minimal Residual Disease (uMRD4) Rates after First-Line Treatment with Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) in the Phase 2 CAPTIVATE Study

Badros, A. Z.

675 - Daratumumab Plus Lenalidomide (D-R) Versus Lenalidomide (R) Alone As Maintenance Therapy in Newly Diagnosed Multiple Myeloma (NDMM) after Transplant: Analysis of the Phase 3 Auriga Study Among Clinically Relevant Subgroups

Badstübner, M.

4975 - Autonomous Region-of-Interest Detection, Cell Segmentation and Cell Classification in Bone Marrow Cytomorphology Using Deep Learning

Badu, T.

1801 - Overall Survival and Duration of Treatment in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib Versus Midostaurin or Best Available Therapy in a Real-World Setting

Badwan, O.

3017 - Cardiac Safety Profiles of First-Generation Vs. Second-Generation BTK Inhibitors: A Meta-Analysis

Bae, S.

3808 - Real-World Outcomes of Acute Myeloid Leukemia Patients Undergoing Treatment with Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2

Bae, S.

2918 - Developing a Therapeutic Strategy for Targeting Metabolic Vulnerability of TET2 Mutant Leukemia
4154 - Loss of TET2 Creates a Distinct Immunopeptidome in Acute Myeloid Leukemia
4159 - Loss of TET2 Increases MHC Class I Expression in Acute Myeloid Leukemia

Bae, S. H.

3170 - Predicting Molecular Response through Half Reduction of Neutrophil-to-Lymphocyte Ratio (NLR) in Polycythemia Vera Treatment with Ropeginterferon
4296 - Serial Next-Generation Sequencing for Detection of Germline Predisposition in Acute Myeloid Leukemia

Bae, W.

573 - Improving Outcomes in Plasmablastic Lymphoma: A Multicenter Experience from an American Cohort

Baech, J.

1638 - Survival in Mantle Cell Lymphoma Patients with a Second Primary Malignancy

Baek, G. T.

4425 - Concomitant Use of Antibiotics During Immune Checkpoint Inhibitor (CPI)-Based Salvage Therapy Does Not Impact Post-ASCT Outcomes in Patients with Relapsed/Refractory Hodgkin Lymphoma (RRHL)
4431 - Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting

Baer, C. R.

899 - Secondary Cytogenetic and Molecular Genetic Abnormalities in Newly Diagnosed Multiple Myeloma Patients
1819 - Similarities and Differences of DNMT3A, TET2 and ASXL1 Mutations across Ccus, MDS and AML
1836 - Two Ways to Complex Karyotype in MDS - the Role of Del(5q) and TP53
4318 - Clonal Hematopoiesis Can Precede AML with Defining Cytogenetic Abnormalities - the Frequencies Vary Considerably

Baer, M. R.

Baeten, K.

1871 - First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis

Baez, J.

380 - Serial Clinical and Biomarker Monitoring during Treatment Can Stratify Patients with Low Risk Gvhd

Baez Sosa, V.

- Wellness

Baeza, L.

2376 - Effectiveness and Safety for Re-Treatment with Brentuximab-Vedotin in Patients with Relapsed/Refractory (R/R) CD30+ Malignancies: A Retrospective Medical Chart Review Study in Spain. the Believe Study. NCT:04998331

Bafna, V.

1080 - A Single Mutation in the SENP1 Region Regulates the Excessive Erythropoiesis in the Andes

Bag, A.

256 - Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study

Bagaev, A.

2958 - Circulating Tumor DNA Predicts Time to First Treatment in Previously Untreated Follicular Lymphoma: Analysis from a Prospective Clonal Evolution Study
2981 - Gene Expression-Based Classifier Reclassifies Burkitt Lymphoma, HGBL NOS, DLBCL NOS, and Double/Triple Hit Lymphomas into Subtypes with More Uniform Mutational and Microenvironment Landscapes and Treatment Response
4341 - Comprehensive Analysis of Malignant B-Cell Receptors Provides Insights into B-Cell Lymphoma Pathogenesis
4364 - Evaluating the Clinical Utility of Real-Time Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Diffuse Large B-Cell Lymphoma

Bagal, B.

852 - Machine Learning Identifies Gene Mutations and Variant Allele Fractions That Refine the 2022 European Leukemianet Risk Stratification for Acute Myeloid Leukemia
1550 - Prognostic Significance of Wilms’ Tumor 1 Gene Mutations in Acute Myeloid Leukemia: Risk Stratification and Survival Outcomes
2931 - Double Trouble: Composite Mutations in Driver Genes in Acute Myeloid Leukemia (AML)
2953 - Leukemic Stem Cell Measurable Residual Disease (LSC MRD) Status Is a Better Predictor of Relapse Than Multiparametric Flowcytometric Analysis in Acute Myeloid Leukemia Patients
3161 - Making Treatment Free Remission “Feasible” in Low- and Middle- Income Countries - Outcomes, Patterns of Failure and Compliance of Treatment Free Remission (TFR) in Chronic Myeloid Leukemia (CML) from a Tertiary Care Cancer Centre in India
3755 - Real World Data of Novel Talicabtagene Autoleucel (humanized CD19 CAR-T) from India; Ensuring Equitable Access with Excellent Safety and Efficacy Profile
4290 - Mutational Landscape and Factors Affecting Prognosis in Acute Myeloid Leukaemia (AML) with RUNX1::RUNX1T1
4310 - Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia (AML)
4901 - Diagnostic Value, Predictive Significance and Kinetics of Fecal Calprotectin in Suspected Acute Gut Gvhd / Gvhd Flare Post Allogeneic Stem Cell Transplant

Bagashev, A.

3424 - Co-Targeting of the Thymic Stromal Lymphopoietin Receptor to Decrease Immunotherapeutic Resistance in CRLF2-Rearranged Ph-like and Down Syndrome ALL

Bagg, A.

1155 - Myofibroblast to T-Zone Reticular Cell Ratio Identifies Unicentric Castleman Disease Lymph Nodes
1156 - The Development of Diagnostic Criteria and Utilization of Excisional Lymph Node Biopsies Shorten Time to Diagnosis for Idiopathic Multicentric Castleman Disease
3083 - Title: Development of a Pathologic Prognostic Index (PPI) for Newly Diagnosed Large B Cell Lymphoma Patients Treated with R-CHOP

Baggett, D. W.

825 - The Histone Acetyltransferase MOZ (KAT6A) Is a Molecular Dependency and Therapeutic Target in NUP98-Rearranged Acute Myeloid Leukemia

Baggott, C.

2817 - Role of B Cell Recovery in Relapse Risk and CD19 Phenotype Following Real-World Use of Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia: A Multi-Institutional Retrospective Study

Baghdadi, S. L.

1257 - Anticoagulation Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
2633 - Thrombolytic Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis

Baghdadi, T. A.

4597 - Association between Smoking Intensity, Genetic Mutations, and Disease Progression in Myelodysplastic Syndromes

Bagley, E.

1690 - Asparaginase Treatment Patterns, Toxicity, and Outcomes Among Patients with Extranodal NK/T-Cell Lymphoma: A North American Multicenter Retrospective Cohort Study

Bagley, R. G.

211 - Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia

Bagnardi, V.

2186 - Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Retrospective Multicenter Analysis on 285 Procedures Performed between 2000 and 2020

Bagnasco, F.

1327 - Application of Machine Learning in the Diagnostic Work-up of Telomere Biology Disorders

Bagnasco, S.

4473 - Impact of MYC Alterations in De Novo and Transformed Large B-Cell Lymphoma: An Italian Single Center Experience

Bagnato, G.

3740 - Immune Checkpoint Inhibitors in Primary Mediastinal B-Cell Lymphoma: A Monocentric Real-Life Experience and Future Potential

Bagnoli, F.

1681 - Bendamustine in Combination with Gemcitabine and Vinorelbine As Salvage Regimen for Relapsed or Refractory Peripheral T-Cell Lymphomas: A Retrospective Single Center Experience

Bagot, M.

1609 - Lacutamab in Patients with Relapsed and/or Refractory Sézary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial

Bagot, M.

3056 - Mogamulizumab in Patients with Mycosis Fungoides/Sézary Syndrome: Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing a 4-Weekly Dosing Schedule

Bagratuni, T.

1600 - Genomic Characterization of Ibrutinib-Resistant Waldenström’s Macroglobulinemia
1603 - The Combined Treatment of Btkis with Venetoclax Exhibits an Enhanced Therapeutic Effect on Waldenström Macroglobulinemia Cells Bearing CXCR4 Mutations
4352 - Determining the Mutational Landscape of Waldenström’s Macroglobulinemia By Liquid Biopsy: Results of the Prospective Ecwm-2 Trial of the European Consortium for Waldenström’s Macroglobulinemia

Bagri, J.

190 - Delayed Trp53 Activation Protects Dnmt3a-Mutant Haematopoietic Stem Cells from Inflammatory Attrition

Bahabri, A.

4470 - Prior History of Severe Infection in Children, Adolescents and Young Adults with Lymphoma As Proxy for Inborn Errors of Immunity: Prevalence and Impact on Post-Lymphoma Outcomes

Bahaj, W.

850 - Clinical and Molecular Insights into the Classification Dilemma: Are MDS/AML Cases Distinct from Secondary AML?
3199 - Could Somatic Gene Rescue Explain Frequency of Compound Heterozygous and Concurrent Receptor Tyrosine Kinase Mutations in Hematological Diseases?

Bahar, F.

1490 - Outcomes of Acute Promyelocytic Leukemia (APL) during Pregnancy: A Systematic Review of Outcomes

Baheig, G.

3495 - CMV Reactivation Kinetics in Patients Undergoing Haploidentical Stem Cell Transplantation Using Low-Dose Post-Transplant Cyclophosphamide: A Single Center Experience

Bahl, R.

3938 - Randomised Controlled Trial of High Dose Dexamethasone and Methylprednisolone in Immune Thrombocytopenia (HDMI Trial)

Bahlis, N. J.

247 - Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma
362 - Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial
591 - NF-Kb Pathway Activation Driven By TRAF3 Loss Mediates Resistance to Anti-BCMA T-Cell Based Therapies in Multiple Myeloma
592 - Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma
594 - Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide
1021 - Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies
1892 - Tumor Intrinsic and Antigen-Independent Resistance Mechanisms to Bispecific T Cell Engagers in Multiple Myeloma
1899 - Timing Antigenic Escape in Multiple Myeloma Treated with T-Cell Redirecting Immunotherapies
1933 - The Effect of Elranatamab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Naïve and Exposed to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Updated Follow-Up from the MagnetisMM-3 Study
1996 - Efficacy and Safety of Selinexor, Pomalidomide, and Dexamethasone (SPd) for Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
3261 - Biomarker Analyses of the CC-92480-MM-001 Trial to Guide Combinatorial Strategies for Mezigdomide
4642 - Immune and Tumor Mediators of Resistance to Daratumumab-IMiDs Based Therapies in Relapsed Multiple Myeloma
4651 - BCMA Extracellular Domain Functional Hotspots and Resistance to Variable Anti-BCMA T Cell Engagers in Multiple Myeloma
4738 - MagnetisMM-3: Long-Term Update and Efficacy and Safety of Less Frequent Dosing of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma
- International Medical Graduates

Bahlis, N. J.

677 - Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial

Bahr, R.

59 - A Randomised Comparison of CPX-351 Versus Standard Daunorubicin and Cytarabine Plus Fractionated Gemtuzumab Ozogamicin in Older Adults with AML without Adverse Risk Cytogenetics: Results of the NCRI AML18 Trial

Bahtina, V.

3782 - Efficacy of Isa-Pom-Dex Therapy in Double Refractory Multiple Myeloma (MM) Patients in Real Clinical Practice

Bai, A.

2780 - Preclinical Proof-of-Concept of a Novel mRNA-Based Therapeutic Combination of an FcRH5 Targeted NK Cell Engager and an IL-15 Superagonist for the Treatment of Multiple Myeloma

Bai, B.

3066 - Autologous Transplant Consolidation Vs. Immunotherapy Maintanance Therapy in Patients with Relapsed or Refractory NK/T Lymphoma Treated While in Complete Remission
3071 - Clinical Features and CSF-Ctdna Characteristics in Extranodal Natural Killer/T‐Cell Lymphoma Patients with Central Nervous System Involvement
4450 - Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Study

Bai, D.

2074 - 1‰ Regular Dose of Metabolically Armored CD19 CAR-T Cells Induces Robust In Vivo Expansion and Complete Remission in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients

Bai, G.

1485 - Venetoclax Combined with Intensive Chemotherapy As an Induction Chemotherapy in Newly Diagnosed FLT3-ITD Positive AML
1505 - Venetoclax Combined with Three-Day Multi-Frequency Decitabine and Homoharringtonine (DEC3-VEN-HHT) As Induction Therapy in Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia
2885 - 7-Day Venetoclax Combined with Intensive Chemotherapy As Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia
4279 - Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) in the Treatment of Adult Patients with De Novo Acute Myeloid Leukemia

Bai, J.

3175 - Clinical Characterization of Myeloid Neoplasms Patients with Fanconi Anemia Gene Mutations
3937 - Optimized Recombinant Human Thrombopoietin(rhTPO) Regimen Versus Eltrombopag for Pre-Treated Patients with Primary Immune Thrombocytopenia: Interim Results from a Prospective, Multicenter, Randomized Trial (TE-ITP study)
4101 - Characterization of Hemophagocytic Lymphohistiocytosis Associated with Myeloid Neoplasms at Single-Cell Resolution
4562 - Remarkable Molecular Response in Patients with Polycythemia Vera Treated with Ropeginterferon Alfa-2b

Bai, J.

26 - Chromatin Modifier Hmga1 Maintains Hematopoietic Stem Cell Integrity in Stress Conditions
2488 - Pharmacological Evaluation of a First-in-Class Hemoglobin Elevating Agent (HbEA) AND017 in Townes SCD Mouse Model
4140 - Pharmacological Evaluation of a First-in-Class Hemoglobin Elevating Agent (HbEA) AND017 in a Mouse MDS Model of an Inducible Mutant c-Myc Knock-in

Bai, J.

3113 - Cyclophosphamide, Mitoxantrone Hydrochloride Liposome, Vincristine, and Prednisone Regimen with or without Rituximab (CMOP±R) Shows High Efficacy As a First-Line Treatment for Non-Hodgkin's Lymphoma: A Phase II Clinical Trial with Matching-Adjusted Indirect Treatment Comparison (MAIC) Analysis

Bai, J.

1096 - Pulmonary Dysfunction in Patients with Transfusion-Dependent Thalassemia

Bai, M.

923 - A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with Relapsed/Refractory Multiple Myeloma Including Those with Extramedullary Disease

Bai, O.

1723 - Exploration of Rituximab Plus Lenalidomide（R²）in Newly Diagnosed Diffuse Large B Cell Lymphoma with Adverse Prognostic Factors As Maintenance Therapy
4447 - The Short-Term Efficacy and Safety of Brentuximab Vedotin Chemotherapy Combined with Chidamide in the Treatment of CD30-Positive Peripheral T-Cell Lymphoma
4490 - Chidamide: A New Exploration of Maintenance Therapy for DLBCL Patients with HBV Infection

Bai, Q.

1767 - Olverembatinib-Therapy in Patients with Accelerated-Phase Chronic Myeloid Leukaemia: A Multi-Centre Retrospective Study from China

Bai, X.

2082 - Efficacy and Safety of CAR-T Therapy Targeting CLL1 in Patients with Extramedullary Diseases of Acute Myeloid Leukemia

Bai, Y.

1485 - Venetoclax Combined with Intensive Chemotherapy As an Induction Chemotherapy in Newly Diagnosed FLT3-ITD Positive AML
1505 - Venetoclax Combined with Three-Day Multi-Frequency Decitabine and Homoharringtonine (DEC3-VEN-HHT) As Induction Therapy in Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia
2885 - 7-Day Venetoclax Combined with Intensive Chemotherapy As Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia
4279 - Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) in the Treatment of Adult Patients with De Novo Acute Myeloid Leukemia

Bai, Y.

4109 - Protein Tyrosine Phosphatase PRL2 Promotes MLL-Rearranged Acute Myeloid Leukemia Development through Inhibiting the p53 Pathway

Baiardi, E.

1620 - Impaired rRNA Synthesis Contributes to BCL-2 Induced Chemoresistance in Diffuse Large B-Cell Lymphoma

Baichoo, M.

671 - A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma
4943 - Dietary Sucrose Exacerbates Antibiotic-Induced Microbiome Injury in Allo-HCT

Baidoun, F.

570 - Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma
4406 - Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma

Baidoun, F.

571 - Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort
3790 - Disparities in Multiple Myeloma (MM): Race/Ethnicity-Specific Sociodemographic and Economic Factors That May Drive Patient Decisions to Refuse Treatment
4723 - Early Mortality in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Sociodemographic and Economic Factors Contributing to the Disparity

Baig, H.

772 - Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial
3359 - Efficacy Outcomes By Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated with Belantamab Mafodotin Plus Bortezomib and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone: Analysis from the Dreamm-7 Trial

Baik, J.

1589 - Genomic Characterization and Classification of BCL6 Rearranged Follicular Lymphomas

Baile González, M.

405 - The Impact of Frailty on Outcomes and Quality of Life in Allogeneic Hematopoietic Cell Transplantation: Summary of Results from a Collaborative Prospective Study Conducted on Behalf of the Geth-TC
2108 - Impact of Ptcy on Early Cardiac Toxicity after HLA-Matched Allo-HCT in Patients with Acute Myeloid Leukemia. Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)
5148 - Frailty and Outcomes in Multiple Myeloma Patients Eligible for Autologous Hematopoietic Cell Transplantation: A Prospective Study of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)

Baile Gonzalez, M.

598 - HCT-Adapted ELN 2022 Risk Classification: Validation of a Very Poor Risk Group (Adverse-Plus) in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)
2156 - Sativex Oromucosal Spray in Patients with Chronic Graft Versus Host Disease: Effect on Sclerodermal Features and Refractory Muscle Cramps
4884 - Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation in a Spanish Multicenter Cohort on Behalf of Geth

Bailen, R.

2044 - Molecular Tumor Burden and Clonal Evolution As Factors Associated with Early Progression in Large B-Cell Lymphomas Treated with CAR-T Therapy
2113 - Predictive Value of Liver Sitffness Measurement for Early Diagnosis of Veno-Occlusive Disease and Final Stem-Cell Outcomes
4872 - At-Home Allogeneic Stem Cell Transplantation: A Single Centre Experience
4889 - Outcomes of Allogeneic Transplantation with Clofarabine and Post-Transplant Cyclophosphamide-Based Conditioning in Patients with Very High-Risk Acute Myeloid Leukemia

Bailey, A.

4019 - The Incidence and Risk of Venous Thromboembolism in Patients with Active Malignancy and Isolated Superficial Venous Thrombosis: A Systematic Review and Meta-Analysis. (The IROVAM-iSVT review)

Bailey, C.

616 - Efficacy of a Concise Training Curriculum for the Joint and Activity Damage Exam (J.A.D.E) to Facilitate International Harmonization of Musculoskeletal Ultrasound in Hemophilia
3965 - Assessment of Annual Rate Changes of Intraarticular Tissue Measurements in Hemophilic Joints Experiencing Acute Bleeding Using the Joint Activity Damage Exam (JADE) Ultrasound Protocol

Bailey, C.

1904 - The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
1937 - Identification of Risk Factors for Myeloma Progression in African American Patients
4676 - Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression
4713 - Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
4729 - Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages

Bailey, L. C.

1064 - Defining the Impacts of Iron Overload in Children Receiving Hematopoietic Stem Cell Transplantation for Non-Malignant Hematologic Disorders: A Multicenter Analysis

Bailey, M.

524 - Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma
3111 - Updated Response and Safety for Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Bailey, M.

3223 - Clinical Response to Azacitidine in Myelodysplastic Neoplasms Is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor Cells In Vivo

Bailey, M.

3639 - International Clinical Consensus on Leukocyte Adhesion Deficiency-I: A Modified Delphi Analysis

Bailey, N.

524 - Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma
1870 - Outcomes of Therapies Following Discontinuation of Non-Covalent Bruton’s Tyrosine Kinase Inhibitors for Patients with Chronic Lymphocytic Leukemia and Richter Transformation: Results from an International, Multicenter Study
3111 - Updated Response and Safety for Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
3409 - Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Bailey, S. L.

124 - T-Cell Transcriptomic Signatures in Adults with Primary Untreated Immune Thrombocytopenia Segregate By Age, Revealing Distinct Druggable Pathways

Bailly, C.

1596 - Predictive Power of Early, Sequential Minimal Residual Disease and Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Monitoring in Young Patients with Mantle Cell Lymphoma in the Lyma Trial: A Lysa Study
4505 - Health-Related Quality of Life after Axi-Cel As a Second-Line Therapy in Patients with High-Risk Relapsed/Refractory Large B-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Results of the Alycante Phase II Trial

Bailly, S.

4354 - Circulating Tumor DNA for Primary Mediastinal B-Cell Lymphoma Genotyping: A Prospective Multicenter Study

Baim, A.

3409 - Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Bain-Wendlinger, C.

1434 - Switch of Asparaginase Formulation Based on Antibody Monitoring in Adults with Philadelphia-Negative Adult Lymphoblastic Leukemia. Results of the Graall-2014 Trial

Bainbridge, J.

5001 - Clinical and Economic Impact of Long-Term Disease Modifying Transfusions in Adults As a Prophylactic Intervention for Sickle Cell Disease Crises
5002 - Clinical and Economic Impact of Long-Term Disease Modifying Transfusions in Paediatrics As a Prophylactic Intervention for Sickle Cell Disease Crises

Baines, A. C.

1907 - Novel T-Cell Receptor Signature Linked to Plasma Cell Dyscrasias

Bainha, K.

4815 - Characterizing the Role of Interferon-γ Signaling in Natural Killer Cell Dysfunction in Venetoclax-Resistant Acute Myeloid Leukemia

Bainter, W.

88 - A Versatile B Cell Engineering Platform Enables Development of B Cell Medicines for Sustained Delivery of Therapeutic Biologics

Baiocchi, E.

1403 - Targeting the DNA Damage Response through TBL1X in Mantle Cell Lymphoma

Baiocchi, R.

70 - Updated Clinical Results: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein–Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab Plus Chemotherapy
573 - Improving Outcomes in Plasmablastic Lymphoma: A Multicenter Experience from an American Cohort
809 - Targeting PRMT5 in Primary Hemophagocytic Lymphohistiocytosis: A Novel Therapeutic Approach Using a Perforin-Deficient Mouse Model
870 - Daratumumab with Dose-Adjusted EPOCH Is Feasible in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 105
1403 - Targeting the DNA Damage Response through TBL1X in Mantle Cell Lymphoma
1611 - Transcriptome Analysis at Locus-Specific Resolution Identified Alteration in Human Endogenous Retroviruses, a Class of Transposable Elements in Mantle Cell Lymphoma
1719 - Nivolumab in Combination with Dose Adjusted (DA) R-EPOCH for First-Line Treatment of Large B-Cell Lymphoma: Results from a Phase II Trial
3737 - Impact of Baseline Osseous Involvement on Outcomes in Patients with Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom’s Macroglobulinemia (WM)
3747 - Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy Is Associated with Inferior Survival for Patients with Relapsed or Refractory Large B-Cell Lymphoma
4350 - Transcriptomic Analysis in Mantle Cell Lymphoma Patients Identified MALAT1 Long-Non-Coding RNA to Regulate Cell Cycle Progression By Modulating EZH2/p57/Sox11 Axis
4371 - Tumor Microenvironment-Induced Interleukin-6 Regulates Proliferation and Survival in Patients with Mantle Cell Lymphoma (MCL) By Activating FGFR1 Signaling
4460 - Patterns of Use and Outcomes of Novel Agents in Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Single-Center Retrospective Analysis
4507 - Steroid Prophylaxis in Patients Receiving CAR T-Cell Therapy for Relapsed and Refractory Non-Hodgkin Lymphoma
5135 - Comparison of Treatment Outcomes with V-EPOCH Vs DA-EPOCH for First-Line Plasmablastic Disease

Bair, S. M.

4392 - Clinical Outcomes of Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM) in the Targeted Therapy Era: A US Multicenter Retrospective Analysis

Baird, C.

135 - A Novel Factor VIII Mutation with Increased Activity, Severe Thrombosis and Resistance to Activated Protein C
2579 - Low Normal Levels of Factor V Enhance Thrombin Generation in Hemophilia a in a Tissue Factor Pathway Inhibitor Independent Manner

Baird, J. H.

69 - CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up
911 - CD22-Directed CAR T Cell Single Cell Multiomic Features Associated with Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)
2278 - Outpatient Administration of Brexucabtagene Autoleucel (brexu-cel) for Acute Lymphoblastic Leukemia (ALL) and Mantle Cell Lymphoma (MCL) Is Safe and Feasible
3127 - Favorable Safety Profile and Durable Responses to Pmb-CT01 (BAFFR-CAR T Cell) Therapy in Patients with B-Cell Lymphomas Ineligible for or Who Failed CD19-Targeted Therapy, Including CD19-Negative Disease
1742.1 - A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Baird, J. H.

609 - Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Baird, K.

1717 - Clinical Features and Outcomes of Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Single-Center Analysis

Bairey, O.

1862 - Phase II Prospective Trial of Fixed Duration Obinutuzumab, Ibrutinib and, Venetoclax in an Elderly Cohort of Patients with Richter's Syndrome-Givers Regimen

Bajaj, J.

563 - Compartmentalized Niche and Spatially Heterogenous Inflammatory Landscape Regulate Tet2^+/-- Mediated Clonal Hematopoiesis
1302 - Temporal Single Cell Analysis of Myeloid Leukemia Microenvironment

Bajaj, P.

252 - Circulating Tumor DNA As a Minimally Invasive Predictor of Early Relapse in Multiple Myeloma

Bajaj, P.

3665 - A Medical Chart Review of Healthcare Costs in Patients with Systemic Amyloid Light Chain Amyloidosis By Mayo 2012 Stage in the United States

Bajel, A.

51 - Venetoclax-Based Measurable Residual Disease Directed Therapy in Acute Myeloid Leukemia Is Associated with Emergent TP53 Microclones in Remission
217 - A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax +/- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial
653 - DNA Damage Repair Pathway Variants Are Frequent in Patients Undergoing CAR-T Cell Therapy for Lymphoma and Associated with Increased Risk of Myeloid Neoplasia Post Cytotoxic Therapy
3450 - WU-CART-007 (WT-7), an Allogeneic CAR T-Cell Targeting CD7 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Phase 2 Results
3799 - Real-World Patterns of Care and Outcomes for Non-Favourable Risk Acute Myeloid Leukemia Treated with Intensive Chemotherapy across Australia and New Zealand- Data Linkage between the ALLG National Blood Cancer Registry (NBCR) and the Australia and New Zealand Transplant and Cellular Therapy (ANZTCT) Registry
4257 - WUN101-01: First in Human Human (FIH) Phase 1 Study of WU-NK-101 (W-NK1) in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
4928 - Clonal Architecture of Donor-Derived Leukemia/Clonal Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplant
5015 - Evaluating a Multidisciplinary Model of Care for Inherited Bone Marrow Failure and Predisposition to Hematological Malignancy
2883.3 - Phase 1/2, Open-Label, Multi-Center Study Assessing the Safety, Tolerability and Preliminary Efficacy of CD123 Natural Killer Cell Engager (NKCE), SAR443579, in Combination with Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy

Bajpai, A.

1147 - Axatilimab Abrogates Inflammatory Cytokines and Chemokines and Interrupts the Differentiation of Monocytes to Macrophages, a Pathogenic Driver of Inflammation and Fibrosis in cGVHD

Bajwa, A. T.

4706 - Impact of Kidney Transplantation on Hospitalization Outcomes in Patients with Multiple Myeloma

Bajwa, S.

1640 - Waldenström Macroglobulinemia: A Retrospective Survival Analysis Study from SEER Database
5170f - Global and Regional Burden of Multiple Myeloma from 1980 to 2021: An Analysis of Gbd Study 2021

Bajwa, U.

1640 - Waldenström Macroglobulinemia: A Retrospective Survival Analysis Study from SEER Database

Bakanay Ozturk, S. M.

4929 - Return to Work after Allogeneic HSCT: Further Insights in the Patients-Related Predictive Factors (The SOPRALLO Project)

Baker, B.

5147 - Impact of Socioeconomic Status on Utilisation of ASCT and Overall Survival in Multiple Myeloma: A Report from the Australian and New Zealand (ANZ) Myeloma and Related Diseases Registry (ANZ MRDR)

Baker, C. D.

1302 - Temporal Single Cell Analysis of Myeloid Leukemia Microenvironment

Baker, C. L.

3691 - Qualitative Interview Study to Characterize the Treatment Experiences of Participants with Sickle Cell Disease and Assess Perceptions of Red Blood Cell Transfusions

Baker, E.

3715 - Individual- and Area-Level Socioeconomic Disadvantage and Risk of Death Due to Chronic Health Conditions Among Autologous Blood or Marrow Transplant (autoBMT) Recipients for Lymphoma: A BMT Survivor Study (BMTSS) Report

Baker, J.

2012 - Erythropoietin Promotes GvHD Prevention through Type 1 Conventional Dendritic Cells

Baker, P.

1193.1 - Design of a Phase 3, Multicenter, Randomized, Open-Label Study of Nipocalimab or IVIG in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia (FREESIA-3)

Baker, R.

1001 - Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis

Baker, R. I.

773 - Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study

Baker, S. D.

1300 - Mesenchymal Stromal Cell Expansion in FLT3-ITD+ Zebrafish Treated with Gilteritinib

Bakesova, D.

2806 - Central Nervous System Involvement Does Not Worsen Survival in Hematologic or Molecular Relapse of Adult Acute Lymphoblastic Leukemia Patients – Retrospective Analysis By the Czech Leukemia Study Group for Life (CELL)

Bakhshi, S.

2870 - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results

Bakhtiari, K.

1248 - First in-Human Study with Okl-1111, a Novel Small Molecule Universal Anticoagulant and Platelet Inhibitor Reversal Agent

Bakhtiari, M.

1365 - Single-Cell Profiling of the Immune Response Following Siglec 15 Knockout in Leukemia Cells
3258 - Integrated Coding and Non-Coding Transcriptional Single-Cell Atlas of Multiple Myeloma: Unraveling the Effects of Myeloma Genotype on the Bone Marrow Microenvironment

Bakirov, B. A.

4614 - Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax

Bakkacha, O.

3450 - WU-CART-007 (WT-7), an Allogeneic CAR T-Cell Targeting CD7 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Phase 2 Results
3461 - WU-CART-007 (WT-7) Is an Effective Treatment for Adolescent Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL) – Subgroup Analysis of WU-CART-007 1001
4257 - WUN101-01: First in Human Human (FIH) Phase 1 Study of WU-NK-101 (W-NK1) in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Bakkar, M.

518 - Outpatient Hematopoietic Stem Cell Transplant for Adult Sickle Cell Disease Patients Is Safe, Reduce Inpatient Bed Utilization and Improve Access to Care
2173 - Short and Long-Term Toxicities of Allogeneic Stem Cell Transplant for Adult Patients with Sickle Cell Disease

Bakker, G.

3108 - Brigatinib Monotherapy in Children with R/R ALK+ ALCL, IMT, or Other Solid Tumors: Updated Results from the Brigaped (ITCC-098) Phase 1 Dose-Escalation Study

Bakkus, M.

3312 - Comprehensive (Epi)Genetic Tumor Characterization and Disease Follow-Up in Multiple Myeloma Using Blood-Derived Cell-Free DNA

Bakr, M. N.

202 - In Vivo Genetic Screen Identifies Chromatin Remodeling Gene SET As a Collaborating Oncogenic Driver in Initiation and Maintenance of Acute Lymphoblastic Leukemia

Baksa, B.

2884 - Dose of Venetoclax in Combination with Hypomethylating Agents and Outcomes of Patients with Acute Myeloid Leukemia: A Retrospective Study

Bakshi, K.

594 - Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide

Bakshi, N.

4231 - Saudi Acute Myeloid Leukaemia (AML) Genome Reveals Significant Differences from That in the Western Population

Bakshi, N.

291 - Integrative Strong Body and Mind Training for Sickle Cell Disease (I-STRONG)—an Interdisciplinary, Multicomponent Treatment Approach for Pediatric Chronic SCD Pain
3899 - Sickle Pain-Related Impact (SPiRIt): A Prospective Study of Impact of Chronic Pain in Sickle Cell Disease

Bal, E.

4128 - Role of Glucocorticoid Receptor in Normal and Malignant Germinal Center B Cells

Bal, S.

257 - Optimal MRD-Based Endpoint in the Setting of Upfront Quadruplets (QUADs) to Support Response-Adapted Treatment Cessation in Newly Diagnosed Multiple Myeloma (NDMM)
363 - Implications of MRD Progression in Newly Diagnosed Multiple Myeloma (NDMM) Treated with Quadruplet Therapy and Autologous Stem Cell Transplantation
2387 - Longitudinal Trajectories of Patient-Reported Outcomes Among Older Adults with Multiple Myeloma (MM) Following Autologous Stem Cell Transplantation (ASCT)
3449 - Phase 2 Trial of Siltuximab for the Treatment of Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Related to CAR-T Cell Therapy
3767 - Decisional Regret Among Older Adults with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation
5145 - Factors Associated with Post-Transplant Complications Among Older Adults with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation

Bal, S.

922 - Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM)
2069 - BMS-986393, a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1–3 Prior Regimens: Updated Phase 1 Safety and Efficacy Results
3368 - Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium
5151 - Real World Evidence on Patient Reported Outcomes Among Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Regimens in Frontline (1L)
2000.1 - MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial

Bala, N. S.

4010 - Insights and Characteristics of Pediatric Central Venous Catheter Malfunction and Catheter-Associated Deep Vein Thrombosis: A Subanalysis of the Circle Study

Balabanian, K.

4343 - Inflammatory Waldenström Macroglobulinemia Is Associated with Clonal Hematopoiesis: A Multicentric Cohort

Balabanov, S.

568 - PET-Guided Brecadd in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma: Results of the Phase 2 Part of the GHSG HD21 Trial
4307 - MDS-AML Aggregative Risk Classification System (MARCS): A Novel, Enhanced Risk Stratification System Derived from the Combined Unsupervised Analysis of 7,480 MDS and AML Patients

Balabiyev, A.

1148 - Control of Macrophage Fusion By Sensing the Physical Properties of Fibrin(ogen) Matrices

Balachandran, M.

4641 - Characterization of AT02 Bioactivity and an Assessment of Its Potential Use As an Amyloid-Clearing Therapeutic for AL Amyloidosis

Balachandran, N.

3884 - Hindsight 20/20: The Role of Hemoglobin F in Sickle Cell Retinopathy

Balaguer Rosello, A.

399 - Hematopoietic Stem Cell Transplantation in Hepatosplenic T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
2105 - Treosulfan/Fludarabine Versus Thiotepa/Busulfan/Fludarabine for Allogeneic Hematopoietic Cell Transplantation in Patients with Lymphomas in the Ptcy Era: A Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)
2111 - Current Challenges in the Assessment of Related Donors for Hematopoietic Stem Cell Transplantation
3497 - Central Nervous System Disorders (CNSD) Following Hematopoietic Stem Cell Transplantation (HSCT): A Prospective Study from the Infectious Diseases Working Party (IDWP) and the Transplant Complications Working Party (TCWP), European Society of Blood and Marrow Transplantation (EBMT)
3565 - Allogeneic Stem Cell Transplantation As Consolidation Therapy in Patients with Relapsed-Refractory B-Cell Lymphoma Exposed to Bispecific Antibodies: A Study on Behalf of Grupo Español De Transplante y Terapia Celular (GETH-TC)
4947 - Effect of Consolidation with Allogeneic Hematopoietic Cell Transplant Versus No Consolidation in Patients with Non-Hodgkin Lymphomas Treated with Bispecific Antibodies

Balaian, L.

1385 - Identifying the Impact of ADAR1 Inhibition on LSC Niche Remodeling in 3D Nanobioreactors
4068 - A 3D Niche Nanobioreactor Supports Long-Term Tracking of Hematopoietic Stem and Progenitor Cell Cycle Kinetics, Self-Renewal and Cell Fate Determination

Balaji, N.

1960 - Automated Body Composition Analyses Reveal Significant Associations with Mortality in Myeloma Patients Following Immunotherapy with Bispecific Antibodies

Balakrishnan, K.

2982 - Use of Molecular Immune Signatures for Frontline Treatment Selection in Patients with Advanced Stage Follicular Lymphoma
4348 - Genomic and Spatial Proteomic Characterization of the Microenvironment of Diffuse Large B-Cell Lymphoma in African American Patients
4364 - Evaluating the Clinical Utility of Real-Time Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Diffuse Large B-Cell Lymphoma
4396 - Treatment Patterns and Real World Outcomes with Clinical Trials for Patients with Follicular Lymphoma across Lines of Therapy

Balakrishnan, S.

2321 - The Association of Anemia and Patient Reported Outcomes in the New Era of PNH Treatment

Balandrán, J.

4170 - PAX5 Loss Compromises CD22 Protein Levels and Responses to Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia

Balas, N.

Balasa, V. V.

1216 - Athn 10 – Novel Variants in Persons with Rare Coagulation Disorders across Hemophilia Treatment Centers in the United States

Balasis, M.

481 - A Phase 2 Study of Fedratinib in Patients with MDS/MPN and Chronic Neutrophilic Leukemia

Balasubramanian, P.

647 - Rationalization of Anti-PD-1 Therapy Using Receptor Occupancy Data to Guide Drug Dosing – a Single Arm Phase II Trial Using Immunomodulation in Relapsed/Refractory Hodgkin Lymphoma
2150 - Lower Mycophenolic Acid Exposure in Patients Undergoing Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide/ Cyclosporine a-Based GvHD Prophylaxis – Need for Dose Intensification
4879 - EASIX_d0 Predicts Early Transplant-Related Mortality in Patients Undergoing Haploidentical Transplantation with Post-Transplant Cyclophosphamide-Mycophenolate Mofetil-Based GvHD Prophylaxis

Balasubramanian, S.

1874 - A Phase 2 Study of Zanubrutinib and Venetoclax (ZV) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Balasubramanian, S. K.

214 - Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007
842 - Clinical and Molecular Characteristics of RAS and RAS-like Mutational Signature in Acute Myeloid Leukemia
850 - Clinical and Molecular Insights into the Classification Dilemma: Are MDS/AML Cases Distinct from Secondary AML?
927 - Predictive Modeling of Hematopoietic Stem Cell Transplant Outcomes: Discovering the Role of Immunogenetic Features through Machine Learning Models
1540 - Clonal Evolution of TP53 Configurations with Treatment Predict Prognosis in Myeloid Neoplasms
2768 - Combined Use of Ziftomenib and Selinexor Is Effective in NPM1 Mutant Acute Myeloid Leukemia
2880 - Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET‑007
3206 - Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome – a Multicenter Retrospective Analysis
4254 - Longitudinal Sequencing to Investigate Clonal Evolution in Myeloid Neoplasms

Balasubramanian, T.

1118 - The Utility of Maternal Placental Growth Factor (PlGF) for Prediction of Pre-Eclampsia in Pregnancies Complicated By Sickle Cell Disease

Balasundaram, N.

827 - Targeting Mitochondrial Metabolism to Promote Viral Mimicry and Type I Interferon Response in Acute Myeloid Leukemia

Balbin-Cuesta, G.

938 - The LSD1 Inhibitor RN1 Rescues Congenital Dyserythropoietic Anemia Type II

Baldauf, H.

776 - Follow-up of the Randomized ASAP Trial Shows No Survival Advantage for Patients with Poor Responsive or Relapsed AML Who Received Intensive Salvage Chemotherapy for Remission Induction Prior to Allogeneic Transplantation Compared to Immediate Allogeneic Transplantation

Balderman, S.

1473 - Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients between 65-75 Years and Treated with Intensive Induction Chemotherapy Versus Hypomethylating Agents and Venetoclax: A Propensity Score Adjusted Cohort Study
1488 - A Comprehensive Analysis of FLT3 Mutation Profiles and Clinical Outcomes in Adult Patients with Acute Myeloid Leukemia: A Single Institution Experience
1777 - Cardiovascular Profile of Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia: A 16-Year Observational Study
2848 - Salvage Reinduction Chemotherapy Versus Alternative Regimens after Failed AML Intensive Induction Regimen, a Single Center Experience
2862 - Impact of Cytogenetic Response on Long-Term Survival in Acute Myeloid Leukemia: A Retrospective Cohort Study
2868 - Outcomes of Blast-Phase MPN and JAK2, MPL, and CALR Mutated de Novo AML Compared to AML with Wild-Type JAK2, MPL, and CALR Genes: A Propensity Score-Adjusted Cohort Study
3153 - Impact of Non-ABL1 Mutations on Outcomes in Patients with Chronic Myeloid Leukemia
4221 - Impact of TP53 Mutation on Survival Outcomes in Acute Lymphoblastic Leukemia at a Tertiary Center
4248 - Survival Outcomes of Patients Diagnosed with Myeloid Sarcoma Versus Acute Myeloid Leukemia: A Retrospective Cohort Study
4249 - Comprehensive Analysis of KMT2A Alterations in Acute Myeloid Leukemia and Their Impact on Survival and Response Rates; A Single Center Experience
4297 - The Prognostic Significance of Chromosome 17 Addition Vs. Complete and Partial Loss in Patients with Acute Myeloid Leukemia, a Single Center Experience
5059 - Analysis of Factors Influencing Enrollment Success in Hematology Malignancy Cancer Clinical Trials (2008-2023)

Baldeviano, C.

2047 - Enabling Potent T Cell Delivery and Mitigating Key Off-Target Concerns of In Vivo

CAR T Lentiviral Vectors with the Targeted Paramyxovirus Fusogen System

Baldi, T.

407 - Profiling Baseline Health-Related Quality of Life of Patients with Newly Diagnosed Myeloid Malignancies: A Pooled Analysis of 3349 Patients with AML, APL and MDS from the International Proactive Project

Baldridge, M.

435 - Gut Microbiota-Driven Tonic Type I IFN Signaling Supports Steady-State Hematopoiesis

Balduini, A.

1165 - Silk Bone Marrow Niches to Model Fibrosis and Altered Megakaryopoiesis in Myeloproliferative Neoplasms
1169 - Altered Calcium Signaling Via STIM1 Drives Aberrant Megakaryopoiesis and Myelofibrosis
2452 - 3D Silk-Based Bone Marrow Models Identify Autophagy As a Critical Mechanism in Red Blood Cell Production

Baldus, C. D.

318 - Drug Sensitivity and Treatment Response Are Modulated By the Cell of Origin, the Underlying Gene Fusion, and Patient Age in KMT2A-Rearranged BCP-ALL
631 - IDH2 Mutations from Clonal Hematopoiesis and Acquired IKZF1 Deletions Define a Novel B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma
961 - Chemotherapy or Stem Cell Transplantation in Adult High Risk Ph/BCR::ABL1-Negative ALL Patients with Early MRD Negativity: Results of the Randomized GMALL Trial 08/2013
1458 - C/EBP Family Member Gene Fusions and Cooperating Genomic Events Define Two Distinct Molecular Sub-Groups in Adult B Precursor ALL
1460 - Data-Informed, Refined Immunophenotypic Classification of Adult T-Lineage Acute Lymphoblastic Leukemia
2211 - Age-Stratified Game-Theory-Informed Machine Learning of Molecular Alterations Unveils Prognostic Divergence in 3062 Pediatric and Adult Acute Myeloid Leukemia Patients
2934 - The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients
2948 - HLA‑DR Expression on Leukemic Progenitor Cells before Allogeneic Hematopoietic Cell Transplantation Adds Prognostic Value in the Presence of MRD
2959 - Circulating Tumor DNA Kinetics at Day 14 after CAR T-Cell Therapy Identifies Patients with B-Cell Lymphoma at Risk for Early Treatment Failure
4173 - Preclinical Development of a Novel Humanized and Fc-Engineered Antibody-Drug Conjugate for the Therapy of T-Cell Acute Lymphoblastic Leukemia
4213 - Integrateall, a Machine Learning Pipeline for Multi-Level Data Extraction from RNA-Seq Profiles Unravels Novel Drivers and Systematic Subtype Classification in B-Cell Precursor ALL
4337 - Clonal Dynamics of Leukemic and Clonal Hematopoiesis Mutations Predict Relapse in Single Cell MRD Analysis of AML in First Complete Remission
1527.1 - Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1-Mutated AML – the SAL/AMLCG Vincent Trial

Balduzzi, A.

112 - “Real World” Outcome of Hematopoietic Stem Cell Transplantation after CAR19 T Cell Therapy in Children and Adults with B-ALL: A Gocart Coalition Study on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT
965 - Second Infusion of CAR T-Cells in Patients with Relapsed /Refractory B-Cell Acute Lymphoblastic Leukemia: Results from a Gocart Coalition Analysis on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT
2126 - Evidence-Based Choice of Conditioning Regimen for Hematopoietic Stem Cell Transplantation (HSCT) in Acute Leukemia: The Italian Cellular Therapy and Stem Cell Transplant Group (GITMO) Guidelines
2333 - Real-World Outcomes of CD19-Targeted CAR T-Cell Therapy in Adult and Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Insights from the GoCART Coalition on Behalf of the PDWP, ALWP, and CTIWP of the EBMT
3540 - Total Body Irradiation Versus Chemotherapy Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphoblastic Leukemia Patients Aged 2 to 4 Years: A Retrospective Study of the EBMT Pediatric Diseases Working Party
4864 - Comparative Results of Pediatric Patients with ALL Receiving Either of Two Different Types of Human Anti-T Lymphocyte Globulin Prior to Hematopoietic Stem Cell Transplantation: Findings from the International Prospective Forum Study

Balestra, T.

369 - Autologous CD33CART for Children and Adolescents/Young Adults with Relapsed/Refractory AML: Phase 1/2 Clinical Trial Correlative Biology Analyses Demonstrate Potent in Vitro, In Vivo, and Ex Vivo Anti-Leukemia Activity
3424 - Co-Targeting of the Thymic Stromal Lymphopoietin Receptor to Decrease Immunotherapeutic Resistance in CRLF2-Rearranged Ph-like and Down Syndrome ALL

Balev, M.

3781 - Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort

Balev, M.

256 - Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study

Balgansuren, G.

22 - Anti-HLA Antibody Specificities Are Differentially Associated with Immune Platelet Transfusion Refractoriness in Patients at Lower Calculated Panel Reactive Antibody (cPRA) Levels

Balitsky, A. K.

286 - COVID-19 Humoral Immunity Improves with Third and Subsequent Vaccine Doses in Patients with Plasma Cell Dyscrasias, Particularly in Those Receiving antiCD38 Therapy
3749 - Subsequent Primary Malignancies in Patients with Indolent B Cell Non-Hodgkin Lymphoma Receiving Frontline Bendamustine Rituximab Therapy
3753 - Longitudinal Changes in Cognition in Older Individuals Receiving Lymphoma-Directed Therapy: A Pilot Feasibility Study
3822 - Development of an Electronic Learning Module for CAR-T Education in Canadian Hematology Residents

Baljevic, M.

1985 - A Phase 1b Study of Step-up Dosing with ABBV-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma
1994 - Exposure-Response (ER) and Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Optimal Step-up Dose (SUD) Selection to Improve Cytokine Release Syndrome (CRS) Safety Profile of Abbv-383 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
1996 - Efficacy and Safety of Selinexor, Pomalidomide, and Dexamethasone (SPd) for Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
5143 - AL Amyloidosis: Understanding the Clinical Prodrome and Delays in Diagnosis
2000.1 - MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial

Balke-Want, H.

367 - Targeting Lymphoma Associated Myeloid-Monocytic Cells through CSF1R Blockade Enhances CAR-T Cell Response in Aggressive B Cell Lymphoma

Ball, B. J.

729 - TP53 Mutations Increased the Risk of CD19 Negative Relapse Following Blinatumomab in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)
1043 - Final Analysis of Phase 2a Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome (MDS), or Myelofibrosis (MF)
4264 - Phase 1 Trial of Navitoclax/Venetoclax/Decitabine Combination in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
4935 - Outcomes of Hypomethylating Agents/Venetoclax (HMA/VEN) Treatment for Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplant (alloHCT)
2134.1 - Trial in Progress: Cureaa - a Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia, Blood and Marrow Transplant Clinical Trials Network (BMT CTN) #2207

Ball, C. R.

1563 - ACSL4-Associated Lipid Metabolism Is a Distinct Therapeutic Vulnerability in KMT2A-Rearranged Acute Myeloid Leukemia

Ball, E. D.

1385 - Identifying the Impact of ADAR1 Inhibition on LSC Niche Remodeling in 3D Nanobioreactors
2767 - The Proteostasis Network Is a Therapeutic Target in Acute Myeloid Leukemia

Ball, N.

131 - Real-World Experience of Switching to Prophylactic Efanesoctocog Alfa in Patients with Moderate and Severe Hemophilia a: An Analysis of the Adelphi Hemophilia Wave III Disease Specific Programme
2314 - Unmet Needs in People with Hemophilia Receiving Prophylaxis Treatment: A Real-World Survey
5082 - Treatment Adherence, Satisfaction and Quality of Life of Adult Patients with Severe Haemophilia a: Results from a Real-World Survey of Physicians and Patients

Ball, S.

532 - A Prospective Evaluation of Impact of Disease, Treatment, Sex, and Race Disparities on Quality of Life and Financial Toxicity in Patients with Myelodysplastic Syndromes
664 - Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
1474 - Impact of Co-Mutations, Monocytic Differentiation, and Choice of Hypomethylating Agent Combined with Venetoclax on the Predictive Value of Molecular Prognostic Risk Signature in Newly Diagnosed AML Patients
1477 - Epidemiological Trends in Incidence, Death and Associated Risk Factors of Leukemia 1990-2021 and Projection to 2040
1520 - A Phase 1 Study of CPX-351 Plus Gilteritinib in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
1845 - Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 (SF3B1^del5q): Outcomes and Response to Treatment
3206 - Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome – a Multicenter Retrospective Analysis
3219 - Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database
4578 - Synchronous Dual Hematologic Neoplasms of Myeloid and Lymphoid Lineage Are of Common Clonal Origin
4569.2 - A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm

Ballantyne, C. M.

13 - Association of Clonal Hematopoiesis of Indeterminate Potential (CHIP) with Incidence of Venous Thromboembolism Varies By Age: The Atherosclerosis Risk in Communities Study
948 - IL-11 Signaling Drives Clonal Hematopoiesis-Associated Cardiac Dysfunction

Ballapuram, A.

978 - Toll-like Receptor 7/8 Pathway Is a Therapeutic Target in Primary CNS Lymphoma

Ballardini, F.

3114 - GMALL B ALL/NHL 2002 Protocol Yields High Response Rates and Durable Responses in High-Grade B Cell Lymphoma: A Retrospective, Single-Center Study

Ballas, B.

2091 - Comparative Analysis of Dexamethasone-Enhanced Pre-Medication in Motixafortide-Induced Hematopoietic Stem Cell Mobilization for Multiple Myeloma: A Retrospective Study

Balleari, E.

3800 - Myelodysplastic Neoplasms Patients’ and Caregivers’ Unmet Needs and Their Impact on Their Quality of Life and Symptoms

Ballerini, F.

339 - Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from "FOLL12" Phase III Trial of the Fondazione Italiana Linfomi
1577 - TP53, CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial
1580 - Longitudinal Monitoring of Circulating Tumor DNA to Predict Survival in Newly Diagnosed Peripheral T-Cell Lymphoma Patients
4362 - Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)

Ballesteros Andrés, M.

5050 - Integration of Geriatric Assessment and Genetic Profile Facilitates Personalized Treatment Selection and Follow-up in Old Patients with Newly Diagnosed Acute Myeloid Leukemia

Ballesteros, J.

3478 - Innovative Bone Marrow CAR-T Cell Manufacturing for AML: Enhancing Viability and Tumor Migration

Ballew, N.

3187 - Overall Survival with Momelotinib Vs Best Available Therapy in Patients with Ruxolitinib-Experienced Myelofibrosis: A Matching-Adjusted Indirect Comparison

Balli, N. R.

1105 - Single Cell Hemoglobin Quantification Reveals HbF and HbS Increases in Sickle Erythrocytes from Patients Treated with Hydroxyurea

Ballili, M.

518 - Outpatient Hematopoietic Stem Cell Transplant for Adult Sickle Cell Disease Patients Is Safe, Reduce Inpatient Bed Utilization and Improve Access to Care
2173 - Short and Long-Term Toxicities of Allogeneic Stem Cell Transplant for Adult Patients with Sickle Cell Disease

Balliu, M.

1795 - Homozygosity of the JAK2 46/1 or GGCC Haplotype Contributes to Phenotype and Outcome Diversity Among Patients with Polycythemia Vera

Ballotta, L.

75 - High IGHV Intraclonal Diversification Identifies CLL with Good Prognosis, Features of Anergy and Specific T-Cell Profiles

Ballweg, A.

608 - Comparable Outcomes of Point-of-Care and Commercial CD19 CAR-T Therapies: A Patient-Matched Analysis in Large B-Cell Lymphoma
3752 - Comparative Real-World Outcomes of Commercial CD19-Directed CAR T-Cell Therapies in Large B-Cell Lymphoma
4943 - Dietary Sucrose Exacerbates Antibiotic-Induced Microbiome Injury in Allo-HCT

Balmaceda, J.

5170e - Treatment Outcomes of Monoclonal Gammopathy of Renal Significance with Novel Agents

Baloch, M.

3100 - Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications

Balogh, A.

493 - Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial

Balogun, B.

173 - A Novel Direct Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease – In Vivo Efficacy of Ilx-002 in Humanized Mice

Balogun, M. F.

3748 - Treatment-Related Neuropathy Following Brentuximab-Vedotin in African Americans Treated for Lymphoma: A Retrospective Chart Review

Balp, M. M.

5012 - Incremental Effectiveness of Iptacopan Compared with C5 Inhibitors in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from a Modelling Analysis

Balsalobre, P.

405 - The Impact of Frailty on Outcomes and Quality of Life in Allogeneic Hematopoietic Cell Transplantation: Summary of Results from a Collaborative Prospective Study Conducted on Behalf of the Geth-TC
2108 - Impact of Ptcy on Early Cardiac Toxicity after HLA-Matched Allo-HCT in Patients with Acute Myeloid Leukemia. Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)
3531 - Current Prophylaxis and Treatment of Gvhd: Analysis of a Large Real-World Cohort. Spanish Group of Hematopoietic Transplantation and Cellular Therapy (GETH/TC)
3757 - Frailty's Impact on CAR T-Cell Therapy Outcomes in Patients with Lymphoprolipherative Disorders: Insights from a Spanish Multicenter Pilot Study Conducted on Behalf of the Geth-CT
4869 - Incidence, Clinical Risk Factors, and Biomarkers of SOS/VOD Following Allogeneic HSCT in Adults: A Real-Life Study By the Spanish Group of Hematopoietic Stem Cell Transplantation and Cell Therapy (GETH-TC)
5148 - Frailty and Outcomes in Multiple Myeloma Patients Eligible for Autologous Hematopoietic Cell Transplantation: A Prospective Study of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)

Balsat, M.

731 - Determinants of Isolated CNS Relapse in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia. from Graall-2005 to -2014 Trials
1434 - Switch of Asparaginase Formulation Based on Antibody Monitoring in Adults with Philadelphia-Negative Adult Lymphoblastic Leukemia. Results of the Graall-2014 Trial

Balser, C.

1859 - Impact of Ibrutinib on Quality of Life in Patients with Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia: Results from the Phase III CLL12 Trial

Baltes, V.

3840 - Cold Autoimmune Hemolytic Anemia Secondary to Mycoplasma Pneumoniae Infection in Adults: Results from a Large French Observational Study (MYCOLD study)

Baltz, A.

2402 - Impact of Social Vulnerability Index and Travel Distance on Access to Chimeric Antigen Receptor T-Cell Therapy
3074 - Cutaneous Involvement By Peripheral T-Cell Lymphoma: Incidence, Characteristics, Treatment Trends, and Outcomes in the United States (2000-2021)

Baluapuri, A.

540 - STAT5 Facilitates Terminal Erythroid Maturation in Concert with the Integrator Complex

Baluch, A.

2103 - Delayed Immune Reconstitution and Increased Infections in Allogeneic Transplant Recipients with B Cell Malignancies Treated Previously with CAR T-Cell Therapy
2130 - Letermovir Prophylaxis Reduces the Risk of Cytomegalovirus Infection in HLA-Matched and Mismatched Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide

Balusu, R.

2714 - FLT3-ITD Signaling Continuously Degrades p53 By the Ubiquitin-Proteosome Pathway Explaining Chemo-Resistance

Balwani, M.

1089 - Results from the Aurora Study: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Bitopertin in Erythropoietic Protoporphyria
1970 - Enhanced Detection of Pathogenic Germline Variants in Plasma Cell Disorders: Impact of a Targeted Genetic Counseling Referral Pathway
3631 - The EPP LIGHT Study: A Survey Describing the Burden of Erythropoietic Protoporphyria and X-Linked Protoporphyria

Balzarini, P.

453 - B Cell Receptor Silencing Reveals Origin and Impacts Treatment of High-Grade B Cell Lymphomas with MYC and BCL2 Rearrangements

Balzarotti, M.

1577 - TP53, CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial
1681 - Bendamustine in Combination with Gemcitabine and Vinorelbine As Salvage Regimen for Relapsed or Refractory Peripheral T-Cell Lymphomas: A Retrospective Single Center Experience

Bambace, N. M.

1502 - UM171 Cord Blood Transplantation for TP53 Mutated and EVI1 Rearranged Myelodysplasia/Acute Myeloid Leukemia
4916 - Long Term Follow up of UM171 Expanded Cord Blood Transplantation Patients Does Not Reveal Any Late Toxicity

Bamezai, S.

4114 - An Aberrantly Overexpressed Short Isoform of TET1 Lacking a DNA Binding Domain Drives Aberrant 5-Hydroxymethylation Marks, Oncogenic Pathways, and Growth in Acute Myeloid Leukemia

Bamopoulos, S. A.

1351 - Parallel Sequencing of Transposons and Transcriptomes in Single Cells for Genome-Wide Cancer Gene Discovery

Ban, B.

208 - CBX250 Is a Novel Cathepsin G Peptide-HLA-Targeting T Cell Engager That Exhibits High Tumor Antigen Selectivity and Potent Antileukemic Activity In Vivo

Ban, D.

2222 - Measuring the Mosaicism of Genome Integrity and Toxicity Events Associated with Gene and Cell Therapies at a Single-Cell Level

Banaag, L.

4102 - Mutations in Cohesin Subunits STAG2 and SMC3 Are Non-Synonymous in NPM1-Mutated Acute Myeloid Leukemia

Banach, E.

792 - Impact of Fee-for-Service Versus Managed Care Medicare Insurance on the Quality of End-of-Life Care Among Older Adults with Blood Cancers

Bañares, R.

2113 - Predictive Value of Liver Sitffness Measurement for Early Diagnosis of Veno-Occlusive Disease and Final Stem-Cell Outcomes

Banaszak, L.

Banchev, A. M.

718 - Safety and Efficacy of Mim8 Prophylaxis Administered Once Every Two Weeks for Patients with Hemophilia A with or without Inhibitors: Interim Analysis of the FRONTIER4 Open-Label Extension Study

Band, H.

2730 - CBL Loss or Mutations Reduces MHCII Expression through Downregulating ERG in Myeloid Malignancies
4574 - CBL Loss or Mutations Upregulates AXL to Promote Cytokine-Independent Growth in Myeloid Malignancies: AXL Upregulation Promotes Cytokine-Independent Growth in CBL-Mutant CMML

Banda, K.

4032 - Low Rate of Red Blood Cell Alloimmunization Among Transfused Children with Sickle Cell Anemia in Malawi without Pre-Transfusion Screening or Antigen Matching

Banda, O.

2202 - In Utero mRNA Lipid Nanoparticle Delivery in a Murine Model of Fanconi Anemia

Bandali, T.

1677 - Long-Term Outcomes with Mogamulizumab Alone or in Combination with Other Therapies for the Treatment of Cutaneous T-Cell Lymphoma

Bandian, A. M.

2829 - Differential in Vitro Sensitivity of BCR::ABL1 Kinase Domain Mutations to Tyrosine Kinase Inhibitors Depending on the p190 or p210 Background

Bandikatla, S.

1466 - Molecular Classification and Clinical Correlation Utilizing Next-Generation Sequencing in Adult B-Cell Acute Lymphoblastic Leukemia
2622 - Uncovering the Risks: Bleeding and Thrombotic Complications of JAK Inhibitors in Hematological Conditions: A Comprehensive Systematic Review and Meta-Analysis
3947 - Trends and Disparities in Idiopathic Thrombocytopenic Purpura-Related Mortality in the United States: A Retrospective Study over Two Decades

Bandini, L.

2916 - T/NK Cell-Associated Transcriptomic Profile Informs Response to FLT3 Inhibitors in Acute Myeloid Leukemia

Bando, H.

741 - Spatially Resolved Single-Cell Transcriptomics of T Cells in Follicular Lymphoma Reveals Distinct Immune Ecosystems

Bando, Y.

4683 - Development of a Novel and Rapid Diagnostic Technique for Cardiac Amyloidosis Using Raman Spectroscopy

Bandyo, R.

161 - Optimized Multi-Class VTE-BERT Large Language Model for Prediction of Cancer Associated Thrombosis Phenotype
3641 - Implementation of Automated Thrombosis and Bleeding Risk Assessment in Cancer Patients Undergoing Systemic Therapy
3727 - Clinical Outcomes and Patterns of Care Among Patients with Newly Diagnosed Hodgkin Lymphoma in a Safety-Net Health System
4013 - Circulating Tumor DNA Predicts Venous Thromboembolism in Minority Patients with Cancers

Bandyopadhyay, A.

4559 - Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)

Bandyopadyay, S.

1464 - Interferon-Activated Gene Signatures Associate with Chemotherapy Resistance and Sensitivity to JAK-Inhibition in Refractory ETP-ALL

Banefelt, J.

4430 - Risk of Hematologic Malignancy Following Infectious Mononucleosis Caused By Epstein-Barr Virus: A Danish and Swedish Observational Study over 40 Years

Banegas, D.

3638 - Serious Adverse Drug Reactions (sADRs) Involving Hematology and Resulting in Black Box Warnings or FDA Non-Approval: Results from the First Quarter Century of RADAR/Sonar

Banegas, M.

2407 - Cytomegalovirus Infections Following CAR T-Cell Therapy: A Systematic Review and Meta-Analysis

Banerjee, A.

3878 - Identifying Clinical and Socioeconomic Factors Associated with Neuropsychological Impairment in Pediatric Patients with Sickle Cell Disease

Banerjee, K.

1031 - Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial
4825 - Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety with 34-Month Median Follow-up

Banerjee, P.

4841 - Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation in Patients with High-Risk Myeloid Malignancies

Banerjee, R.

81 - 24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702
496 - ABBV-383 Plus Daratumumab-Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Dose-Escalation and Safety Expansion Study
897 - Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
931 - Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)
934 - Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
2392 - Real-World Talquetamab Utilization Patterns and Dose Schedules in the United States: An Analysis Using Claims Data
3337 - Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab
3661 - Associations of Long-Term Financial Hardship with Autologous Transplant and Overall Survival in Patients with Multiple Myeloma
3765 - Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium
3772 - Trends in Pre-CAR-T Attrition in Relapsed/Refractory Multiple Myeloma: Prevalence, Risk Factors, and Outcomes at a Tertiary Academic Medical Center
3792g - Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes of Patients with Multiple Myeloma Treated with Teclistamab within Vs. after the First Year of FDA Approval
3792h - Upfront Use of Anti-CD38 Monoclonal Antibodies Is Associated with Improvement in Renal Failure in Multiple Myeloma: A Flatiron Real World Analysis from 2010 to 2023
4721 - Health Related Quality of Life (HRQoL) in Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review (SLR) and Meta-Analysis
5170b - Real-World Step-up Dosing Practice for Patients Who Initiated Talquetamab in US Hospitals: An Analysis of the All-Payer US Hospital Administrative Premier Healthcare Database
2000.1 - MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial

Banerjee, R.

435 - Gut Microbiota-Driven Tonic Type I IFN Signaling Supports Steady-State Hematopoiesis

Banerjee, S.

3481 - KITE-753: An Autologous Rapid Manufactured Anti-CD19/CD20 CAR-T Product for the Treatment of B-Cell Malignancies

Banez, M.

468 - Randomized Phase 2 Trial of the Anti-PD-L1 Monoclonal Antibody Durvalumab Plus Lenalidomide Versus Single-Agent Durvalumab in Patients with Refractory/Advanced Cutaneous T Cell Lymphoma

Bang, S.

3370 - First Results from the Dose Escalation Part of the Phase 1 Study of KTX1001, an Oral, First-in-Class, Potent Inhibitor of MMSET/NSD2 for Relapsed/Refractory Multiple Myeloma (RRMM)

Bang, S. M.

1799 - Ropeginterferon in Low-Risk Patients with Polycythemia Vera
3170 - Predicting Molecular Response through Half Reduction of Neutrophil-to-Lymphocyte Ratio (NLR) in Polycythemia Vera Treatment with Ropeginterferon

Bangirana, P.

543 - Neurocognitive Improvement with Hydroxyurea Therapy in Children with Sickle Cell Anemia in Uganda: Analysis from the Completed 30-Month BRAIN Safe II Trial

Bangolo, A. I.

2408 - Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis

Baniel, C.

2116 - A Standard Operating Protocol for Pre-Transplant Low Dose Splenic Radiotherapy for Patients with Myelofibrosis

Bankar, A.

449 - FRAIL-HRU-AML: Impact of Frailty Assessment on Health Resource Utilization in Acute Myeloid Leukemia Patients: A Population-Based Study from Ontario, Canada
1483 - Intensive Chemotherapy Vs. Azacitidine + Venetoclax for AML with Secondary Mutations
4273 - FLAG-IDA Plus Venetoclax in High-Risk Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia: The Princess Margaret Cancer Center Experience
5193 - What Is the Prognostic Relevance of Responses Less Than a CR(Sub-CR) to Initial AML Treatment?

Bankas, E.

3 - Double-Blind, Placebo-Controlled Randomized Controlled Trial of Hydroxyurea for HbSC: Results of the Prospective Identification of Variables As Outcomes for Treatment (PIVOT) Trial

Banker, A.

1570 - Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in the Patients with CCAAT Enhancer-Binding Protein a Gene (CEBPA) Mutated Acute Myeloid Leukemia

Banker, L.

262 - Stabilization of HIF-1α By the Prolyl Hydroxylase Inhibitor Roxadustat Reduces Gastrointestinal Graft-Versus-Host Disease

Bankole, L.

3672 - Addressing Patient Representation in Hematopoietic Cell Transplant Clinical Trials: Insights Gained through the Access Trial

Banks, C. E.

4386 - Macrophages in Waldenstrom Macroglobulinemia: Implications for the Tumor Microenvironment

Bannasch, P.

3918 - L-Asparaginase Treatment Induces Reversible Immunoregulatory and Immunosuppressive Effects in Non-Malignant B Cells in a Model of T-Cell Dependent B Cell Activation

Bannatyne Undabeitia, J.

1642 - Zanubrutinib Is Effective in the Treatment of Patients with Waldenström's Macroglobulinemia and Bing-Neel Syndrome: A Retrospective Multicenter Study

Banner, L.

3063 - The Risk of Developing Non-Melanoma Skin Cancers in Patients with Cutaneous T-Cell Lymphoma

Bannoura, S.

2768 - Combined Use of Ziftomenib and Selinexor Is Effective in NPM1 Mutant Acute Myeloid Leukemia

Banos, A.

349 - Early Versus Late Onset of ESA in Lower Risk Anemic MDS Patients: Results of the GFM Randomized Phase III EPO-Pretar Trial
979 - Prospective, Multicentric, Phase II Randomized Controlled Trial Comparing the Efficacy and Toxicity of Methotrexate to Cyclophosphamide in Large Granular Lymphocyte Leukemia: A French National Study (NCT01976182)
1839 - Enasidenib (ENA) Monotherapy in Patients with IDH2 mutated Myelodysplastic Syndrome (MDS), the Ideal Phase 2 Study By the GFM and Emsco Groups
4275 - Real-World Multicenter Comparison of Venetoclax and Azacitidine Versus Intermediate or High Dose Cytarabine-Based Salvage for Patients with AML in First Relapse after Front Line Intensive Chemotherapy. a Dataml-IPC-Auraml Consortium Study

Bansal, D.

1073 - Establishing a Patient-Derived Immortalized Erythroid Progenitor Cell Model to Investigate Disease Mechanisms and Lentiviral Gene Therapy Vector in Congenital Dyserythropoietic Anemia Type II

Bansal, H.

767 - Single-Cell Multi-Omic Profiling of Patients with BCMA-Targeted Therapy Identifies Molecular and Cellular Factors Associated with Responsiveness and Treatment Effects
1584 - Characterization of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Using Single Cell Transcriptomic Analysis
3024 - Prognostic Significance of TP53 Mutations in Lymphoplasmacytic Lymphoma
3272 - Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma
4687 - Clearance of Circulating Multiple Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
4737 - Personalized Neoantigen Peptide Vaccine with or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma (SMM) to Prevent Progression to Multiple Myeloma (MM)

Bansal, K.

1250 - Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase Therapy
3796 - Disseminated Intravascular Coagulation and Early Thrombo-Hemorrhagic Complications in Acute Promyelocytic Leukemia

Bansal, R.

936 - Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma
2274 - Real World Outcomes with Evolving Management of Cytokine Release Syndrome in CAR-T Therapy
2372 - Correlation between Pre-Apheresis Biomarkers and Development of Severe Cytopenias and Therapy-Related Myeloid Neoplasms in Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy
3785 - Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
4695 - Frailty-Based Outcomes with Bispecific Antibodies in Older Patients with Multiple Myeloma
5166 - Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee

Bansal, R.

2147 - Factors Associated with Acute and Chronic Graft-Versus-Host Disease after Matched Unrelated Donor Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based GvHD Prophylaxis

Bansal, S.

1542 - Isomarker: An Explainable Machine Learning Framework for Identification of Cell State Markers in Acute Myeloid Leukemia
2724 - The Exportin, CSE1L, Regulates Ribosome Biogenesis and Is a Selective Dependency in Childhood and Young Adult Acute Myeloid Leukemia
2924 - ATLAS-AML: An Automated Bioinformatics Pipeline for Drug Target Characterization in Acute Myeloid Leukemia

Bansal, V.

1029 - CAR-T Cell Therapy in Advanced Myeloma with Extramedullary Disease – an In Vivo Imaging and Molecular Monitoring Study (CARAMEL): First Results of Cu-64 Radiolabelled Nanoparticle PET-CT and PET-MRI

Bantan, A.

1889 - Mapping Disease Transitions from Premalignant, Asymptomatic to Advanced Myeloma through Integrative Epigenomic and Transcriptional Analyses

Bantilan, K. S.

4485 - Sequential R-CHOP/(R)-ICE and Dose-Adjusted EPOCH-R Are Both Appropriate Frontline Treatments for Newly Diagnosed Primary Mediastinal B-Cell Lymphoma: Results of a Retrospective Analysis

Bao, A.

509 - TBI-Based Myeloablative Conditioning Two-Step Haploidentical Allogeneic Hematopoietic Stem Cell Transplant Yields Excellent Outcomes in Fit Patients with High-Risk Hematologic Malignancies, Results of a Prospective Trial
2176 - Cardiac Toxicity in Recipients of Hematopoietic Stem Cell Transplant with Post Transplant Cyclophosphamide
4891 - A Novel Chemo-Based Reduced Intensity Haploidentical Two-Step Allogeneic Hematopoietic Stem Cell Transplantation, Results of a Prospective Clinical Trial

Bao, J.

4399 - Orelabrutinib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) Who Are Intolerant to Prior Bruton Tyrosine Kinase Inhibitors (BTKi): Updated Results from a Phase 2 Study

Bao, K.

886 - BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Bao, L.

4746 - SG301, a Novel Anti-CD38 Monoclonal Antibody, in Patients with Relapsed/Refractory Multiple Myeloma: A First-in-Human, Multicentre, Phase 1 Trial

Bao, L.

498 - A Phase I Study of a Novel BCMA×CD3 Bispecific Antibody Emb-06 in Relapsed or Refractory Multiple Myeloma
5159 - Comparison of Ixazomib, Lenalidomide Plus Dexamethasone (IRd) and Bortezomib, Lenalidomide Plus Dexamethasone (VRd) in Newly Diagnosed Multiple Myeloma in China

Bao, M.

3141 - Immune-Related Signatures Predict Prognosis in Chronic Myeloid Leukemia (CML) Patients Receiving the 3^rd-Generation Tyrosine-Kinase Inhibitors (3G-TKIs)
4528 - Olverembatinib-Based Therapy in Patients with Philadelphia Chromosome-Positive Acute Leukemia: A Multi-Centre Retrospective Study from China

Bao, W.

619 - IFN-I Promotes T Cell-Independent Immunity and RBC Autoantibodies Via Modulation of B-1 Cell Subsets in Murine SCD
1108 - Quinine-Hemin Compound As an Anti-Inflammatory Therapy in Sickle Cell Disease
3834 - Effect of Obexelimab Surrogate Monoclonal Antibody on Inhibition of Autoimmune Hemolytic Anemia (AIHA) Induction in Mice

Bao, Y. C.

2128 - Comparison of Engraftment Syndrome after Haploidentical Hematopoietic Stem Cell Transplantation between Patients with ALL and AML

Baosic, A.

2729 - Chromatin-Based Cellular Dependency of HOXA9/MEIS1-Driven Acute Myeloid Leukemia

Bapodra, N.

2336 - Real-World Outcomes of Frontline Polatuzumab and Impact of Frailty in Older Adults with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Baptista, A.

3702 - Usage of Disease-Specific Patient Reported Outcome Measures (PROMs) for Assessing Quality of Life (QoL) in Industry Sponsored Hemophilia Interventional Trials

Baptista, M.

2771 - Preclinical Evaluation of Stx-0712, a CCR2 Cytotoxicity Targeting Chimera (CCR2-CyTAC) for the Treatment of Chronic Myelomonocytic Leukemia

Baptista, R. L.

983 - Refining Prognostication in Peripheral T Cell Lymphoma (PTCL): A Risk-Adapted Prognostic Model for Patients with Limited-Stage PTCL
1687 - Clinical Features, Therapy Patterns and Survival Outcomes of Limited-Stage Peripheral T-Cell Lymphomas: A Cross-Continental Study
1692 - The Number of Extranodal Sites Matters! a Proposal for a Feasible Prognostic Model in Nodal PTCL. a Collaborative Study grupo De Estudio Latino-Americano De Linfoproliferativos (GELL) & T-Cell Brazil Project (TCBP)
3064 - Central Nervous System Involvement in Aggressive ATLL: Can We Predict the Risk in a Devastating Complication? Epidemiology and Clinical Features from Latin America. a Collaborative Study from Grupo De Estudio Latino-Americano De Linfoproliferativo (GELL) & T-Cell Brazil Project (TCBP)
4413 - Importance of Access Inequality and Biological Prognostic Factors in Mantle Cell Lymphoma Outcomes in Brazil: A Real-World Evidence Study from a Third World Country

Bar, N.

1032 - Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1–3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial
2002 - Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial
3390 - Updated Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2–4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Bar-Natan, M.

970 - A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) – Topline Results
1250 - Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase Therapy
1576 - Opening Pandora’s Box: Ultra-Deep Duplex Sequencing in Long Survivors with Acute Myeloid Leukemia
2798 - Relative Influence of Socioeconomic and Biological Determinants of Outcomes in Adult Acute Lymphoblastic Leukemia

Barajas, J. M.

325 - Genetic and Functional Characterization of NUP98-Rearranged Leukemia
1352 - Oncogenic Potential and Sensitivity to Menin Inhibitors of a Novel Fusion KAT6B::NUTM2B in Congenital Myeloid Sarcoma with Bone Marrow Involvement

Barajas, S.

4109 - Protein Tyrosine Phosphatase PRL2 Promotes MLL-Rearranged Acute Myeloid Leukemia Development through Inhibiting the p53 Pathway

Barakat, L.

1066 - Community Health Worker and Mobile Health Programs to Help Young Adults with Sickle Cell Disease Transition to Using Adult Healthcare Services -- the Comets Study; Results from Patient-Reported Outcomes at 6 Months

Barakat, M.

284 - Balancing Treatment Intervals and Quality of Life in Multiple Myeloma Patients: Patient Perspectives and Recommendations

Barakat, P.

5170g - Multiple Myeloma (MM) Clinical Characteristics, Prognostic Factors and Survival in Adolescents and Young Adults (AYA)

Barakat, S.

5057 - Costs of Healthcare Resource Utilization in the Management of Patients with Higher-Risk Myelodysplastic Syndrome in Canada

Baran, A. M.

4741 - Hyperbaric Oxygen (HBO) Effects on Blood Count Recovery and Post Transplant Outcomes Following High-Dose Therapy and Autologous HSPC Transplantation for Multiple Myeloma: Final Analysis of the Multicenter Phase II Randomized Clinical Trial

Baran, N.

2753 - Elucidating Transcriptional Heterogeneity in Venetoclax Resistant AMLs
2759 - ERK1/2 Inhibition Mediates Bax Dependent Proteolysis of OPA1 and Induces Mitochondrial Cristae Remodeling to Overcome Resistance to Venetoclax

Baran-Marszak, F.

3241 - Prognosis of the IGLV3-21^R110 Mutation in a Real-Life Chronic Lymphocytic Leukemia Cohort
4796 - Dissection of Single-Cell Landscapes for the Development of Chimeric Antigen Receptor T Cells in Hodgkin Lymphoma

Baranowsky, A.

4940 - Reconstructing Skeletal Homeostasis through Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis

Baranwal, A.

2372 - Correlation between Pre-Apheresis Biomarkers and Development of Severe Cytopenias and Therapy-Related Myeloid Neoplasms in Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy
3213 - Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms
4918 - Risk of Relapse Post Reduced Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with High-Risk Myeloid Neoplasms Based on Ptcy Vs TAC/MTX Gvhd Prophylaxis

Barat, V.

3086 - CD20-Negative Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphomas and Mature B-Cell Leukemia in Children, Adolescent and Young Adults: A Retrospective Review

Barata, A.

2330 - Pre-Transplant Patient-Reported Outcomes Are Associated with Health Care Utilization and Transplant-Related Complications at One-Year Post-Transplant
4917 - Developing Evidence-Based Guidelines for Optimal Patient Communication Prior and Post Allogeneic Stem Cell Transplantation

Baratam, P.

1840 - PF-08046040 (SEA-CD70), a Nonfucosylated CD70-Directed Antibody, in Combination with Azacitidine for Patients with Myelodysplastic Syndromes (MDS): A Phase 1 Dose-Finding and Dose Expansion Study

Baratam, P.

662 - Results from a Phase 1 Open-Label Dose Escalation and Expansion Trial of Oral Azacitidine + Cedazuridine (ASTX030) in Patients with Myelodysplastic Syndromes (MDS) and MDS/Myeloproliferative Neoplasms (MPN)
1841 - Ivosidenib in Patients with Mutant Isocitrate Dehydrogenase 1 (mIDH1) Relapsed/Refractory Myelodysplastic Syndromes: Update of the Phase 1 Substudy per the International Working Group 2023 Response Criteria
3226 - Improved Hematologic Recovery with Ivosidenib in Patients with mIDH1 Relapsed or Refractory MDS: Results from a Phase 1 Substudy

Barau, C.

1105 - Single Cell Hemoglobin Quantification Reveals HbF and HbS Increases in Sickle Erythrocytes from Patients Treated with Hydroxyurea
2500 - Voxelotor Impact after 6 Months on Blood Rheology in Patients with Sickle Cell Disease
2506 - Improvement in Kidney Function after 6 Months of Voxelotor in Sickle Cell Disease Patients

barazani-Brutman, T.

430 - A Novel Murine Model Rebalancing Coagulation Enables Gene Therapy Studies for Severe Protein C Deficiency, a Lethal Pro-Thrombotic Disorder

Barba, P.

67 - Rapcabtagene Autoleucel (YTB323) in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Phase II Trial Clinical Update
112 - “Real World” Outcome of Hematopoietic Stem Cell Transplantation after CAR19 T Cell Therapy in Children and Adults with B-ALL: A Gocart Coalition Study on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT
471 - Site-Specific Analysis of Extranodal Involvement Reveals Distinct Efficacy Outcomes with CAR T-Cell Therapy in Large B-Cell Lymphoma Patients
962 - Prognostic Impact of the Genetic Risk at Baseline Associated to the MRD Clearance in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. Preliminary Results of Pethema LAL19 Trial
1437 - Similar Outcome of Adolescents and Young Adults (AYA) and Older Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) without Philadelphia Chromosome (Ph-) Included in the Pethema LAL-2019 Trial
1714 - Inflammation-Based Scores Predict Survival after CD3xCD20 Bispecific T Cell Engagers in R/R LBCL
2105 - Treosulfan/Fludarabine Versus Thiotepa/Busulfan/Fludarabine for Allogeneic Hematopoietic Cell Transplantation in Patients with Lymphomas in the Ptcy Era: A Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)
2333 - Real-World Outcomes of CD19-Targeted CAR T-Cell Therapy in Adult and Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Insights from the GoCART Coalition on Behalf of the PDWP, ALWP, and CTIWP of the EBMT
3009 - Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma
3414 - Enhancing CAR-T Cell Therapy for Non-Hodgkin Lymphoma through Gut Microbiota and Butyrate
3545 - Long-Term Outcomes and Late Complications of Allogeneic Stem Cell Transplant with CD34+ Positive Selection in Adults with Acute Leukaemia and Myelodysplastic Syndrome: A Single-Centre Study
3656 - Real-World Practice Patterns of Patient Management in the Peri-CAR T-Cell Therapy Setting for Patients with Mantle Cell Lymphoma: An International Survey on Behalf of the EBMT Lymphoma Working Party
4186 - Clinical Outcomes of Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Autologous Chimeric Antigen Receptor T-Cell Therapy: A Meta-Analysis of 1,154 Patients Included in Clinical Trials
2883.2 - Resolve AML 001: An Adaptive Open-Label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of Cctx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients with r/r AML

Barbaric, D.

309 - A Reduced Daunorubicin Dose during Induction Is Equally Effective As Standard Dose in Children with Acute Lymphoblastic Leukemia (ALL) and Favorable Prognostic Features: Long-Term Results of the Phase 3 Trial AIEOP-BFM ALL 2009
730 - Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy

Barbarito, G.

3525 - T-allo10 Immunotherapy Results in Enhanced Early Immune Reconstitution and Reduced GvHD with Excellent Clinical Outcomes Post Αβ-Depleted HSCT in Pediatric and Young Adult Hematologic Malignancy Patients

Barbati, M.

1592 - Circulating Cell-Free DNA in Classical Hodgkin Lymphoma in Children, Adolescents and Young Adults. Results from the Holy Study, a French Ancillary Study of Euronet PHL-C2 Protocol

Barbello, J.

3409 - Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Barberi, W.

302 - Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race Study

Barbero, L.

3214 - The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms

Barbet, C.

139 - Obinutuzumab in Rituximab Refractory or Intolerant Immune-Mediated Thrombotic Thrombocytopenic Purpura

Barbier, V.

166 - Endotoxemia As Possible Cause of Inflammatory Bowel Diseases-Associated Anemia
1286 - Endothelial Protein C Receptor CD201 Enables Identification of Transplantable Mouse Hematopoietic Stem Cells in Inflammatory Conditions Unlike SCA1

Barbieri, D. A.

4051 - Vitamin A Directly Enhances TET2 Activity and Suppresses Clonal Hematopoiesis

Barbieri, E.

1639 - Survival after First Relapse in Marginal Zone Lymphomas: Prospective Data from the International Observational NF10 Study By the Fondazione Italiana Linfomi
4699 - Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Barbieri, T.

2723 - AML Cells Have Increased Mitochondrial RNA Degradation and Inhibiting This Degradation Promotes Cell Differentiation, Decreases Viability, and Increases Sensitivity to Immune-Mediated Killing

Barbosa, I.

27 - Stable Contribution of Lineage-Restricted Stem Cells to Steady-State Aged Human Hematopoiesis
3198 - Large-Scale Transcriptome Analysis Supports Genomic Taxonomy and Predicts Response to Hypomethylating Agents in Myelodysplastic Neoplasms

Barboy, O.

4788 - Single Cell Analysis of Pre-Treatment Peripheral Immune Composition Can Predict CAR-T Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Barbui, A. M.

3114 - GMALL B ALL/NHL 2002 Protocol Yields High Response Rates and Durable Responses in High-Grade B Cell Lymphoma: A Retrospective, Single-Center Study
3131 - Outcomes of CAR T-Cells Therapy in High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas: A Weighted Comparison Analysis from CAR-T SIE Study
4387 - Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

Barbui, T.

245 - Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition
1785 - Revised International Working Group Risk Model for Survival in Polycythemia Vera
3169 - Monocytosis Is an Independent Risk Factor for Survival in Essential Thrombocythemia - a Revised Triple-a Prognostic Score (AAA+A) Based on Age and Absolute Monocyte, Neutrophil, and Lymphocyte Counts
3185 - Thrombosis Risk Assessment in Polycythemia Vera (TRAP): A 4,636-Patient-Year Analysis of Arterial and Venous Thrombosis in Low-Risk Patients
4552 - Cancers in Polycythemia Vera and Essential Thrombocythemia: A before and after Diagnosis Survey and Analysis of Risk Factors

Barbullushi, K.

1696 - Post-Transplant Lymphoproliferative Disorders (PTLD) in a Referral Center
3547 - Early Tapering of Immunosuppression in MRD Positive Myelofibrosis Patients Induces Molecular Response and Excellent Outcome after Hematopoietic Stem Cell Transplantation

Barcella, L.

3859 - Pregnancy and Childbirth in Women with Thalassemia: Past and Present
4023 - Fibrinogen and D-Dimer Predict Venous Thromboembolism (VTE) in a Prospective Observational Cohort of Metastatic Breast Cancer Patients

Barcellini, W.

302 - Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race Study
1086 - Toward the Creation of Diagnostic Algorithms for Congenital Hemolytic Anemia Using Advanced Parameters from Modern Hematology Analyzers
2321 - The Association of Anemia and Patient Reported Outcomes in the New Era of PNH Treatment
2457 - Iptacopan Monotherapy in Patients with Cold Agglutinin Disease: Phase II Study Results
2464 - Reaction - Real Life Use of Ravulizumab in Italian Patients with Paroxysmal Nocturnal Hemoglobinuria a Multicenter Observational Retrospective and Prospective Cohort Study, Final Results
2465 - Not so Rare, Not so Mild Disease: Defects of Flippase Activity Due to ATP11C Mutations. Description of Three New Cases
2692 - Danicopan As Add-on Therapy to Ravulizumab or Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Patient-Reported Outcomes from the Phase 3 ALPHA Trial
3836 - Part a Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Patients with Warm Autoimmune Hemolytic Anemia (wAIHA): Multicenter, Open-Label, Phase 2b Study
3844 - Mixed Type Autoimmune Hemolytic Anemia: A Single Center Observational Study
4076 - Aplastic Anemia in the Elderly: Treatment Patterns and Outcomes from an International Observational Study

Barcenas-Lopez, D. A.

370 - Gilteritinib Augments Preclinical FLT3 and CD19 CAR T Cell Immunotherapy in High-Risk Pediatric Leukemias
3424 - Co-Targeting of the Thymic Stromal Lymphopoietin Receptor to Decrease Immunotherapeutic Resistance in CRLF2-Rearranged Ph-like and Down Syndrome ALL

Bard, A.

5058 - Impact of Ultra Rapid Molecular Profiling on Treatment Delays and Healthcare Utilization of Patients Hospitalized for Acute Leukemia

Bardahl, J.

126 - NT-I7, a Long-Acting Interleukin-7 Molecule, Promotes T Cell Reconstitution Following Radiation Injury through Thymic-Dependent and Independent Pathways

Bardakhchyan, S.

2870 - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results

Bardenheuer, K.

2388 - Evolution of Treatment Patterns and Survival Outcomes in European Patients with Multiple Myeloma from 2012-2023 through the Honeur Federated Data Network

Bardet, V.

226 - Flow MRD Monitoring Combining Laip/Dfn and CD34+CD38- LSCs Is a Strong Predictor of Outcome in Adult AML Independently of the ELN-2022 Risk: First Results from the Multicentric Acute Leukemia French Intergroup MRD Flow Network

Bardey-Kanaan, M.

2435 - The Impact of Ponatinib on Pregnancy Outcomes
3816 - Ponatinib Safety Profile: An Analysis of 10 Years of Real-World Experience

Bardy, P.

3213 - Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms
4928 - Clonal Architecture of Donor-Derived Leukemia/Clonal Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplant

Bareau, B.

774 - The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma

Barel, O.

2065 - T-Lymphoblastic Lymphoma in a Patient with Pearson Syndrome Following Mitochondrial Augmentation

Barella, S.

3859 - Pregnancy and Childbirth in Women with Thalassemia: Past and Present

Barello, F.

3268 - A Novel Ribonuclease Targeting Small Molecule RNA-Degrader (MYC-RiboTAC) Overcomes MYC Dependency in Multiple Myeloma

Baresi, G.

2142 - Improvement of Survival By Use of New Tecniques of Manipulation after Haploidentical Hematopoietic Stem Cell Transplantation: Report of 230 Transplants in Paediatric Patients with Primary Immunodeficiencies and Oncological Diseases

Barette, L.

4316 - Prognostic Significance of Monocytic-like Phenotype in AML Patients Treated with Venetoclax and Azacytidine

Barg, A.

1181 - Pediatric Extreme Thrombocytosis, Etiology, Management and Outcome

Bargay, J.

365 - Clinical Value of Peripheral Residual Disease (PRD) and Measurable Residual Disease (MRD) in Newly Diagnosed Elderly Patients in the GEM2017FIT Trial
489 - Reevaluating the IMWG Multiple Myeloma Complete Response Criterion in the Era of Mass Spectrometry: A Critical Analysis
678 - GEM2017Fit Phase 3 Trial in Fit Elderly Patients (Aged 65-80) with Newly Diagnosed Myeloma: Impact of Daratumumab at Induction and/or Consolidation
1838 - Impact of Transfusion Dependency on Patients Diagnosed with Myelodysplastic Syndrome According to IPSS-M Risk Group
1957 - Unraveling Long-Term Survival of Multiple Myeloma Patients, the GEM2000 Experience
3374 - Survival Improvement of Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma in Two Consecutive Randomized Phase III Trials: Long-Term Follow up of GEM05 and GEM12 Trials

Barge, L.

4416 - Practices and Outcomes during a Watch and Wait Approach for Follicular Lymphoma: A Study from the Australasian Lymphoma Alliance

Bariana, M.

824 - Immunotherapy of Acute Myeloid Leukemia Enabled By Targeting of Pan-Cancer Molecular Patterns with a Novel Trispecific T Cell Engager

Barican, A. G.

590 - Bone Marrow Spatial Signatures Predict Survival Outcomes and Toxicities after CAR-T Therapy in Patients with Relapsed/Refractory Multiple Myeloma

Barila, G.

4699 - Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials
5153 - Pomalidomide, Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Lenalidomide and Anti-CD38 Monoclonal Antibodies: A Multicentric Italian Retrospective Study

Barilà, G.

4132 - Activating STAT3 Mutations Drive CD38 Expression in T-Large Granular Lymphocytic Leukemia

Barisa, M.

4793 - Preclinical Efficacy of CD276 (B7-H3) CAR T in Acute Myeloid Leukemia

Barizza, C.

1565 - Resistance to FLT3 Inhibitors in FLT3-Mutated AML Is Associated with CD45RA⁺CD200^-leukemic Cells and Can be Overcome By Combination with SMAC Mimetics

Barkauskas, D.

1581 - NPM::ALK Transcript Levels and Anti-ALK Autoantibody Titers As Biomarkers for Outcome in Pediatric ALK+ Anaplastic Large Cell Lymphoma Treated with Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy: COG ANHL12P1
2838 - Immunoglobulin Sequencing Biologically Distinguishes B-Lymphoblastic Lymphoma from Acute Lymphoblastic Leukemia and Reveals a Spectrum of Disease Dissemination across Clinical Stages

Barker, D.

553 - A Randomized, Placebo-Controlled, Multicenter Proof-of-Concept (POC) Study to Assess the Safety and Efficacy of the Novel Allosteric AKT Inhibitor, VAD044, in Adults with Hereditary Hemorrhagic Telangiectasia (HHT)

Barker, J. N.

2351 - Non-White and Hispanic Patients Have Significantly Longer Time from Intent to CAR T Infusion (“Brain-to-Vein” Time) in Multiply Relapsed Diffuse Large B Cell Lymphoma

Barker, S.

2363 - Prophylactic Corticosteroids Allow Safe Outpatient Administration of Axicabtagene Ciloleucel with Comparable Toxicities to Other CAR-T Therapies in Large Cell Lymphoma

Barkey, S.

3397 - TNFR2, GITR and DR3 Agonists Exert Distinct Response Durations in Treg-Mediated Acute Graft-Versus-Host Disease Protection

Barlera, S.

577 - Final Analysis of the Safety and Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma
1873 - Reduction of Tumor Lysis Syndrome Risk after Debulking with Obinutuzumab in Patients Treated with Venetoclax–Obinutuzumab in the Randomized Phase 3 CRISTALLO Trial
3237 - CRISTALLO: Results from a Phase III Trial of Venetoclax–Obinutuzumab Versus Fludarabine, Cyclophosphamide and Rituximab or Bendamustine–Rituximab in Patients with Untreated Chronic Lymphocytic Leukemia without Del(17p) or TP53 Mutations

Barlev, A.

3083 - Title: Development of a Pathologic Prognostic Index (PPI) for Newly Diagnosed Large B Cell Lymphoma Patients Treated with R-CHOP

Bärmann, B. N.

2003 - Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma

Barmettler, S.

3353 - Hypogammaglobulinemia and Daratumumab in Multiple Myeloma: Risk Factors, Infections, Immunoglobulin Replacement, and Mortality

Barna, G.

2805 - Diagnosing and Staging Central Nervous System Involvement in Pediatric ALL: A Global Survey on Its Heterogeneity

Barnard, E.

190 - Delayed Trp53 Activation Protects Dnmt3a-Mutant Haematopoietic Stem Cells from Inflammatory Attrition

Barnea, R.

1246 - Imaging Predictors of Intracerebral Hemorrhage in Patients with Brain Tumors Treated with Anticoagulation

Barnea Slonim, L.

1664 - Extended Follow up and Immune Alterations in Patients with Classic Hodgkin Lymphoma (cHL) Treated with Frontline Single Agent Pembrolizumab Followed By AVD Chemotherapy

Barner, J.

5201 - Impact of an Educational Intervention on Emergency Department Residents' Knowledge and Perceptions of Sickle Cell Disease: A Pilot Study

Barnes, B. J.

808 - Serine Threonine Protein Kinase 25 (STK25) Is a New Mediator of Myelopoiesis and Myeloid Cell Effector Function(s) during Injury and Inflammation
1076 - Dexamethasone Targets E2F4 to Induce Erythroid Progenitor Renewal

Barnes, C.

2585 - Unmet Needs of Patients with Hemophilia a/B with or without Inhibitors: Real-World End-of-Study Results from the explorer6 Non-Interventional Study

Barnes, G. D.

158 - Improving Guideline Concordant Primary Prevention Aspirin Use through a Multiclinic Antithrombotic Stewardship Intervention
699 - Treatment Versus Prophylactic Apixaban or Rivaroxaban for Extended Venous Thromboembolic Disease Management
- Improving Systems-Level Management of Anticoagulants Within and Across Care Settings

Barnes, J. A.

459 - A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma
465 - Development of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium
1370 - Integrative Analysis of 3D Chromatin Organization Revealed Regulation Mechanisms in Angioimmunoblastic T-Cell Lymphoma
1867 - Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)

Barnes, J. A.

866 - Efficacy and Safety of Odronextamab Monotherapy in Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR T-Cell Therapy: Primary Analysis from the ELM-1 Study

Barnes, M. S.

283 - National Healthtree Survey on Pain and Opioid Use Patterns and Perceptions Among Patients with Multiple Myeloma
2281 - Patient Preferences on Clinical Decision-Making in Myeloma: A 747-Patient Survey
5143 - AL Amyloidosis: Understanding the Clinical Prodrome and Delays in Diagnosis
5144 - First Ever National Survey on Patient-Reported Efficacy and Safety of Cannabis in Patients with Multiple Myeloma

Barnes, M.

3675 - Infusion Immediate Care: Improving Hematology/Oncology Practice Quality through Expanded and Timely Access to Infusion Care

Barnes, Y.

4757.2 - Trial in Progress: Phase 2 Study of Subcutaneous Isatuximab, Administered By an on-Body Delivery System, in Combination with Weekly Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (SubQSA)

Barnett, K. R.

203 - ETS1 Recruits the Canonical Baf Complex to Reactivate the Hematopoietic Stem Cell MYB Enhancer in the T-Cell Leukemia Context
830 - EBF1 Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin
4131 - Crispri Essentiality Screen Reveals the Essential Enhancers and Oncogenes Comprising the “Regulome” of the Notch-Collaborating Transcription Factor ETS1 in Human T-ALL

Barnhizer, T.

468 - Randomized Phase 2 Trial of the Anti-PD-L1 Monoclonal Antibody Durvalumab Plus Lenalidomide Versus Single-Agent Durvalumab in Patients with Refractory/Advanced Cutaneous T Cell Lymphoma

Barnidge, D.

3279 - Early Serum Protein Clonal Dynamics Preceding Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma Years before Diagnosis

Baro, B.

2456 - Investigating a Novel Erythrocyte Kinase and Its Impact on Plasmodium Falciparum Infection

Baron, F.

404 - The Prognostic Value for Survival of Self-Reported Fatigue in Patients with Newly Diagnosed Myelodysplastic Syndromes: An International Prospective Observational Study By the Gimema

Baron, F.

851 - Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation in First Remission: On Behalf of the EBMT Acute Leukemia Working Party
4894 - Decreased Chronic GvHD with Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelofibrosis Allografted with Unrelated Donor: A Study from the Chronic Malignancies Working Party of the EBMT
4895 - Separation of Gvl Effects from GvHD with Ptcy-Based Gvhd Prophylaxis in Mmud Transplantation: A Study from the ALWP of the EBMT
4942 - Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party
4945 - Prognostic Impact of t(9;11) and Del(7q) As Intermediate-Risk Abnormalities in AML Following Allo-Transplant: Insights from the ELN 2022 Classification – an EBMT ALWP Study

Baron, Sr., F.

3558 - Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques

Baron, K.

111 - Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study
4425 - Concomitant Use of Antibiotics During Immune Checkpoint Inhibitor (CPI)-Based Salvage Therapy Does Not Impact Post-ASCT Outcomes in Patients with Relapsed/Refractory Hodgkin Lymphoma (RRHL)
4431 - Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting

Baronciani, D.

2136 - Age Is a Crucial Determinant of GFRS with Incidence of Severe Chronic GVHD Reducing over Time in Haemopoietic Cell Transplantation for Transfusion Dependent Thalassaemia: Real World Data from 2010-2021. an Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party

Barone, D.

3326 - Multiple Myeloma and Smoldering Myeloma: Prospective Evaluation of 3 T Whole Body MRI and 18F-FDG PET/CT and Their Impact on Clinical Management
4725 - Radiopsy, Quantitative Wb-Mri Adc and Fat Fraction Sequences for Discrimination of Smoldering Multiple Myeloma and Multiple Myeloma: A Prospective Observational Study

Barone, M.

1754 - Clinical Implications of Plasma-Derived Extracellular Vesicles in Myeloproliferative Neoplasms: Unveiling Inflammatory Potential and Biomarkers for Cancer Treatment

Baroni, M.

3992 - Very Long-Chain Saturated Fatty Acids Are Inversely Correlated with Thrombin Generation and Linked to a Reduced Risk of Coronary Artery Disease and Myocardial Infarction: Preliminary Findings from an Angiographically-Controlled Study

Baroudjian, B.

4513 - JAK Inhibition Results in Aggressive Cutaneous Squamous Cell Carcinoma through MAPK Pathway Activation and Shapes the Tumor Immune Microenvironment to Create Novel Therapeutic Opportunities

Barouma, I.

5196 - Indirect Treatment Comparison of Ivosidenib and Other Therapies in Patients with Newly Diagnosed Acute Myeloid Leukemia

Barqawi, Y. K.

5031 - Cost-Offset Analysis Performed Utilizing Covalent Bruton's Tyrosine Kinase Inhibitors Safety Profiles Among Medicare Patients with Chronic Lymphocytic Leukemia

Barr, H.

1017 - Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants
1019 - A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome
1894 - Novel Non-Coding Candidate Drivers of Multiple Myeloma Linked to Plasma Cell Tumor Biology and B Cell Development
1895 - Single-Cell RNA-Sequencing of 6 Million Tumor and Immune Cells in 365 Patients with MGUS and SMM Demonstrates Complex Progressive Changes in Immune Cell Functionality with a Distinct Footprint on Tumor Cell Biology and Disease Control
1903 - Comprehensive Characterization of the Plasma Proteome of Multiple Myeloma and Its Precursor Conditions and Identification of a Proteomic Signature to Improve Risk Prediction of Disease Progression
4637 - Single-Cell Profiling of ~1.7 Million Plasma Cells across >250 Individuals Reveals Transcriptional Signatures of Progression and Clonal Expansion in Multiple Myeloma and Its Precursor Stages
4984 - Deep Learning Unveils Characteristics of Immune B Cell Aging in >17,000 Samples and Identifies Changes in the Immunoglobulin Repertoire Distribution and the Development of Monoclonal Gammopathy

Barr, P. M.

886 - BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
1869 - Consistently High 5.5-Year Progression-Free Survival (PFS) Rates in Patients with and without Bulky Baseline Lymphadenopathy ≥5 Cm Are Associated with High Undetectable Minimal Residual Disease (uMRD4) Rates after First-Line Treatment with Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) in the Phase 2 CAPTIVATE Study
4615 - Treatment with First-Line Ibrutinib Improves Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) and High-Risk Genomic Features to Rates Approximating an Age-Matched US Population: Pooled Analysis of Phase 3 Trials with 10 Years of Follow-up
4625 - Treatment Outcomes of Patients Treated with Venetoclax-Obinutuzumab Therapy Vs Btki Therapies in 1L CLL: An International Real-World Study

Barrachina, M.

422 - Tet2 Age-Associated Somatic Mutations Impair Megakaryopoiesis and Platelet Function in Clonal Hematopoiesis
819 - Cytokine Secretion from Megakaryocytes Is Governed By Small GTPASES through Autophagy
1171 - Acute CCL5 Exposure Promotes Megakaryopoiesis through Non-Canonical Pathways
1173 - Priming of Megakaryopoiesis and Platelet Production through DNA Damage Repair Inhibition
3930 - Bone Marrow Remodeling and Pro-Inflammatory Megakaryocytes in a Murine Model of Chronic Kidney Disease

Barraclough, A.

4376 - T Cell CD62L Expression Following Nivolumab Therapy Is Associated with Long Term Response to Rituximab-Nivolumab in Treatment Naïve Follicular Lymphoma: Results from the 1^st FLOR Study

Barraco, D.

3800 - Myelodysplastic Neoplasms Patients’ and Caregivers’ Unmet Needs and Their Impact on Their Quality of Life and Symptoms

Barraco, F.

33 - Dynamics of Oligoclonal Hematopoiesis in Severe Aplastic Anemia Patients Undergoing Immunosuppressive Treatment: Longitudinal Somatic Mutation Analysis from the EBMT Race Trial
302 - Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race Study

Barragán, E.

1512 - Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3-ITD Negative AML
1552 - Enhanced Validation of the FLT3-like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in FLT3-ITD Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial
2895 - Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3-ITD–Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial
4986 - A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML

Barranco Lampón, G. I.

119 - Challenges in Leukemia Diagnosis and Treatment in Mexico: A Survey By the Alliance for Leukemias in Mexico on Resource Availability, Infrastructure, and Access to Advanced Therapies for Leukemia Patients

Barrans, S.

229 - Pathogenesis and Clinical Relevance of Diffuse Large B-Cell Lymphoma Proteogenotypes

Barrena, N.

670 - An IFNγ-Mediated Immune Inflamed Microenvironment State in Multiple Myeloma with TP53 Loss That Can be Therapeutically Exploited

Barrenetxea Lekue, C.

1313 - Phase III Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Eculizumab

Barrera Carmona, C.

4569.3 - A Phase 3, Randomized, Double-Blind, Active-Comparator-Controlled Study of Bomedemstat Versus Hydroxyurea in Patients with Essential Thrombocythemia Naïve to Cytoreductive Therapy

Barrera, G. D.

21 - “Platelet Fatigue” during Cold Storage
1269 - Reduction of Lactate Production By Phospholipase C Inhibition in Cold Stored Platelets

Barrera, S.

962 - Prognostic Impact of the Genetic Risk at Baseline Associated to the MRD Clearance in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. Preliminary Results of Pethema LAL19 Trial
1437 - Similar Outcome of Adolescents and Young Adults (AYA) and Older Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) without Philadelphia Chromosome (Ph-) Included in the Pethema LAL-2019 Trial

Barrera, V.

1943 - Prognostic Impact of Measurable Residual Disease Evaluated By Next Generation Flow and PET-CT in Clinical Practice at Fundación Santa Fe De Bogotá Hospital, Colombia

Barret, A.

3840 - Cold Autoimmune Hemolytic Anemia Secondary to Mycoplasma Pneumoniae Infection in Adults: Results from a Large French Observational Study (MYCOLD study)

Barreto, J.

5047 - Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization

Barrett, A.

571 - Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort

Barrett, D.

3481 - KITE-753: An Autologous Rapid Manufactured Anti-CD19/CD20 CAR-T Product for the Treatment of B-Cell Malignancies

Barrett, D.

725 - Aberrant Stemness Transcription Signature Unveils a Mechanism of Chemotherapy Resistance through Blunting p53-Mediated Response in Acute Myeloid Leukemia

Barrett, T. J.

2542 - Tetraspanin CD37 Regulates Platelet Hyperreactivity and Thrombosis

Barretts, N.

3611 - Transformer-Based Multi-Modal Deep-Learning for Enrichment-Free Highly Sensitive Detection and Isolation of Circulating Plasma Cells in Multiple Myeloma

Barreyro, L.

215 - Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Barrientos, J. C.

4615 - Treatment with First-Line Ibrutinib Improves Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) and High-Risk Genomic Features to Rates Approximating an Age-Matched US Population: Pooled Analysis of Phase 3 Trials with 10 Years of Follow-up

Barrientos, J. C.

1866 - Preliminary Results from a Phase 1b Study of Non-Covalent Pan-Mutant BTK Inhibitor Docirbrutinib (AS-1763) in Patients with Previously Treated B-Cell Malignancies

Barriere, S.

58 - Real-World Multicenter Evaluation of Venetoclax and Azacitidine for Molecular Relapse after First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Filo Study

Barrio, E.

1642 - Zanubrutinib Is Effective in the Treatment of Patients with Waldenström's Macroglobulinemia and Bing-Neel Syndrome: A Retrospective Multicenter Study

Barrionuevo, C.

2974 - The Fusion Landscape of Anaplastic Large Cell Lymphoma: An L.L.M.P.P. Study

Barrios Garcia, M.

1512 - Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3-ITD Negative AML
1552 - Enhanced Validation of the FLT3-like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in FLT3-ITD Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial
2895 - Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3-ITD–Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial
4986 - A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML

Barrios García, M.

319 - Clinical Features and Outcomes in 228 Patients Diagnosed with Blastic Plasmocytoid Dendritic Cell Neoplasm: A Pethema/PALG Study
320 - Treatment Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Data from the Pethema and PALG Epidemiologic Registry

Barrios, J. C.

4452 - Extranodal NK/T-Cell Lymphoma in Latin America: A Retrospective Multinational Analysis of Clinical Features, Therapeutic Approaches and Outcomes from the Latin American Group of Lymphoproliferative Disorders (GELL)

Barrios, M.

4952 - Second Transplant Offers the Possibility of Long Term Graft-Versus-Host-Disease-Free Relapse-Free Survival

Barros, S.

3427 - In Vivo panCAR-Mediated Depletion of B Cells in Non-Human Primates Using a Circular (oRNA^®) Anti-CD20 CAR

Barroso, F.

2294 - Multicentric Standardization of Minimal/Measurable Residual Disease in Acute Myeloid Leukemia Using Multiparametric Flow Cytometry – a Brazilian Society of Bone Marrow Transplantation (SBTMO) Project
3064 - Central Nervous System Involvement in Aggressive ATLL: Can We Predict the Risk in a Devastating Complication? Epidemiology and Clinical Features from Latin America. a Collaborative Study from Grupo De Estudio Latino-Americano De Linfoproliferativo (GELL) & T-Cell Brazil Project (TCBP)

Barrott, I.

493 - Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial

Barrow, P.

3623 - Paths Grant: Using the Hub and Spoke Model to Improve Access to Care for Adults Living with Sickle Cell Diseases

Barta, B.

1403 - Targeting the DNA Damage Response through TBL1X in Mantle Cell Lymphoma

Barta, S. K.

1699 - Outcomes in Primary CNS Lymphoma: A Single Institution Experience from the Abramson Cancer Center at the University of Pennsylvania
2344 - Evaluation of Risk Factors for Histological Transformation in Patients with Marginal Zone Lymphoma (MZL): Results from a Multicenter Cohort Study

Barta, S. K.

398 - Addition of Monoclonal Protein to MALT-IPI Improved Identification of MALT Patients at High Risk of Progression with Current First-Line Therapies
473 - Efficacy, Toxicity, and Predictors of Outcomes with CD3-CD20 Bi-Specific Antibodies Post CAR T-Cell Failure for Aggressive B-Cell Lymphoma
500 - CD5 Elimination Enhances CART Cell Proliferation through JAK-STAT Activation
525 - Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis
573 - Improving Outcomes in Plasmablastic Lymphoma: A Multicenter Experience from an American Cohort
612 - Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy
870 - Daratumumab with Dose-Adjusted EPOCH Is Feasible in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 105
982 - Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort
1690 - Asparaginase Treatment Patterns, Toxicity, and Outcomes Among Patients with Extranodal NK/T-Cell Lymphoma: A North American Multicenter Retrospective Cohort Study
1746 - Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study
1750 - Clinical Activity of Tisagenlecleucel in Large B Cell Lymphomas According to the 5^th Edition of the Who Classification
2275 - Comparison of CRS- and Icans-Related Outcomes for Large B Cell Lymphoma Patients Treated with Commercial Axicabtagene Ciloleucel with or without Prophylactic Dexamethasone
2377 - Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers
3052 - Investigating the Novel Combination of the Innate Cell Engager (ICE^®) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK^® in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study
3083 - Title: Development of a Pathologic Prognostic Index (PPI) for Newly Diagnosed Large B Cell Lymphoma Patients Treated with R-CHOP
4342 - Prediction of Clinical Response By Phased Variants in Circulating Tumor DNA (ctDNA) in the VALENTINE-PTCL01 Trial of Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)
4406 - Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma
4433 - Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors
4848 - Evaluating Efficacy and Safety of Rapid-Manufactured CD5KO CART5 Cells in Preclinical Models of T Cell Malignancies
5123 - Real-World Outcomes of Early Relapsed/Refractory Large B Cell Lymphoma Patients Treated with 2^nd Line CAR T Therapy

Bartalucci, N.

65 - Identification of Genomic Structural Variants (SVs) with Adverse Prognostic Significance in Normal-Karyotype (nk) Acute Myeloid Leukemia (AML) Patients
1795 - Homozygosity of the JAK2 46/1 or GGCC Haplotype Contributes to Phenotype and Outcome Diversity Among Patients with Polycythemia Vera

Bartels, M.

3583.1 - RP-L301, a Lentiviral-Mediated Gene Therapy for Pyruvate Kinase Deficiency (PKD): A Phase 2 Clinical Trial Design

Barth, L.

5015 - Evaluating a Multidisciplinary Model of Care for Inherited Bone Marrow Failure and Predisposition to Hematological Malignancy

Barth, P.

2032 - Novel Natural Ligand Chimeric Antigen Receptors (CARs) Targeting CD70 with a Redesigned CD27 Binding Interface Provide Enhanced Potency Against Acute Myeloid Leukemia

Barthelemy, C.

740 - A Single Cell Atlas of Follicular Lymphoma across Clinical Stages Defines Tumor B Cell Archetypes, Immune Microenvironment Heterogeneity and Novel Cell States Associated with High-Risk FL
1597 - Single-Cell Atlas of Diffuse Large B-Cell Lymphoma Reveals Integrated Malignant B Cell and Tumor Microenvironment Characteristics Associated with Clinical Response

Bartilomo, A.

2774 - Selective SMARCA2 Degradation Promotes Leukemic Differentiation and Synergizes with CDK9 Inhibition to Potently Induce Death in Pre-Clinical Models of Acute Myeloid Leukemia

Bartlett, N. L.

110 - Representation of Minorities in Therapeutic Clinical Trials – a 15-Year Review of Lymphoma Cooperative Group Studies (Alliance A152123)
398 - Addition of Monoclonal Protein to MALT-IPI Improved Identification of MALT Patients at High Risk of Progression with Current First-Line Therapies
460 - Updated Analysis of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Nonbulky, Early-Stage Classical Hodgkin Lymphoma
831 - Disrupting IL10 Signaling Overcomes Compound Copy Number Variation-Driven Clinical Resistance to CDK4/6 and BTK Inhibition in Mantle Cell Lymphoma
865 - Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study
985 - Phase I Results of Acalabrutinib in Combination with Durvalumab in Primary Central Nervous System Lymphoma: Safety, Efficacy, and Central Nervous System Penetration
990 - Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072
1631 - Glofitamab Induces High Response Rates and Durable Remissions in Patients (Pts) with Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL), Including Those with a Poor Prognosis: Subgroup Results from a Phase I/II Study
1645 - Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II
1646 - Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma
1726 - Primary Results of the Health-Related Quality of Life (HRQoL) and Tolerability Assessments from the Phase I/II NP30179 Study of Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
2344 - Evaluation of Risk Factors for Histological Transformation in Patients with Marginal Zone Lymphoma (MZL): Results from a Multicenter Cohort Study
3045 - Brentuximab Vedotin (BV) and Nivolumab (nivo) for Untreated Patients with Hodgkin Lymphoma (HL): Long-Term Results
3101 - Durability of Complete Responses in Patients from the ECHELON-3 Study
4406 - Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma
4407 - Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study
4409 - Long-Term Follow-up of Bendamustine/Rituximab – Rituximab/Cytarabine (BR/RC) Induction Therapy for Previously Untreated Transplant-Eligible Patients with Mantle Cell Lymphoma (MCL)
4414 - Mosunetuzumab Plus Polatuzumab Vedotin Induces Early Complete Responses in Previously Untreated High Tumor Burden Follicular Lymphoma
4425 - Concomitant Use of Antibiotics During Immune Checkpoint Inhibitor (CPI)-Based Salvage Therapy Does Not Impact Post-ASCT Outcomes in Patients with Relapsed/Refractory Hodgkin Lymphoma (RRHL)
4431 - Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting
4483 - Outcomes in Older Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study
4489 - Outcomes By Refractory Status and Prior Therapies Received in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study
1661.3 - Trial in Progress – Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma
3132.1 - ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after Response to Standard Therapy
4502.4 - Trial in Progress – Alliance A051901 – Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed By Lenalidomide and Nivolumab Maintenance in Primary Central Nervous System Lymphoma (PCNSL)
- Sequencing Bispecific Antibodies and CAR T-cells for FL

Bartlett, N. L.

236 - Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181

Bartolucci, P.

Barton, J. W.

4779 - Humanization of Clinically Used Murine CD45 Antibody for Optimized CD45-Targeted Radioimmunotherapy

Barton, J.

4780.1 - Trials in Progress: Decoy-Resistant Interleukin-18 (DR-18) for Relapse or Pre-Emptive Treatment of Measurable Residual Disease after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome (DR. DREAM), a Phase I Trial

Barton, J.

3335 - Prevalence and Clinical Implications of Germline Variants in Multiple Myeloma Patients

Bartram, J.

2816 - Blinatumomab with De-Escalated Chemotherapy for Infant KMT2A-Rearranged B-Cell Acute Lymphoblastic Leukemia
2830 - A Non-Canonical Lymphoblast in Refractory Childhood T-Cell Acute Lymphoblastic Leukemia
4206 - Bridging Pediatric B-Cell Acute Lymphoblastic Leukemia (ALL) Patients to CAR-T Cell Therapy: A National Perspective
4317 - Single Cell Multimodal Framework Identifies CD84 As a Leukaemic Stem Cell Target in Paediatric AML

Barua, S.

664 - Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database

Baruchel, A.

968 - Favourable Outcomes in Newly Diagnosed Paediatric AML with Gemtuzumab Ozogamicin and Risk-Stratified Therapy: Results from the International Phase III Myechild 01 Trial
1433 - Characteristics and Outcome Determinants in Children, Adolescents and Young Adults Who Failed Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia
2814 - How to Administer Pegaspargase during Induction Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents? Results of the Caall-F01, a Multicentre Randomized Clinical Trial from the French Pediatric Cancer Society (SFCE)
3450 - WU-CART-007 (WT-7), an Allogeneic CAR T-Cell Targeting CD7 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Phase 2 Results
3461 - WU-CART-007 (WT-7) Is an Effective Treatment for Adolescent Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL) – Subgroup Analysis of WU-CART-007 1001
- Plenary Introducer

Barulli, S.

4532 - Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact Project, a CML Campus Study

Barva, B.

3127 - Favorable Safety Profile and Durable Responses to Pmb-CT01 (BAFFR-CAR T Cell) Therapy in Patients with B-Cell Lymphomas Ineligible for or Who Failed CD19-Targeted Therapy, Including CD19-Negative Disease

Barve, M.

1739 - Safety and Efficacy in Patients with Advanced Lymphomas from a Global Phase 1a/1b, First-in-Human Study of CS5001, a Novel Anti-ROR1 ADC

Barwe, S. P.

209 - Identification of DLK1 As a Novel Therapeutic Target in Down Syndrome Myeloid Leukemia
4103 - Mesothelin Promotes Acute Myeloid Leukemia Cell Proliferation, Adhesion, and Chemoresistance through Novel Binding Partner Lyn
4156 - Interferon Synergizes with Inhibition of Pro-Apoptotic Proteins to Reduce Leukemia Burden in PDX Models of ML-DS

Barwick, B. G.

251 - DNA Methylation Analysis of Commpass Reveals Distinct Epigenetic Programs of High-Risk Disease
1359 - Ectopic NSD2 Remodels H3K36me2 and DNA Methylation to Promote Oncogenic Gene Expression in Multiple Myeloma
4663 - Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2
- PhD

Barz Leahy, A.

3454 - Preinfusion Risk Factors for the Development of Severe Immune Effector Cell Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T-Cell Infusion in Pediatric Patients
3470 - Cost-Effective Manufacture and Promising Initial Efficacy of huCART19 Cells Manufactured Using the Clinimacs Prodigy Platform

Barz, M. J.

318 - Drug Sensitivity and Treatment Response Are Modulated By the Cell of Origin, the Underlying Gene Fusion, and Patient Age in KMT2A-Rearranged BCP-ALL
631 - IDH2 Mutations from Clonal Hematopoiesis and Acquired IKZF1 Deletions Define a Novel B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma
1458 - C/EBP Family Member Gene Fusions and Cooperating Genomic Events Define Two Distinct Molecular Sub-Groups in Adult B Precursor ALL

Barz, M.

2199 - Optimization of Targeted Lipid Nanoparticle for the Treatment of RUNX1::ETO Driven AML

Bas Bernal, A.

4401 - Impact of Bone Marrow Evaluation Using Bone Marrow Biopsy, Flow Cytometry, and PET/CT in B-Cell Non-Hodgkin Lymphomas

Basak, A.

645 - Cytokine-Linked Remodeling of the Immune Microenvironment Is a Hallmark of Transformation in Follicular Lymphoma

Basak, G.

600 - Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia – a Study on Behalf of the Chronic Malignancies Working Party of the EBMT
1421 - Meta-Analysis of Complete Remission Rates Following First-Line Salvage Treatment after Anti-CD19 CAR-T Failure in Adult Patients with Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia
4268 - The Experience of Commercially Available CPX-351 Use As First-Line Treatment for Patients with Acute Myeloid Leukemia – a Report of Polish Adult Leukemia Group (PALG)

Basak, G.

3497 - Central Nervous System Disorders (CNSD) Following Hematopoietic Stem Cell Transplantation (HSCT): A Prospective Study from the Infectious Diseases Working Party (IDWP) and the Transplant Complications Working Party (TCWP), European Society of Blood and Marrow Transplantation (EBMT)

Basali, D.

5167 - A Pilot Screening and Patient Navigation Program for Early Detection of Multiple Myeloma to Address Cancer Disparities

Basalobre, P.

598 - HCT-Adapted ELN 2022 Risk Classification: Validation of a Very Poor Risk Group (Adverse-Plus) in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)

Basanthakumar, A. T.

205 - Posttranslational Changes in Histone Modification Driven By USP48 Loss Increase Sensitivity to Hypomethylating Agents in Acute Myeloid Leukemia
626 - Riboflavin Drives Nucleotide Biosynthesis and Iron-Sulfur Metabolism to Promote Acute Myeloid Leukemia

Basappa, J.

1602 - Inosine Monophosphate Dehydrogenase-2 (IMPDH2) As the Potential Novel Therapeutic Target in Mantle Cell Lymphoma (MCL): The Underlying Tyrosine Phosphorylation-Based Activation Mechanism and Translational Implications
4120 - Mitochondrial ACSS1 Regulates Oncometabolite 2-Hydroxyglutarate and De Novo Pyrimidine Biosynthesis in Lymphoma Cells: Functional Insights and Translational Implications

Basara, M.

547 - Critical Bleeding in Adults and Children with Immune Thrombocytopenia: A Multicentre Cohort Study

Basavanhally, T.

579 - Golcadomide (GOLCA) Plus R-CHOP Has High Minimal Residual Disease (MRD) Negativity across High-Risk, Untreated Aggressive B-Cell Lymphoma (a-BCL)

Basch, E.

2299 - Incorporating Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) into Dose Review in a Phase I Clinical Trial

Basharat, A.

1119 - Beyond the Binary: Analysis of Sickle Cell Disease Crisis Hospitalizations in the Transgender Population in United States: National Inpatient Data Base Study from 2012-2020
1128 - Beyond the Binary: Analysis of Sickle Cell Disease Crisis Hospitalizations in the Transgender Population in United States
2102 - Outcomes after Matched Sibling Donor Versus Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
2622 - Uncovering the Risks: Bleeding and Thrombotic Complications of JAK Inhibitors in Hematological Conditions: A Comprehensive Systematic Review and Meta-Analysis
3555 - Outcomes of Hematopoietic Stem Cell Transplantation in Primary Plasma Cell Leukemia: A Systematic Review and Meta-Analysis
4932 - Outcomes with Venetoclax and Hypomethylating Agents in Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis

Basharat, M.

554 - Clinical and Economic Outcome Analysis of First-Line Immunosuppression in Acquired Hemophilia a

Bashaw, L.

158 - Improving Guideline Concordant Primary Prevention Aspirin Use through a Multiclinic Antithrombotic Stewardship Intervention

Basheer, F.

722 - Acute Resistance to BET Inhibitors Remodels Compensatory Transcriptional Programs Via p300 Co-Activation

Bashey, A.

695 - Likelihood of finding an 8/8 HLA-matched unrelated donor (Donor Search Prognosis) is not associated with survival: Primary results from BMT CTN 1702
1450 - Improved Outcomes of Adult Patients with Philadelphia-like Acute Lymphoblastic Leukemia (Ph-Like ALL) Treated within an Integrated Leukemia/Transplant Program with Incorporation of Pediatric Inspired Regimens and Early Allogeneic Transplant
1522 - Comparison of FLAG-Idarubicin to FLAG-Idarubicin Plus Venetoclax for Treatment of Newly Diagnosed AML in Patients Eligible for Intensive Induction. Analysis of 200 Consecutive Patients Treated at a Single Center
2363 - Prophylactic Corticosteroids Allow Safe Outpatient Administration of Axicabtagene Ciloleucel with Comparable Toxicities to Other CAR-T Therapies in Large Cell Lymphoma
3501 - Intensive Conditioning with Fludarabine Plus Melphalan Versus Total Body Irradiation Prior to Haploidentical Transplant and Post-Transplant Cyclophosphamide
3528 - Safety and Efficacy of Ibrutinib Added to Rituximab-Based Primary Therapy of Chronic Graft-Versus-Host-Disease
4912 - Extracorporeal Photopheresis (ECP) in the Era of New Chronic Graft-Versus-Disease (GVHD) Therapies
4913 - The Degree of HLA-DPB1 Mismatch Predicted By Evolutionary Divergence Scoring Informs the Risk of Chronic Graft-Versus-Host Disease after Haploidentical Transplantation with Post-Transplant Cyclophosphamide
4948 - High HLA Evolutionary Divergence in Donor HLA-B Locus Impacts Transplant Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide

Bashir, A.

1544 - Karyotype AI for Precision Oncology

Bashir, H. S.

1152 - PU.1 Promotes Monocyte Development in Part By Transcriptionally Activating c-Fos, Egr-1 and Egr-2

Bashir, Q.

506 - Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial
1047 - A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
1497 - Long-Term Follow-up of Crenolanib Maintenance after Allogeneic Transplantation in Newly Diagnosed and Relapsed FLT3 Mutated AML
1922 - Predictive Factors for Transplant Outcomes of Cardiac AL Amyloidosis
1923 - Impact of Age on Autologous Stem Cell Transplantation Outcomes for AL Amyloidosis
3344 - Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant
3514 - Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis
5154 - Impact of Ethnicity on Long Term Outcomes of High-Dose Chemotherapy and Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma

Bashyal, P.

155 - Pharmacological Targeting of IRF4 As a Therapeutic Strategy for Multiple Myeloma

Basi, A.

1301 - Spatial Analysis of Human p53 Mutated AML Bone Marrow Reveals Novel MRD Clusters and Spatial Microenvironmental Features of p53 Mutated AML
2681 - Multimodal Spatial Profiling in Acute Myeloid Leukemia

Basi, G.

4995 - Single-Cell Proteogenomic Analysis of Clonal Evolution in Patient-Derived Xenograft Models of AML Treated with IDH Inhibitors

Bašić-Kinda, S.

2337 - Bone Mineral Density in Hodgkin Lymphoma Patients Treated with Escalated Beacopp: Focus on Steroid Administration and Age-Related Effects
3049 - The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin’s Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)

Basilico, C.

113 - Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia
2863 - Venetoclax and Hypomethylating Agents Confirmed to be Standard Therapy in De Novo and ELN17 Not Adverse Acute Myeloid Leukemia Patients, Unfit for Chemotherapy According to SIE/Sies/GITMO Criteria. a Multicentric Real-Life Study on 379 Patients, By the Hematological Network Rete Ematologica Lombarda (REL)
5188 - Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results

Baskar, J.

1001 - Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis

Baskar, P.

4982 - Accelerating Drug Discovery: AI-Powered Indication Exploration for Ropeginterferon Alfa-2b

Baslan, T.

1404 - Cytarabine Resistance Leads to a Specific Mutator Phenotype in Leukemic Cells

Basnet, S.

397 - Prevalence, Genetic Predispositions and Clinical Consequences of Non-CLL-Type MBL: Screening in 10,330 Individuals

Bason, R.

2834 - CD19 CAR T Cells Drive a Remodeling of the Immune Microenvironment Associated with T-Cell Dysfunction in Acute Lymphoblastic Leukemia

Basood, M. M.

5124 - Epcoritamab for Relapsed/Refractory B Cell Lymphoma – the Israeli Real-World Experience of a Compassionate Use Program

Basquiera, A. L.

5 - Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3)

Basrai, S.

1954 - Analysis of Chip Mutations Pre-and Post-Transplant in Multiple Myeloma (MM): Expanded Results from a Prospective Longitudinal Study

Bass, F.

2379 - Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis from the Worldwide Network for Blood and Marrow Transplantation Global Study
4733 - Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study

Bassa, B.

813 - The Thrombosis in Patients with Lower Limb Injuries Requiring Immobilisation Study . (TILLIRI study)

Basse, M.

4144 - Targeting the IRE1α-XBP1s Pathway to Enhance Venetoclax Effectiveness in AML

Bassermann, F.

264 - Immunomodulatory Microbial Metabolites Protect Against Graft-Vs-Host Disease and Enhance Anti-Leukemia Responses in Mice and Patients Receiving Stem Cell Transplantation
493 - Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial
780 - Recovery of the Intestinal Microbiome in Patients at Day +100 after Allogeneic Stem Cell Transplantation Is Defined By Microbial Metabolite Profiles and Linked to Long-Term Outcomes
895 - Pre-Apheresis Prediction of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma
3513 - Omitting Ciprofloxacin Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation Does Not Result in Inferior Outcomes
4688 - Prevalence and Mutational Make-up of Secondary Hematologic Neoplasms in Multiple Myeloma Patients after CAR-T Cell Therapy
4904 - Loss of Microbiota-Derived Metabolites Is Associated with Mucosal-Barrier-Injury Bloodstream Infection in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Basset, M.

889 - Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis

Bassett, R. L.

506 - Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial
1047 - A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
5154 - Impact of Ethnicity on Long Term Outcomes of High-Dose Chemotherapy and Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma

Basso, K.

47 - Differential Role of Crebbp Missense and Truncating Mutations in the Malignant Transformation of Germinal Center B Cells
4128 - Role of Glucocorticoid Receptor in Normal and Malignant Germinal Center B Cells

Basso-Ricci, L.

4050 - Poisoning of Healthy Hematopoiesis Is an Unanticipated Mechanism Driving Clonal Dominance in Vexas Syndrome

Bassolli De Oliveira Alves, L.

4458 - Outcomes and Toxicity Profile in Elderly and Very-Elderly Diffuse Large B-Cell Lymphoma Patients: A Real-World and Comparative Study Involving Three Different Dose-Modulated Anthracycline-Based Immunochemotherapy Regimens in LATAM

Bastard, P.

2201 - Gene Therapy for Artemis-SCID and Artemis-Leaky-SCID Patients: Preliminary Results of the French Artegene Phase I/II Clinical Trial

Bastian, L.

318 - Drug Sensitivity and Treatment Response Are Modulated By the Cell of Origin, the Underlying Gene Fusion, and Patient Age in KMT2A-Rearranged BCP-ALL
631 - IDH2 Mutations from Clonal Hematopoiesis and Acquired IKZF1 Deletions Define a Novel B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma
1458 - C/EBP Family Member Gene Fusions and Cooperating Genomic Events Define Two Distinct Molecular Sub-Groups in Adult B Precursor ALL
4213 - Integrateall, a Machine Learning Pipeline for Multi-Level Data Extraction from RNA-Seq Profiles Unravels Novel Drivers and Systematic Subtype Classification in B-Cell Precursor ALL

Bastida Bermejo, J. M.

713 - Avespa Study: Effectiveness and Safety of Avatrombopag in Immune Thrombocytopenia (ITP). a Real-World Study of the Spanish ITP Group (GEPTI)

Bastida, J. M.

3948 - Investigating the Effectiveness and Safety of Combining Thrombopoietin Receptor Agonist and Immunosuppressant Drugs for Patients with Multirefractory Immune Thrombocytopenia after Second-Line Monotherapy Treatments

Bastidas Torres, A. N.

4846 - Indolent CD8+ CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucel Therapy for Relapsed/Refractory Multiple Myeloma

Bastie, J. N.

4756 - High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)

Bastien, J. P.

3472 - Deciphering Minor Histocompatibility Antigen Immunoreactivity through Optimized T Cell Expansion Strategies

Bastien, M.

1531 - Inflammatory Biomarkers Predict Response and Survival in Chemotherapy-Ineligible and Untreated Acute Myeloid Leukemia Patients Receiving Venetoclax-Azacytidine As Front-Line Therapy

Bastola, S.

2859 - NCAM1 (CD56) As a Predictor of Response to Standard Intensive Induction in Newly Diagnosed Acute Myeloid Leukemia
2872 - Trends in Acute Myeloid Leukemia (AML) Hospitalization: Incidence, Mortality, Length of Stay, and Financial Burden from 2011 to 2018

Bastos, A.

3589 - PIM447, a Pan-PIM Kinase Inhibitor, in Combination with Venetoclax Exerts a Potent Anti-Tumor Activity in the Bone Marrow Niche
3692 - Impact and Aggravating Factors of Chronic Pain in Sickle Cell Disease: Results of the Analysis of Promis® Questionnaires and the Metabolomic Profile of Brazilian Adult Patients
4968 - Novel MET Inhibitors Provide a Therapeutic Opportunity for AML By Overcoming the Protective Action of the Bone Marrow Niche

Bastos-Oreiro, M.

471 - Site-Specific Analysis of Extranodal Involvement Reveals Distinct Efficacy Outcomes with CAR T-Cell Therapy in Large B-Cell Lymphoma Patients
1708 - Primary Mediastinal B Cell Lymphoma (PMBCL): A Multicentric Observational Study of Spanish Lymphoma Group Geltamo
2044 - Molecular Tumor Burden and Clonal Evolution As Factors Associated with Early Progression in Large B-Cell Lymphomas Treated with CAR-T Therapy
2356 - Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)
3009 - Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma
3109 - Real-World Management Patterns of Acute Toxicity Following Bispecific Antibody Therapy for Patients with B-Cell Lymphoma - the Geltamo (Spanish Lymphoma Group) Experience
3414 - Enhancing CAR-T Cell Therapy for Non-Hodgkin Lymphoma through Gut Microbiota and Butyrate
4403 - Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study
4422 - Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance?
4471 - Real World Epidemiology and Treatment Strategies of Limited Stage Large B Cell Lymphoma: Spanish Multicenter Geltamo Study
4478 - A New Prognostic Index Including Baseline Clinico-Biological Variables Predicts Outcome in Plasmablastic Neoplasms

Bastos-Oreiro, M.

577 - Final Analysis of the Safety and Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma
989 - A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
1715 - Real World Evidence of Second Line Therapy in Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geltamo Study
3049 - The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin’s Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)

Basu, J.

2716 - Oncogenic Nexus of TET2 with Thpok in Myeloid Neoplasia

Basu, M.

2203 - High-Throughput Drug Repurposing Identifies SN-38 As a Potent Inhibitor of AML with Synergistic Effects in Combination with PARP and BCL-2 Inhibitors for Treating KMT2A-Rearranged Leukemias

Basu, S.

1059 - Multimodal Spatial Transcriptomic Profiling Elucidates Niche-Specific Dynamics in Medullary and Extramedullary Acute Myeloid Leukemia

Basu, S.

362 - Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial

Basudhar, D.

3382 - Cross-Cohort Correlative Analysis of Clinically High-Risk Patients (pts) Treated with Idecabtagene Vicleucel (ide-cel) in KarMMa-2: Association between Progression-Free Survival (PFS) and Tumor Burden and Immune Status at Apheresis
3388 - Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up

Basyal, M.

61 - Single-Cell Multiomics Unveils Venetoclax-Resistant Monocytic Differentiation and Immune Evasion in TP53 Mutant AML Clones
330 - TP53 Mutations within T Cells Induce T-Cell Exhaustion and Functional Impairment in TP53 Mutant AML

Bat, T.

850 - Clinical and Molecular Insights into the Classification Dilemma: Are MDS/AML Cases Distinct from Secondary AML?
1315 - Using Machine Learning to Predict the Risk of Evolution to Paroxysmal Nocturnal Hemoglobinuria in Patients with Aplastic Anemia
2695 - Predicting Extravascular Hemolysis in Paroxysmal Nocturnal Hemoglobinuria
2700 - Absolute Immature Platelet Count As an Accessible Diagnostic Tool for Aplastic Anemia Vs. Immune Thrombocytopenia

Bat-Erdene, D.

1045 - Feasibility, Safety and Efficacy of Oral Maintenance Therapy with Venetoclax Plus Decitabine/Cedazuridine after Venetoclax Plus FluBu2 for High Risk MDS/AML Undergoing RIC Allo-HCT

Bataclan, C.

4061 - Single-Cell Transcriptomic and Spatial Characterization of Multipotent Stromal Cells in Homeostatic,Remodeled, and In Vitro Expanded Human Bone Marrow

Batah, H.

1473 - Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients between 65-75 Years and Treated with Intensive Induction Chemotherapy Versus Hypomethylating Agents and Venetoclax: A Propensity Score Adjusted Cohort Study
1488 - A Comprehensive Analysis of FLT3 Mutation Profiles and Clinical Outcomes in Adult Patients with Acute Myeloid Leukemia: A Single Institution Experience
2848 - Salvage Reinduction Chemotherapy Versus Alternative Regimens after Failed AML Intensive Induction Regimen, a Single Center Experience
2862 - Impact of Cytogenetic Response on Long-Term Survival in Acute Myeloid Leukemia: A Retrospective Cohort Study
2868 - Outcomes of Blast-Phase MPN and JAK2, MPL, and CALR Mutated de Novo AML Compared to AML with Wild-Type JAK2, MPL, and CALR Genes: A Propensity Score-Adjusted Cohort Study
4248 - Survival Outcomes of Patients Diagnosed with Myeloid Sarcoma Versus Acute Myeloid Leukemia: A Retrospective Cohort Study
4249 - Comprehensive Analysis of KMT2A Alterations in Acute Myeloid Leukemia and Their Impact on Survival and Response Rates; A Single Center Experience
4297 - The Prognostic Significance of Chromosome 17 Addition Vs. Complete and Partial Loss in Patients with Acute Myeloid Leukemia, a Single Center Experience

Bataillard, E.

2342 - Multi-Centre Real-World Outcomes of Large B-Cell Lymphoma Patients Treated with 2L Axicabtagene Ciloleucel in the UK

Bataller, A.

56 - Phase II Study of Cladribine with Low Dose Cytarabine and Venetoclax Alternating with Azacytidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia
661 - Oral Decitabine/Cedazuridine in Patients with MDS and TP53 Mutations: A Propensity Score Matching Analysis from the Phase II and III Trials
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1011 - Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
1332 - A Dedicated System Accounting for Specific Germline/Somatic Genomic Constellations Is Essential to Predict Outcomes in DDX41-Mutant Myeloid Neoplasia
1511 - Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia
1572 - Impact of Flow Cytometry-Based Measurable Residual Disease Clearance Kinetics in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy
2853 - Clinical Outcomes Associated with NPM1 Mutations in Newly Diagnosed AML
2861 - Establishing Benchmarks for Relapse-Free and Overall Survival Among Patients (Pts) with Newly Diagnosed AML Not Undergoing Allogeneic Stem Cell Transplantation (SCT) in First Remission
2896 - Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy
4272 - Phase Ib/II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
4277 - Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First Remission
4293 - Patterns of Relapse Following Venetoclax-Based Therapies of Differing Intensity in Acute Myeloid Leukemia
4584 - Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis

Batavia, A.

3763 - Design and Methodological Considerations for Real World Data-Derived Progression-Free Survival in Multiple Myeloma

Batayneh, O.

4244 - Does Time Matter from Diagnosis to Induction in Acute Myeloid Leukemia?

Batchelor, E.

627 - Rbmx Regulates YTHDC1 Nuclear Condensates to Promote Nascent Transcription in Acute Myeloid Leukemia
4106 - Uncovering the HOXA9 Translational Regulatory Complex That Promotes AML Leukemic Stem Cells

Batchi-Bouyou, A. L.

1285 - Predictive Modeling of Clonal Hematopoiesis across Diverse Cohorts

Bateman, B.

4157 - Targeting Chronic Myeloid Leukemia with Potent and Specific BCR::ABL1 Degraders

Bates, B.

4157 - Targeting Chronic Myeloid Leukemia with Potent and Specific BCR::ABL1 Degraders

Bates, J.

978 - Toll-like Receptor 7/8 Pathway Is a Therapeutic Target in Primary CNS Lymphoma

Bates, S.

4007 - Validation of a Simplified Diagnostic Algorithm for Deep Vein Thrombosis

Bates, S. E.

4446 - Survival and Treatment Response in CTCL Can be Predicted Using Volumetric Lymph Node Size and Dynamic Changes in Lymph Node Size and Skin Score

Bath, N.

2100 - Preclinical Proof of Concept for Decentralized Manufacturing of a MAGE-A4/CD8alpha-Expressing Autologous T-Cell Therapy for Solid Tumors

Bathla, T.

3962 - Dietary Tryptophan Contributes to Indoleamine 2,3-Dioxygenase 1(IDO-1)-Mediated Cancer-Associated Venous Thrombogenicity in Mice

Batista, L.

25 - Dnmt3a Controls Hematopoietic Stem Cells Via DNA Methylation-Independent Regulation of Telomeres
630 - Fetal Differentiation Programs Afford a Protective Barrier to NUP98 Fusion-Driven AML That Dissipates Shortly after Birth
1173 - Priming of Megakaryopoiesis and Platelet Production through DNA Damage Repair Inhibition

Batistick, M.

824 - Immunotherapy of Acute Myeloid Leukemia Enabled By Targeting of Pan-Cancer Molecular Patterns with a Novel Trispecific T Cell Engager

Batlevi, C. L.

108 - Deep Learning Predicts Risk of Large B-Cell Lymphoma Progression upon R-CHOP Therapy from Baseline Histology
989 - A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
2373 - Characterizing the US Patient Population Receiving Rituximab with Gemcitabine and Oxaliplatin (R-GemOx) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Using Real-World Data

Batlevi, C. L.

469 - Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes
3093 - Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study

Batlle, A.

597 - Donor Cell-Derived Hematologic Neoplasms: Role of Germline Predisposition and Clonal Hematopoiesis

Bats, M. L.

3133 - Increased Thromboinflammation Is Associated with High Thrombotic Risk in Patients with Myeloproliferative Neoplasms: A Multicentric Study of 394 Cases By the French Intergroup of Myeloproliferative Neoplasms (FIM)

Batsis, I.

1163 - Long-Term Safety and Efficacy of Autologous Hematopoietic Cell Transplantation for Patients with Progressive Systemic Sclerosis
3408 - Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) and Growth Differentiation Factor-15 (GDF-15) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients
3484 - Long-Term Safety and Efficacy of Treosulfan-Based Conditioning Regimens of Allogeneic Hematopoietic Cell Transplantation
4778 - Genetic Susceptibility in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease

Batsuli, G.

1206 - Immune Toleration Induction with Emicizumab in Hemophilia a Patients with Inhibitors: A Systematic Review

Batta, K.

880 - Granulocyte Derived Resistin Induces Classical Monocyte Repartition and Immune Suppression in CMML
4579 - Incorporating TET2 Variant Allele Frequency Enhances Prognostication in CMML: Insights from 849 Patients across Multiple Institutions

Battaglia, M.

2800 - Ph-like ALL Is Associated with Unfavorable Outcomes in Hispanics and Native Americans: A Multicenter Analysis

Battaglio, B.

3155 - CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or ≤ 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study

Battezzati, P. M.

1182 - Mean Platelet Volume in Patients with Liver Cirrhosis and Chronic Liver Disease: A Case-Control Study

Battipaglia, G.

2690 - Methodology and Clinical Significance of Longitudinal UBA1 Clonal Burden Evaluation in Vexas Syndrome
4797 - Secondary Myeloid Neoplasms after CD19 CAR-T Cell Therapy: Real-Life Multicenter Data from the Clonhema Study
4894 - Decreased Chronic GvHD with Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelofibrosis Allografted with Unrelated Donor: A Study from the Chronic Malignancies Working Party of the EBMT

Battipaglia, G.

693 - No Differences in Transplant Outcomes with Post-Transplant Cyclophosphamide in One Antigen Mismatched Unrelated Donor Compared to Matched Unrelated Donor Recipients Receiving Antithymocyte Globulin in Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT
3558 - Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques
3559 - Impact of Donor Type on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis
4944 - Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Haploidentical Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Battistella, M.

Battistini, R.

2440 - Clinician’s Knowledge and Awareness of Patient-Reported Outcomes in Immune Thrombocytopenia: Results of a National Survey (ITP NET, GIMEMA Working Group Anemia and Thrombocytopenia)

Battiwalla, M.

523 - Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above
2300 - Comparison of 15- Vs. 30-Day Remote Patient Monitoring for Outpatient Chimeric Antigen Receptor T-Cell Therapy (CAR-T) across a Large Health System
3734 - The Patient Journey and Treatment Outcomes Comparing Inpatient Versus Outpatient Axicabtagene Ciloleucel in Non-Hodgkin’s Lymphoma (NHL) - a Large, Multicenter Study
4200 - NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival

Battram, A.

359 - Enhanced Antitumoral Efficacy of ARI0002h CAR-T with CD28-TMD in Normal and Low BCMA Expressing Myeloma Cells

Batts, K.

291 - Integrative Strong Body and Mind Training for Sickle Cell Disease (I-STRONG)—an Interdisciplinary, Multicomponent Treatment Approach for Pediatric Chronic SCD Pain

Battula, V. L.

330 - TP53 Mutations within T Cells Induce T-Cell Exhaustion and Functional Impairment in TP53 Mutant AML

Bauchat, A.

374 - Critical Care Support in Infants Post-Allogeneic HCT: Large Single-Center Cohort Experience
1158 - Cultured Thymus Tissue Implantation for Congenital Athymia Post FDA Approval: Auto-Immunity and Novel Genetic Mutations
2170 - Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
4921 - Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States

Baudi, F. K.

1955 - Impact of Serial Serum Free Light Chain Measurements on Response and Progression Assessments in Multiple Myeloma Patients with Measurable Disease

Baudin, E.

1289 - Emergence of DNA Damage Repair Clonal Hematopoiesis after Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors

Bauer, D.

172 - A Novel Small Molecule Drug-Based Approach for Treating Beta-Globinopathies
414 - IGF2BP1 Orchestrates Post-Transcriptional Control of Globin Switching through Direct Binding to Globins and Their Regulators
4767 - Epitope Editing Combined with Extended Schedule Anti-KIT Antibody Treatment Allows Immune-Based In Vivo Selection of Multiplex Genome-Engineered Cells
- Sickle Cell Disease

Bauer, D.

4819 - Successful Generation of iPSC-Derived CD4⁺ and CD8⁺ CAR T Cells with Αβ-like T Cell Function, Including Antigen-Dependent Expansion and IL-2 Production

Bauer, K. A.

17 - Leveraging Population-Scale Multiomic Datasets to Elucidate the Risk of Thrombosis Associated with Protein S (PROS1) Deficiency
18 - Use of Large-Scale Genomic Datasets to Identify Additional Modifiers of Thrombosis Risk Among 26,436 Carriers of the Factor V Leiden and Prothrombin G20210A Mutations
701 - Glucagon-like Peptide 1 Receptor Agonists Reduce the Risk of Venous Thromboembolism in Patients with Diabetes Irrespective of Obesity: A Propensity Score-Matched Multicenter Database Analysis

Bauer, M. A.

4729 - Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages

Baues, C.

566 - Metabolic Tumor Volume after Two Cycles of Chemotherapy in Patients Treated for Advanced-Stage Hodgkin Lymphoma: Analysis of the German Hodgkin Study Group Phase III HD18 and HD21 Trials
4428 - Abscopal Effect of Radiotherapy and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Results of the International GHSG Phase II Aern Trial

Baughman, J.

4142 - BMS-986397, a First-in-Class Molecular Glue Degrader of Casein Kinase 1α (CK1α) for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Harboring Functional TP53

Baughn, L. B.

249 - Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax
592 - Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma
1981 - Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience
3263 - Preclinical Development of a Novel Pan-RAS Inhibitor Against Relapsed/Refractory Multiple Myeloma
4635 - The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma
4728 - Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes

Baum, N.

914 - A Novel Platform Technology for the Development of NK Cell-Based Cellular Immunotherapies
4173 - Preclinical Development of a Novel Humanized and Fc-Engineered Antibody-Drug Conjugate for the Therapy of T-Cell Acute Lymphoblastic Leukemia

Baumann, I.

1835 - Refractory Cytopenia in Childhood Under Watch and Wait Strategy: Safe until Adulthood?

Baumann Kreuziger, L.

16 - Anticoagulation Management of Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: A Global Abdominal/Splanchnic Thrombosis Retrospective Observational Study in 486 MPN Patients (GASTRO-MPN)
1229 - A Subset of Antibodies to the Spike Protein's Receptor-Binding Domain in Severe COVID-19 Activate Platelets
1246 - Imaging Predictors of Intracerebral Hemorrhage in Patients with Brain Tumors Treated with Anticoagulation
5014 - Comparative Analysis of Perioperative Anticoagulation Management Guidelines across U.S. Institutions
- Maternal Health
- Closing Remarks

Baumann, S.

3425 - Divergent Population Dynamics and Gene Signaling in Monocytes Distinctly Influence Responses to CD19-Targeted CAR T-Cells in Relapsed/Refractory B-NHL

Baumeister, S. H.

369 - Autologous CD33CART for Children and Adolescents/Young Adults with Relapsed/Refractory AML: Phase 1/2 Clinical Trial Correlative Biology Analyses Demonstrate Potent in Vitro, In Vivo, and Ex Vivo Anti-Leukemia Activity
2817 - Role of B Cell Recovery in Relapse Risk and CD19 Phenotype Following Real-World Use of Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia: A Multi-Institutional Retrospective Study

Baumgart, M.

5054 - An Inpatient Advance Care Planning Intervention for Older Patients with Hematologic Malignancies: A Single-Arm Pilot Study

Baumgarten, L. V.

856 - Modulation of the Tumor Microenvironment By CCL19 in Primary CNS Lymphomas
1583 - Guiding Treatment and Clinical Management of Patients with CNS Lymphomas By Minimal-Invasive Detection of Circulating Tumor DNA in Cerebrospinal Fluid
2957 - High Grade B-Cell Lymphoma with BCL2 and MYC Rearrangement (Double-Hit High-Grade Lymphoma; DH-HGL): Establishment of a Human Model System for Ex Vivo and In Vivo Studies

Baumgartner, F.

1351 - Parallel Sequencing of Transposons and Transcriptomes in Single Cells for Genome-Wide Cancer Gene Discovery
2732 - A Unified Post-Transcriptional Mechanism Regulates Intron Retention in Splicing Factor-Mutant MDS

Baumhardt, T. M.

1901 - Functional and Molecular Analyses Reveal Impaired HSPCs in Multiple Myeloma Patients Post-Induction

Baumhover, S.

2444 - Cold Agglutinin Disease: Virtual Patient Simulation Improves Performance in Diagnosis and Management

Bauquet, A.

3457 - SMART101 Donor T-Lymphoid Progenitors to Accelerate Immune Reconstitution Post HLA Mismatched Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide: Reset-02 First-in-Human Phase I/II

Baurmann, H.

367 - Targeting Lymphoma Associated Myeloid-Monocytic Cells through CSF1R Blockade Enhances CAR-T Cell Response in Aggressive B Cell Lymphoma

Bautista, F.

4265.3 - APAL2020K/ITCC-101: A Phase I Trial of the Menin Inhibitor Ziftomenib in Combination with Chemotherapy in Children with Relapsed/Refractory KMT2A-rearranged, NUP98-rearranged, or NPM1-mutant Acute Leukemias

Baverel, P. G.

2881 - MP0533 (CD33 x CD123 x CD70 x CD3), a Tetra-Specific CD3-Engaging Darpin for the Treatment of Patients with Relapsed/Refractory AML or MDS/AML: Results of an Ongoing Phase 1/2a Study

Bawek, S.

4236 - Optimal Therapy for Secondary Acute Myeloid Leukemia after Prior Hypomethylating Therapy
4678 - Differences in Immune Cell Populations between Individuals with or without MGUS
5158 - Impact of Social Determinants of Health on Survival Outcomes in Multiple Myeloma Patients at a Major Cancer Center

Bawwab, A.

1473 - Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients between 65-75 Years and Treated with Intensive Induction Chemotherapy Versus Hypomethylating Agents and Venetoclax: A Propensity Score Adjusted Cohort Study
1488 - A Comprehensive Analysis of FLT3 Mutation Profiles and Clinical Outcomes in Adult Patients with Acute Myeloid Leukemia: A Single Institution Experience
2848 - Salvage Reinduction Chemotherapy Versus Alternative Regimens after Failed AML Intensive Induction Regimen, a Single Center Experience
2862 - Impact of Cytogenetic Response on Long-Term Survival in Acute Myeloid Leukemia: A Retrospective Cohort Study
2868 - Outcomes of Blast-Phase MPN and JAK2, MPL, and CALR Mutated de Novo AML Compared to AML with Wild-Type JAK2, MPL, and CALR Genes: A Propensity Score-Adjusted Cohort Study
4248 - Survival Outcomes of Patients Diagnosed with Myeloid Sarcoma Versus Acute Myeloid Leukemia: A Retrospective Cohort Study
4249 - Comprehensive Analysis of KMT2A Alterations in Acute Myeloid Leukemia and Their Impact on Survival and Response Rates; A Single Center Experience
4297 - The Prognostic Significance of Chromosome 17 Addition Vs. Complete and Partial Loss in Patients with Acute Myeloid Leukemia, a Single Center Experience

Bay, J. O.

528 - Hemophagocytic Lymphohistiocytosis-like Syndrome after Anti-CD19 CAR T-Cells for B-Cell Lymphoma and B-Cell Acute Lymphoblastic Leukemia: A Lysa, Sfce and Graall Study from the Descar-T Registry
596 - Long-Term Outcome of Unrelated Cord Blood Transplantation in Patients with Idiopathic Refractory Severe Aplastic Anemia: A Nationwide Phase 2 Study
749 - Outcome of Hematopoietic Stem Cell Transplantation for Follicular Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
3027 - Hematopoietic Stem Cell Transplantation for Marginal Zone Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
3483 - Sequential Intensified Conditioning Regimen Allogeneic Transplantation in Younger Adult Patients with Adverse-Risk Acute Myeloid Leukemia: A Multi-Center Prospective Study from the Acute Leukemia French Intergroup on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
4505 - Health-Related Quality of Life after Axi-Cel As a Second-Line Therapy in Patients with High-Risk Relapsed/Refractory Large B-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Results of the Alycante Phase II Trial
4909 - Cyclosporine Versus Cyclosporine Plus Mycophenolate Mofetil in Reduced Intensity Allogeneic Stem Cell Transplantation for Intermediate-Risk AML: A Multi-Center Randomized Study from the Acute Leukemia French Intergroup, on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
4946 - Allogeneic Stem-Cell Transplantation for Relapsed/Refractory ALK–Positive Anaplastic Large-Cell Lymphoma: A Study from the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)

Bay, J. O.

3129 - A Real-World Weighted Comparison of Tisagenlecleucel and Axicabtagene Ciloleucel CAR T Cells in Relapsed or Refractory Diffuse Large B Cell Lymphoma Aged 75 Years and Older : A Lysa Study from the Descar-T Registry

Baya, M.

2892 - Optimizing Venetoclax Duration in Combination with Hypomethylating Agents for Newly Diagnosed AML: Impact on Treatment Response and Survival Outcomes
3566 - Clinical Impact of Pretransplant Blinatumomab in Predominantly Hispanic Adults with B-Cell Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Bayer, F.

4307 - MDS-AML Aggregative Risk Classification System (MARCS): A Novel, Enhanced Risk Stratification System Derived from the Combined Unsupervised Analysis of 7,480 MDS and AML Patients

Bayer, M.

901 - Memory CD4⁺ T Cells Recognize Divergent HLA-DP Immunopeptidomes and Contribute to Leukemia Control after Allogeneic HCT

Bayer, R.

1664 - Extended Follow up and Immune Alterations in Patients with Classic Hodgkin Lymphoma (cHL) Treated with Frontline Single Agent Pembrolizumab Followed By AVD Chemotherapy

Bayerl, J.

2235 - Systematic Identification of Gene-Drug Interactions Using an Advanced CRISPR Screening Platform to Predict Therapy Response across Cancer Types

Bayle, H.

3434 - Engineered-NK Cells Expressing Chimeric Ilt Receptors (CIR™) Expand and Eliminate Bone Marrow-Resident HLA-G⁺ AML in NSG Mice

Baylis, R.

121 - Cancer Versus Cardiac Mortality Risk with Adult Thymectomy

Bayoumy, M. S.

176 - Allogeneic Transplantation for Sickle Cell Disease Offers High Rates of Cure with Low Incidence of Severe Chronic GVHD in Both Children and Adults: Real World Data from 2010-2021. An Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party

Bayraktar, L.

1611 - Transcriptome Analysis at Locus-Specific Resolution Identified Alteration in Human Endogenous Retroviruses, a Class of Transposable Elements in Mantle Cell Lymphoma

Baz, R.

247 - Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma
896 - Comprehensive Analysis of Pre-Treatment Biomarkers Associated with Toxicity and Durable Responses in Idecabtagene Vicleucel Therapy for Relapsed/Refractory Multiple Myeloma
1906 - De Novo Resistance and Relapse from Daratumumab Monotherapy in NDMM Is Associated with Immune Evasion and Immunosuppression
1995 - Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Final Results of a Phase II Study
2004 - Predictive Markers for Outcomes after Disease Progression Post BCMA-Directed CAR T-Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma
3021 - Clinical Characteristics and Outcomes of Patients with MYD88 Positive Waldenström Macroglobulinemia: A Single Center Retrospective Analysis
3369 - Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study
3784 - Single Center Real World Experience of Talquetamab in Patients with Relapsed and Refractory Multiple Myeloma
4692 - Patterns of Progression and Outcomes in Multiple Myeloma after Anti-BCMA CAR T-Cell Therapy
4740 - Activity and Safety of Venetoclax (VEN)-Based Treatment in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (R/R MM)
5165 - Meaningful Change in Patient-Reported Outcomes after CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma in Standard of Care: Differences By Race and Ethnicity
5168 - Effect of Talquetamab on Responses in Patients with Relapsed and Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies

Bazarbachi, A. H.

3067 - Promising Safety and Efficacy Data for Peginterferon Alfa-2a (PEG-IFN) and Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy) in a North American Adult T-Cell Leukemia Lymphoma (NA-ATLL) Cohort of Patients

Bazarbachi, A. H.

287 - Development of a Risk Prediction Model for 6-Month Early Mortality in Patients with Systemic Light Chain Amyloidosis Treated with Daratumumab-Based Frontline Therapy

Bazarbachi, A.

Bazaz, A. S.

4706 - Impact of Kidney Transplantation on Hospitalization Outcomes in Patients with Multiple Myeloma

Bazeos, A.

1631 - Glofitamab Induces High Response Rates and Durable Remissions in Patients (Pts) with Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL), Including Those with a Poor Prognosis: Subgroup Results from a Phase I/II Study

Bazinet, A.

Bazinet, A.

1820 - Prognostic Impact of the Number of TET2 Mutations in Myelodysplastic and Myeloproliferative Chronic Myelomonocytic Leukemia (CMML)
3204 - Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia
4593 - Predictors of Blast Transformation (BT) and Post-BT Survival in Chronic Myelomonocytic Leukemia (CMML)

Bazoum, H. M.

621 - Rap-536, a Murine Luspatercept Analog Ameliorates Anemia and Vaso-Occlusion in Experimental Model of Sickle Cell Disease

Bazzi, L.

1664 - Extended Follow up and Immune Alterations in Patients with Classic Hodgkin Lymphoma (cHL) Treated with Frontline Single Agent Pembrolizumab Followed By AVD Chemotherapy

Bazzo Catto, M.

1330 - Novel Germline ZCCHC8 Mutations Causes Dyskeratosis Congenita with Genetic Rescue By Uniparental Disomy of Chromosome 12q

Bazzoni, F.

4132 - Activating STAT3 Mutations Drive CD38 Expression in T-Large Granular Lymphocytic Leukemia

Bdeir, K.

185 - Antiphospholipid Syndrome (APS) Is a Platelet Factor 4 (PF4)-Centric Immunothrombotic Disorder

Bea, S.

333 - CD70 Deregulation in Follicular Lymphoma at Diagnosis Is Associated with Relapse and Opens New Avenues for Dual CD19-CD70 CAR-T Therapy

Bear, B.

605 - Empowering Adolescents and Young Adults with Sickle Cell Disease: Development of a Shared Decision-Making Toolkit for Disease-Modifying Therapies

Beas, F.

1935 - Ultra-Deep Sequencing of TP53 in Multiple Myeloma: Double-Hit Prevalence and Clinical Phenotype

Beasley, K.

291 - Integrative Strong Body and Mind Training for Sickle Cell Disease (I-STRONG)—an Interdisciplinary, Multicomponent Treatment Approach for Pediatric Chronic SCD Pain

Beattie, G.

669 - Tumour-Intrinsic Features Shape T-Cell Differentiation through Myeloma Disease Evolution
2830 - A Non-Canonical Lymphoblast in Refractory Childhood T-Cell Acute Lymphoblastic Leukemia

Beattie, K.

4610 - Topic Modeling of Genotyping of Transcriptomes Reveals Collaboration between BTK^C481S-Mutant and Wild Type Cells in Btki-Resistant Chronic Lymphocytic Leukemia

Beatty, B.

1867 - Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)

Beatty, N.

3432 - Correlation of Serum Inflammatory State and Macrophage Phenotype with CAR T Cell Expansion and Clinical Outcomes

Beatty, W.

4041 - Loss of Microtubule Protein Stathmin-1 Impairs Autophagy in Hematopoietic Stem Cells

Beauchemin, M. P.

785 - Churn, Churn Churn! a Mixed Methods Analysis of Young Adult Leukemia and Lymphoma Survivors’ Experience Navigating the Insurance Landscape in a Post Affordable Care Act Era
5042 - Association between Food Insecurity, Financial Toxicity, and Healthcare Utilization in Patients with Lymphoma

Beaudet, M. E.

Beaudin, A. E.

2648 - Mitochondrial Metabolism Underlies Developmental Programming of Hematopoietic Stem Cell Function By Prenatal Folate

Beaulieu, V.

353 - Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Beaumont, T.

2011 - Long-Lasting AML-Specific Antibody Responses after Allogeneic Hematopoietic Progenitor Cell Transplantation

Beauvais, D.

965 - Second Infusion of CAR T-Cells in Patients with Relapsed /Refractory B-Cell Acute Lymphoblastic Leukemia: Results from a Gocart Coalition Analysis on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT
4903 - Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe

Beauvais, D.

2333 - Real-World Outcomes of CD19-Targeted CAR T-Cell Therapy in Adult and Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Insights from the GoCART Coalition on Behalf of the PDWP, ALWP, and CTIWP of the EBMT

Beauvais, D.

2079 - Myeloid Neoplasia after CD19 Directed CAR-T Cells : Cumulative Incidence, Risk Factors and Outcome

Beaven, A. W.

919 - CD30.CAR-T Cells Co-Expressing the CCR4 Chemokine Receptor in Relapsed/Refractory Hodgkin Lymphoma
982 - Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort
3468 - Phase 1 Trial of CD30-Directed, CCR4 Co-Expressing Chimeric Antigen Receptor T-Cells in Patients with CD30⁺ Cutaneous T-Cell Lymphomas Refractory to Brentuximab Vedotin
1661.3 - Trial in Progress – Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma

Beber, L. B.

861 - Iopofosine I 131 in Previously Treated Patients with Waldenstrom Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaM)

Bebrevska, L.

180 - Pharmacokinetics/Pharmacodynamics, Safety, and Efficacy of Crizanlizumab in Patients with Sickle Cell Disease Aged 6 to <12 Years: 2-Year Data from the Phase 2 Solace-Kids Study

Becerra, H.

1134 - Differences in the in-Hospital Outcomes of Sickle Cell Crisis Among Patients with and without Liver Cirrhosis: A Nationwide in-Patient Analysis
1930 - Prognostic Factors for Survival in Multiple Myeloma Patients That Receive Bispecific Antibodies: Does Relative Dose Intensity Matters?
5170g - Multiple Myeloma (MM) Clinical Characteristics, Prognostic Factors and Survival in Adolescents and Young Adults (AYA)

Bech, S. C.

1806 - Identification of Calr Mutations in Individuals of the Background Population Reveals Undiagnosed Myeloproliferative Neoplasms and Surprisingly Stable Low Levels of Calr Mutant Allele Burden in Individuals Not Developing Myeloproliferative Neoplasm during 10-14 Year Follow-up

Bechara, S. B.

2617 - Can Machine Learning Supplant the Plasmic Score in Improving the Early Diagnosis of Thrombotic Thrombocytopenic Purpura?

Bechtold Javier, E.

1838 - Impact of Transfusion Dependency on Patients Diagnosed with Myelodysplastic Syndrome According to IPSS-M Risk Group

Becicka, W.

807 - The Ectopyrase CD73 Is a Critical Checkpoint in Thromboinflammation

Becilli, M.

2827 - Rescuing of the Chemotherapy Sensitivity in Relapsed/Refractory, Pediatric Acute Lymphoblastic Leukemia (r/r ALL) through the Combination of Navitoclax (NAV) and Venetoclax (VEN): Results of Compassionate Use across Four European Countries
3561 - Outcomes of Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia Given Blinatumomab As Last Consolidation Treatment before Allogeneic Hematopoietic Cell Transplantation
4830 - CD7.Pebl-CART for Patients with Relapsed/Refractory (r/r) T-Cell Acute Lymphoblastic Leukemia (T-ALL)
4834 - Phase I/II Clinical Trial on CD19-Chimeric Antigen Receptor (CAR) T Cells Generated with an Automated Process, from Fresh Apheresis, and Reinfused As Fresh Drug Product for Pediatric/Young Adult Patients with Relapsed/Refractory (r/r) B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

Beck, A.

4143 - The Bispecific Innate Cell Engager AFM28 Can Leverage AML Patient’s NK Cells in Addition to Allogeneic NK Cells, Enabling Elimination of CD123+ Leukemic Stem and Progenitor Cells in AML and MDS

Beck, C. E.

547 - Critical Bleeding in Adults and Children with Immune Thrombocytopenia: A Multicentre Cohort Study

Beck, D. B.

187 - The Mechanism of Cell Autonomous Inflammation in VEXAS Syndrome Is Mediated By Proteotoxic Stress
2686 - DNMT3A Mutant Clonal Hematopoiesis in Vexas Syndrome Epigenetically Potentiates IL-13 and IL-15 Inflammatory Pathways and Is Associated with Increased Mortality

Beck, J.

961 - Chemotherapy or Stem Cell Transplantation in Adult High Risk Ph/BCR::ABL1-Negative ALL Patients with Early MRD Negativity: Results of the Randomized GMALL Trial 08/2013

Beck, J.

1583 - Guiding Treatment and Clinical Management of Patients with CNS Lymphomas By Minimal-Invasive Detection of Circulating Tumor DNA in Cerebrospinal Fluid
4374 - The Effect of Ibrutinib on the Myeloid Cell Compartment in Central Nervous System Lymphoma Slice Cultures

Beck, S.

3005 - High Tumor Mutational Burden Associates with Increased CD8 T-Cell Presence, Decreased Tumor Heterogeneity, and Increased AICDA Expression in an HIV-Inclusive Cohort of Diffuse Large B-Cell Lymphoma
4344 - Immunogenomic Profiles of EBV-Associated Classic Hodgkin Lymphoma in an HIV-Inclusive Cohort

Beckedorff, F.

4051 - Vitamin A Directly Enhances TET2 Activity and Suppresses Clonal Hematopoiesis

Becker, H.

406 - Intraindividual Comparison of Recognition of Symptom Burden in MPN between Patient- and Physician-Reported Assessment and Its Impact on Survival – an Analysis By the German Study Group for MPN (GSG-MPN)

Becker, I. C.

422 - Tet2 Age-Associated Somatic Mutations Impair Megakaryopoiesis and Platelet Function in Clonal Hematopoiesis
819 - Cytokine Secretion from Megakaryocytes Is Governed By Small GTPASES through Autophagy
1171 - Acute CCL5 Exposure Promotes Megakaryopoiesis through Non-Canonical Pathways
1173 - Priming of Megakaryopoiesis and Platelet Production through DNA Damage Repair Inhibition
3930 - Bone Marrow Remodeling and Pro-Inflammatory Megakaryocytes in a Murine Model of Chronic Kidney Disease

Becker, L.

189 - The High Mobility Group A1 (HMGA1) Chromatin Regulator Induces Inflammatory Signals and Promotes Atherogenesis in Tet2 Mutant Clonal Hematopoiesis

Becker, M. W.

1302 - Temporal Single Cell Analysis of Myeloid Leukemia Microenvironment
2711 - The LMO2-LDB1-TAL1 Complex Regulates Transcription Networks in AML Relapse

Becker, M.

2728 - PTBP1, an RNA Binding Protein and Splicing Regulator, Binds RUNX1 and Co-Localizes at Target Gene Promoters in Leukemia

Becker, M.

2798 - Relative Influence of Socioeconomic and Biological Determinants of Outcomes in Adult Acute Lymphoblastic Leukemia

Becker, N.

768 - Multiomics Data Integration in the Complete Myeloma Genome Reveals Frequent Centromeric Rearrangements and Their Epigenomic Consequences
1882 - Phylogenetic Analysis Reveals Distinct Evolutionary Patterns in Multiple Myeloma Patient Derived Xenografts
4644 - Reconstructing Catastrophic Chromothripsis Events Using Multiomic Data Reveals Their Functional Impact in Multiple Myeloma
4667 - Non-Hotspot DIS3 Mutations in Multiple Myeloma Result in Loss of Function Accompanied By Transcriptional and Proteomic Dysregulation

Becker, P. S.

729 - TP53 Mutations Increased the Risk of CD19 Negative Relapse Following Blinatumomab in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)
733 - Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial
1293 - iPSC Reprogramming Identifies the Role of Cryptic Drivers in Preleukemic Clonal Evolution
2758 - Combined CXCR-4 Inhibition with Novel Agent GPC-100 (burixafor) and Beta 2 Adrenergic Receptor Blockade Enhances Cytarabine Response for Acute Myeloid Leukemia Blasts on Stroma
4935 - Outcomes of Hypomethylating Agents/Venetoclax (HMA/VEN) Treatment for Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplant (alloHCT)

Becker, S. A.

2022 - Characterizing the Microbiome-Immune Axis in Hematopoietic Stem Cell Recipients

Becker, S.

4354 - Circulating Tumor DNA for Primary Mediastinal B-Cell Lymphoma Genotyping: A Prospective Multicenter Study

Becker-Hapak, M.

4414 - Mosunetuzumab Plus Polatuzumab Vedotin Induces Early Complete Responses in Previously Untreated High Tumor Burden Follicular Lymphoma

Beckerich, F.

4875 - Erythroid-Specific Chimerism Analysis after Allogeneic-Hematopoietic Stem Cell Transplantation Using a Human Leukocyte Antigen-Identical Sibling Donor in Sickle Cell Disease Patients

Beckers, E. A.

1174 - The Use of ATP-Release Identifies Platelet Function Disorders in Patients with Bleeding Disorder of Unknown Cause (BDUC) and Normal LTA Results
2251 - Health Related Quality of Life (HrQoL) in Patients with Bleeding Disorder of Unknown Cause (BDUC)

Beckford, C.

4092 - Germline Variant Burden Warrants Universal Genetic Testing in Pediatric AML

Beckman, A.

2949 - Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children’s Oncology Group

Beckman, J. D.

16 - Anticoagulation Management of Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: A Global Abdominal/Splanchnic Thrombosis Retrospective Observational Study in 486 MPN Patients (GASTRO-MPN)
- JAK-STAT Inhibition of Endothelial Activation

Beckmann, L.

645 - Cytokine-Linked Remodeling of the Immune Microenvironment Is a Hallmark of Transformation in Follicular Lymphoma
3250 - Venetoclax May Overcome the Prognostic Disadvantage of Short Telomeres Regarding Progression Free Survival in Previously Untreated CLL Patients with Coexisting Conditions: A Study By the German CLL Study Group (GCLLSG)

Beckwith, J. D.

1019 - A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome
1894 - Novel Non-Coding Candidate Drivers of Multiple Myeloma Linked to Plasma Cell Tumor Biology and B Cell Development

Becnel, M. R.

1584 - Characterization of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Using Single Cell Transcriptomic Analysis
1922 - Predictive Factors for Transplant Outcomes of Cardiac AL Amyloidosis
1923 - Impact of Age on Autologous Stem Cell Transplantation Outcomes for AL Amyloidosis
1971 - Unveiling Clinical Potential: Exploring Cytogenomic Aberrations through Optical Genomic Mapping in Multiple Myeloma
3024 - Prognostic Significance of TP53 Mutations in Lymphoplasmacytic Lymphoma
3272 - Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma
4687 - Clearance of Circulating Multiple Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
4737 - Personalized Neoantigen Peptide Vaccine with or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma (SMM) to Prevent Progression to Multiple Myeloma (MM)
5154 - Impact of Ethnicity on Long Term Outcomes of High-Dose Chemotherapy and Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma

Bedard, K.

2785 - LY4152199, a First-in-Class BAFF-RxCD3 Bispecific Antibody for the Treatment of B Cell Malignancies

Bedell, V.

2976 - HIV-Associated Diffuse Large B-Cell Lymphoma Shows Different Genomic Patterns between EBV-Positive and EBV-Negative Tumors

Bedelu, Y. B.

111 - Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study
1473 - Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients between 65-75 Years and Treated with Intensive Induction Chemotherapy Versus Hypomethylating Agents and Venetoclax: A Propensity Score Adjusted Cohort Study
1488 - A Comprehensive Analysis of FLT3 Mutation Profiles and Clinical Outcomes in Adult Patients with Acute Myeloid Leukemia: A Single Institution Experience
2848 - Salvage Reinduction Chemotherapy Versus Alternative Regimens after Failed AML Intensive Induction Regimen, a Single Center Experience
2862 - Impact of Cytogenetic Response on Long-Term Survival in Acute Myeloid Leukemia: A Retrospective Cohort Study
2868 - Outcomes of Blast-Phase MPN and JAK2, MPL, and CALR Mutated de Novo AML Compared to AML with Wild-Type JAK2, MPL, and CALR Genes: A Propensity Score-Adjusted Cohort Study
4221 - Impact of TP53 Mutation on Survival Outcomes in Acute Lymphoblastic Leukemia at a Tertiary Center
4248 - Survival Outcomes of Patients Diagnosed with Myeloid Sarcoma Versus Acute Myeloid Leukemia: A Retrospective Cohort Study
4249 - Comprehensive Analysis of KMT2A Alterations in Acute Myeloid Leukemia and Their Impact on Survival and Response Rates; A Single Center Experience
4297 - The Prognostic Significance of Chromosome 17 Addition Vs. Complete and Partial Loss in Patients with Acute Myeloid Leukemia, a Single Center Experience

Beder, T.

318 - Drug Sensitivity and Treatment Response Are Modulated By the Cell of Origin, the Underlying Gene Fusion, and Patient Age in KMT2A-Rearranged BCP-ALL
631 - IDH2 Mutations from Clonal Hematopoiesis and Acquired IKZF1 Deletions Define a Novel B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma
1458 - C/EBP Family Member Gene Fusions and Cooperating Genomic Events Define Two Distinct Molecular Sub-Groups in Adult B Precursor ALL
2832 - Recurrent Molecular Variants, Clonal Evolution and Clinical Relevance in T-Cell Lymphoblastic Neoplasia Comparing Lymphoma and Leukemia Samples Derived from Children and Adults
4213 - Integrateall, a Machine Learning Pipeline for Multi-Level Data Extraction from RNA-Seq Profiles Unravels Novel Drivers and Systematic Subtype Classification in B-Cell Precursor ALL

Bedi, K.

1528 - Identification of Novel Genes Underlying Human AML Expansion at Relapse from Chemotherapy
4151 - AML Blasts Intrinsic Interferon Production Causes Resistance to Venetoclax in Human Acute Myeloid Leukemia Via Upregulation of MCL1, BCL2A1 and BCL-XL

Bedirian, K.

2870 - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results

Bednarski, J. J.

375 - Alemtuzumab, Fludarabine, Melphalan, and Thiotepa As Reduced-Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Inborn Errors of Immunity
1335 - Loss of BCLAF1 Impairs AML Pathogenesis
2088.1 - NK Cell Immunotherapy to Reduce Relapse after Haploidentical Transplant for High-Risk Pediatric and Young Adult AML

Bedognetti, D.

4368 - Impact of Inflammation, Tumor and Product Attributes on Clinical Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Axicabtagene Ciloleucel

Bedoy, A.

61 - Single-Cell Multiomics Unveils Venetoclax-Resistant Monocytic Differentiation and Immune Evasion in TP53 Mutant AML Clones
330 - TP53 Mutations within T Cells Induce T-Cell Exhaustion and Functional Impairment in TP53 Mutant AML
1301 - Spatial Analysis of Human p53 Mutated AML Bone Marrow Reveals Novel MRD Clusters and Spatial Microenvironmental Features of p53 Mutated AML
4155 - Reactivation of p53 in TP53-Y220C Mutant AML: Mechanism of Action and Mechanism-Based Drug Combinations

Beebe, L.

2205 - Characterization of the Biochemical Activity of Ktx-1001, a Selective Small Molecule NSD2 Inhibitor, in Surface Plasmon Resonance (SPR)

Beedupalli, K.

137 - Targeting Neutrophil CD14 Inhibits Deep Vein Thrombus Formation and Enhances Thrombus Resolution Following Inferior Vena Cava Stenosis in Mice

Beeker, A.

1013 - Improved Efficacy with Response- and MRD-Guided Ibrutinib–Obinutuzumab (IO) Intensification after Ibrutinib-Venetoclax (IV) in First Line Chronic Lymphocytic Leukemia (CLL) Patients: Primary Analysis of the HOVON 158/Next STEP Phase 2 Trial
1588 - Cell-Free DNA Genomic and Fragmentomic Features for Early Outcome Prediction in Diffuse Large B-Cell Lymphoma
4380 - Immunosuppressed Tumor Microenvironment in MYC-Rearranged High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas, Not Otherwise Specified

Beeler, J. S.

1285 - Predictive Modeling of Clonal Hematopoiesis across Diverse Cohorts

Beenen, L. F.

1246 - Imaging Predictors of Intracerebral Hemorrhage in Patients with Brain Tumors Treated with Anticoagulation

Beer, S. A.

4464 - Primary Vitreoretinal Lymphoma: A Comprehensive Retrospective Analysis of 65 Cases at Two European Centers

Beer, T. C.

2398 - Dosing Patterns and Early Safety and Effectiveness Outcomes in Patients with Multiple Myeloma Treated with Teclistamab in the Community Setting

Beerenwinkel, N.

4307 - MDS-AML Aggregative Risk Classification System (MARCS): A Novel, Enhanced Risk Stratification System Derived from the Combined Unsupervised Analysis of 7,480 MDS and AML Patients

Beesam, R.

1019 - A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome
1894 - Novel Non-Coding Candidate Drivers of Multiple Myeloma Linked to Plasma Cell Tumor Biology and B Cell Development

Beggiato, E.

2321 - The Association of Anemia and Patient Reported Outcomes in the New Era of PNH Treatment
2464 - Reaction - Real Life Use of Ravulizumab in Italian Patients with Paroxysmal Nocturnal Hemoglobinuria a Multicenter Observational Retrospective and Prospective Cohort Study, Final Results

Beghin, A.

2142 - Improvement of Survival By Use of New Tecniques of Manipulation after Haploidentical Hematopoietic Stem Cell Transplantation: Report of 230 Transplants in Paediatric Patients with Primary Immunodeficiencies and Oncological Diseases

Begic, X.

4751 - Final Results of Phase 1 Clinical Trial of Belantamab Mafodotin Combined with Carfilzomib, Lenalidomide, and Dexamethasone for Multiple Myeloma after One to Three Prior Lines of Therapy

Begley, S.

5194 - Outcomes with Real-World Use of Azacitidine and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Are Comparable to Long-Term Viale-a Results

Begley, V.

1104 - Small Activating RNA-Mediated Induction of HBG Via Liposome Delivery for In Vivo Treatment of Sickle Cell Disease and Beta-Thalassemia

Begna, K.

244 - TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance
1798 - Pacritinib Therapy for JAK2 Inhibitor-Naïve or -Experienced Patients with Myelofibrosis: Mayo Clinic Series of 60 Consecutive Patients Treated Outside of Clinical Trials
2852 - Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
2878 - A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
3169 - Monocytosis Is an Independent Risk Factor for Survival in Essential Thrombocythemia - a Revised Triple-a Prognostic Score (AAA+A) Based on Age and Absolute Monocyte, Neutrophil, and Lymphocyte Counts
3213 - Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms
4247 - Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent

Béguelin, W.

739 - Follicular Dendritic Cells Represent a Therapeutic Vulnerability in Early Follicular Lymphoma

Beguin, Y.

112 - “Real World” Outcome of Hematopoietic Stem Cell Transplantation after CAR19 T Cell Therapy in Children and Adults with B-ALL: A Gocart Coalition Study on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT
4907 - The Use of MSCs in Steroid-Refractory Acute GvHD in Europe: A Survey from the EBMT Cellular Therapy & Immunobiology Working Party

Begun, J.

166 - Endotoxemia As Possible Cause of Inflammatory Bowel Diseases-Associated Anemia

Behan, M.

2550 - A Freeze-Dried Platelet-Derived Hemostat Decreases Bleeding in a Novel Murine Model of Type 1 Hermansky-Pudlak Syndrome

Behan, P.

4983 - Application of a Novel Artificial Intelligence Algorithm to Understand Spatial Immune Cell Relationships in Newly Diagnosed Multiple Myeloma

Behbehani, G. K.

954 - A Protein-Coding Circular RNA That Regulates DNA Damage Response in BCR::ABL-Positive Leukemias
2078 - Initial Results of a First-in-Human, Phase I Study Point-of-Care Manufacturing of Trispecific CAR-T Cells Targeting CD19/20/22 in B-Cell Malignancies
2432 - Real-World Experience of Venetoclax Target Dosing with Concomitant Posaconazole in Adult Patients with Acute Myeloid Leukemia
4286 - A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination with Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

Beheshti, R.

380 - Serial Clinical and Biomarker Monitoring during Treatment Can Stratify Patients with Low Risk Gvhd

Behjati, S.

2830 - A Non-Canonical Lymphoblast in Refractory Childhood T-Cell Acute Lymphoblastic Leukemia

Behl, R.

3132.1 - ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after Response to Standard Therapy

Behman, J.

2181 - Comparative Analysis of Donor and Conditioning Intensity in the MRD and Ptcy Era in Philadelphia + Acute Lymphoblastic Leukemia (Ph+ ALL). a 12-Year Span Report of 119 Center CIBMTR Report

Behrendt, M. A.

152 - The Transcriptional Activators p300/Crebbp Are Context-Dependent Functional Repressors of Interferon Genes, Offering Therapeutic Promise in AML
722 - Acute Resistance to BET Inhibitors Remodels Compensatory Transcriptional Programs Via p300 Co-Activation

Behrens, E.

168 - TNFα Plays Essential Role in Resolution of Anemia of Inflammation in Tnfαko Mice Treated with Heat-Killed Brucella Abortus

Behrens, Y. L.

1835 - Refractory Cytopenia in Childhood Under Watch and Wait Strategy: Safe until Adulthood?

Behringer, K.

1662 - Patient-Reported Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classical Hodgkin Lymphoma Treated with BrECADD and eBEACOPP in the HD21 Trial
2346 - Estimation of Health State Utility Values for Patients Undergoing First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the HD21 Trial
4426 - Impact of Treatment-Related Morbidity on Health-Related Quality of Life in Patients with Advanced-Stage Classical Hodgkin Lymphoma Receiving Multiagent Therapy: Findings from the HD21 Study

Behrmann, L.

2831 - Cerebrospinal Fluid Flow Cytometry Improves Patient Stratification in Central Nervous System Acute Lymphoblastic Leukaemia but Requires Careful Standardization: Results from the ALLTogether1 CSF-FLOW Sub-Study

BEI, J. X.

2963 - Frequent Copy Gains of Viral LMP-1 Confers Radiosensitivity in Natural-Killer/T Cell Lymphoma

Beier, F.

1327 - Application of Machine Learning in the Diagnostic Work-up of Telomere Biology Disorders
1835 - Refractory Cytopenia in Childhood Under Watch and Wait Strategy: Safe until Adulthood?
2179 - Outcome after Allogeneic Stem Cell Transplant in Adults with Inherited Myeloid Malignancies – a Multicenter Retrospective Analysis on Behalf of the German Cooperative Transplant Study Group
3250 - Venetoclax May Overcome the Prognostic Disadvantage of Short Telomeres Regarding Progression Free Survival in Previously Untreated CLL Patients with Coexisting Conditions: A Study By the German CLL Study Group (GCLLSG)
4082 - The Impact of Body Mass Index (BMI) in Patients with Aplastic Anemia Receiving Weight-Adjusted Horse Anti-Thymocyte Globulin (hATG) on Outcome, Response and Relapse Rate

Beier, R.

3548 - Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia: Results of the AML BFM Study Group

Beilhack, A.

2018 - Local Myeloid Network Resilience Determines Organ-Specific Acute GvHD Outcomes
2023 - CD47 Upregulation Inhibits Phagocytic Clearance of Alloreactive Donor T Cells after Allo-HCT
3397 - TNFR2, GITR and DR3 Agonists Exert Distinct Response Durations in Treg-Mediated Acute Graft-Versus-Host Disease Protection
3402 - Allogeneic Hematopoietic Cell Transplantation Promotes Atherosclerosis in Mice Driven By Donor CD8+ T Cells
4665 - CD31 and JAM-a Expressing Circulating Tumor Plasma Cells As Prognostic Biomarkers for Multiple Myeloma Disease

Beishuizen, A.

2985 - High Clinical Benefit of Diagnostic RNA Sequencing in Pediatric T-Cell Lymphoblastic Lymphoma for the Identification of Potentially Targetable Risk Groups
3055 - Pembrolizumab in Children, Adolescents, and Young Adults with High-Risk Classic Hodgkin Lymphoma (cHL) with Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study
3108 - Brigatinib Monotherapy in Children with R/R ALK+ ALCL, IMT, or Other Solid Tumors: Updated Results from the Brigaped (ITCC-098) Phase 1 Dose-Escalation Study

Beiske, K.

231 - Biological and Prognostic Subgroups of Plasmablastic Lymphoma Defined By EBV Status and MYC Rearrangement– an L.L.M.P.P. Study
747 - Acalabrutinib and Rituximab in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma Including a Matched Population-Based External Comparator- the Nordic Lymphoma Group NLG-MCL8 (ALTAMIRA) Phase II Trial

Beitinjaneh, A. M.

70 - Updated Clinical Results: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein–Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab Plus Chemotherapy
337 - Loncastuximab Tesirine with Rituximab Induces Robust and Durable Complete Metabolic Responses in High-Risk Relapsed/Refractory Follicular Lymphoma
3765 - Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium
4388 - Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2

Beitz, L. O.

502 - Vivovec™ Surface-Engineered Lentiviral Particles Mediate In Vivo CAR T Generation with Potent and Highly Durable Activity in Non-Human Primates

Bejan, C.

3607 - Combined Natural Language Processing and Gpt-4 Pathology Report Interpretation Efficiently Identify a Myelodysplastic Syndrome Cohort for Large Scale Clinical Research Applications

Bejanyan, N.

1046 - Measurable Residual Disease Monitoring By Duplex Sequencing for TP53 in the Post Allogeneic Stem Cell Transplantation Study with Eprenetapopt (APR-246) + Azacitidine Strongly Predicts Outcomes
1048 - Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms
2071 - Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
2103 - Delayed Immune Reconstitution and Increased Infections in Allogeneic Transplant Recipients with B Cell Malignancies Treated Previously with CAR T-Cell Therapy
2130 - Letermovir Prophylaxis Reduces the Risk of Cytomegalovirus Infection in HLA-Matched and Mismatched Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide
4826 - Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic Transplantation
4871 - Similar Cardiac Toxicity Following Allogeneic Hematopoietic Cell Transplant (alloHCT) with Post-Transplant Cyclophosphamide Versus Calcineurin Inhibitor-Based Graft-Versus-Host Disease Prophylaxis
4881 - Low Risk of Relapse and Favorable Survival after Allogeneic Transplantation with Fludarabine and Melphalan Conditioning for Measurable Residual Acute Myeloid Leukemia

Bejar, R.

1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1831 - Progression of Myelodysplastic Syndromes in the MDS Natural History Study (MDS NHS)
3220 - Robust Copy Number Alteration Detection (RCNA): A Novel Algorithm for Detecting Copy-Number Alterations for Targeted Gene Sequencing Experiments
4255 - Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML
4597 - Association between Smoking Intensity, Genetic Mutations, and Disease Progression in Myelodysplastic Syndromes

Bejarano Garcia, J. A.

2096 - Assessing CAR-T Cell Product Quality: The Crucial Role of Metabolic and Persistence Analysis after Antigen Stimulation
3395 - Role of Antiapoptotic Protein Mcl1 in Graft-Versus-Host Disease
3478 - Innovative Bone Marrow CAR-T Cell Manufacturing for AML: Enhancing Viability and Tumor Migration

Bekadja, M. A.

2379 - Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis from the Worldwide Network for Blood and Marrow Transplantation Global Study
4733 - Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study

Bekendam, R. H.

1173 - Priming of Megakaryopoiesis and Platelet Production through DNA Damage Repair Inhibition

Bekiranov, S.

2711 - The LMO2-LDB1-TAL1 Complex Regulates Transcription Networks in AML Relapse

Bekkers, M.

1408 - JNJ-87801493 (CD20xCD28), a Potential First-in-Class CD20 Targeted CD28 Costimulatory Bispecific Antibody, Enhances the Activity of B-Cell Targeting T-Cell Engagers in Preclinical Models

Bekri, S.

4513 - JAK Inhibition Results in Aggressive Cutaneous Squamous Cell Carcinoma through MAPK Pathway Activation and Shapes the Tumor Immune Microenvironment to Create Novel Therapeutic Opportunities

Beksac, M.

487 - Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study
494 - Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial
674 - Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial
3328 - An International Study of 343 Newly Diagnosed MM Patients with Acute Renal Failure Due to Cast Nephropathy: Assessment of Factors Affecting Renal Response
3355 - Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM)
4731 - Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide
4733 - Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study

Beksac, M.

362 - Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial
773 - Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study
891 - Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study
2000 - Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)
2411e - Real-World Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Iona-MM Second Interim Analysis
3352 - Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study

Bektic, L.

1199 - Preclinical Evaluation of NXT007 Using in Vitro and In Vivo Models of Hemostasis and Thrombosis

Belachew, A.

969 - Venetoclax Plus Azacitidine for Newly Diagnosed Younger Acute Myeloid Leukemia Patients Independent of Fitness for Intensive Chemotherapy
4259 - Results from a Clinical Study of the All-Oral Regimen of CC-486 (Oral Azacitidine) and Venetoclax for Newly Diagnosed and Relapsed and Refractory Acute Myeloid Leukemia

Belada, D.

342 - Fixed-Duration Epcoritamab + R² Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial
581 - Fixed-Duration Epcoritamab + R-CHOP Induces High Complete Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Withhigh-Risk Features: Long-Term Results from the Epcore NHL-2 Trial
867 - Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma
1626 - High-Risk Subgroups and MRD: An Updated Analysis of the Phase 3 ECHO Trial of Acalabrutinib with Bendamustine/Rituximab in Previously Untreated Mantle Cell Lymphoma
1697 - The Survival Improvement of Transplant-Eligible Primary CNS Lymphoma Patients within Last 15 Years
1711 - PCNSL Patients Treated with the Matrix Regimen in the Real World Have Similar Outcome to Those in the IELSG 32 Trial
3106 - Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial
4411 - Odronextamab Monotherapy in Previously Untreated Patients with High-Risk Follicular Lymphoma (FL): Results of the Safety Lead-in of the Phase 3 Olympia-1 Study

Beland, S.

5068 - Validitation of the Rowland Universal Dementia Assessment Scale (RUDAS) for the Detection of Cognitive Impairment Among Adults with Sickle Cell Disease

Belani, R.

2083 - Late Polyclonal P-BCMA-101 CAR-T Cell Re-Expansion and Rapid Complete Response in a Patient with Relapsed Multiple Myeloma Treated with One Cycle of Talquetamab, More Than 3 Years after CAR-T Infusion
4805 - P-CD19CD20-ALLO1: Potent Fully Allogeneic CAR-T Therapy Targeting CD19 and CD20 with Superior Efficacy over Single-Target Products
4828 - A Phase 1 Study of P-BCMA-ALLO1, a Non-Viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM): Results from Optimized Lymphodepletion Cohort

Belay, K.

381 - Multi-Omics Immune Profiling of Graft-Versus-Host Disease (GvHD) in Humans

Belcher, H.

2388 - Evolution of Treatment Patterns and Survival Outcomes in European Patients with Multiple Myeloma from 2012-2023 through the Honeur Federated Data Network
3300 - A Novel Approach to Lower Risk Monoclonal Gammopathy of Undetermined Significance (MGUS) Follow-up Based on Isotype-Specific Annualised Progression Risk: A Retrospective Real World Evidence Single Centre UK Study

Belcher, J. D.

2482 - Bruton Tyrosine Kinase Inhibitor Rilzabrutinib Reduces Vaso-Occlusion and Markers of Inflammation and Adhesion in Transgenic Mice with Sickle Cell Disease
3866 - Oral Administration of Nitrous Oxide Reduces Acute Vaso-Occlusive Pain in Mice with Sickle Cell Disease

Belderbos, M. E.

2735 - Single-Cell Whole Genome Sequencing Reveals the Evolution and Migration of Lymphoma
4062 - Characterizing the Bone Marrow Stromal Niche in Pediatric Acute Myeloid Leukemia

Beldinanzi, M.

2836 - Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial

Beldzinska-Gondek, K.

4268 - The Experience of Commercially Available CPX-351 Use As First-Line Treatment for Patients with Acute Myeloid Leukemia – a Report of Polish Adult Leukemia Group (PALG)

Belendez, C.

176 - Allogeneic Transplantation for Sickle Cell Disease Offers High Rates of Cure with Low Incidence of Severe Chronic GVHD in Both Children and Adults: Real World Data from 2010-2021. An Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party
3463 - Alloreactive Vs IL15 Ex Vivo Stimulated Natural Killer Cells As Adoptive Cell Therapy in Haploidentical Transplantation for Pediatric Acute Leukemia: A Phase I/II Clinical Trial

Belew, M. S.

4806 - A Regulated Cytokine Engineering Strategy to Augment in Vitro and In Vivo persistence of Allogeneic iPSC Derived CD8 T-Cells

Belhabri, A.

846 - Measurable Residual Disease (MRD) Determinants, Kinetics and Its Impact on Survival in Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia in Frontline Setting : A Multicentric Study from French Auraml Group
1475 - Infectious Complications Among Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia: A Multicentric Real-Life Analysis of the French Auraml Group
1518 - Azacitidine and Venetoclax As a Salvage Therapy for Relapse after Allogeneic Transplantation for Acute Myeloid Leukemia : A Multicentric Study from French Auraml Group
3564 - Allogeneic Hematopoietic Cell Transplantation in Newly Diagnosed and Relapse/Refractory AML Patients Post Venetoclax-Azacitidine Treatment: A Multicenter Real-Life Analysis By the French Auraml Group
4335 - Azacytidine and Venetoclax As a Salvage Therapy in Measurable Residual Disease (MRD) Relapse Post Intensive Chemotherapy or Allogenic Stem Cell Transplantation in Acute Myeloid Leukemia Patients : A Multicentric Study from French Auraml Group

Belhadj Merzoug, K.

2286 - Reducing Infection Risks of Anti-BCMA Bispecific Antibodies in Multiple Myeloma: In-Hospital Vs. Hospital-at-Home Treatment
4756 - High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)
5141 - Infection Risk and Efficacy of Anti-BCMA Bispecific Antibodies in Multiple Myeloma: A Real-World Propensity Score-Matched Study

Belhadj Merzoug, K.

1979 - Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Belickova, M.

4294 - Interferon-Related DNA Damage Resistance Signature Genes Predict Chemoresistance in Acute Myeloid Leukemia
4571 - Dysregulation of Transposable Elements and Piwi-Interacting RNAs in Myelodysplastic Neoplasms

Beligaswatte, A. M.

4928 - Clonal Architecture of Donor-Derived Leukemia/Clonal Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplant

Belizaire, R.

379 - Heterogeneity of PD-1⁺regulatory T Cells after Low-Dose IL-2 Therapy for Patients with Chronic Graft-Versus-Host Disease

Belkina, N.

4854 - Multiplexed Cytokine Assessment of T- and NK-Cell Responses to Tumor Cells: Parallel Assessment of Biomarkers Associated with Efficacy, Safety, and Persistence

Belknap, K.

667 - Multiple Myeloma Progression Is Accelerated By Microenvironmental-Derived Fatty Acid Binding Proteins 4 and 5 (FABP4/FABP5) in a Murine Model

Bell, A.

1964 - Mass Spectrometry (MS)-Based Exent® Solution Reveals High Prevalence of Multiple M-Proteins in African American Patients with Multiple Myeloma (MM) and Precursor Conditions
2053 - CAR-T Cell Subsets and Immune Repertoire Are Associated with Immune-Related Adverse Events and Efficacy after CD19 CAR T-Cell Therapy in B Cell Lymphoma
2669 - Clonal Hematopoiesis of Indeterminate Potential Is Associated with Decreased Inflammatory Toxicity and Increased Late Cytopenia in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy

Bell, B.

3341 - Risk Factors for Suboptimal Treatment in Patients with Newly Diagnosed Multiple Myeloma across US Healthcare Systems
5169 - Evaluation of Socioeconomic Barriers Impacting Patients with Newly Diagnosed Multiple Myeloma
- Integration of Health Literacy Universal Precautions into Clinical Practice as a Strategy to Improve Patient-Reported Outcomes in Patients with Hematologic Malignancies and Limited English Proficiency

Bell, C.

4162 - Transient Menin Inhibition Is Sufficient to Induce Irreversible Polycomb-Mediated Silencing and Potent Anti-Proliferative Effects in MLL-Rearranged AML

Bell, G.

4113 - Repolarisation of M2 Macrophages Via Cgas-Sting Activation Enhances Phagocytosis of Acute Myeloid Leukaemia

Bell, H. L.

4580 - Dual Bclxl and BCL2 Inhibition with Navitoclax (NAV), Venetoclax (VEN), and Decitabine (DEC) for Advanced Myeloid Neoplasms (MN): Safety and Biological Activity in a Phase 1 Study

Bell, J.

4208 - Safety and Feasibility of Blinatumomab As Frontline Therapy for Pediatric Patients with B-Acute Lymphoblastic Leukemia and Lymphoma: St. Jude Total Therapy Study XVII

Bell, K.

5167 - A Pilot Screening and Patient Navigation Program for Early Detection of Multiple Myeloma to Address Cancer Disparities

Bell, S.

585 - IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax: Report of the UK NCRI FLAIR Study

Bell-Burdett, K.

2801 - Clinical Characteristics and Outcomes of Mixed Phenotype Acute Leukemia (MPAL): A Large Multi-Center Retrospective Study

Bellach, A.

685 - The Composite Health Risk Assessment Model (CHARM) Predicts Risks of Toxicities, Functional and Cognitive Decline Among Survivors of Allogeneic Hematopoietic Cell Transplantation (allo-HCT): A Prospective BMT-CTN Study 1704

Bellach, A.

2134.1 - Trial in Progress: Cureaa - a Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia, Blood and Marrow Transplant Clinical Trials Network (BMT CTN) #2207

Bellamkonda, A.

5170g - Multiple Myeloma (MM) Clinical Characteristics, Prognostic Factors and Survival in Adolescents and Young Adults (AYA)

Bellanger, C.

3282 - Voltage-Dependent Anion Channel 2 Controls Mitochondrial Priming through BAK Stabilization in Multiple Myeloma

Bellani, V.

4550 - Prognostic Insights on PRE-Fibrotic Primary Myelofibrosis: A Clinical-Pathological Perspective in 762 Patients

Bellavia, T.

2001 - Characterizing and Risk Stratifying Musculoskeletal Toxicities after BCMA CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

Bellefleur, R.

3812 - Treatment with Asciminib As a Second Line after One Prior Tyrosine Kinase Inhibitor (TKI) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) – a Chart Review Study in the United States

Bellemare, K.

3875 - Further Validation of Flow Adhesion of Whole Blood to P-Selectin (FA-WB-PSEL) to Assess Targeted P-Selectin Therapies in Sickle Cell Disease (SCD)

Bellesso, M.

983 - Refining Prognostication in Peripheral T Cell Lymphoma (PTCL): A Risk-Adapted Prognostic Model for Patients with Limited-Stage PTCL
1687 - Clinical Features, Therapy Patterns and Survival Outcomes of Limited-Stage Peripheral T-Cell Lymphomas: A Cross-Continental Study

Belleville, A.

343 - Mis-Splicing Derived Neoantigens and Cognate T Cell Receptors in Splicing Factor Mutant Myeloid Neoplasms

Belli, A. J.

3743 - End-of-Life Care Patterns in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Real-World Setting
5101 - Impact of the Diagnosis-to-Treatment Interval (DTI) on Outcomes in Older Adults with Diffuse Large B-Cell Lymphoma (DLBCL) Treated in the Real-World Setting

Bellia, M.

762 - Prevalence and Clinical Impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Chronic Lymphocytic Leukemia and Richter Transformation

Bellido, M.

883 - Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1
888 - Quality of Life in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Improves after Minimal Residual Disease-Guided Treatment with Ibrutinib Plus Venetoclax
1013 - Improved Efficacy with Response- and MRD-Guided Ibrutinib–Obinutuzumab (IO) Intensification after Ibrutinib-Venetoclax (IV) in First Line Chronic Lymphocytic Leukemia (CLL) Patients: Primary Analysis of the HOVON 158/Next STEP Phase 2 Trial

Bellissant, E.

979 - Prospective, Multicentric, Phase II Randomized Controlled Trial Comparing the Efficacy and Toxicity of Methotrexate to Cyclophosphamide in Large Granular Lymphocyte Leukemia: A French National Study (NCT01976182)

Bello, C. M.

3021 - Clinical Characteristics and Outcomes of Patients with MYD88 Positive Waldenström Macroglobulinemia: A Single Center Retrospective Analysis
3065 - A Phase I Study of Duvelisib in Combination with Oral Azacitidine (BMS-986345) in Mature T Cell Lymphoma

Bello, F.

2425 - Real-World Treatment Patterns and Outcomes with Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia

Bello, L.

2093 - Comparison of Cryopreserved Versus Non-Cryopreserved Strategies for Autologous Stemcell Transplantation in Multiple Myeloma in Two Centers in Uruguay

Bello-Manga, H.

2245 - Understanding the Experiences of Caregivers for Children Five Years and Above Living with Sickle Cell Diseases in Kaduna, Nigeria

Bellomarino, V.

2836 - Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial

Bellomi, A. B.

4518 - Synergistic Effect of Tamoxifen and Ruxolitinib Combination in Reducing Disease Burden in Myeloproliferative Neoplasms

Bellón, J. M.

4869 - Incidence, Clinical Risk Factors, and Biomarkers of SOS/VOD Following Allogeneic HSCT in Adults: A Real-Life Study By the Spanish Group of Hematopoietic Stem Cell Transplantation and Cell Therapy (GETH-TC)

Bellone, M.

671 - A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma
765 - The Mitochondrial Protease Clpp Is a Metabolic Vulnerability and an Immunogenic Trigger Against Multiple Myeloma

Bellosillo, B.

4351 - Genetic Characterization of Marginal Zone Lymphomas in Tissue and cfDNA

Bellosillo, B.

4566 - Diagnostic Challenges in Patients with Clinical Suspicion of Myeloproliferative Neoplasms and JAK2V617F≤1%

Belman, J.

1536 - Early Drivers of Clonal Hematopoiesis Shape the Subsequent Evolutionary Trajectories of De Novo AML

Belot, A.

649 - Senior-IPI: An Easily Applicable and Meaningful Prognostic Index for First-Line LBCL Patients Older Than 80 Years Treated with Age-Adapted Immunochemotherapy

Belotti, A.

82 - Early Identification of Functional High Risk Multiple Myeloma Patients after Transplant with Diffusion-Weighted Whole-Body MRI: Predictive Role of Fat Fraction in Addition to RAC Score
674 - Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial
2000 - Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)
5153 - Pomalidomide, Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Lenalidomide and Anti-CD38 Monoclonal Antibodies: A Multicentric Italian Retrospective Study

Belotti, D.

4849 - Cord Blood-Derived Carcik Cells As Off-the-Shelf Non-Viral Cell Therapy for Hematological Malignancies

Belov, A.

390 - AI Predicts Early Relapse Post-Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma Patients in a Multi-Center Real-World Study

Belperio, Y.

4530 - Evaluating the Impact of Cross-over from Imatinib to Nilotinib on the Overall Survival in Chronic Myeloid Leukemia Using Inverse Probability of Censoring Weighting: Results from the Gimema Sustrenim Study

Belsky, G.

707 - Real-World Effectiveness of Immunoglobulin Replacement Therapy on Hypogammaglobulinemia and Infectious Complications in Patients with Multiple Myeloma

Belsky, J.

2510 - Osteopathic Medical Treatment Improves Pain and Constipation in Children and Adolescents with Sickle Cell Disease

Beltempo, M.

298 - Clinical Outcomes of Neonatal Central Line-Related Thrombosis: A Multicentric Retrospective Cohort Study

Belton, J. M.

4973 - Hi-C Allows Genome-Wide Characterization of Enhancer-Driven Oncogene Rearrangements in Formalin-Fixed Lymphoid Cancer Biopsies

Belton, T.

617 - Community Health Worker Engagement with Adolescents and Young Adults with Sickle Cell Disease: Findings from the Comets Study
1066 - Community Health Worker and Mobile Health Programs to Help Young Adults with Sickle Cell Disease Transition to Using Adult Healthcare Services -- the Comets Study; Results from Patient-Reported Outcomes at 6 Months

Beltrame, M. P.

2294 - Multicentric Standardization of Minimal/Measurable Residual Disease in Acute Myeloid Leukemia Using Multiparametric Flow Cytometry – a Brazilian Society of Bone Marrow Transplantation (SBTMO) Project

Beltrami, G.

1574 - Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML
1778 - Treatment-Free Remission in CML Patients Discontinuing Post-First Line Therapy
2891 - Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia
3162 - Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: Observational Study of 673 Patients in Italy
4532 - Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact Project, a CML Campus Study

Beltrami Moreira, M.

2661 - Targeting Inflammation in Tet2 Mutant Clonal Hematopoiesis Via Inhibition of Brd4 Demonstrates Activity in Both Murine and Human Models

Beltran, B.

1692 - The Number of Extranodal Sites Matters! a Proposal for a Feasible Prognostic Model in Nodal PTCL. a Collaborative Study grupo De Estudio Latino-Americano De Linfoproliferativos (GELL) & T-Cell Brazil Project (TCBP)
1718 - Using Polatuzumab Plus Chemotherapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real-World Study from the Grupo De Estudio De Linfoproliferativos De Latinoamerica (GELL)
3718 - Uncovering the Epidemiology, Therapy Patterns and Outcomes of MALT Lymphoma in Latin America: A Multinational Retrospective Cohort Study
4452 - Extranodal NK/T-Cell Lymphoma in Latin America: A Retrospective Multinational Analysis of Clinical Features, Therapeutic Approaches and Outcomes from the Latin American Group of Lymphoproliferative Disorders (GELL)

Beltran, B. E.

983 - Refining Prognostication in Peripheral T Cell Lymphoma (PTCL): A Risk-Adapted Prognostic Model for Patients with Limited-Stage PTCL
1687 - Clinical Features, Therapy Patterns and Survival Outcomes of Limited-Stage Peripheral T-Cell Lymphomas: A Cross-Continental Study
2370 - The Impact of Social Determinants and Diagnostic Inequities in Hodgkin Lymphoma Outcomes: A Comparative Analysis of South America and the United States
3064 - Central Nervous System Involvement in Aggressive ATLL: Can We Predict the Risk in a Devastating Complication? Epidemiology and Clinical Features from Latin America. a Collaborative Study from Grupo De Estudio Latino-Americano De Linfoproliferativo (GELL) & T-Cell Brazil Project (TCBP)

Beltrán, E.

4796 - Dissection of Single-Cell Landscapes for the Development of Chimeric Antigen Receptor T Cells in Hodgkin Lymphoma

Belyaeva, S.

3332 - The Impact of Circulating Plasma Cells on Overall Survival (OS) in Patients with Newly Diagnosed Multiple Myeloma (MM) - Results of a Multicenter Study

Belyanskaya, L.

2571 - Extracoagulative Role of FVIII: Impact on in Vitro and In Vivo Murine Bone Cell Differentiation and Function
3956 - Role of Factor VIII As a Regulator of Angiogenesis and Promoter of Endothelial Barrier Stability
3991 - Role of Factor VIII in Angiogenesis, Vessel Stability and the Regulation of Extracellular Matrix Proteins

Belzer, A. C.

2670 - Primary Hematopoietic Cells of Vexas Patients Are Highly Sensitive to Treatment with TAK-243 and Pevonedistat

Ben Abdeljelil, N.

595 - Role of Age and Donor Type in 3646 Severe Aplastic Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
3497 - Central Nervous System Disorders (CNSD) Following Hematopoietic Stem Cell Transplantation (HSCT): A Prospective Study from the Infectious Diseases Working Party (IDWP) and the Transplant Complications Working Party (TCWP), European Society of Blood and Marrow Transplantation (EBMT)

Ben Lamine, C.

4536 - Evaluating the Safety and Efficacy of Tyrosine Kinase Inhibitors in Pregnant Patients with Chronic Myeloid Leukemia: A Comprehensive 15-Year Single-Center Study

Ben Uri, R.

4813 - A Spatial Atlas of Human Gastro-Intestinal Acute Gvhd Reveals Epithelial and Immune Dynamics Underlying Disease Pathophysiology

Ben-Ezra, N.

1670 - SUVR (SUVmax Lymphoma/SUVmax Liver) Vs Deauville Score for Predicting Relapse in Hodgkin Lymphoma

Ben-Neriah, S.

231 - Biological and Prognostic Subgroups of Plasmablastic Lymphoma Defined By EBV Status and MYC Rearrangement– an L.L.M.P.P. Study
742 - A Novel Genetics-Based Classification of Advanced Follicular Lymphoma Identifies Prognostic Subgroups Following Bendamustine-Rituximab Immunochemotherapy
855 - CSF2RB Mutations Result in Cytokine-Dependent Gain-of-Function Phenotypes in Classic Hodgkin Lymphoma

Benachour, N.

1032 - Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1–3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial
2002 - Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial

Benajiba, L.

1755 - SH2B3 Loss of Function Variants Are Potential Drivers of Severe Thrombocytosis
3167 - Outcome of Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms Ineligible for Intensive Chemotherapy or Allogeneic Hematopoietic Cell Transplantation Treated By Azacitidine Alone or in Combination – a FIM Study
4513 - JAK Inhibition Results in Aggressive Cutaneous Squamous Cell Carcinoma through MAPK Pathway Activation and Shapes the Tumor Immune Microenvironment to Create Novel Therapeutic Opportunities

Benakli, M.

305 - Improved Outcomes in Paroxysmal Nocturnal Hemoglobinuria Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
595 - Role of Age and Donor Type in 3646 Severe Aplastic Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
2193 - Optimizing Haploidentical Transplant for Adults with Acute Lymphoblastic Leukemia: The Role of Donor and Graft Selection. a Study from the ALWP of the EBMT
2379 - Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis from the Worldwide Network for Blood and Marrow Transplantation Global Study
3010 - Long Term Outcomes of Hematopoietic Stem Cell Transplantation in Patients with Waldenström’s Macroglobulinemia. Report from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (LWP EBMT)
4733 - Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study

Benaoudia, S.

591 - NF-Kb Pathway Activation Driven By TRAF3 Loss Mediates Resistance to Anti-BCMA T-Cell Based Therapies in Multiple Myeloma
1892 - Tumor Intrinsic and Antigen-Independent Resistance Mechanisms to Bispecific T Cell Engagers in Multiple Myeloma
4642 - Immune and Tumor Mediators of Resistance to Daratumumab-IMiDs Based Therapies in Relapsed Multiple Myeloma
4651 - BCMA Extracellular Domain Functional Hotspots and Resistance to Variable Anti-BCMA T Cell Engagers in Multiple Myeloma

Benard, F.

461 - Omission of Bleomycin in Limited Stage Classic Hodgkin Lymphoma Patients with a Negative PET Scan Following 2 Cycles of ABVD Is Associated with Comparable Outcomes and Reduced Pulmonary Toxicity

Benavente Cuesta, C.

1131 - Non-Invasive Prenatal Diagnosis of Sickle Cell Disease in Spain
2230 - Leveraging AI for Predicting Genetic Alterations in Multiple Myeloma through Morphological Analysis of Bone Marrow Aspirates
4000 - External Validation of the French Score in Thrombotic Microangiopathies: Real-World Experience in a Large Retrospective Cohort of 1483 Patients

Benbrahim, O.

584 - Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group
3256 - Preemptive Therapy with Venetoclax for High-Risk Stage a CLL Patients: First Analysis of Prevene, a Phase II Trial of the Filo Group
4756 - High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)

Bence, N.

169 - Development of a ZBTB7A and Wiz Dual Degrading, HbF-Activating CELMoD™ for the Treatment of Sickle Cell Disease
957 - BMS-986458 a Potential First-in-Class, Highly Selective, Potent and Well Tolerated BCL6 Ligand Directed Degrader (LDD) Demonstrates Multi-Modal Anti-Tumor Efficacy for the Treatment of B-Cell Non-Hodgkin’s Lymphoma
1881 - Multi-Omics Integration to Elucidate the Cis-Regulatory Network Re-Wiring upon NSD2 Degradation in t(4;14) Multiple Myeloma

Bencheikh, L.

1105 - Single Cell Hemoglobin Quantification Reveals HbF and HbS Increases in Sickle Erythrocytes from Patients Treated with Hydroxyurea
2500 - Voxelotor Impact after 6 Months on Blood Rheology in Patients with Sickle Cell Disease
2506 - Improvement in Kidney Function after 6 Months of Voxelotor in Sickle Cell Disease Patients
2508 - Parameters Associated with Improved Peripheral Oxygen Extraction in Sickle Cell Patients Treated with Voxelotor
2608 - Red Blood Cell-Derived Particles Induce Endothelial Damage Via the Alternative Complement Pathway

Bencherif, Y.

4080 - High Proportion of PNH Type II Neutrophils, I.e. Relative Percentage ≥3%, Is Associated with Thrombosis in Patients Displaying a PNH Clone >1%: Evidence from Analysis of the 5-Year French Nation-Wide Multicenter Observational Study

Bendapudi, P. K.

17 - Leveraging Population-Scale Multiomic Datasets to Elucidate the Risk of Thrombosis Associated with Protein S (PROS1) Deficiency
18 - Use of Large-Scale Genomic Datasets to Identify Additional Modifiers of Thrombosis Risk Among 26,436 Carriers of the Factor V Leiden and Prothrombin G20210A Mutations
133 - Coagulation Factor XII (F12) Haploinsufficiency Is Protective Against Venous Thromboembolism
143 - Using Large-Scale Multiomic Datasets to Assess the Population Frequency of ADAMTS13 Loss-of-Function Variants in the United States and United Kingdom
1196 - Rare Germline Loss-of-Function Variants in C1-Inhibitor (SERPING1) Are Associated with Venous Thromboembolism in Population-Scale Sequencing Datasets

Bende, G.

95 - Efficacy and Safety of TAK-007, Cord Blood-Derived CD19 CAR-NK Cells, in Adult Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

Bender, B.

3288 - Targeting the PI3K/AKT Pathway and Fatty Acid Synthase in AL Amyloidosis: Mechanistic Insights and Therapeutic Implications

Bender, M. T.

3961 - Proteolysis of Annexin A2 Leads to Inflammasome-Mediated Proinflammatory Response in Human Sepsis

Bender, R.

943 - Elevated Clonal Hematopoiesis in Environmentally Exposed Responders Has Distinct Age-Related Patterns and Relies on IL1RAP for Clonal Expansion

Bender, S.

892 - Efficacy and Safety of Isatuximab, Pomalidomide and Dexamethasone in Relapsed AL Amyloidosis: Interim Results of the Isamyp Phase 2 Joint Study from the IFM and ALLG

Bendig, S.

318 - Drug Sensitivity and Treatment Response Are Modulated By the Cell of Origin, the Underlying Gene Fusion, and Patient Age in KMT2A-Rearranged BCP-ALL
631 - IDH2 Mutations from Clonal Hematopoiesis and Acquired IKZF1 Deletions Define a Novel B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma
914 - A Novel Platform Technology for the Development of NK Cell-Based Cellular Immunotherapies
4213 - Integrateall, a Machine Learning Pipeline for Multi-Level Data Extraction from RNA-Seq Profiles Unravels Novel Drivers and Systematic Subtype Classification in B-Cell Precursor ALL

Bendit, I.

2802 - Impact of Ph-like Gene Signatures on Clinical Outcomes in Adult B-ALL Patients in Resource-Constrained Settings

Bendtsen, S. K.

3831 - Satisfy: A Eurobloodnet Multicenter, Single-Arm Phase 2 Trial of Mitapivat in Adult Patients with Erythrocyte Membranopathies and Congenital Dyserythropoietic Anemia Type II – Results from the 8-Week Dose-Escalation Period

Bene Tchaleu, F.

865 - Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study
1631 - Glofitamab Induces High Response Rates and Durable Remissions in Patients (Pts) with Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL), Including Those with a Poor Prognosis: Subgroup Results from a Phase I/II Study
1726 - Primary Results of the Health-Related Quality of Life (HRQoL) and Tolerability Assessments from the Phase I/II NP30179 Study of Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Beneat, A. F.

808 - Serine Threonine Protein Kinase 25 (STK25) Is a New Mediator of Myelopoiesis and Myeloid Cell Effector Function(s) during Injury and Inflammation

Benedetti, F.

1580 - Longitudinal Monitoring of Circulating Tumor DNA to Predict Survival in Newly Diagnosed Peripheral T-Cell Lymphoma Patients

Benedict, A.

2280 - Life Years Gained from the FDA Accelerated Approval Program in Hematology: A Portfolio Model

Benefield, A.

2322 - Chive-Impact: Establishing the Clonal Hematopoiesis and Inflammation in the Vasculature (CHIVE) Registry and Biorepository in Underserved Areas

Beneforti, L.

3908 - Prognostic Value of BRAFV600E in Peripheral Blood of Children with Langerhans Cell Histiocytosis: A Multicenter Project of the European Consortium for Histiocytosis

Beneit Villena, P.

1790 - Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia

Beneitez, D.

290 - Oxygen Gradient Ektacytometry Is Associated with Markers of Hemolysis and Inflammation in a Large Sickle Cell Disease Cohort within the GenoMed4ALL Project
409 - ENERGIZE-T: A Global, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia
1138 - Data Driven Research through the European RADeep Registry and the Use of Artificial Intelligence Towards Personalized Medicine in Sickle Cell Disease

Benes, V.

276 - Unraveling Molecular Subgroup-Specific Pathway Dependencies in Chronic Lymphocytic Leukemia through Drug-Perturbed Transcriptomic Profiling and Statistical Modeling
1282 - A Senescent Subset in Human Hematopoietic Stem Cell (HSC) Compartment As Target for Senotherapy
1339 - Specific U6 Small Nucleolar RNAs Are Present on the Surface of Primary AML Specimens and Are Accompanied By Short Fragments of Longer RNAs
3584 - Cancer Pathway Connectivity Resolved By Drug Perturbation and RNA Sequencing

Benesova, K.

1697 - The Survival Improvement of Transplant-Eligible Primary CNS Lymphoma Patients within Last 15 Years
1711 - PCNSL Patients Treated with the Matrix Regimen in the Real World Have Similar Outcome to Those in the IELSG 32 Trial
1713 - BMI and Its Changes As a Predictor of Survival in DLBCL Patients
2979 - Vitreous Body Cell Free DNA Sequencing As a Reliable Method for Vitreoretinal Lymphoma Diagnostics
3012 - Intensified Immunochemotherapy with Autologous Stem Cell Transplantation for Mantle Cell Lymphoma - Could It Still be Considered the Standard of Care?
3081 - Validation of the CNS-IPI-C Prognostic Model in Patients with Systemic DLBCL in the Real World

Benet, C.

2555 - Early Treatment Use of Fostamatinib for Immune Thrombocytopenia (ITP): Efficacy and Safety As Second/Third ITP Treatment Lines in Clinical Practice in Spain

Benetton, M.

640 - Pursuing Leukemia Stem Cells Definition in Pediatric Acute Myeloid Leukemia
2910 - Novel Promising Therapeutic Strategies for Advancing the Treatment of KMT2A-Rearranged AML

Benevolo, G.

242 - Revised ELN Criteria in Polycythemia Vera Identify an Increased Risk Phenotype for Thrombotic Events Beyond Conventional Risk Stratification. a Multicenter Cooperative Study
245 - Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition
655 - Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients
3013 - Ibrutinib or Chemo-Immunotherapy As Second Line Treatment in Waldenstrom Macroglobulinaemia? a Real-Life Multicentre Study
3179 - Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor
4390 - Determining Outcome in IgM Gammopathies: Integration of Molecular, Flow Cytometry and Clinical Factors in an International, Multicenter Series (the SAL-TO Study)
4550 - Prognostic Insights on PRE-Fibrotic Primary Myelofibrosis: A Clinical-Pathological Perspective in 762 Patients

Beneyto-Calabuig, S.

1292 - Mapping Genotype to Phenotype in Clonal Hematopoiesis Uncovers Downregulated MHC-II Molecules in DNMT3A^R882- Mutant Hematopoietic Stem Cells

Benfatto, S.

273 - Rapid Epigenomic Classification of Acute Leukemia

Benge, C.

262 - Stabilization of HIF-1α By the Prolyl Hydroxylase Inhibitor Roxadustat Reduces Gastrointestinal Graft-Versus-Host Disease

Bengsch, B.

3392 - FLT3-ITD Driven CMTM6 Expression Contributes to Immune Escape of Acute Myeloid Leukemia
4514 - CD39, CD73 and the Adenosine Pathway Mediate Immune Escape in Juvenile Myelomonocytic Leukemia (JMML)

Bengtzén, S.

639 - Deciphering the Heterogeneity of Acute Myeloid Leukemia through Chromatin Accessibility Profiling
1565 - Resistance to FLT3 Inhibitors in FLT3-Mutated AML Is Associated with CD45RA⁺CD200^-leukemic Cells and Can be Overcome By Combination with SMAC Mimetics

Benhaim, P.

1117 - Autoimmune and Inflammatory Diseases in Children with Sickle Cell Disease: A French Multicenter Observational Study on Diagnostic and Therapeutic Issues

Benini, F.

3561 - Outcomes of Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia Given Blinatumomab As Last Consolidation Treatment before Allogeneic Hematopoietic Cell Transplantation

Benintende, G.

4621 - Comparison of Familial Versus Sporadic Forms of Chronic Lymphocytic Leukemia: An Italian Multicenter Case-Control Study

Benintende, G.

4835 - Distinct Safety and Toxicity Profile of CD19-Directed CAR T-Cell Therapy in Systemic Lupus Erythematosus Versus B-Cell Lymphoma – a Single-Center Experience

Benites, B. D.

3692 - Impact and Aggravating Factors of Chronic Pain in Sickle Cell Disease: Results of the Analysis of Promis® Questionnaires and the Metabolomic Profile of Brazilian Adult Patients

Benitez, L.

3105 - Risk Factors for Severe Infection in Patients Receiving Bispecific Antibody Therapies for Lymphoma

Benitez-Ribas, D.

2084 - The CAR-Hematotox Identifies Patients at High Risk of Infectious/Inflammatory Complications in a Cohort of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Treated with ARI-0001 (Varnimcabtagene Autoleucel)

Benjamin, C.

1052 - Factor VIII Expression from a Novel F8 Transgene through a Lentiviral Vector Transduced CD34+ Autologous Hematopoietic Stem Cells for Gene Therapy of Severe Hemophilia Α: Final Results from a Phase 1 Clinical Trial

Benjamin, J. E.

4824 - First Results of IMPT-314, an Autologous Bispecific CD19/CD20 Chimeric Antigen Receptor (CAR) in Enriched Naive and Central Memory T Cells, for the Treatment of Large B Cell Lymphoma (LBCL)

Benjamin, R.

4743 - MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Benjamin, R. J.

2501 - Tracking Entire Units of Transfused Pathogen-Reduced Red Cells in Sickle Cell Patients Using a Novel Acridine Marker

Benjamini, O.

1862 - Phase II Prospective Trial of Fixed Duration Obinutuzumab, Ibrutinib and, Venetoclax in an Elderly Cohort of Patients with Richter's Syndrome-Givers Regimen
1871 - First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis
4504 - CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia
1875.2 - Nemtabrutinib Versus Ibrutinib or Acalabrutinib for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: The Phase 3, Open-Label, Randomized Bellwave-011 Study

Benkerrou, M.

2522 - Effect of Rituximab on Spleen and Blood B-Cell Subpopulations in Allo-Immunized Children with Sickle Cell Anemia

Benlabiod, C.

752 - Amplification of Von Willebrand Factor-Positive CALR^mut Disease-Initiating Hematopoietic Stem Cells Is Associated to the Activation of the PERK/EiF2a Branch of Unfolded Protein Response
871 - Development of a First-in-Class CAR-T Therapy Against Calreticulin-Mutant Neoplasms and Evaluation in the Relevant Human Tissue Environment

Bennani, N. N.

1651 - Correlation between Peak Absolute Lymphocyte Count Post Brexucabtagene Autoleucel Infusion and Outcomes in Mantle Cell Lymphoma
2274 - Real World Outcomes with Evolving Management of Cytokine Release Syndrome in CAR-T Therapy
3181 - Subclassification of Erdheim-Chester Disease: Distinct Clinical and Molecular Findings between Classical and Non-Classical Forms
4563 - Efficacy of Targeted Agents and Immune Checkpoint Inhibitors in Patients with Malignant Histiocytosis
4564 - Efficacy of Small Molecule Kinase Inhibitors in Histiocytic Neoplasms with Non-BRAFV600E Mutations: Concordance of Pre-Clinical Predictions to Clinical Responses

Benner, A.

84 - Impact of Clonal Heterogeneity in Newly Diagnosed, Transplant-Eligible Multiple Myeloma – Subgroup Analysis of the GMMG HD6 Phase III Trial
218 - 10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years
364 - Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial
769 - Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
844 - The Prognostic Impact of Myelodysplasia-Related Gene Mutations in Acute Myeloid Leukemia with FLT3-ITD Mutations
961 - Chemotherapy or Stem Cell Transplantation in Adult High Risk Ph/BCR::ABL1-Negative ALL Patients with Early MRD Negativity: Results of the Randomized GMALL Trial 08/2013
5140 - Long-Term Follow-up Analysis of Progression-Free and Overall Survival in Newly Diagnosed Multiple Myeloma Patients from the GMMG Myeloma Registry Following the Randomized Phase III GMMG-HD6 Trial

Benner, C.

1173.1 - Delivering Transcutaneous Auricular Neurostimulation to Reduce Heavy Menstrual Bleeding in Von Willebrand Disease Patients

Bennett, C. M.

709 - Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children

Bennett, C.

4517 - Dysregulated Complement Activation in Polycythemia Vera: A Novel Mechanism for Thrombosis in Myeloproliferative Neoplasms Uncovered By Proteomic Analysis

Bennett, C.

3638 - Serious Adverse Drug Reactions (sADRs) Involving Hematology and Resulting in Black Box Warnings or FDA Non-Approval: Results from the First Quarter Century of RADAR/Sonar

Bennett, D.

1074 - RBC eNOS Regulates O₂ Delivery Phenotype during Circulatory Transit Via Control of Intracellular pH
2453 - Oxygen Responsive Myosin Activation Governs Oscillatory Piezo1 Signaling in RBCs during Circulatory Transit

Bennett, E.

4115 - A Novel in Vitro Model of Pre-Leukemic Competition Reveals “Super-Competitive” TET2-Mutant Hematopoietic Stem Cell Clones

Bennett, E.

2767 - The Proteostasis Network Is a Therapeutic Target in Acute Myeloid Leukemia

Bennett, L.

1066 - Community Health Worker and Mobile Health Programs to Help Young Adults with Sickle Cell Disease Transition to Using Adult Healthcare Services -- the Comets Study; Results from Patient-Reported Outcomes at 6 Months

Bennett, L. F.

168 - TNFα Plays Essential Role in Resolution of Anemia of Inflammation in Tnfαko Mice Treated with Heat-Killed Brucella Abortus
559 - Spatial Transcriptomics Characterize Dynamic and Polarized Niche for Embryonic Hematopoiesis at Single-Cell Level

Bennett, R.

582 - A Randomized Phase 2, Investigator-Led Trial of Glofitamab-R-CHOP or Glofitamab-Polatuzumab Vedotin-R-CHP (COALITION) in Younger Patients with High Burden, High-Risk Large B-Cell Lymphoma Demonstrates Safety, Uncompromised Chemotherapy Intensity, a High Rate of Durable Remissions, and Unique FDG-PET Response Characteristics
1700 - Real-World Outcomes of Patients with High-Grade B-Cell Lymphoma with MYC and BCL2 rearrangements Treated in the Contemporary Era
4410 - Obinutuzumab, Lenalidomide and Venetoclax for the Initial Treatment of Patients with Advanced-Stage Follicular Lymphoma: Primary Analysis of an Investigator-Initiated Phase Ib/II, Multicenter Study (LEVERAGE)

Bennett, S.

1445 - Health-Related Quality of Life in Adolescents and Young Adults Treated with Blinatumomab Consolidation for CD19+ Ph-Negative Acute Lymphoblastic Leukemia in the Australasian Lymphoma and Leukaemia Group (ALLG) ALL09 "Sublime” Study

Bennett, S. N.

327 - Phip Is a Potent Leukemia Oncogene Identified in Acute Myeloid Leukemia (AML) Patients of African Ancestry

Bennett, S.

4971 - Targeting Metabolism to Restore Hematopoiesis in Inherited Bone Marrow Failure Syndromes: Preclinical Insights from Zebrafish Models

Benoist, J. F.

1434 - Switch of Asparaginase Formulation Based on Antibody Monitoring in Adults with Philadelphia-Negative Adult Lymphoblastic Leukemia. Results of the Graall-2014 Trial
2814 - How to Administer Pegaspargase during Induction Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents? Results of the Caall-F01, a Multicentre Randomized Clinical Trial from the French Pediatric Cancer Society (SFCE)

Benoodt, L.

563 - Compartmentalized Niche and Spatially Heterogenous Inflammatory Landscape Regulate Tet2^+/-- Mediated Clonal Hematopoiesis

Benovic, J.

424 - Mechanistic Insights and Clinical Implications of the Thrombotic Risks of a Highly Prevalent GRK5 Variant Affecting Platelets

Benrashid, S.

2661 - Targeting Inflammation in Tet2 Mutant Clonal Hematopoiesis Via Inhibition of Brd4 Demonstrates Activity in Both Murine and Human Models

Benrashid, S.

3587 - Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel LP-168 (Rocbrutinib) Combinations Targeting BCL-2 Protein Members for Chronic Lymphocytic Leukemia

Bensalah, M.

3241 - Prognosis of the IGLV3-21^R110 Mutation in a Real-Life Chronic Lymphocytic Leukemia Cohort

Bensing, B.

3998 - Streptococcus Gordonii Binds VWF Via Its Sialoglycan-Binding Adhesins Under Shear to Initiate Infective Endocarditis

Bensiradj, F.

2500 - Voxelotor Impact after 6 Months on Blood Rheology in Patients with Sickle Cell Disease

Bensiradj, F.

1105 - Single Cell Hemoglobin Quantification Reveals HbF and HbS Increases in Sickle Erythrocytes from Patients Treated with Hydroxyurea
2506 - Improvement in Kidney Function after 6 Months of Voxelotor in Sickle Cell Disease Patients
2508 - Parameters Associated with Improved Peripheral Oxygen Extraction in Sickle Cell Patients Treated with Voxelotor
2520 - Improvement in Cerebral Vasoreactivity after 6 Months of Voxelotor Measured By Near-Infrared Spectroscopy (NIRS) in Sickle Cell Disease Patients
4875 - Erythroid-Specific Chimerism Analysis after Allogeneic-Hematopoietic Stem Cell Transplantation Using a Human Leukocyte Antigen-Identical Sibling Donor in Sickle Cell Disease Patients

Benson, A.

2196 - Relieving Restriction in Resting CD8+ T Cells Increases Gene Transfer and Improves Tumor Killing after Transduction with CD8-Targeted CD19CAR Fusosome

Benson, C. B.

3500 - BK Virus Reactivation and Disease after Allogeneic Hematopoietic-Cell Transplantation: A Natural History Study

Benson, D.

285 - Lovesick: Examining Couples Health during Myeloma Transplant
4717 - Cytomegalovirus Reactivation in Patients with Multiple Myeloma Treated with Teclistamab: Risk Factors and Clinical Impact

Benson, R.

1491 - Treatment Outcomes in Acute Promyelocytic Leukemia Patients Using a Uniform ATRA + ATO Consolidation Therapy Regimen across All Risk Groups: A Single Centre Study from India

Benthall, K. N.

2232 - Targeted Non-Viral Gene Delivery through Transcutaneous Ultrasound Enables Robust, Redosable, Titratable, and Durable FVIII and FIX Gene Expression in the Liver in Murine Models

Bentley, T. M.

2035 - CRG-023 Is a Novel Tri-Specific CAR T Product Candidate Engineered to Prevent Antigen Escape and Sustain Durable Anti-Tumor Functionality Against B-Cell Malignancies

Bento, C.

794 - uRADAR: European Patients Referral Frame to Improve Access to New Drugs and Therapies in Ultra-Rare Anemia Disorders and Severe Hereditary Spherocytosis

Bento De Miguel, L.

1715 - Real World Evidence of Second Line Therapy in Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geltamo Study
2105 - Treosulfan/Fludarabine Versus Thiotepa/Busulfan/Fludarabine for Allogeneic Hematopoietic Cell Transplantation in Patients with Lymphomas in the Ptcy Era: A Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)
3531 - Current Prophylaxis and Treatment of Gvhd: Analysis of a Large Real-World Cohort. Spanish Group of Hematopoietic Transplantation and Cellular Therapy (GETH/TC)
3565 - Allogeneic Stem Cell Transplantation As Consolidation Therapy in Patients with Relapsed-Refractory B-Cell Lymphoma Exposed to Bispecific Antibodies: A Study on Behalf of Grupo Español De Transplante y Terapia Celular (GETH-TC)
5148 - Frailty and Outcomes in Multiple Myeloma Patients Eligible for Autologous Hematopoietic Cell Transplantation: A Prospective Study of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)

Bento, L.

4471 - Real World Epidemiology and Treatment Strategies of Limited Stage Large B Cell Lymphoma: Spanish Multicenter Geltamo Study

Bentur, O. S.

3061 - Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial
3074.1 - A Multicenter, Open-Label, Phase 3, Randomized Controlled Trial of Duvelisib Versus Investigator’s Choice of Gemcitabine or Bendamustine in Patients with Relapsed/Refractory Nodal T Cell Lymphoma with T Follicular Helper Phenotype

Bentz, C. C.

5204 - Call Me Maybe: An Analysis of Hematology Fellowship Home-Call Burden, Perceptions, and Attitudes

Bentz, M.

4498 - Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Bentzen, H. H.

883 - Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1

Benvenuti, P.

4699 - Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Benzaquen, A.

471 - Site-Specific Analysis of Extranodal Involvement Reveals Distinct Efficacy Outcomes with CAR T-Cell Therapy in Large B-Cell Lymphoma Patients
2105 - Treosulfan/Fludarabine Versus Thiotepa/Busulfan/Fludarabine for Allogeneic Hematopoietic Cell Transplantation in Patients with Lymphomas in the Ptcy Era: A Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)

Beorlegui Murillo, P.

405 - The Impact of Frailty on Outcomes and Quality of Life in Allogeneic Hematopoietic Cell Transplantation: Summary of Results from a Collaborative Prospective Study Conducted on Behalf of the Geth-TC
5148 - Frailty and Outcomes in Multiple Myeloma Patients Eligible for Autologous Hematopoietic Cell Transplantation: A Prospective Study of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)

Beppu, L. W.

1568 - Single-Cell Multi-Omic Analysis of AML MRD Reveals Differences in Clonal Architecture between Relapse and Non-Relapse Cases
3919 - Expanding the Role of SH2B3: T Cell Large Granular Lymphocytosis (LGL) and Common Variable Immune Deficiency in the Setting of Biallelic SH2B3 Mutations
4309 - Evaluation of ELN2022 Risk Stratification in NPM1 Mutated AML: A Study from the Fred Hutch and SWOG

Bequignon, E.

2511 - Evaluation of Sleep Apnea in Adult Sickle Cell Disease; About 107 SS and Sβ°Thal Patients

Bera, E.

226 - Flow MRD Monitoring Combining Laip/Dfn and CD34+CD38- LSCs Is a Strong Predictor of Outcome in Adult AML Independently of the ELN-2022 Risk: First Results from the Multicentric Acute Leukemia French Intergroup MRD Flow Network
4080 - High Proportion of PNH Type II Neutrophils, I.e. Relative Percentage ≥3%, Is Associated with Thrombosis in Patients Displaying a PNH Clone >1%: Evidence from Analysis of the 5-Year French Nation-Wide Multicenter Observational Study

Berastegui, N.

879 - Unveiling ZMAT2 and SMARCD3 As Therapeutic Targets to Mitigate Aberrant Hematopoiesis in MDS
4798 - Molecular Mechanisms Promoting Long-Term Cytopenia after BCMA CAR-T Therapy in Multiple Myeloma

Berberich-Siebelt, F.

3402 - Allogeneic Hematopoietic Cell Transplantation Promotes Atherosclerosis in Mice Driven By Donor CD8+ T Cells

Berceanu, A.

1434 - Switch of Asparaginase Formulation Based on Antibody Monitoring in Adults with Philadelphia-Negative Adult Lymphoblastic Leukemia. Results of the Graall-2014 Trial

Berchialla, P.

1778 - Treatment-Free Remission in CML Patients Discontinuing Post-First Line Therapy
3162 - Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: Observational Study of 673 Patients in Italy

Bercovitz, R. S.

1257 - Anticoagulation Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
2633 - Thrombolytic Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis

Berdalli, S.

3860 - Abrupt Increases in Ferritin Levels May Indicate a Malignant Process and Not Changes in Iron Overload in Thalassemic Patients

Berdeja, J. G.

Berdel, A. F.

4242 - “As Treated” Validation of the European LeukemiaNet (ELN) Classification for Adult Acute Myeloid Leukemia (AML) Patients (pts) Treated in a Large AML-Referral Center from 2010-2022

Berdel, W. E.

776 - Follow-up of the Randomized ASAP Trial Shows No Survival Advantage for Patients with Poor Responsive or Relapsed AML Who Received Intensive Salvage Chemotherapy for Remission Induction Prior to Allogeneic Transplantation Compared to Immediate Allogeneic Transplantation
2934 - The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients
4242 - “As Treated” Validation of the European LeukemiaNet (ELN) Classification for Adult Acute Myeloid Leukemia (AML) Patients (pts) Treated in a Large AML-Referral Center from 2010-2022

Berent-Maoz, B.

3481 - KITE-753: An Autologous Rapid Manufactured Anti-CD19/CD20 CAR-T Product for the Treatment of B-Cell Malignancies

Berentsen, S.

2444 - Cold Agglutinin Disease: Virtual Patient Simulation Improves Performance in Diagnosis and Management

Bereznyakova, O.

521 - Baseline Neurological Morbidity Assessment in Adult Patients with Sickle Cell Disease : The Montreal Brain-SCD Cohort
804 - Lifetime Prevalence of Stroke within an Adult Population with Sickle Cell Disease: A Cross-Sectional Study
3883 - Systematic Transcranial Doppler Examination in Adults with Sickle Cell Disease : A Cross-Sectional Single Center Study
5068 - Validitation of the Rowland Universal Dementia Assessment Scale (RUDAS) for the Detection of Cognitive Impairment Among Adults with Sickle Cell Disease

Berg, M.

969 - Venetoclax Plus Azacitidine for Newly Diagnosed Younger Acute Myeloid Leukemia Patients Independent of Fitness for Intensive Chemotherapy

Berg, S.

2958 - Circulating Tumor DNA Predicts Time to First Treatment in Previously Untreated Follicular Lymphoma: Analysis from a Prospective Clonal Evolution Study

Berg, T.

2764 - The Transcription Factor IRF8 Regulates the Sensitivity of AML Cells to LSD1 Inhibition and All-Trans Retinoic Acid

Bergantim, R.

4718 - Predicting Caregiver Burden in Multiple Myeloma: Insights from the Carmma Study Using Machine Learning Models

Bergantinos, R.

1293 - iPSC Reprogramming Identifies the Role of Cryptic Drivers in Preleukemic Clonal Evolution

Bergendahl Sandstedt, A.

600 - Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia – a Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Berger, C.

141 - Recombinant ADAMTS13 Prophylaxis in Pediatric Patients with Congenital Thrombotic Thrombocytopenic Purpura: Results from the Phase 3 Randomized, Crossover Study and the Phase 3b Continuation Study

Berger, J. S.

2542 - Tetraspanin CD37 Regulates Platelet Hyperreactivity and Thrombosis

Berger, K.

2281 - Patient Preferences on Clinical Decision-Making in Myeloma: A 747-Patient Survey

Berger, L.

2446 - The Effects of an Online Curriculum Based Approach to CME on Hematologist/Oncologists’ Ability to Treat Patients with BTK Inhibitors for Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Berger, M. G.

478 - 18-Months Follow-up of the Trial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting

Berger, M.

4350 - Transcriptomic Analysis in Mantle Cell Lymphoma Patients Identified MALAT1 Long-Non-Coding RNA to Regulate Cell Cycle Progression By Modulating EZH2/p57/Sox11 Axis
4371 - Tumor Microenvironment-Induced Interleukin-6 Regulates Proliferation and Survival in Patients with Mantle Cell Lymphoma (MCL) By Activating FGFR1 Signaling

Berger, S. C.

2073 - CD19-Directed CAR T Cell Therapy in 4 Patients with Refractory Multiple Sclerosis

Berger, T. R.

2025 - Novel CD2-Targeting Trispecific Immune Effector Cell Engager (TRIEC) Coupled with CD19 CAR-T Overcomes Resistant B-Cell Lymphoma

Bergeron, J.

521 - Baseline Neurological Morbidity Assessment in Adult Patients with Sickle Cell Disease : The Montreal Brain-SCD Cohort
3620 - Feasibility, Safety and Effectiveness of Intranasal Fentanyl in the Treatment of Acute Pain Episodes Among Adults with Sickle Cell Disease: A Retrospective Single Center Study
5068 - Validitation of the Rowland Universal Dementia Assessment Scale (RUDAS) for the Detection of Cognitive Impairment Among Adults with Sickle Cell Disease
5069 - How Does Cognition Impact Healthcare Transition Skills, Engagement and Utilization in Young Adults Living with Sickle Cell Disease?

Bergeron, J.

4211 - Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial

Bergeron, J.

779 - Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial

Bergerova, V.

2806 - Central Nervous System Involvement Does Not Worsen Survival in Hematologic or Molecular Relapse of Adult Acute Lymphoblastic Leukemia Patients – Retrospective Analysis By the Czech Leukemia Study Group for Life (CELL)

Bergerud, K. B.

4215 - Divergent CD4+ T-Cell Fates Govern Relapse and Remission in B-Cell Acute Lymphoblastic Leukemia

Berges, J.

1153 - Deciphering Inflammasome Activation in Gaucher Macrophages and Its Role in the Development of Multiple Myeloma

Bergesio, F.

854 - A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Ctdna
2960 - Non-Coding Mutations of BCL6 in Classical Hodgkin Lymphoma

Berglund, M.

1623 - Plasma Proteomic Profiling Identifies Prognostic Biomarkers in Mantle Cell Lymphoma
2995 - Rule-Based Machine Learning Analysis of the Blood Proteome Identifies MCL Patients with High Risk of Early Disease Progression
4370 - Plasma Proteomics Differentiates between Patients with B-Cell Lymphomas

Bergman, P.

4634 - Severity of COVID-19 in Individuals with Chronic Lymphocytic Leukemia throughout the Pandemic in Sweden: A Nationwide Multiple Register Cohort Study Conducted from 2020 to 2023

Bergmann, A.

847 - Prognostic Impact of Subclinical FLT3-ITD Microclones in Patients with Acute Myeloid Leukemia

Bergmann, C.

684 - Update on Monocentric CD19-CAR T-Cell Therapy in 30 Patients with Autoimmune Disease

Bergmeier, W.

133 - Coagulation Factor XII (F12) Haploinsufficiency Is Protective Against Venous Thromboembolism

Bergoend, E.

3892 - Very Premature Bioprosthetic and Valve Repair Degeneration in Sickle Cell Disease Patients

Bergonzi, G. M.

1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
2690 - Methodology and Clinical Significance of Longitudinal UBA1 Clonal Burden Evaluation in Vexas Syndrome
4050 - Poisoning of Healthy Hematopoiesis Is an Unanticipated Mechanism Driving Clonal Dominance in Vexas Syndrome

Bergsagel, L.

249 - Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax
356 - Celmod-Dexamethasone Combination Overcomes Primary Resistance to T Cell Engagers Caused By High Tumor Burden in a Human CRBN⁺ Preclinical Model of Multiple Myeloma
358 - Combination with Cytotoxic Therapy and Checkpoint Blockade Overcomes Primary Resistance to BCMA Bispecific Antibody Therapy and Leads to Durable Remission of Vk*MYC Multiple Myeloma
592 - Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma
671 - A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma
1981 - Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience
3269 - A Proteogenomic Approach to Identify Potential Drivers of Hyperdiploid Multiple Myeloma
3275 - Abundance of C1q Expressing Macrophages Promotes Resistance to Modern Therapy
3382 - Cross-Cohort Correlative Analysis of Clinically High-Risk Patients (pts) Treated with Idecabtagene Vicleucel (ide-cel) in KarMMa-2: Association between Progression-Free Survival (PFS) and Tumor Burden and Immune Status at Apheresis
3388 - Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up
4635 - The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma
4655 - Mutationally Enriched Regions of the Non-Coding Genome Harbor Functionally Impactful Mutations That Dysregulate Key Genes Involved in Multiple Myeloma Pathogenesis
4728 - Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes
4685.1 - Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)

Bergua Burgues, J. M.

319 - Clinical Features and Outcomes in 228 Patients Diagnosed with Blastic Plasmocytoid Dendritic Cell Neoplasm: A Pethema/PALG Study
320 - Treatment Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Data from the Pethema and PALG Epidemiologic Registry
733 - Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial
1512 - Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3-ITD Negative AML
1552 - Enhanced Validation of the FLT3-like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in FLT3-ITD Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial
2895 - Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3-ITD–Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial
4483 - Outcomes in Older Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study
4986 - A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML
2883.1 - A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of Cln‑049 for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease

Bergüa Burgues, J. M.

2874 - A Multicenter, Prospective, Non-Randomized, Phase I-II Trial to Asses the Efficacy and Safety of the Combination or Oral Quizartinib and the FLAG-IDA Chemotherapy Regimen in First Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Bergua, J. M.

1957 - Unraveling Long-Term Survival of Multiple Myeloma Patients, the GEM2000 Experience

Bergvall, E.

2958 - Circulating Tumor DNA Predicts Time to First Treatment in Previously Untreated Follicular Lymphoma: Analysis from a Prospective Clonal Evolution Study

Berinstein, N.

3921 - Navigating Lineage Options: A Data-Driven Quest to Uncover T Cell Fate Decision Trajectories

Berk, K.

3955 - Warfarin Exposure Leads to Loss of Binding of Emicizumab to Factor IX

Berkahn, L.

59 - A Randomised Comparison of CPX-351 Versus Standard Daunorubicin and Cytarabine Plus Fractionated Gemtuzumab Ozogamicin in Older Adults with AML without Adverse Risk Cytogenetics: Results of the NCRI AML18 Trial
4255 - Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML

Berkeley, S.

1982 - Phase II Study of Isatuximab, and Weekly Carfilzomib + Dexamethasone in Relapsed and Refractory Multiple Myeloma (RRMM)

Berkova, Z.

4737 - Personalized Neoantigen Peptide Vaccine with or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma (SMM) to Prevent Progression to Multiple Myeloma (MM)

Berkovits, A.

1742.2 - Golseek-1: A Phase 3, Double-Blind, Randomized Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Vs R-CHOP in Patients with Previously Untreated, High-Risk, Large B-Cell Lymphoma
4569.3 - A Phase 3, Randomized, Double-Blind, Active-Comparator-Controlled Study of Bomedemstat Versus Hydroxyurea in Patients with Essential Thrombocythemia Naïve to Cytoreductive Therapy

Berkowitz, C.

1219 - Physician-Assessed Vs. Patient-Reported Bleeding Scores in an Undiagnosed Clinic Population

Berlanga, O.

1964 - Mass Spectrometry (MS)-Based Exent® Solution Reveals High Prevalence of Multiple M-Proteins in African American Patients with Multiple Myeloma (MM) and Precursor Conditions

Berliner, N.

2531 - Multinational Assessment of Absolute Neutrophil Counts and White Blood Cell Counts Among Healthy Individuals with the Duffy Null Phenotype or Genotype

Berlinski, A.

4364 - Evaluating the Clinical Utility of Real-Time Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Diffuse Large B-Cell Lymphoma

Bermack, C.

983 - Refining Prognostication in Peripheral T Cell Lymphoma (PTCL): A Risk-Adapted Prognostic Model for Patients with Limited-Stage PTCL
1687 - Clinical Features, Therapy Patterns and Survival Outcomes of Limited-Stage Peripheral T-Cell Lymphomas: A Cross-Continental Study
1692 - The Number of Extranodal Sites Matters! a Proposal for a Feasible Prognostic Model in Nodal PTCL. a Collaborative Study grupo De Estudio Latino-Americano De Linfoproliferativos (GELL) & T-Cell Brazil Project (TCBP)
3064 - Central Nervous System Involvement in Aggressive ATLL: Can We Predict the Risk in a Devastating Complication? Epidemiology and Clinical Features from Latin America. a Collaborative Study from Grupo De Estudio Latino-Americano De Linfoproliferativo (GELL) & T-Cell Brazil Project (TCBP)
3435 - Developing Novel Cellular Therapies for Cutaneous T Cell Lymphoma (CTCL): Combining Immunopeptidomics and Endogenous T Cell (ETC) Therapy Platforms to Identify and Target Shared CTCL-Associated Antigens

Berman, E.

221 - Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML
1556 - Adult AML Patients with NUP98 Fusions Are Frequently Therapy-Related, and Are Associated with Monocytic Differentiation, Recurring Mutations in NRAS, DNMT3A and WT1 and Poor Outcome

Berman, J. N.

1342 - KMT2C Mutations Co-Operate with KMT2A-MLLT1 Fusion to Inhibit Hematopoietic Differentiation in a Zebrafish Model of Infant Leukemia
2949 - Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children’s Oncology Group
4971 - Targeting Metabolism to Restore Hematopoiesis in Inherited Bone Marrow Failure Syndromes: Preclinical Insights from Zebrafish Models

Bermejo-Peláez, D.

2230 - Leveraging AI for Predicting Genetic Alterations in Multiple Myeloma through Morphological Analysis of Bone Marrow Aspirates

Bermejo-Vega, N.

2555 - Early Treatment Use of Fostamatinib for Immune Thrombocytopenia (ITP): Efficacy and Safety As Second/Third ITP Treatment Lines in Clinical Practice in Spain

Bermúdez, A.

305 - Improved Outcomes in Paroxysmal Nocturnal Hemoglobinuria Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
1642 - Zanubrutinib Is Effective in the Treatment of Patients with Waldenström's Macroglobulinemia and Bing-Neel Syndrome: A Retrospective Multicenter Study
3531 - Current Prophylaxis and Treatment of Gvhd: Analysis of a Large Real-World Cohort. Spanish Group of Hematopoietic Transplantation and Cellular Therapy (GETH/TC)
4869 - Incidence, Clinical Risk Factors, and Biomarkers of SOS/VOD Following Allogeneic HSCT in Adults: A Real-Life Study By the Spanish Group of Hematopoietic Stem Cell Transplantation and Cell Therapy (GETH-TC)

Bermudez, M.

1207 - Trends in Outcomes and Hospitalisation of Head and Neck of Femur Fractures in Patients with Hemophilia - an Analysis of the National Inpatient Sample (NIS) (2016-2020)
3177 - Trends in Outcomes and Hospitalization of Gastrointestinal Bleeding in Patients with Myeloproliferative Neoplasms- an Analysis of the National Inpatient Sample (NIS) (2016-2020)
4555 - Disparities in Depression: The Role of Race and Gender in Patients with Myeloproliferative Neoplasms, an Analysis of the National Inpatient Sample (NIS) (2016-2020)

Bermudez Rodriguez, M. A.

2190 - Peripheral Blood Stem Cell Versus Bone Marrow Graft for Non-T-Depleted Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Patients with Secondary Acute Myeloid Leukemia in First Complete Remission: A Study from the ALWP/EBMT

Bern, M.

4100 - VISTA As a Mediator of Immune Suppression in AML Initiated By DNMT3A and NPM1 mutations

Bernal, A.

2579 - Low Normal Levels of Factor V Enhance Thrombin Generation in Hemophilia a in a Tissue Factor Pathway Inhibitor Independent Manner

Bernal Del Castillo, T.

319 - Clinical Features and Outcomes in 228 Patients Diagnosed with Blastic Plasmocytoid Dendritic Cell Neoplasm: A Pethema/PALG Study
320 - Treatment Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Data from the Pethema and PALG Epidemiologic Registry
1512 - Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3-ITD Negative AML
2895 - Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3-ITD–Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial
3207 - Preliminary Safety and Efficacy of Luspatercept Initiated at Maximum Approved Dose in Patients with Transfusion Dependent Anemia Due to Very Low, Low and Intermediate Risk MDS with Ring Sideroblasts: First Results of the Lusplus Trial

Bernal, D. O.

1240 - Characteristics of Patients with Inflammatory Bowel Disease and Impact on Outcomes Following Heparin-Induced Thrombocytopenia: A 5-Year Nationwide Analysis

Bernal, P.

1943 - Prognostic Impact of Measurable Residual Disease Evaluated By Next Generation Flow and PET-CT in Clinical Practice at Fundación Santa Fe De Bogotá Hospital, Colombia

Bernal, T.

666 - Newly Developed Prognostic Score for Myelodysplastic Syndrome (MDS) with Isolated 5q Deletion (IPSS-del(5q))

Bernal, T.

1552 - Enhanced Validation of the FLT3-like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in FLT3-ITD Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial
2874 - A Multicenter, Prospective, Non-Randomized, Phase I-II Trial to Asses the Efficacy and Safety of the Combination or Oral Quizartinib and the FLAG-IDA Chemotherapy Regimen in First Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
4255 - Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML
4986 - A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML

Bernal-Mizrachi, L.

3748 - Treatment-Related Neuropathy Following Brentuximab-Vedotin in African Americans Treated for Lymphoma: A Retrospective Chart Review

Bernard, E.

1830 - Genetic Diversity Drives Differing Morphological and Clinical Presentation and Survival in Myelodysplastic-Type CMML with a Low Absolute Monocyte Count

Bernard, E.

3198 - Large-Scale Transcriptome Analysis Supports Genomic Taxonomy and Predicts Response to Hypomethylating Agents in Myelodysplastic Neoplasms

Bernard, L.

1502 - UM171 Cord Blood Transplantation for TP53 Mutated and EVI1 Rearranged Myelodysplasia/Acute Myeloid Leukemia
2873 - A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)
4916 - Long Term Follow up of UM171 Expanded Cord Blood Transplantation Patients Does Not Reveal Any Late Toxicity

Bernard, M.

1531 - Inflammatory Biomarkers Predict Response and Survival in Chemotherapy-Ineligible and Untreated Acute Myeloid Leukemia Patients Receiving Venetoclax-Azacytidine As Front-Line Therapy

Bernard, O.

474 - Post-Therapeutic Tumor Losses of B-Cell Receptor Components CD20/CD19, a New Challenge in the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
857 - A Multiomic Analysis of Waldenstrom's Macroglobulinemia Identifies Three Subtypes of Disease Based on Impaired Plasma Cell Differentiation

Bernard, S.

246 - Prognostic Implications of Pulmonary Hypertension in Myeloproliferative Neoplasms and Predictors of Hematologic Progression
3188 - Incidence, Risk Factors, and Prognostic Implications of Heart Failure Hospitalizations Among Patients with Myeloproliferative Neoplasms

Bernardi, F.

3992 - Very Long-Chain Saturated Fatty Acids Are Inversely Correlated with Thrombin Generation and Linked to a Reduced Risk of Coronary Artery Disease and Myocardial Infarction: Preliminary Findings from an Angiographically-Controlled Study

Bernardi, M.

929 - Single Cell Transcriptomics to Characterize the Features of Bone Marrow Natural Killer Cells in Different Relapse Modalities
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
2849 - CPX-351 Induces High Rate of Complete Remission in the New ICC/ELN 2022 Adverse-Risk Entity ‘AML with MDS-Related Gene Mutations’: Evidence from a Large Real-World Italian Study
2863 - Venetoclax and Hypomethylating Agents Confirmed to be Standard Therapy in De Novo and ELN17 Not Adverse Acute Myeloid Leukemia Patients, Unfit for Chemotherapy According to SIE/Sies/GITMO Criteria. a Multicentric Real-Life Study on 379 Patients, By the Hematological Network Rete Ematologica Lombarda (REL)

Bernardi, M.

4532 - Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact Project, a CML Campus Study

Bernardi, M.

4656 - Single Cell Transcriptomics on Bone Marrow Biopsies Unveils Peculiar Bone Microenvironment Cell Subtypes and Highlights Alterations Correlated with High-Risk Features in Precursor Monoclonal Gammopathies and Multiple Myeloma Patients

Bernardi, S.

4532 - Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact Project, a CML Campus Study
4797 - Secondary Myeloid Neoplasms after CD19 CAR-T Cell Therapy: Real-Life Multicenter Data from the Clonhema Study

Bernardicius, D.

327 - Phip Is a Potent Leukemia Oncogene Identified in Acute Myeloid Leukemia (AML) Patients of African Ancestry

Bernardino, G.

5161 - Multiple Lines of Therapy and Progression to Next Lines in Multiple Myeloma Patients: Real-World Studies in Argentina (TOTEMM-A) and Brazil (TOTEMM-B)

Bernardo, M.

2883.3 - Phase 1/2, Open-Label, Multi-Center Study Assessing the Safety, Tolerability and Preliminary Efficacy of CD123 Natural Killer Cell Engager (NKCE), SAR443579, in Combination with Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy

Bernasconi, D.

470 - Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
472 - Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Bernat, S.

2555 - Early Treatment Use of Fostamatinib for Immune Thrombocytopenia (ITP): Efficacy and Safety As Second/Third ITP Treatment Lines in Clinical Practice in Spain

Bernat, S. B.

713 - Avespa Study: Effectiveness and Safety of Avatrombopag in Immune Thrombocytopenia (ITP). a Real-World Study of the Spanish ITP Group (GEPTI)
3948 - Investigating the Effectiveness and Safety of Combining Thrombopoietin Receptor Agonist and Immunosuppressant Drugs for Patients with Multirefractory Immune Thrombocytopenia after Second-Line Monotherapy Treatments

Berndt, S. I.

4339 - Genome-Wide Meta-Analysis Identifies Multiple Germline Genetic Variants Associated with Increased Risk of Follicular Lymphoma
4358 - Expanded Genome-Wide Association Study (GWAS) Identifies Nine Novel Germline Risk Loci for Waldenström Macroglobulinemia (WM) and Lymphoplasmacytic Lymphoma (LPL)

Berne, L.

4978 - Novel Single-Cell RNA Technology Simplifies Measurement of Anti-BCMA CAR-Ts in Patient Samples

Bernhard, F.

419 - Flavopiridol Restores Granulopoiesis in an Experimental Model of Severe Congenital Neutropenia

Bernhardt, M. B.

4190 - Evaluation of Methotrexate Pharmacogenomic Variants to Predict Acute Neurotoxicity in Children with Acute Lymphoblastic Leukemia

Bernhardt, M. B.

1438 - Understanding the Associations between High-Dose Methotrexate Pharmacokinetics and the Risk of Adverse Events in Children and Adolescents with Down Syndrome Associated High-Risk Acute Lymphoblastic Leukemia

Bernheisel, C.

3700 - Real-World Treatment Patterns and Outcomes in Patients with Primary Immune Thrombocytopenia Treated with Avatrombopag in the United States: Real-AVA 2.0 Interim Analysis Results

Berning, P.

464 - Autologous and Allogeneic Stem Cell Transplantation for Major T-Cell Lymphoma Entities: An Analysis of the EBMT Lymphoma Working Party
1412 - Targeting β-Catenin Protein Degradation in Refractory B-Cell Malignancies
3070 - Autologous Hematopoietic Stem Cell Transplantation in Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
3383 - Idecabtagene Vicleucel (ide-cel) Shows Similar Efficacy and Toxicity in Patients with Multiple Myeloma Aged 70 and Older Compared to Younger Patients: A Multicenter Cohort Study
4125 - Identification of High-Efficiency β-Catenin Protein Degradation As Critical Vulnerability in B-Cell Malignancies
4242 - “As Treated” Validation of the European LeukemiaNet (ELN) Classification for Adult Acute Myeloid Leukemia (AML) Patients (pts) Treated in a Large AML-Referral Center from 2010-2022

Berning, P.

2177 - Post-Transplant Relapse in Patients Transplanted with Active Acute Myeloid Leukemia (AML) – Treatment Options and Outcomes at a Large AML Referral Center
3818 - Outcomes of Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Multicenter Real-World Analysis
4759 - Efficacy of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma and Prior Central Nervous System Manifestation: A Retrospective Real-World Analysis

Bernini, J. C.

4190 - Evaluation of Methotrexate Pharmacogenomic Variants to Predict Acute Neurotoxicity in Children with Acute Lymphoblastic Leukemia

Berns, B.

4265 - Encouraging Efficacy of Bexmarilimab with Azacitidine in Relapsed or Refractory MDS in Bexmab Ph1/2 Study

Bernstein, M.

3327 - Characterization of the Tumor Microenvironment of Diagnostic Bone Marrow Core Biopsies from African American Multiple Myeloma Patients Using Imaging Mass Cytometry

Bernt, K. M.

316 - Multimodal Single-Cell Profiling of Minimal Residual Disease in B Acute Lymphoblastic Leukemia Reveals Genetic and Non-Genetic Factors of Early Drug Resistance
725 - Aberrant Stemness Transcription Signature Unveils a Mechanism of Chemotherapy Resistance through Blunting p53-Mediated Response in Acute Myeloid Leukemia
1455 - KMT2A-Rearranged ALL Requires DYRK1A for Regulation of ERK Signaling and Cell Proliferation

Berreby, G.

807 - The Ectopyrase CD73 Is a Critical Checkpoint in Thromboinflammation

Berridge-Green, A.

2414 - Consent to Future Use of Residual and Banked Specimens Among Adults with Hematologic Malignancies: Analyzing SWOG Clinical Trial Data from 2000-2024

Berrien-Elliott, M. M.

916 - W-NK1 Choreographs Innate and Adaptive Immune Responses to Provide a Robust and Durable Anti-AML Response
4257 - WUN101-01: First in Human Human (FIH) Phase 1 Study of WU-NK-101 (W-NK1) in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Berrios, D.

767 - Single-Cell Multi-Omic Profiling of Patients with BCMA-Targeted Therapy Identifies Molecular and Cellular Factors Associated with Responsiveness and Treatment Effects
3272 - Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma

Berry, J.

1247 - Anticoagulation and Major Bleeding or Recurrent Thrombosis in Patients with Isolated Cancer-Associated Splanchnic Vein Thrombosis: A Multi-Center Cohort Study

Berry, L.

2784 - Sky-1214, a Small Molecule Splicing Modulator Targeting FANCL and Fanci, Provides a New Mechanism of Action Targeting Multiple Myeloma and Non-Hodgkin’s Lymphoma

Berry, T.

998 - Trial Update from IMproveMF, an Ongoing, Open-Label, Dose-Escalation and -Expansion, Phase 1/1B Trial to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Novel Combination of Imetelstat with Ruxolitinib in Patients with Intermediate-1, Intermediate-2, or High-Risk Myelofibrosis (MF)
4590 - Initial Results from the QTc Substudy of the IMerge Phase 3 Trial Demonstrate Clinically Meaningful Efficacy, Manageable Safety, and Absence of Proarrhythmic Risk in Patients with Lower-Risk Myelodysplastic Syndromes Who Received Prior Therapies Beyond Erythropoiesis Stimulating Agents
1808.1 - Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-Label, Phase 3 Trial

Bershadsky, J.

2045 - A Layered Cloaking Strategy to Generate Allogeneic iPSC-Derived CD8 T-Cells That Evade NK Clearance

Bertaina, A.

2015 - Evaluation of Bone Marrow in Fanconi Anemia Patients Treated with Briquilimab Antibody-Based Conditioning and TCRαβ⁺ T-Cell/CD19⁺ B-Cell Depleted Haploidentical Grafts
3525 - T-allo10 Immunotherapy Results in Enhanced Early Immune Reconstitution and Reduced GvHD with Excellent Clinical Outcomes Post Αβ-Depleted HSCT in Pediatric and Young Adult Hematologic Malignancy Patients

Bertaina, V.

3086 - CD20-Negative Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphomas and Mature B-Cell Leukemia in Children, Adolescent and Young Adults: A Retrospective Review
3561 - Outcomes of Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia Given Blinatumomab As Last Consolidation Treatment before Allogeneic Hematopoietic Cell Transplantation
4830 - CD7.Pebl-CART for Patients with Relapsed/Refractory (r/r) T-Cell Acute Lymphoblastic Leukemia (T-ALL)
4834 - Phase I/II Clinical Trial on CD19-Chimeric Antigen Receptor (CAR) T Cells Generated with an Automated Process, from Fresh Apheresis, and Reinfused As Fresh Drug Product for Pediatric/Young Adult Patients with Relapsed/Refractory (r/r) B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

Bertamini, L.

487 - Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study
1019 - A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome
1894 - Novel Non-Coding Candidate Drivers of Multiple Myeloma Linked to Plasma Cell Tumor Biology and B Cell Development
3279 - Early Serum Protein Clonal Dynamics Preceding Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma Years before Diagnosis

Bertamini, L.

1928 - Tumor-Intrinsic and Immune Predictors of Response to Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
4984 - Deep Learning Unveils Characteristics of Immune B Cell Aging in >17,000 Samples and Identifies Changes in the Immunoglobulin Repertoire Distribution and the Development of Monoclonal Gammopathy

Bertheau, P.

4813 - A Spatial Atlas of Human Gastro-Intestinal Acute Gvhd Reveals Epithelial and Immune Dynamics Underlying Disease Pathophysiology

Berthier, A.

865 - Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study
1718.1 - SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)

Berthon, C.

2424 - Treatments and Outcomes of Adult Patients with AML in the Real-Life – First Report of the French Observational ALFA-PPP Study

Berthon, C.

227 - Secondary Genetic Alterations and Measurable Residual Disease in Core Binding Factor Acute Myeloid Leukemia - a Study from the Acute Leukemia French Intergroup

Bertolazzi, G.

453 - B Cell Receptor Silencing Reveals Origin and Impacts Treatment of High-Grade B Cell Lymphomas with MYC and BCL2 Rearrangements

Bertoldi, L.

1380 - Ex-Vivo Evaluation of Stx-0712, a CCR2 Cytotoxicity Targeting Chimera (CCR2-CyTAC) for the Treatment of Acute Myeloid Leukemia

Bertoli, R.

1404 - Cytarabine Resistance Leads to a Specific Mutator Phenotype in Leukemic Cells
4126 - The Hypomethylating Agent 5-Aza-4’-Thio-2’-Deoxycytidine Targets Early B Progenitor Cells and Leads to B Cell Precursor Acute Lymphoblastic Leukemia in Rag1 Knockout Mice

Bertoli, S.

58 - Real-World Multicenter Evaluation of Venetoclax and Azacitidine for Molecular Relapse after First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Filo Study
2934 - The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients
4275 - Real-World Multicenter Comparison of Venetoclax and Azacitidine Versus Intermediate or High Dose Cytarabine-Based Salvage for Patients with AML in First Relapse after Front Line Intensive Chemotherapy. a Dataml-IPC-Auraml Consortium Study

Bertolini, F.

1620 - Impaired rRNA Synthesis Contributes to BCL-2 Induced Chemoresistance in Diffuse Large B-Cell Lymphoma

Bertolucci, C. M.

2294 - Multicentric Standardization of Minimal/Measurable Residual Disease in Acute Myeloid Leukemia Using Multiparametric Flow Cytometry – a Brazilian Society of Bone Marrow Transplantation (SBTMO) Project

Bertomeu, T.

976 - Metabolic Determinants of Ferroptosis in B-Cell Lymphoma

Berton, G.

1508 - Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed By Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid Leukemia

Berton, M.

75 - High IGHV Intraclonal Diversification Identifies CLL with Good Prognosis, Features of Anergy and Specific T-Cell Profiles

Bertone, P.

754 - Engrafted JAK2V617F Clone Hijacks Resident Non-Mutated Hematopoietic System to Drive Myeloproliferative Neoplasm

Bertoni, F.

73 - Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated By Epigenetic Plasticity of Residual Disease and By-Pass Signaling Via MAPK Pathway
1578 - Clonal Hematopoiesis in Diffuse Large B-Cell Lymphoma: Clinical and Molecular Correlations

Bertorello, N.

310 - Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and Outcomes
4217 - Frequency and Early Prognostic Significance of Gene-Class Fusions Identified By RNA-Seq in Children and Adolescent with T-Cell Acute Lymphoblastic Leukemia Enrolled on AIEOP-BFM ALL 2017 Study

Bertrand, K. A.

4680 - Epidemiological Characteristics and Clinical Outcomes of Patients with Monoclonal Gammopathy of Renal Significance (MGRS) Diagnosed in a Large Safety-Net Hospital in the US

Bertrand, Y.

968 - Favourable Outcomes in Newly Diagnosed Paediatric AML with Gemtuzumab Ozogamicin and Risk-Stratified Therapy: Results from the International Phase III Myechild 01 Trial
2814 - How to Administer Pegaspargase during Induction Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents? Results of the Caall-F01, a Multicentre Randomized Clinical Trial from the French Pediatric Cancer Society (SFCE)

Bertsch, U.

84 - Impact of Clonal Heterogeneity in Newly Diagnosed, Transplant-Eligible Multiple Myeloma – Subgroup Analysis of the GMMG HD6 Phase III Trial
364 - Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial
493 - Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial
769 - Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
898 - Early Relapse in Patients with Newly-Diagnosed Multiple Myeloma: A European Myeloma Network/Harmony Alliance Analysis Including 10843 Patients
1963 - Quality of Life in the Multicenter, Randomized, Phase 3 GMMG-HD6 Trial Applying Elotuzumab, Lenalidomide, Bortezomib and Dexaemethason in Patients with Newly-Diagnosed Multiple Myeloma
2226 - Development and Validation of Novel Machine Learning-Based Risk Scores for Multiple Myeloma: Insights from the Harmony Alliance Big Data Platform
5140 - Long-Term Follow-up Analysis of Progression-Free and Overall Survival in Newly Diagnosed Multiple Myeloma Patients from the GMMG Myeloma Registry Following the Randomized Phase III GMMG-HD6 Trial

Bertuccio, S.

325 - Genetic and Functional Characterization of NUP98-Rearranged Leukemia

Bertuch, A. A.

2703 - Incidence of Myeloid Malignancy in Shwachman-Diamond Syndrome: An International Cohort Study

Bertuch, A. A.

441 - Outcomes of Hematopoietic Stem Cell Transplantation for High-Risk Marrow Features without Malignancy in Shwachman-Diamond Syndrome

Bertuglia, G.

4699 - Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Bertulfo, K.

823 - Crebbp Inhibition Potentiates JAK2 Inhibition in Post-MPN Acute Myeloid Leukemia
- Therapeutic Targeting of JAK/STAT Signaling and Histone Acetyltransferase Activity in Post-Myeloproliferative Neoplasm Secondary AML

Bertz, H.

2864 - A Prospective, Multicenter Study Assessing Functional and Psychosocial Parameters in AML Patients ≥ 60 Years Receiving Induction Chemotherapy

Berube, B.

1777 - Cardiovascular Profile of Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia: A 16-Year Observational Study

Besemer, B.

84 - Impact of Clonal Heterogeneity in Newly Diagnosed, Transplant-Eligible Multiple Myeloma – Subgroup Analysis of the GMMG HD6 Phase III Trial
364 - Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial
708 - Single Vs. Tandem Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Real-World Multi-Center Study from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)
769 - Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
770 - Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study
1963 - Quality of Life in the Multicenter, Randomized, Phase 3 GMMG-HD6 Trial Applying Elotuzumab, Lenalidomide, Bortezomib and Dexaemethason in Patients with Newly-Diagnosed Multiple Myeloma
3352 - Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study
5140 - Long-Term Follow-up Analysis of Progression-Free and Overall Survival in Newly Diagnosed Multiple Myeloma Patients from the GMMG Myeloma Registry Following the Randomized Phase III GMMG-HD6 Trial

Besikli-Dimou, S.

2358 - Improving Quality of Life Based on Electronic Patient Reported Outcomes in Patients with CLL and MDS: The Mypal Study
4619 - Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study

Beşışık, S.

770 - Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study

Besley, C.

595 - Role of Age and Donor Type in 3646 Severe Aplastic Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
2342 - Multi-Centre Real-World Outcomes of Large B-Cell Lymphoma Patients Treated with 2L Axicabtagene Ciloleucel in the UK

Besley, C.

3456 - Impact of Fludarabine Dosage on Outcomes in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy: A Retrospective Study on Behalf of the Ctiwp of the EBMT
3729 - The Impact of Lymphodepleting Chemotherapy Dose Modifications on Axicabtagene Ciloleucel Expansion and Treatment Outcome in Patients with Relapsed or Refractory CD19-Positive Diffuse Large B-Cell Lymphoma

Besser, M.

5001 - Clinical and Economic Impact of Long-Term Disease Modifying Transfusions in Adults As a Prophylactic Intervention for Sickle Cell Disease Crises
5002 - Clinical and Economic Impact of Long-Term Disease Modifying Transfusions in Paediatrics As a Prophylactic Intervention for Sickle Cell Disease Crises

Besses, C.

4566 - Diagnostic Challenges in Patients with Clinical Suspicion of Myeloproliferative Neoplasms and JAK2V617F≤1%

Bessette, P.

499 - Selective Support of CAR-T Cell Therapies By Cis-Targeted IL-2 Enhances Anti-Tumor Activity and Obviates the Need for Lymphodepletion in Non-Human Primates

Bessig, N.

894 - Efficacy and Safety of Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for the Treatment of Relapsed and Refractory AL Amyloidosis
1030 - Efficacy of HBI0101, an Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for Relapsed/Refractory Multiple Myeloma

Bessnow, A. C.

4408 - Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)
4617 - Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL

Besson, T.

1455 - KMT2A-Rearranged ALL Requires DYRK1A for Regulation of ERK Signaling and Cell Proliferation

Bessot, B.

2201 - Gene Therapy for Artemis-SCID and Artemis-Leaky-SCID Patients: Preliminary Results of the French Artegene Phase I/II Clinical Trial

Best, S.

5015 - Evaluating a Multidisciplinary Model of Care for Inherited Bone Marrow Failure and Predisposition to Hematological Malignancy

Best, S.

1332 - A Dedicated System Accounting for Specific Germline/Somatic Genomic Constellations Is Essential to Predict Outcomes in DDX41-Mutant Myeloid Neoplasia

Best, T.

527 - Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report
3734 - The Patient Journey and Treatment Outcomes Comparing Inpatient Versus Outpatient Axicabtagene Ciloleucel in Non-Hodgkin’s Lymphoma (NHL) - a Large, Multicenter Study

Best, T.

526 - Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Bester, A.

4118 - Ppara Deletion Promotes Monocytic Leukemia Granulocytic Differentiation

Bestoso, E.

995 - FATE and Role of Peripheral Blood CD26+ Leukemia STEM CELLS at Diagnosis in Chronic Myeloid Leukemia Patients: FINAL Results of Prospective Flowers Study

Betensky, M.

296 - Mechanical Thromboprophylaxis and Hospital-Acquired Venous Thromboembolism: A Report from the Children’s Healthcare Advances in Thrombosis Consortium
1234 - Plasma Hypercoagulability and Hypofibrinolysis Are Associated with Increased Markers of Inflammation in Pediatric VTE: Findings from the Kids-DOTT Trial Biobank
1257 - Anticoagulation Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
2629 - Hospital-Acquired Venous Thromboembolism (HA-VTE) Epidemiology and Risk Factors Among Critically Ill Children and Young Adults with Diabetic Ketoacidosis
2633 - Thrombolytic Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
4015 - Systematic Review of Pediatric Venous Thromboembolism Associated with Inferior Vena Cava (IVC) Anomalies
- Duration of Therapy for Provoked and Unprovoked VTE in Pediatric Patients

Bethge, W. A.

399 - Hematopoietic Stem Cell Transplantation in Hepatosplenic T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
776 - Follow-up of the Randomized ASAP Trial Shows No Survival Advantage for Patients with Poor Responsive or Relapsed AML Who Received Intensive Salvage Chemotherapy for Remission Induction Prior to Allogeneic Transplantation Compared to Immediate Allogeneic Transplantation
965 - Second Infusion of CAR T-Cells in Patients with Relapsed /Refractory B-Cell Acute Lymphoblastic Leukemia: Results from a Gocart Coalition Analysis on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT
3554 - Impact of Allogeneic Hematopoietic Cell Transplantation Post-Sars-Cov-2 Infection: A Retrospective Analysis By the German Cooperative Transplant Study Group
3560 - Impact of FLT3 Inhibitor Maintenance Therapy on Post-Transplant Outcomes in FLT3-Mutated AML Patients: A Real World Analysis from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)

Bethune, M. T.

2035 - CRG-023 Is a Novel Tri-Specific CAR T Product Candidate Engineered to Prevent Antigen Escape and Sustain Durable Anti-Tumor Functionality Against B-Cell Malignancies

Betke, L.

901 - Memory CD4⁺ T Cells Recognize Divergent HLA-DP Immunopeptidomes and Contribute to Leukemia Control after Allogeneic HCT

Betriu, S.

3452 - Euplagia-1: A Phase 1/2 Trial of GLPG5201, a Fresh Stem-like Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, in Patients with Relapsed/Refractory CLL and RT

Bettache, N.

3620 - Feasibility, Safety and Effectiveness of Intranasal Fentanyl in the Treatment of Acute Pain Episodes Among Adults with Sickle Cell Disease: A Retrospective Single Center Study

Bettelli, S.

2975 - Dissecting Diffuse Large B Cell Lymphoma Heterogeneity: New Insights from a State-Specific Molecular Characterization

Better, O.

2669 - Clonal Hematopoiesis of Indeterminate Potential Is Associated with Decreased Inflammatory Toxicity and Increased Late Cytopenia in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy

Betti, S.

1763 - Familial Predisposition in Myeloproliferative Neoplasms: An NGS-Driven Analysis

Bettinotti, M.

927 - Predictive Modeling of Hematopoietic Stem Cell Transplant Outcomes: Discovering the Role of Immunogenetic Features through Machine Learning Models

Betts, B.

3445 - Influence of Myeloma Cell Expressed CD28 and CD86 on BCMA CAR T Cell Efficacy and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS)

Betts, M. R.

3924 - Trafficking, Not Lymphoproliferation, Promotes Lymphadenopathy in Idiopathic Multicentric Castleman Disease

Betz, B.

3214 - The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms

Betz, H.

2776 - ULK1 Presents As a Therapeutic Target to Sensitize Resistant Acute Myeloid Leukemia Cells to Venetoclax

Betz, K.

3516 - Five-Year Outcomes of the “Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease (GVHD) Prophylaxis: A Randomized Controlled Trial” (‘ABA2’)

Beuger, B. M.

2454 - Lu/BCAM Expression Defines Functionally Distinct Red Blood Cells
2483 - Alterations in the Immune Phenotype of Adaptive Immune Cells in Sickle Cell Disease: A Conventional and Computational Flow Cytometry Analysis
3527 - Dynamics of Immune Reconstitution in Adults with Sickle Cell Disease Undergoing Nonmyeloablative Matched Sibling Donor Stem Cell Transplantation: A Conventional and Computational Analysis

Beumer, J.

3112 - Etctn P10500: Phase 1 Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma

Beutel, G.

406 - Intraindividual Comparison of Recognition of Symptom Burden in MPN between Patient- and Physician-Reported Assessment and Its Impact on Survival – an Analysis By the German Study Group for MPN (GSG-MPN)
847 - Prognostic Impact of Subclinical FLT3-ITD Microclones in Patients with Acute Myeloid Leukemia
1090 - Reliable Assessment of Iron Deficiency in Patients with Myeloproliferative Neoplasms through Fluorescence Spectroscopy-Based Measurement of Zinc Protoporphyrin (ZPP)

Beveridge, L.

2687 - Phase III Randomized COMMODORE 2 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Naive to Complement Inhibition

Beverley, M.

3624 - One ST3P Further: Optimizing Transition Care for Pediatric Sickle Cell Patients at Atrium Health

Beverloo, B.

3906 - Comprehensive Analysis of Diagnosis, Treatment and Outcome in a Retrospective Cohort of HES Patients in the South-West of the Netherlands between 2000-2020
4300 - Transcriptional Profiling Directs the Classification of Mixed Phenotype Acute Leukemias into AML, B-ALL or T-ALL

Bewarder, M.

4498 - Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Bewersdorf, J. P.

Bewicke-Copley, F.

2965 - Multi-Modal Analysis Reveals the Differences between Double Expressor and Non-Double Expressor Primary Central Nervous System Lymphomas
4445 - Delays to Diagnosis of Peripheral T-Cell Lymphoma and Clinical Utility of Molecular Profiling: A UK Multicentre Real-World Study

Beyar Katz, O.

608 - Comparable Outcomes of Point-of-Care and Commercial CD19 CAR-T Therapies: A Patient-Matched Analysis in Large B-Cell Lymphoma
3752 - Comparative Real-World Outcomes of Commercial CD19-Directed CAR T-Cell Therapies in Large B-Cell Lymphoma
4393 - Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma

Beyar-Katz, O.

912 - CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes
1714 - Inflammation-Based Scores Predict Survival after CD3xCD20 Bispecific T Cell Engagers in R/R LBCL
1746 - Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study
1748 - Reduction in Platelet Counts May Predict the Development of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma
2369 - When Can We Define Cure after CAR-T Therapy in LBCL? Insights from Serial Landmark Analyses
3482 - The Ability of Currently Used Scoring Systems to Predict 30 and 100-Days Non-Relapse Mortality Among Older Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
4504 - CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia
4509 - CAR T-Cell Therapy for DLBCL with CNS Involvement: Overall Safe and Effective with Limited Efficacy in Patients with Leptomeningeal Disease

Beyer, M.

2447 - Microlearning As a Tool to Enhance Treatment of Acute Lymphoblastic Leukemia: Outcomes from a Focused Educational Intervention on MRD-Guided Therapy in B-ALL

Beyfuss, K.

1674.2 - PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies

Beygi, S.

4368 - Impact of Inflammation, Tumor and Product Attributes on Clinical Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Axicabtagene Ciloleucel

Beylergil, V.

4446 - Survival and Treatment Response in CTCL Can be Predicted Using Volumetric Lymph Node Size and Dynamic Changes in Lymph Node Size and Skin Score

Beylot-Barry, M.

Beyou, A.

740 - A Single Cell Atlas of Follicular Lymphoma across Clinical Stages Defines Tumor B Cell Archetypes, Immune Microenvironment Heterogeneity and Novel Cell States Associated with High-Risk FL

Beyrath, J.

1248 - First in-Human Study with Okl-1111, a Novel Small Molecule Universal Anticoagulant and Platelet Inhibitor Reversal Agent

Beysen, D.

431 - A Novel Cause of Type 1 VWD: Impaired Exocytosis of Weibel-Palade Bodies Due to Biallelic Mutations in Madd

Bezavada, L.

940 - An Essential Role for the N-Terminus of GATA1 in Metabolic Regulation during Erythropoiesis
1272 - Hematopoietic Stem Cell Function and Differentiation Is Regulated By DCAF7 through Polycomb Repressive Complex 1 (PRC1) Modulation

Bezerra, E.

523 - Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above
524 - Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma
2078 - Initial Results of a First-in-Human, Phase I Study Point-of-Care Manufacturing of Trispecific CAR-T Cells Targeting CD19/20/22 in B-Cell Malignancies
3446 - Association between Post-CART Terminal Complement Complex Levels and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
3747 - Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy Is Associated with Inferior Survival for Patients with Relapsed or Refractory Large B-Cell Lymphoma
4200 - NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival
4507 - Steroid Prophylaxis in Patients Receiving CAR T-Cell Therapy for Relapsed and Refractory Non-Hodgkin Lymphoma
5092 - Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR^® Registry

Bezieau, S.

3842 - Hereditary Erythrocytosis: Results from Europe's Largest Idiopathic Erythrocytosis Database

Bezman, N.

358 - Combination with Cytotoxic Therapy and Checkpoint Blockade Overcomes Primary Resistance to BCMA Bispecific Antibody Therapy and Leads to Durable Remission of Vk*MYC Multiple Myeloma

Bezzerri, V.

4090 - Eif6 Dosage Alleviates Activation of the Tp53 Pathway in Sbds-Deficient Cells: A Mechanism for Somatic Genetic Rescue in Shwachman-Diamond Syndrome

Bezzi, D.

3326 - Multiple Myeloma and Smoldering Myeloma: Prospective Evaluation of 3 T Whole Body MRI and 18F-FDG PET/CT and Their Impact on Clinical Management
4725 - Radiopsy, Quantitative Wb-Mri Adc and Fat Fraction Sequences for Discrimination of Smoldering Multiple Myeloma and Multiple Myeloma: A Prospective Observational Study

Bhagat, G.

47 - Differential Role of Crebbp Missense and Truncating Mutations in the Malignant Transformation of Germinal Center B Cells
465 - Development of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium
3409 - Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL
4128 - Role of Glucocorticoid Receptor in Normal and Malignant Germinal Center B Cells
4361 - Neuronal-Glial and Immune Microenvironment Signatures Show Prognostic Effects in Primary CNS Lymphoma

Bhagat, T. D.

878 - TGF-β1-SMAD2 Axis Regulates Hematopoiesis and β-Globin Gene Expression Via Super-Enhancer Associated Chromatin Reorganization

Bhagnani, T.

3226 - Improved Hematologic Recovery with Ivosidenib in Patients with mIDH1 Relapsed or Refractory MDS: Results from a Phase 1 Substudy

Bhagwat, A. S.

2040 - CAR T Cells Accelerate Disease Progression in AMLs Harboring an Inflammatory Transcriptional Signature
2946 - Serum-Based Proteomic Analysis of Cytokine Release Syndrome in Pediatric AML Patients Receiving CART123

Bhagwat, M.

3335 - Prevalence and Clinical Implications of Germline Variants in Multiple Myeloma Patients

Bhagwat, N.

809 - Targeting PRMT5 in Primary Hemophagocytic Lymphohistiocytosis: A Novel Therapeutic Approach Using a Perforin-Deficient Mouse Model
2774 - Selective SMARCA2 Degradation Promotes Leukemic Differentiation and Synergizes with CDK9 Inhibition to Potently Induce Death in Pre-Clinical Models of Acute Myeloid Leukemia
3215 - Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Patients with Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies
4156 - Interferon Synergizes with Inhibition of Pro-Apoptotic Proteins to Reduce Leukemia Burden in PDX Models of ML-DS

Bhakta, N.

4208 - Safety and Feasibility of Blinatumomab As Frontline Therapy for Pediatric Patients with B-Acute Lymphoblastic Leukemia and Lymphoma: St. Jude Total Therapy Study XVII

Bhalla, K. N.

346 - Clonal Origin of Therapy-Related Myeloid Neoplasms after Autologous Stem Cell Transplant
841 - Characteristics and Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) and FLT3-Tyrosine Kinase Domain (TKD) Mutations
1349 - ASXL1 Mutations in AML Are Associated with a Distinct Epigenetic State Which Highlights Vulnerabilities to Specific Epigenetic-Targeted Agents
1373 - Identifying ‘Druggable’ Targets and Preclinically Overcoming Non-Genetic/Adaptive Resistance to Menin Inhibitors in AML with MLL1r or mtNPM1
2749 - Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML
3142 - Evaluation of the Lethal Activity and Its Mechanism of Tasquinimod in Advanced Myeloproliferative Neoplasm (MPN) in Blastic Phase
4306 - Cohesin Complex Gene Mutated Acute Myeloid Leukemia (AML) Responds Favorably to Venetoclax Based Frontline Therapy

Bhalla, R.

1104 - Small Activating RNA-Mediated Induction of HBG Via Liposome Delivery for In Vivo Treatment of Sickle Cell Disease and Beta-Thalassemia

Bhalla, S.

4658 - Immune Profiling Reveals Distinct Features of Multiple Myeloma Subtypes Defined By Multi-Omics Network Analysis

Bhandari, N. R.

5033 - Continuity of Care for Patients with Chronic Lymphocytic Leukemia: An Analysis of Real-World Data
5114 - Overall Survival Associated with Real-World Treatment Sequences in Patients with CLL/SLL in the United States

Bhandari, R.

2411d - Long-Term Health Outcomes in Older (≥60 Years) Blood or Marrow Transplantation (BMT) Recipients: A Report from the Blood or Marrow Transplant Survivor Study (BMTSS)
4924 - Social Vulnerability Is an Important Predictor of Cardiovascular Disease Risk after Allogeneic Hematopoietic Cell Transplantation

Bhandari, S. K.

2431 - Outcomes and Trends of Allogenic Hematopoietic Stem Cell Transplant Among MDS Patients- NIS 2016-2020
2498 - Hidden Dangers: Pulmonary Embolism Risk in Sickle Cell Trait – Insights from the NIS Database 2020
3953 - Impact of Intravenous Immunoglobulin (IVIG) on Venous Thromboembolism/Pulmonary Embolism in Immune Thrombocytopenic Purpura- an NIS 2020 Database Analysis

Bhandari, S.

4628 - A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter’s Syndrome (RS)

Bhangu, G.

1249 - Characterizing Diagnostic Investigations for Suspected Pulmonary Embolism in Postpartum Individuals

Bhanot, U.

248 - Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease
817 - Single-Cell Spatial Transcriptomics Identifies Lymphoid Aggregates with Location-Specific Alterations of Adaptive Immune Cells in Human MDS Bone Marrow

Bhansali, R. S.

473 - Efficacy, Toxicity, and Predictors of Outcomes with CD3-CD20 Bi-Specific Antibodies Post CAR T-Cell Failure for Aggressive B-Cell Lymphoma
525 - Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis
612 - Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy
1455 - KMT2A-Rearranged ALL Requires DYRK1A for Regulation of ERK Signaling and Cell Proliferation
2740 - Defining Oncogenic Transcriptional Networks Regulated By LDB1 in T-Cell Acute Lymphoblastic Leukemia

Bhanushali, C.

534 - Chronic Myeloid Leukemia: Impact of Social and Demographic Disparities on Survival Outcomes
3720 - Incidence of Second Primary Malignancies in Hairy Cell Leukemia: US Population-Based Study from 2000- 2021

Bhanushali, F.

465 - Development of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium

Bhanushali, V.

3720 - Incidence of Second Primary Malignancies in Hairy Cell Leukemia: US Population-Based Study from 2000- 2021

Bhar, S.

688 - Biomarker Dynamics in Pediatric Transplantation-Associated Thrombotic Microangiopathy (TA-TMA): A Prospective Cohort and Nested Case-Control Study

Bhar, S.

2604 - Tissue Kallikrein 1 and Alternative Complement Pathway Activation in Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

Bharadwaj, H.

910 - A Clonally Expanded Nodal T Cell Population Diagnosed As T Cell Lymphoma after CAR-T Therapy

Bharadwaj, S.

69 - CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up
96 - Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms
368 - CCL8/CCL13-Producing Tumor-Associated Macrophages Linked to Poor Outcomes after CAR T Cell Therapy for LBCL
386 - Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Octogenarian Patients (Aged ≥ 80) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
679 - Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL
2006 - Anti-BCMA CAR T-Cell Expansion and Its Association with Response and Toxicity in Multiple Myeloma
2064 - CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma
4846 - Indolent CD8+ CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucel Therapy for Relapsed/Refractory Multiple Myeloma

Bharatham, N.

2207 - Selective Inhibition of the m⁶a RNA Reader, YTHDC1, As a Novel Therapeutic Strategy for MYC-Driven Acute Myeloid Leukemia

Bharathi, V.

1011 - Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
4272 - Phase Ib/II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Bhardwaj, V.

1618 - Cytokine-Inducible SH2-Containing Protein (CISH) Is an Intracellular Immune Checkpoint That Controls T Regulatory Cells in Splenic Marginal Zone Lymphoma

Bhasin, M.

1365 - Single-Cell Profiling of the Immune Response Following Siglec 15 Knockout in Leukemia Cells
3258 - Integrated Coding and Non-Coding Transcriptional Single-Cell Atlas of Multiple Myeloma: Unraveling the Effects of Myeloma Genotype on the Bone Marrow Microenvironment
4302 - CAR-Machine: CAR-T Cell Target Identification Platform for Pediatric Acute Leukemia and Implementation to Identify Novel Targets for Pediatric AML
4658 - Immune Profiling Reveals Distinct Features of Multiple Myeloma Subtypes Defined By Multi-Omics Network Analysis

Bhasin, N.

1256 - Venous Thromboembolism in Individuals with Sickle Cell Disease- a Retrospective Review of This Understudied Problem
2239 - Reproductive Health Surveys Administered in Sickle Cell Clinics Can Inform Personalized Care and Multidisciplinary Collaboration

Bhasin, S.

3258 - Integrated Coding and Non-Coding Transcriptional Single-Cell Atlas of Multiple Myeloma: Unraveling the Effects of Myeloma Genotype on the Bone Marrow Microenvironment
4302 - CAR-Machine: CAR-T Cell Target Identification Platform for Pediatric Acute Leukemia and Implementation to Identify Novel Targets for Pediatric AML

Bhaskar, S.

3409 - Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Bhaskar, S.

527 - Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report
3663 - Impact of Patient Distance from Center on Outcomes and Cost of Therapy for Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma

Bhat, P.

1814 - Distinct Transcriptomic Cell States Differentiate Low-Risk MDS from Healthy Marrow
4577 - Bone Marrow Spatial Multi-Omics Identifies Reduced Interactions between Hematopoietic Stem Cells and Myeloid Cells in Myelodysplastic Syndrome

Bhat, R.

709 - Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
1257 - Anticoagulation Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
2633 - Thrombolytic Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
- Asymptomatic VTE in Pediatric Patients

Bhat, S. A.

1586 - Non-V600E BRAF Gene Alterations in Hairy Cell Leukemia
2078 - Initial Results of a First-in-Human, Phase I Study Point-of-Care Manufacturing of Trispecific CAR-T Cells Targeting CD19/20/22 in B-Cell Malignancies
4629 - Outcomes of Patients with Chronic Lymphocytic Leukemia Discontinuing Bruton Tyrosine Kinase Inhibitors Due to Adverse Effects
5099 - Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy
4634.1 - Prospective Randomized Phase 2 Study of Acalabrutinib + Obinutuzumab or Venetoclax in Previously Untreated CLL

Bhat, S. A.

1870 - Outcomes of Therapies Following Discontinuation of Non-Covalent Bruton’s Tyrosine Kinase Inhibitors for Patients with Chronic Lymphocytic Leukemia and Richter Transformation: Results from an International, Multicenter Study
1875 - Clinical Characteristics and Outcome in a Cohort of CLL Patients with BTK T474 Gatekeeper Mutation
3245 - A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL
3587 - Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel LP-168 (Rocbrutinib) Combinations Targeting BCL-2 Protein Members for Chronic Lymphocytic Leukemia

Bhat, V.

4966 - Abbv-453: A Highly Potent and Selective Next Generation Small Molecule Inhibitor of BCL-2

Bhati, A. S.

618 - A Systematic Review of Communication Tools to Improve Reproductive and Sexual Health Outcomes in Female Cancer Patients Identified Significant Gendered Data Gaps in Care

Bhatia, K. S.

53 - Failure to Execute Caspase Activation Drives Therapy Resistance in TP53 Mutated AML
4305 - Integrating Genomics and Functional Phenotypes to Refine Risk Assessment in Acute Myeloid Leukemia across the Age Spectrum: Insights from Singapore

Bhatia, M.

4886 - Successful Allogeneic Alternative Donor Hematopoietic Stem Cell Transplantation in High-Risk Patients with Severe Sickle Cell Disease
4954 - Durable Clinical Benefits with Exagamglogene Autotemcel for Severe Sickle Cell Disease

Bhatia, P.

1073 - Establishing a Patient-Derived Immortalized Erythroid Progenitor Cell Model to Investigate Disease Mechanisms and Lentiviral Gene Therapy Vector in Congenital Dyserythropoietic Anemia Type II

Bhatia, R.

Bhatia, S.

1160 - Immune Training Enhances Anti-Viral Responses and Improves Outcomes in Pax5^-/+ Mice Susceptible to Chronic Infection

Bhatia, S.

14 - Clonal Hematopoiesis and Venous Thromboembolism Risk in Lymphoma Patients Surviving Autologous Transplantation
403 - Self-Rated Health Is an Independent Predictor of Subsequent Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Myeloid Malignancies: A BMTSS Report
2338 - Self-Rated Health Is an Independent Predictor of Subsequent Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Lymphoid Malignancies: A BMTSS Report
2387 - Longitudinal Trajectories of Patient-Reported Outcomes Among Older Adults with Multiple Myeloma (MM) Following Autologous Stem Cell Transplantation (ASCT)
2411d - Long-Term Health Outcomes in Older (≥60 Years) Blood or Marrow Transplantation (BMT) Recipients: A Report from the Blood or Marrow Transplant Survivor Study (BMTSS)
3715 - Individual- and Area-Level Socioeconomic Disadvantage and Risk of Death Due to Chronic Health Conditions Among Autologous Blood or Marrow Transplant (autoBMT) Recipients for Lymphoma: A BMT Survivor Study (BMTSS) Report
3721 - Household Poverty and Risk of Obesity during Maintenance Therapy for Childhood Acute Lymphoblastic Leukemia (ALL): Children’s Oncology Group (COG) Study AALL03N1 Report
3767 - Decisional Regret Among Older Adults with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation
3796 - Disseminated Intravascular Coagulation and Early Thrombo-Hemorrhagic Complications in Acute Promyelocytic Leukemia
5036 - Predictors of Risky Health Behaviors Among Blood or Marrow Transplant (BMT) Survivors of Lymphoid Malignancies – a BMT Survivor Study (BMTSS)
5053 - Predictors of Risky Health Behaviors Among Blood or Marrow Transplant (BMT) Survivors of Myeloid Malignancies – a BMT Survivor Study (BMTSS)
5145 - Factors Associated with Post-Transplant Complications Among Older Adults with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation
5146 - Self-Rated Health Is an Independent Predictor of Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Plasma Cell Disorders: A BMTSS Report
5151 - Real World Evidence on Patient Reported Outcomes Among Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Regimens in Frontline (1L)
2808.1 - A Children’s Oncology Group Clinical Trial of Long-Term Outcomes in Survivors of Down Syndrome-Associated Acute Leukemia (ALTE22C1): Clinical Trial in Progress

Bhatlapenumarthi, V.

256 - Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study
573 - Improving Outcomes in Plasmablastic Lymphoma: A Multicenter Experience from an American Cohort
3781 - Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort

Bhatnagar, B.

779 - Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial
4211 - Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial

Bhatnagar, S.

3154 - Response Adapted Dasatinib De-Escalation Strategy Compared to Upfront Low-Dose Dasatinib: A Prospective Cohort Study

Bhatnagar, S.

370 - Gilteritinib Augments Preclinical FLT3 and CD19 CAR T Cell Immunotherapy in High-Risk Pediatric Leukemias

Bhatnagar, V.

387 - Feasibility of Multi-Modal Physical Function Data Collection to Assess Treatment Tolerability in Patients with Lymphoma

Bhatraju, P.

688 - Biomarker Dynamics in Pediatric Transplantation-Associated Thrombotic Microangiopathy (TA-TMA): A Prospective Cohort and Nested Case-Control Study

Bhatt, K.

2780 - Preclinical Proof-of-Concept of a Novel mRNA-Based Therapeutic Combination of an FcRH5 Targeted NK Cell Engager and an IL-15 Superagonist for the Treatment of Multiple Myeloma

Bhatt, K. A.

5042 - Association between Food Insecurity, Financial Toxicity, and Healthcare Utilization in Patients with Lymphoma

Bhatt, M.

298 - Clinical Outcomes of Neonatal Central Line-Related Thrombosis: A Multicentric Retrospective Cohort Study

Bhatt, N.

2798 - Relative Influence of Socioeconomic and Biological Determinants of Outcomes in Adult Acute Lymphoblastic Leukemia

Bhatt, N.

2170 - Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States

Bhatt, N. S.

4921 - Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States

Bhatt, N.

1216 - Athn 10 – Novel Variants in Persons with Rare Coagulation Disorders across Hemophilia Treatment Centers in the United States

Bhatt, S.

53 - Failure to Execute Caspase Activation Drives Therapy Resistance in TP53 Mutated AML
271 - Mapping the Drug Combination Landscape for AML: An Integrative Ex Vivo Functional and Computational Approach
1416 - A Combinatorial Functional Precision Medicine Platform to Evaluate Immunotherapy-Based Combinations in Non-Hodkin Lymphoma
4305 - Integrating Genomics and Functional Phenotypes to Refine Risk Assessment in Acute Myeloid Leukemia across the Age Spectrum: Insights from Singapore

Bhatt, S.

375 - Alemtuzumab, Fludarabine, Melphalan, and Thiotepa As Reduced-Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Inborn Errors of Immunity
657 - A Phase 1b Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia

Bhatt, V.

3145 - Molecular Predictors of Disease Progression to Myelofibrosis (MF) in Patients (Pts) with Polycythemia Vera (PV) Enrolled in Reveal
3522 - Real-World Patient Characteristics and Treatment Patterns in Patients with Chronic Graft-Versus-Host Disease Receiving Belumosudil in the United States
4546 - Clinical Outcomes in Patients with Myelofibrosis Treated with Ruxolitinib and Anemia-Supporting Medications
4900 - Real-World Ruxolitinib and Corticosteroid Treatment Patterns in Patients with Chronic Graft-Versus-Host Disease in the United States

Bhatt, V. R.

685 - The Composite Health Risk Assessment Model (CHARM) Predicts Risks of Toxicities, Functional and Cognitive Decline Among Survivors of Allogeneic Hematopoietic Cell Transplantation (allo-HCT): A Prospective BMT-CTN Study 1704
2125 - Association between Malnutrition and Inpatient Mortality in Hematopoietic Stem Cell Transplant (HSCT) Population: A Nationwide Inpatient Sample (NIS) Database Analysis
2878 - A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
3550 - Pre-Hematopoietic Cell Transplantation (HCT) Frailty Is Associated with Lower Cognitive Function and Health-Related Quality of Life (HRQOL) in Older Adults Undergoing HCT

Bhatta, M.

3585 - AUTX703, a Novel and Potent KAT2A and KAT2B Protein Degrader, Induces Differentiation and Offers Survival Advantage in a Primary Human AML Xenograft Model

Bhatta, S.

2377 - Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers
3737 - Impact of Baseline Osseous Involvement on Outcomes in Patients with Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom’s Macroglobulinemia (WM)

Bhatta, S.

3751 - Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Extranodal (EN) B-Cell Non-Hodgkin Lymphoma (NHL): Results from a Multicenter Analysis

Bhattacharya, A.

4606 - Rewiring Cancer Drivers to Induce Apoptosis By Transcriptional Chemical Inducers of Proximity in Chronic Lymphocytic Leukemia

Bhattacharya, S.

1061 - Multiomic Discovery of Neopeptides from Non-Canonical ORFs on SF3B1 Mutation-Driven lncRNAs in Leukemia

Bhattacharyya, A.

4416 - Practices and Outcomes during a Watch and Wait Approach for Follicular Lymphoma: A Study from the Australasian Lymphoma Alliance

Bhattacharyya, A.

2439 - Representation of Women As Leaders of Hemato-Oncology Clinical Trials

Bhatti, M.

1768 - Prognostic Implication of Framingham Risk Score As a Comorbidity Measure on Treatment Outcomes Following First-Line Tyrosine Kinase Inhibitor in Newly Diagnosed CML Patients

Bhatti, S.

3063 - The Risk of Developing Non-Melanoma Skin Cancers in Patients with Cutaneous T-Cell Lymphoma

Bhatwadekar, S.

3686 - Efficacy and Safety of Zoledronic Acid in Sickle Cell Disease Associated Bone Disorders :Single Centre Experience

Bhatwadekar, S.

3686 - Efficacy and Safety of Zoledronic Acid in Sickle Cell Disease Associated Bone Disorders :Single Centre Experience

Bhavanam, S.

1494 - Exploring the Burden of Acute Myeloid Leukemia Attributable to Smoking in G20 Countries: A Three-Decade Analysis from the Gbd 2021

Bhave, A.

2132 - Efficacy of Recombinant Human Erythropoietin in Enhancing Erythroid Hematopoietic Recovery after Allogeneic Hematopoietic Stem Cell Transplantation: A Meta-Analysis

Bhave, A.

3686 - Efficacy and Safety of Zoledronic Acid in Sickle Cell Disease Associated Bone Disorders :Single Centre Experience

Bhave, R.

779 - Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial
2858 - The Impact of Weight Loss Grading Scale, a Measure of Cancer Cachexia, on Clinical Outcomes in Patients with Acute Myeloid Leukemia

Bhavsar, D.

4415 - A Phase I/II Study of Tazemetostat Combined with Abbreviated Rituximab/Bendamustine Therapy for High Tumor Burden Follicular Lymphoma in Frontline Treatment: A Big Ten Cancer Research Consortium Study

Bhavsar, E. B.

4610 - Topic Modeling of Genotyping of Transcriptomes Reveals Collaboration between BTK^C481S-Mutant and Wild Type Cells in Btki-Resistant Chronic Lymphocytic Leukemia

Bhawsar, S.

88 - A Versatile B Cell Engineering Platform Enables Development of B Cell Medicines for Sustained Delivery of Therapeutic Biologics

Bhella, S.

1606 - Shallow Whole Genome Sequencing of Circulating Tumor DNA Is Predictive of Outcome in Diffuse Large B-Cell Lymphoma
3082 - Outcomes of Patients with Refractory and Relapsed Primary Mediastinal B Cell Lymphoma: A Canadian Single-Center Analysis
3787 - Incidence and Severity of Hypogammaglobulinemia, and Profile of Infections in Patients with Relapsed Multiple Myeloma Treated with Belantamab Mafodotin
5134 - A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada

Bhella, S. D.

286 - COVID-19 Humoral Immunity Improves with Third and Subsequent Vaccine Doses in Patients with Plasma Cell Dyscrasias, Particularly in Those Receiving antiCD38 Therapy
401 - Disparities in Clinical Trial Enrollment for Patients with Hematologic Malignancies – a 15-Year Princess Margaret Cancer Centre Experience
1695 - Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy
1954 - Analysis of Chip Mutations Pre-and Post-Transplant in Multiple Myeloma (MM): Expanded Results from a Prospective Longitudinal Study
1956 - Outcomes of Relapsed/Refractory Multiple Myeloma Patients Receiving Sequential Therapies after Exposure to T-Cell Redirected or BCMA-Targeted Novel Immunotherapies
2272 - Real-World Comparison of Healthcare Costs and Resource Utilization Among Patients with Relapsed-Refractory Large B-Cell Lymphoma Treated with CAR T-Cell Therapy Versus Historical Standard-of-Care: A Cost-Consequence Analysis in Ontario, Canada
2352 - Rate of Transformation and Secondary Malignancies in Follicular Lymphoma Patients Treated with First-Line Bendamustine Rituximab and Rituximab Maintenance
3744 - Evaluating the Impact of Socioeconomic Disparities on Access and Outcomes of CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas in Ontario, Canada
4469 - Outcomes of Patients Intended for Autologous Stem Cell Transplantation with CT-Based Partial Response but PET-Based Deauville Score of 5 after Salvage Chemotherapy
4690 - Handgrip Strength – Finetuning an Objective Measure of Frailty in Transplant-Eligible Patients with Multiple Myeloma

Bhimineni, C.

3768 - Disparities in Outcomes for Patients with Multiple Myeloma: A SEER Database Analysis

Bhinder, B.

746 - MRD-Driven Time-Limited Therapy of Acalabrutinib and Lenalidomide Plus Rituximab (ALR) or Obinutuzumab (ALO) in Patients with Treatment-Naïve Mantle Cell Lymphoma: Phase 2 Trial Outcomes with MRD and cfDNA Analyses

Bhise, S.

1571 - MRD Detection in Standard-Risk Pediatric AML Using Single-Cell RNA Sequencing
3601 - Scrhla-Typing: A Method for Quantifying HLA Transcripts in Single Cells

Bhoj, V.

89 - Targeted-Delivery Strategy of Engineered EV Functionalized By Anti-CD3/CD19 Bi-Specific T-Cell Engager in Treating B-Cell Malignancies

Bhojwani, D.

634 - TCL1A Is Associated with Blinatumomab Response and Immune Activation in Pediatric B-ALL
1418 - TBL1 Inhibition Eradicates Drug Resistant Leukemia Initiating Cells in T-ALL
2797 - Examining Disparities By Race, Ethnicity, and Socioeconomic Factors in Children and Young Adults with Relapsed Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
2799 - Monocytic Differentiation in B-Lymphoblastic Leukemia with CRLF2 rearrangement at Diagnosis: Implications for Pathogenesis and Post-Therapeutic Lineage Switch
2845 - Metabolomic Profiling of Asparaginase-Induced Hepatotoxicity in Pediatric Acute Lymphoblastic Leukemia
3450 - WU-CART-007 (WT-7), an Allogeneic CAR T-Cell Targeting CD7 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Phase 2 Results
3461 - WU-CART-007 (WT-7) Is an Effective Treatment for Adolescent Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL) – Subgroup Analysis of WU-CART-007 1001
4204 - A Retrospective Study of Inotuzumab Ozogamicin in Individuals with Down Syndrome and B-Cell Acute Lymphoblastic Leukemia
4827 - Clinical Factors Associated with Prolonged Cytopenias after CD19 Chimeric Antigen Receptor T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia
2828.1 - Trial in Progress: Update on the TACL T2020-003 Randomized Phase 2 Trial to Improve Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL-2)

Bhoopalan, S. V.

195 - Hematopoietic Stem Cells Supporting Fetal Erythropoiesis Are Differentially Regulated By Small and Large Ribosomal Subunits
383 - Memory T-Cell Add Back and Prophylactic blinatumomab Post Tcrαβ Depleted Haploidentical Transplantation Results in Promising Outcomes in Pediatric Patients with High-Risk Acute Leukemia
2704 - Prospective Genomic Study for Optimizing Clonal Hematopoiesis Surveillance in Bone Marrow Failure Syndromes and Related Cytopenia
4088 - Adenine Base Editing Improves Erythropoiesis in Diamond-Blackfan Anemia Syndrome Patient-Derived Induced Pluripotent Stem Cells

Bhoopalan, V.

3939 - Patient-Specific Platelet Phenotypes in Patients with Immune Thrombocytopenia

Bhurani, D.

3154 - Response Adapted Dasatinib De-Escalation Strategy Compared to Upfront Low-Dose Dasatinib: A Prospective Cohort Study

Bhuria, V.

4521 - A Study on Experimentally Induced Thrombus Formation in JAK2-V617F and Calr-del52 Mouse Models Using Ligation of the Inferior Vena Cava (IVC)

Bhutani, D.

256 - Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study
287 - Development of a Risk Prediction Model for 6-Month Early Mortality in Patients with Systemic Light Chain Amyloidosis Treated with Daratumumab-Based Frontline Therapy
1914 - Isatuximab for Treatment of Monoclonal Gammopathy of Renal Significance (MGRS) - Results from a Prospective Phase 2 Trial
1936 - Abnormal Serum Fixation Patterns Are a Common Event Following BCMA CAR-T Therapy in Relapsed Refractory Multiple Myeloma and Are Often Preceded By Immunological Events
3781 - Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort

Bhutani, M.

594 - Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide
891 - Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study
931 - Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)
1964 - Mass Spectrometry (MS)-Based Exent® Solution Reveals High Prevalence of Multiple M-Proteins in African American Patients with Multiple Myeloma (MM) and Precursor Conditions
2287 - Supportive Care Utilization in Patients with Multiple Myeloma—a Single Center Retrospective Study
2404 - Treatment of Relapsed/Refractory Multiple Myeloma with Ciltacabtagene Autoleucel or Idecabtagene Vicleucel in Racial Minorities—a Multicenter Study
2669 - Clonal Hematopoiesis of Indeterminate Potential Is Associated with Decreased Inflammatory Toxicity and Increased Late Cytopenia in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy
3665 - A Medical Chart Review of Healthcare Costs in Patients with Systemic Amyloid Light Chain Amyloidosis By Mayo 2012 Stage in the United States
3769 - Primary Therapy Outcomes By Primary Cytogenetic Subtypes in a Large Cohort of Black Patients with Multiple Myeloma at a Single Center
3792e - Development of the ASH Research Collaborative Multiple Myeloma Program: A Multicenter, Real-World Evidence Generation Network
4702 - Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes
4720 - Prophylactic Dexamethasone and Remote Monitoring for Patients with Relapsed Refractory Multiple Myeloma (RRMM) Receiving Bispecific Antibodies (BsAb): Experience at a Single Institution
4734 - Analysis of Repeat Step-up Dosing and Cytokine Release Syndrome Events Following Prolonged Dosing Intervals of Teclistamab in the Phase 1/2 Majestec-1 Study
4751 - Final Results of Phase 1 Clinical Trial of Belantamab Mafodotin Combined with Carfilzomib, Lenalidomide, and Dexamethasone for Multiple Myeloma after One to Three Prior Lines of Therapy

Bhuyan, G. S.

3223 - Clinical Response to Azacitidine in Myelodysplastic Neoplasms Is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor Cells In Vivo

Bi, C.

4567 - Preliminary Results of Patients with Myelofibrosis (MF) from a Phase I Trial of Jab-8263, a Potent BET Inhibitor

Bi, H.

2451 - ICAM4 Mediates Human Erythroid Centered Island Formation
4093 - Germline DDX41 Mutations Disrupt Hematopoiesis and Microenvironment in Patient-Derived Bone Marrow Organoids
- DDX41 Dissolves G-Quadruplexes to Maintain Erythroid Genomic Integrity and Prevent Cgas Activation-Induced Erythropoiesis Dysfunction

Bi, H.

625 - Mitochondrial RNA Methylation By METTL17 Rewires Metabolism and Regulates Retrograde Mitochondrial-Nuclear Communication in AML

Bi, K.

2187 - Comparison of Outcomes between Haploidentical and Matched Related Donors for Chronic Myelomonocytic Leukemia: A Multicenter Real-World Study

Bi, L.

1725 - Novel Targeted Agents in Combination with R-MINE (RMINE+X) Based on Different Molecular Subtypes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma：a Phase 2 Multicenter Study
3348 - Differential Diagnosis of Multiple Myeloma and Systemic Light Chain Amyloidosis Using Plasma Cell Morphology Based on Deep Learning
4417 - Asymptomatic Multicentric Castleman Disease: A Potential Early Stage of Idiopathic Mcd

Bi, X.

509 - TBI-Based Myeloablative Conditioning Two-Step Haploidentical Allogeneic Hematopoietic Stem Cell Transplant Yields Excellent Outcomes in Fit Patients with High-Risk Hematologic Malignancies, Results of a Prospective Trial
2176 - Cardiac Toxicity in Recipients of Hematopoietic Stem Cell Transplant with Post Transplant Cyclophosphamide
4891 - A Novel Chemo-Based Reduced Intensity Haploidentical Two-Step Allogeneic Hematopoietic Stem Cell Transplantation, Results of a Prospective Clinical Trial

Bi, Y.

5067 - Kidney Outcomes after Hematopoietic Cell Transplantation in Children and Young Adults with Sickle Cell Disease

Biagi, A.

75 - High IGHV Intraclonal Diversification Identifies CLL with Good Prognosis, Features of Anergy and Specific T-Cell Profiles

Bianchessi, A.

3520 - Endothelial Dysfunction and Risk of Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation: END-GAME Prospective Study Final Results

Bianchetti, N.

82 - Early Identification of Functional High Risk Multiple Myeloma Patients after Transplant with Diffusion-Weighted Whole-Body MRI: Predictive Role of Fat Fraction in Addition to RAC Score

Bianchi, B.

339 - Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from "FOLL12" Phase III Trial of the Fondazione Italiana Linfomi

Bianchi, G.

1928 - Tumor-Intrinsic and Immune Predictors of Response to Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
3304 - Elranatamab in Patients with Daratumumab Relapsed and/or Refractory Light Chain Amyloidosis
5143 - AL Amyloidosis: Understanding the Clinical Prodrome and Delays in Diagnosis

Bianchi, P.

794 - uRADAR: European Patients Referral Frame to Improve Access to New Drugs and Therapies in Ultra-Rare Anemia Disorders and Severe Hereditary Spherocytosis
1086 - Toward the Creation of Diagnostic Algorithms for Congenital Hemolytic Anemia Using Advanced Parameters from Modern Hematology Analyzers
2465 - Not so Rare, Not so Mild Disease: Defects of Flippase Activity Due to ATP11C Mutations. Description of Three New Cases
3696 - Clinical Monitoring Practices Among Adult Patients with Pyruvate Kinase Deficiency Who Have Never Been Transfused
4550 - Prognostic Insights on PRE-Fibrotic Primary Myelofibrosis: A Clinical-Pathological Perspective in 762 Patients

Bianco, R.

4699 - Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Bianco, T. M.

1350 - The Oncogenic ΔNp73α Isoform Contributes to Aggressiveness in APL By Leading to ATRA Resistance through NANOG/BMP4 Axis Upregulation
4321 - The Oncogenic Function of the Intrinsically Disordered Transcriptional Regulator MN1 Depends on the Chaperone DNAJB6b

Biancon, G.

4117 - Unraveling the Drivers of the Stress Granule Signature in Splicing Factor-Mutant Myeloid Malignancies

Biasi, M.

3187 - Overall Survival with Momelotinib Vs Best Available Therapy in Patients with Ruxolitinib-Experienced Myelofibrosis: A Matching-Adjusted Indirect Comparison

Biavasco, F.

778 - Multicenter, Real-World Experience Study of FLT3-Inhibitor Post-Transplant Maintenance Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia with FLT3-ITD
4930 - Multicenter Retrospective Analysis on the Clinical Benefit of Post-Transplant Tyrosine Kinase Inhibitor (TKI) Maintenance Therapy in Ph-Positive Acute Lymphoblastic Leukemia Suggests Improved GvHD-Free, Relapse Free Survival and Non-Relapse Mortality, but Not the Risk of Relapse

Bicchieri, M.

105 - Enhancing Personalized Prognostic Assessment of Myelodysplastic Syndromes through a Multimodal and Explainable Deep Data Fusion Approach (MAGAERA)
2221 - A Comprehensive, Artificial Intelligence, Digital Twin Platform Based on Multimodal Real-World Data Integration for Personalized Medicine in Hematology
3597 - The “David Vs Goliath” Study: Application of Large Language Models (LLM) for Automatic Medical Information Retrieval from Multiple Data Sources to Accelerate Clinical and Translational Research in Hematology
3598 - Artificial Intelligence-Powered Digital Pathology to Improve Diagnosis and Personalized Prognostic Assessment in Patient with Myeloid Neoplasms
4981 - Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology
4989 - An Artificial Intelligence-Based Federated Learning Platform to Boost Precision Medicine in Rare Hematological Diseases: An Initiative By GenoMed4all and Synthema Consortia

Bick, A. G.

872 - Mutation-Specific Differences in the Relationship between Obesity and Clonal Hematopoiesis, with a Focus on JAK2^V617F and MPN Prevention
1285 - Predictive Modeling of Clonal Hematopoiesis across Diverse Cohorts
1814 - Distinct Transcriptomic Cell States Differentiate Low-Risk MDS from Healthy Marrow
2322 - Chive-Impact: Establishing the Clonal Hematopoiesis and Inflammation in the Vasculature (CHIVE) Registry and Biorepository in Underserved Areas
3607 - Combined Natural Language Processing and Gpt-4 Pathology Report Interpretation Efficiently Identify a Myelodysplastic Syndrome Cohort for Large Scale Clinical Research Applications
4577 - Bone Marrow Spatial Multi-Omics Identifies Reduced Interactions between Hematopoietic Stem Cells and Myeloid Cells in Myelodysplastic Syndrome
- TCL1A to mCA's

Bickel, L.

5026 - Evaluation of Pharmacist-Managed Thiopurine-Based Leukemia Maintenance Service Via a Collaborative Practice Agreement

Bidet, A.

58 - Real-World Multicenter Evaluation of Venetoclax and Azacitidine for Molecular Relapse after First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Filo Study

Bidgoli, A.

2366 - The Impact of Structural Inequity and Adverse Social Determinants of Health on Hematopoietic Cell Transplant Access in Pediatric Patients with Hematologic Malignancies and Myelodysplastic Syndromes

Bidikian, A.

330 - TP53 Mutations within T Cells Induce T-Cell Exhaustion and Functional Impairment in TP53 Mutant AML

Bidikian, A.

664 - Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database
3219 - Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database
3669 - Identifying Patients with Erythrocytosis Not Requiring JAK2 Testing: External Validation and Decision Analysis of the Jakpot Prediction Rule

Bidikian, N.

488 - Longitudinal Single-Cell Immune Profiling Reveals Distinct Dynamics of Response to Teclistamab in Patients with High-Risk Smoldering Myeloma Compared to Relapsed-Refractory Multiple Myeloma
492 - Single-Cell Whole-Genome Sequencing of Circulating Tumor Cells in Relapsed/Refractory Multiple Myeloma Patients Receiving BCMA- or GPRC5D-Targeted Immunotherapies
1895 - Single-Cell RNA-Sequencing of 6 Million Tumor and Immune Cells in 365 Patients with MGUS and SMM Demonstrates Complex Progressive Changes in Immune Cell Functionality with a Distinct Footprint on Tumor Cell Biology and Disease Control

Biebuyck, N.

141 - Recombinant ADAMTS13 Prophylaxis in Pediatric Patients with Congenital Thrombotic Thrombocytopenic Purpura: Results from the Phase 3 Randomized, Crossover Study and the Phase 3b Continuation Study

Bieker, J. J.

937 - Sting and Vdac Inhibitors Ameliorate Ineffective Erythropoiesis in a Mouse Model of Anemia Induced By Mutation in EKLF/KLF1
941 - The BET Proteins Brd4 and CBP Contribute to Severity of Anemia in EKLF/KLF1 Mutants By Driving Selective Release of Paused RNA Polymerase II

Bielby, H.

4445 - Delays to Diagnosis of Peripheral T-Cell Lymphoma and Clinical Utility of Molecular Profiling: A UK Multicentre Real-World Study

Bielorai, B.

310 - Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and Outcomes
2065 - T-Lymphoblastic Lymphoma in a Patient with Pearson Syndrome Following Mitochondrial Augmentation

Biemond, B. J.

2483 - Alterations in the Immune Phenotype of Adaptive Immune Cells in Sickle Cell Disease: A Conventional and Computational Flow Cytometry Analysis
3527 - Dynamics of Immune Reconstitution in Adults with Sickle Cell Disease Undergoing Nonmyeloablative Matched Sibling Donor Stem Cell Transplantation: A Conventional and Computational Analysis
4996 - Artificial-Intelligence Driven Quantification of Sickle Red Blood Cell Morphology As an Objective Disease Marker

Biemond, B. J.

290 - Oxygen Gradient Ektacytometry Is Associated with Markers of Hemolysis and Inflammation in a Large Sickle Cell Disease Cohort within the GenoMed4ALL Project
1112 - Iron Deficiency in HbSC Disease Is Associated with Less Sickle Cell Disease-Related Complications – a Rationale for Repetitive Phlebotomy As Disease Modifying Therapy
1138 - Data Driven Research through the European RADeep Registry and the Use of Artificial Intelligence Towards Personalized Medicine in Sickle Cell Disease
1250 - Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase Therapy
2507 - The Pulmonary Embolism Rule-out Criteria (PERC) to Rule out Acute Pulmonary Embolism in Patients with Sickle Cell Disease: A Retrospective Cohort Study

Bieniaszewska, M.

970 - A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) – Topline Results

Bieri, K.

1120 - Transcriptomic Profiling Supports the Phenotypic Classification of Stable-State Sickle Cell Disease Patients

Biering-Sørensen, T.

3891 - Unique Nature of Sickle Cell Diastolic Cardiomyopathy: A Tailored Echocardiographic Definition to Refine Prognostic Stratification in Young Adults

Bierings, M.

925 - The Influence of HLA Matching of the Winning and Losing Units in Relapse of Patients Receiving Double Cord Blood Transplantation for Acute Leukemia or Myelodysplastic Syndrome
2182 - Analysis of Outcomes after Second Allogeneic Stem Cell Transplant in Relapsed Acute Myeloid Leukaemia in Children: A Study from the EBMT Pediatric Diseases Working Party
3540 - Total Body Irradiation Versus Chemotherapy Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphoblastic Leukemia Patients Aged 2 to 4 Years: A Retrospective Study of the EBMT Pediatric Diseases Working Party
4864 - Comparative Results of Pediatric Patients with ALL Receiving Either of Two Different Types of Human Anti-T Lymphocyte Globulin Prior to Hematopoietic Stem Cell Transplantation: Findings from the International Prospective Forum Study
4876 - Standard Fludarabine Dosing Results in Overexposure in Young Children Undergoing Hematopoietic Cell Transplantation

Bierings, R.

431 - A Novel Cause of Type 1 VWD: Impaired Exocytosis of Weibel-Palade Bodies Due to Biallelic Mutations in Madd

Bierman, P.

458 - PET-Directed Therapy with ABVD Vs. Bv+AVD Followed By Nivolumab in Patients with Early Stage Hodgkin Lymphoma: A Propensity Score Matched Analysis of CALGB50604 and ACCRULY1601

Bies, J. J.

709 - Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children

Biffi, A.

2182 - Analysis of Outcomes after Second Allogeneic Stem Cell Transplant in Relapsed Acute Myeloid Leukaemia in Children: A Study from the EBMT Pediatric Diseases Working Party
3497 - Central Nervous System Disorders (CNSD) Following Hematopoietic Stem Cell Transplantation (HSCT): A Prospective Study from the Infectious Diseases Working Party (IDWP) and the Transplant Complications Working Party (TCWP), European Society of Blood and Marrow Transplantation (EBMT)

Bigaud, M.

552 - Ianalumab, an ADCC-Enhanced Anti-BAFF-Receptor Antibody, Has Beneficial Effects in an Active Mouse Model of Immune Thrombocytopenia (ITP)

Bigenwald, C.

474 - Post-Therapeutic Tumor Losses of B-Cell Receptor Components CD20/CD19, a New Challenge in the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Bigot, N.

4756 - High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)
4765 - Prognostic Value of Positron Emission Tomography/Computed Tomography in Multiple Myeloma Patients Treated with Ide-Cel CAR-T Cell Therapy: Preliminary Results of a Real-World IFM Study from the Descar-T Registry (CAR MY PET)

Bigun, O.

2293 - Integrating the Sunnybrook Biobank into the Future of Healthcare – Exploring Patient and Healthworker Biobanking Perspectives

Bijou, F.

1649 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory (R/R) Indolent NHL: Results from the Phase 1 CaDAnCe-101 Study
4479 - Valemetostat Monotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma: Primary Results of the Phase 2 Valym Study from the Lysa

Bijukumar, N.

2150 - Lower Mycophenolic Acid Exposure in Patients Undergoing Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide/ Cyclosporine a-Based GvHD Prophylaxis – Need for Dose Intensification
4879 - EASIX_d0 Predicts Early Transplant-Related Mortality in Patients Undergoing Haploidentical Transplantation with Post-Transplant Cyclophosphamide-Mycophenolate Mofetil-Based GvHD Prophylaxis

Bikdeli, B.

697 - Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients with Pulmonary Embolism and Right Ventricular Dysfunction

Bikhet, M.

4689 - The Disproportional Burden of Multiple Myeloma

Bikineyeva, A.

1323.1 - Trial in Progress: A Phase I/II Study of the JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure

Bikkani, T.

22 - Anti-HLA Antibody Specificities Are Differentially Associated with Immune Platelet Transfusion Refractoriness in Patients at Lower Calculated Panel Reactive Antibody (cPRA) Levels

Bikowitz, M.

208 - CBX250 Is a Novel Cathepsin G Peptide-HLA-Targeting T Cell Engager That Exhibits High Tumor Antigen Selectivity and Potent Antileukemic Activity In Vivo

Bila, J.

494 - Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Bilal, K. H.

4992 - Deep Learning-Driven 24-Hour Mortality Risk Assessment through Peripheral Blood Smear Morphology in Hospitalized Cancer Patients

Bilalaga, M. M.

3299 - Early Versus Delayed Intervention in Smoldering Multiple Myeloma: A Meta-Analysis of Clinical Trials
4008 - Incidence of Venous Thromboembolism (VTE) and Hemorrhage in Patients with Bleeding Disorders Hospitalized for Major Surgery/ Trauma: Analysis from National Inpatient Sample

Bilbao, D.

829 - Decoding the Pivotal Roles of BCL10 Activating Mutations in DLBCL Drug Resistance and Lymphomagenesis
2781 - The Cyclin-G Associated Kinase (GAK) Is a Critical Targetable Dependency for Successful Mitosis By Diffuse Large B-Cell Lymphomas Linked to Retinoblastoma Loss of Function
4167 - Translational Disruption of NRF2 By Zotatifin Enhances Sensitivity to Ferroptosis and CAR-T Cells in Diffuse Large B-Cell Lymphoma

Bilbao Martinez, A.

4167 - Translational Disruption of NRF2 By Zotatifin Enhances Sensitivity to Ferroptosis and CAR-T Cells in Diffuse Large B-Cell Lymphoma

Bilbao-Sieyro, C.

3159 - Characteristics of Pediatric and Adolescents and Young Adults (AYA) with Chronic Myeloid Leukemia: Data from the Canarian Registry of CML

Bilek, D.

1887 - Composition and Fitness of T and NK Cells in Extramedullary Myeloma Tumor Microenvironment

Bilger, K.

731 - Determinants of Isolated CNS Relapse in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia. from Graall-2005 to -2014 Trials

Bilger, K.

4903 - Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe
4946 - Allogeneic Stem-Cell Transplantation for Relapsed/Refractory ALK–Positive Anaplastic Large-Cell Lymphoma: A Study from the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)

Bilgin, Y. M.

1588 - Cell-Free DNA Genomic and Fragmentomic Features for Early Outcome Prediction in Diffuse Large B-Cell Lymphoma
4739 - Frailty Subgroups Determine Heterogeneous Outcomes in Elderly Patients with Newly-Diagnosed Multiple Myeloma – Long-Term Follow-up of the HOVON 143 Trial

Bilgrami, Z.

4446 - Survival and Treatment Response in CTCL Can be Predicted Using Volumetric Lymph Node Size and Dynamic Changes in Lymph Node Size and Skin Score

Bilicki, D.

1421 - Meta-Analysis of Complete Remission Rates Following First-Line Salvage Treatment after Anti-CD19 CAR-T Failure in Adult Patients with Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia

Bill, M.

1563 - ACSL4-Associated Lipid Metabolism Is a Distinct Therapeutic Vulnerability in KMT2A-Rearranged Acute Myeloid Leukemia
2934 - The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients

Billett, H. H.

615 - Parenting While in Hematology: Perceived Barriers
2631 - Secondary Prophylaxis with Reduced Dose Apixaban in the Morbidly Obese

Billups, R. L.

2300 - Comparison of 15- Vs. 30-Day Remote Patient Monitoring for Outpatient Chimeric Antigen Receptor T-Cell Therapy (CAR-T) across a Large Health System
3734 - The Patient Journey and Treatment Outcomes Comparing Inpatient Versus Outpatient Axicabtagene Ciloleucel in Non-Hodgkin’s Lymphoma (NHL) - a Large, Multicenter Study

Bilodeau, K.

408 - Understanding the Lived Experience of Fatigue in Adolescents and Young Adults with Myeloproliferative Neoplasms: A Mixed Methods Study

Biltibo, E. A.

5172 - Outcomes of Hematopoietic Stem Cell Transplantation in Patients Aged 70 Years and Older
- Impact of Daratumumab in the Treatment of Vulnerable Transplant Eligible Multiple Myeloma Patients and Its Utilization in Blacks

Bimali, M.

4232 - Intranasal Corticosteroid Use and Risk of Invasive Fungal Sinusitis in Acute Myeloid Leukemia, Myelodysplastic Syndrome and Post Transplant Patients

Bindal, P.

1553 - Characteristics and Clinical Outcomes of Patients with Myeloid Malignancies and Cohesin Mutations
2407 - Cytomegalovirus Infections Following CAR T-Cell Therapy: A Systematic Review and Meta-Analysis
4817 - Advances in CD137-Enriched Adoptive T Cell Therapy for Acute Myeloid Leukemia Via Ex Vivo Immune Cell Priming with DC/AML Fusion Vaccine

Bindels, E.

442 - Hematological Phenotypes in GATA2 Deficiency Syndrome Arise from Secondary Injuries and Maladaptation to Proliferation

Binder, A. F.

3381.1 - A Multi-Institution Phase 2, Single-Arm, Non-Inferiority Study of Limited-Duration Teclistamab for Relapsed and Refractory Multiple Myeloma (LimiTec)

Binder, G.

2855 - Outcomes By Frailty in IC-Ineligible Newly Diagnosed AML – a Real-World Evidence Comparison By Treatment with Hypomethylating Agents + Ivosidenib or Venetoclax

Binder, M.

83 - Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma
1880 - Single-Cell Spatial Proteomic Characterization of Clonal Plasma Cell and Immune Cell Metabolism within the Bone Marrow Microenvironment in High-Risk Smoldering Multiple Myeloma and Its Association with Progression to Multiple Myeloma
1945 - Development of a Three-Gene-Based Proliferation Score (3GPS) to Predict Proliferation Index in Newly Diagnosed Multiple Myeloma
1955 - Impact of Serial Serum Free Light Chain Measurements on Response and Progression Assessments in Multiple Myeloma Patients with Measurable Disease
1981 - Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience
2274 - Real World Outcomes with Evolving Management of Cytokine Release Syndrome in CAR-T Therapy
2400 - Improved Survival with Daratumumab-Cybord Compared to Cybord As Frontline Therapy in Immunoglobulin Light Chain (AL) Amyloidosis
2744 - The Mutational Landscape of Extramedullary Multiple Myeloma Reveals Novel Biologic Insights and Potential Therapeutic Targets for Exploration
3197 - Targeting Aberrant DLK1 Re-Expression in ASXL1-Mutant Chronic Myelomonocytic Leukemia with BRD4 / p300-Directed Epigenetic Small Molecule Therapy
3308 - Predictors of Liver Response in Light Chain (AL) Amyloidosis: A Study with 130 Patients
3315 - Impact of Multiple High-Risk Cytogenetic Abnormalities on the Survival Outcomes of Patients with Primary Plasma Cell Leukemia
4704 - Flow Cytometry-Based Assessment of the Proportion of Monoclonal Plasma Cells in Synthetic Phase (S-phase) Is an Independent Marker of Adverse Prognosis in Patients with Newly Diagnosed Multiple Myeloma
4711 - Radiomics-Based Biomarkers for Risk Stratification in Newly Diagnosed Multiple Myeloma
4716 - Evaluating the Interaction between Baseline Risk Stratification, Post-Transplant Measurable Residual Disease, and Long-Term Outcomes in Multiple Myeloma
4728 - Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes
5047 - Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization
5149 - Characteristics and Outcomes of Patients with Second Hematological Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
4685.1 - Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)

Binder-Blaser, V.

275 - ALL-R: An Anchoring Score to Predict Relapse in Acute Lymphoblastic Leukemia (ALL) Using a Zebrafish Patient-Derived Xenograft Model

Binding, A.

2509 - Evaluating the Effect of Hydroxyurea on Fertility in Individuals Identifying As Women

Binelli, L. S.

1756 - Immune Content of Mature and Licensed Cytotoxic Cells Is Associated with Treatment-Free Remission in Chronic Myeloid Leukemia

Binkley, M. S.

853 - Distinct Molecular Aberrations of Classic Hodgkin Lymphoma in Older Adults Identified By Comprehensive Genomic Profiling
2116 - A Standard Operating Protocol for Pre-Transplant Low Dose Splenic Radiotherapy for Patients with Myelofibrosis
4369 - Comprehensive Characterization of the Cell States and Ecosystems in Classic Hodgkin Lymphoma Using Single-Cell RNA-Seq, Digital Deconvolution, and Machine Learning

Binks, S.

4410 - Obinutuzumab, Lenalidomide and Venetoclax for the Initial Treatment of Patients with Advanced-Stage Follicular Lymphoma: Primary Analysis of an Investigator-Initiated Phase Ib/II, Multicenter Study (LEVERAGE)

Binotto, G.

245 - Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition
1772 - Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50 – 60 Years: A “Campus CML” Study
4532 - Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact Project, a CML Campus Study

Biondi, A.

309 - A Reduced Daunorubicin Dose during Induction Is Equally Effective As Standard Dose in Children with Acute Lymphoblastic Leukemia (ALL) and Favorable Prognostic Features: Long-Term Results of the Phase 3 Trial AIEOP-BFM ALL 2009
730 - Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy
2526 - Investigating Neutropenia in FNIP1 Deficiency: A CRISPR/Cas9 Model in HL-60 Cells
2834 - CD19 CAR T Cells Drive a Remodeling of the Immune Microenvironment Associated with T-Cell Dysfunction in Acute Lymphoblastic Leukemia
3426 - The NFκB/COX2 Pathway Mediates the Inhibition of CAR-T Cell Proliferation and Function By Bone Marrow Stroma
4217 - Frequency and Early Prognostic Significance of Gene-Class Fusions Identified By RNA-Seq in Children and Adolescent with T-Cell Acute Lymphoblastic Leukemia Enrolled on AIEOP-BFM ALL 2017 Study
4849 - Cord Blood-Derived Carcik Cells As Off-the-Shelf Non-Viral Cell Therapy for Hematological Malignancies

Biondo, A.

3591 - ASTX295 a Novel Potent MDM2 Antagonist Induces More Than One Mechanism of Programmed Cell Death (PCD) in Lymphoid Malignancies

Biondo, F.

1053 - Efficacy and Safety of Giroctocogene Fitelparvovec in Adults with Moderately Severe to Severe Hemophilia Α: Primary Analysis Results from the Phase 3 ΑFFINE Gene Therapy Trial
3575 - Results from the Hemophilia Α Cohort of the Non-Investigational Lead-in Study: Prospective Collection of Bleeding Rate in Participants with Hemophilia Α Prior to Phase 3 Study (AFFINE) of Giroctocogene Fitelparvovec
3577 - Use of Fidanacogene Elaparvovec, a Gene Therapy Vector, to Deliver a Stable, Fully Functional Human Factor IX Transgene for the Treatment of Hemophilia B: A Combined Analysis of Safety

Biondo, J. M.

279 - Health Equity Impacts of Funding Emicizumab in People with Severe Hemophilia a in the US: An Aggregate Distributional Cost-Effectiveness Analysis
3008 - Fixed-Duration Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Updated Results from the Phase II Morningsun Study
3699 - Real-World Adherence and Persistence to Emicizumab Using a National US Claims Database
5078 - Real-World Experience with Emicizumab for Hemophilia a from the Physician Perspective Based on Survey Data

Biral, L.

3409 - Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Biran, A.

758 - Impaired Response to Oxidative DNA Damage Underlies Genomic Instability in B-Cell Leukemia Driven By RPS15 Mutation

Biran, N.

1929 - Enhanced Prognostic Value of the SKY92 Classifier over High-Risk Cytogenetic Aberrations in Multiple Myeloma: Results from the Prommis Real-World Study

Biran, N.

1031 - Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial
1888 - Repurposing DNA Methyltranferase Inhibitors As Epigenetic Priming Agents for T Cell Directed Therapies in Multiple Myeloma
1946 - Clonotype-Naïve Detection of Clonality in Patients Suspected of Having Multiple Myeloma or Monoclonal Gammopathy Using Peripheral Blood Cell-Free RNA (cfRNA)
1982 - Phase II Study of Isatuximab, and Weekly Carfilzomib + Dexamethasone in Relapsed and Refractory Multiple Myeloma (RRMM)
1996 - Efficacy and Safety of Selinexor, Pomalidomide, and Dexamethasone (SPd) for Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
2408 - Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis
3316 - Establishing a Distinct Cytokine Signature for Multiple Myeloma Using Bone Marrow RNA and Peripheral Blood Cell-Free RNA (cfRNA)
4758 - Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry

Birch, G. C.

915 - One-Step Construction of Allogeneic CAR-NK Cells Preventing Rejection and Mediating Enhanced Anti-Tumor Responses
917 - Mesothelin Targeting IL12-Engineered CAR Memory-like NK Cells Demonstrate Promising Efficacy in Acute Myeloid Leukemia

Birch, N.

2169 - Has ABO Mismatch Rate Decreased in AML and ALL Transplant Recipients over the Years, a Trend Analysis Using CIBMTR Data
4246 - Hematopoietic Stem Cell Transplantation (HCST) Is Underutilized in Black Patients with Myeloid Neoplasms. Results from a Retrospective Study at Chicago's Leading Minority-Serving Hospital

Birch, S.

3006 - Multiomics Analysis of Paired Diagnosis and Relapse DLBCL Biopsies Shows a Reduction in T Cell Infiltration and Function at Relapse

Bird, J.

385 - Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma – an Economic Evaluation of the Fitness Trial
673 - IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial

Bird, S.

3284 - IMiDs and Celmods Enhance Antigen Presentation Via MHC Class 1 – a Potential Novel Immunostimulatory Effect

Birdwell, C.

1349 - ASXL1 Mutations in AML Are Associated with a Distinct Epigenetic State Which Highlights Vulnerabilities to Specific Epigenetic-Targeted Agents
1373 - Identifying ‘Druggable’ Targets and Preclinically Overcoming Non-Genetic/Adaptive Resistance to Menin Inhibitors in AML with MLL1r or mtNPM1
3142 - Evaluation of the Lethal Activity and Its Mechanism of Tasquinimod in Advanced Myeloproliferative Neoplasm (MPN) in Blastic Phase

Birhiray, M.

5081 - A Systematic Review of 72 ASH Plenary and Late Breaking Abstracts for Racial Representation: A Health Equity Call to Action

Birhiray, R.

4411 - Odronextamab Monotherapy in Previously Untreated Patients with High-Risk Follicular Lymphoma (FL): Results of the Safety Lead-in of the Phase 3 Olympia-1 Study
4757 - In-class Transition from Parenteral Bortezomib to Oral Ixazomib in Newly Diagnosed Multiple Myeloma: Analysis of US MM-6 By Number of Treatment Cycles Received
5081 - A Systematic Review of 72 ASH Plenary and Late Breaking Abstracts for Racial Representation: A Health Equity Call to Action

Birkholz, T.

4085 - Counterpoising Immune Pressure and Privilege: Paroxysmal Nocturnal Hemoglobinuria Evolutionary Dynamics

Birmann, B. M.

4358 - Expanded Genome-Wide Association Study (GWAS) Identifies Nine Novel Germline Risk Loci for Waldenström Macroglobulinemia (WM) and Lymphoplasmacytic Lymphoma (LPL)

Birnbaum, D.

1378 - Dasatinib Overcomes AML Resistance to BCL2 Inhibition By Indirectly Inhibiting MCL1: From Ex Vivo drug Sensitivity/Resistance Profiling to a Phase II Clinical Trial: A Hemato-BIO Study

Birocchi, F.

2025 - Novel CD2-Targeting Trispecific Immune Effector Cell Engager (TRIEC) Coupled with CD19 CAR-T Overcomes Resistant B-Cell Lymphoma

Birocchi, S.

1182 - Mean Platelet Volume in Patients with Liver Cirrhosis and Chronic Liver Disease: A Case-Control Study
3945 - Platelet Laboratory Markers of Failure of First-Line Treatments in Immune Thrombocytopenia (ITP)

Biru, Y.

3658 - Examining Discrepancies in Perspectives of Healthcare Providers and Patients with Relapsed/Refractory Multiple Myeloma on Novel Therapies across Diverse Clinical Landscapes: An International Prospective Study
3788 - Frontiers in Myeloma: Barriers to Clinical Trial Participation in Multiple Myeloma

Bischof, L.

2158 - CT-Based Muscle Quality and Visceral Obesity Prior to Allogeneic Hematopoietic Stem Cell Transplantation Is of Prognostic Relevance in Patients with Acute Myeloid Leukemia
4334 - Measurable Residual Disease Detection of IDH1 or IDH2 Mutations Post but Not Prior to Allogeneic Hematopoietic Stem Cell Transplantation Show High Prognostic Relevance in Patients with Acute Myeloid Leukemia

Bisharat, L.

4256 - Randomized Phase II Trial of Dendritic Cell/AML Fusion Cell Vaccination Compared to Standard of Care Therapy in AML CR1
4817 - Advances in CD137-Enriched Adoptive T Cell Therapy for Acute Myeloid Leukemia Via Ex Vivo Immune Cell Priming with DC/AML Fusion Vaccine

Bishnoi, S.

1739 - Safety and Efficacy in Patients with Advanced Lymphomas from a Global Phase 1a/1b, First-in-Human Study of CS5001, a Novel Anti-ROR1 ADC

Bishop, C.

4382 - Highly Heterogeneous Cellular Composition and Neighborhood Architecture within the Follicular Lymphoma Tumor Microenvironment

Bishop, M. R.

963 - Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes
2026 - Inhibition of PI3Kγ/δ Signaling Promotes an Early Memory State in CAR T Cells and Enhances Their In Vivo Persistence and Efficacy
3458 - Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in the Open-Label, Multi-Center, Global, Single-Arm, Phase Ib/II FELIX Study: The Impact of Bridging Therapies on CAR T-Cell Expansion and Persistence
4503 - CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium
4825 - Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety with 34-Month Median Follow-up
4837 - Healthcare Resource Utilization and Costs Associated with Managing CRS and ICANS in Patients with Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia Receiving Obecabtagene autoleucel (obe-cel)
4845 - Risk Factors Associated with Sub-Optimal Outcomes Following Obecabtagene autoleucel (obe-cel) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): What We Have Learned from the FELIX Trial
4911 - Long Term Outcomes of a Randomized Trial of Anti-T Lymphocyte Globulin to Improve Moderate-Severe Chronic Gvhd Free Survival after Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Analysis
- Late Complications and Long-term Care of Adult CAR T-cell Patients

Bishop, T.

1095 - Benefits of Targeted Next Generation Sequencing (NGS) for Identification of Newborn Hemoglobinopathies: The California Experience

Bisht, K.

1887 - Composition and Fitness of T and NK Cells in Extramedullary Myeloma Tumor Microenvironment

Bisht, K.

166 - Endotoxemia As Possible Cause of Inflammatory Bowel Diseases-Associated Anemia
1149 - Blood Cell Homeostasis Is Maintained in the Absence of Resident Mononuclear Phagocytes in Fetal Liver and Bone Marrow in CSF1R Knockout Rats
1150 - Transcriptomic Analysis of the Functions of CSF1R-Dependent Macrophages in Postnatal Development in the Rat
1286 - Endothelial Protein C Receptor CD201 Enables Identification of Transplantable Mouse Hematopoietic Stem Cells in Inflammatory Conditions Unlike SCA1

Bishton, M. J.

235 - Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich
1641 - A Prospective Analysis of Outcomes Following Successive Lines of Treatment in Mantle Cell Lymphoma in an Unselected Previously Untreated Population: The UK MCL Biobank
3778 - Daratumumab, Bortezomib and Dexamethasone for Previously Treated Myeloma – Comparing Real-World Outcomes in England to the Castor Phase III Clinical Trial

Bisio, V.

4513 - JAK Inhibition Results in Aggressive Cutaneous Squamous Cell Carcinoma through MAPK Pathway Activation and Shapes the Tumor Immune Microenvironment to Create Novel Therapeutic Opportunities

Biss, T.

1257 - Anticoagulation Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
2633 - Thrombolytic Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
- Use of Anticoagulants in Children

Bistrup, C. N.

4545 - Circulating Extracellular Matrix Fragments As Biomarkers in Myeloproliferative Neoplasms – Baseline Data from the Daliah Trial

Biswajit, D.

3078 - Impact of Consolidation Radiotherapy in Bulky Diffuse Large B Cell Lymphoma By PET Based Response Assessment

Biswas, N.

3351 - Survival Following Quadruplet and Triple Therapy in Transplant in-Eligible Multiple Myeloma - a Meta-Analysis of Recent Clinical Trials

Biswas, S.

852 - Machine Learning Identifies Gene Mutations and Variant Allele Fractions That Refine the 2022 European Leukemianet Risk Stratification for Acute Myeloid Leukemia
1550 - Prognostic Significance of Wilms’ Tumor 1 Gene Mutations in Acute Myeloid Leukemia: Risk Stratification and Survival Outcomes
4310 - Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia (AML)

Biswas, S.

1382 - Decitabine Activity Against TP53-Mutated Myeloid Neoplasms Is Enhanced By Combination with a Non-Cytotoxic p53/BAX-Independent Inhibitor of Pyrimidine Synthesis

Bitari, D.

2500 - Voxelotor Impact after 6 Months on Blood Rheology in Patients with Sickle Cell Disease
2506 - Improvement in Kidney Function after 6 Months of Voxelotor in Sickle Cell Disease Patients
2520 - Improvement in Cerebral Vasoreactivity after 6 Months of Voxelotor Measured By Near-Infrared Spectroscopy (NIRS) in Sickle Cell Disease Patients

Bitetti, C.

3155 - CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or ≤ 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study

Bittenbring, J.

3560 - Impact of FLT3 Inhibitor Maintenance Therapy on Post-Transplant Outcomes in FLT3-Mutated AML Patients: A Real World Analysis from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)

Bittenbring, J. T.

1153 - Deciphering Inflammasome Activation in Gaucher Macrophages and Its Role in the Development of Multiple Myeloma
4498 - Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Bitterer, K.

1153 - Deciphering Inflammasome Activation in Gaucher Macrophages and Its Role in the Development of Multiple Myeloma
2023 - CD47 Upregulation Inhibits Phagocytic Clearance of Alloreactive Donor T Cells after Allo-HCT

Bittolo, T.

73 - Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated By Epigenetic Plasticity of Residual Disease and By-Pass Signaling Via MAPK Pathway
75 - High IGHV Intraclonal Diversification Identifies CLL with Good Prognosis, Features of Anergy and Specific T-Cell Profiles
2975 - Dissecting Diffuse Large B Cell Lymphoma Heterogeneity: New Insights from a State-Specific Molecular Characterization
4362 - Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)

Bittrich, M.

4665 - CD31 and JAM-a Expressing Circulating Tumor Plasma Cells As Prognostic Biomarkers for Multiple Myeloma Disease

Bitzas, V.

2291 - Using the Serious Illness Conversation Guide (SICG) in Patients with Hematological Malignancies As a Tool to Address Their Perspectives on Palliative Care

Bixby, D.

2800 - Ph-like ALL Is Associated with Unfavorable Outcomes in Hispanics and Native Americans: A Multicenter Analysis

Bjeije, H.

25 - Dnmt3a Controls Hematopoietic Stem Cells Via DNA Methylation-Independent Regulation of Telomeres
628 - EZH2-Mediated Methylation Regulates JARID2 Protein Stability in Normal and Neoplastic Hematopoiesis
3398 - In Vivo and Ex Vivo Expansion of Functional Human Repopulating Cells through JARID2 Inhibition

Bjelosevic, S.

626 - Riboflavin Drives Nucleotide Biosynthesis and Iron-Sulfur Metabolism to Promote Acute Myeloid Leukemia

Björkholm, M.

1601 - Clonal Hematopoiesis Mutations and Cell-Free DNA Characteristics in Patients with High-Risk Large B-Cell Lymphomas

Björklund, A. C.

3198 - Large-Scale Transcriptome Analysis Supports Genomic Taxonomy and Predicts Response to Hypomethylating Agents in Myelodysplastic Neoplasms

Bjorklund, C. C.

3261 - Biomarker Analyses of the CC-92480-MM-001 Trial to Guide Combinatorial Strategies for Mezigdomide
4650 - BCMA Mutational Screening Reveals Differential Cytotoxic Activity between T-Cell Engagers in Preclinical Co-Culture Models

Bjorklund, C. C.

1409 - Genomic and Single Cell Investigation of MRD Clonality in Genetically Engineered Mouse Models of Multiple Myeloma
1881 - Multi-Omics Integration to Elucidate the Cis-Regulatory Network Re-Wiring upon NSD2 Degradation in t(4;14) Multiple Myeloma
2739 - Golcadomide-Mediated Degradation of Aiolos/Ikaros Synergizes with BET Inhibitors through Bidirectional Restructuring of the Directly Regulated Epigenetic Environment in DLBCL

Blachly, J. S.

211 - Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia
641 - Transcriptomically Defined Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) Phenotype Governs Mutation-Based Disease Group Assignment
2432 - Real-World Experience of Venetoclax Target Dosing with Concomitant Posaconazole in Adult Patients with Acute Myeloid Leukemia
2661 - Targeting Inflammation in Tet2 Mutant Clonal Hematopoiesis Via Inhibition of Brd4 Demonstrates Activity in Both Murine and Human Models
2921 - BRAF-Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML
2922 - A Rapid Diagnostic Assay to Detect a DNA Methylation Signature of Menin Inhibitor Response in Acute Myeloid Leukemia
4286 - A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination with Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia
- Medical Informatics & AI

Black, H.

3007 - Frontline R-CHOP and BR Have Similar Outcomes By SUV_max in Follicular Lymphoma

Black, R. G.

4771 - Identification of Microbiota-Reactive CD4+ T Cells in the Post-Transplant Setting

Blackburn, H. N.

1815 - MISTRG6kit^W41: Enhanced Engraftment in a Cytokine Humanized Patient-Derived Xenotransplantation Mouse Model

Blackburn, J.

154 - Large-Scale In Vivo Zebrafish Drug Screen Uncovers Novel Insights into Leukemia Stem Cell Biology

Blackburn, L.

285 - Lovesick: Examining Couples Health during Myeloma Transplant
4717 - Cytomegalovirus Reactivation in Patients with Multiple Myeloma Treated with Teclistamab: Risk Factors and Clinical Impact

Blacklow, S.

43 - The Follicular Lymphoma and Chronic Lymphocytic Leukemia Proliferative Microenvironment at Single-Cell Resolution

Blackmon, A.

729 - TP53 Mutations Increased the Risk of CD19 Negative Relapse Following Blinatumomab in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)
4264 - Phase 1 Trial of Navitoclax/Venetoclax/Decitabine Combination in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
4935 - Outcomes of Hypomethylating Agents/Venetoclax (HMA/VEN) Treatment for Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplant (alloHCT)

Bladé, J.

365 - Clinical Value of Peripheral Residual Disease (PRD) and Measurable Residual Disease (MRD) in Newly Diagnosed Elderly Patients in the GEM2017FIT Trial
489 - Reevaluating the IMWG Multiple Myeloma Complete Response Criterion in the Era of Mass Spectrometry: A Critical Analysis
678 - GEM2017Fit Phase 3 Trial in Fit Elderly Patients (Aged 65-80) with Newly Diagnosed Myeloma: Impact of Daratumumab at Induction and/or Consolidation
898 - Early Relapse in Patients with Newly-Diagnosed Multiple Myeloma: A European Myeloma Network/Harmony Alliance Analysis Including 10843 Patients
1879 - Multiomic Characterization of Clonotypic B Cells in Patients with Monoclonal Gammopathies
1957 - Unraveling Long-Term Survival of Multiple Myeloma Patients, the GEM2000 Experience
2000 - Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)
3321 - Real-World Treatment Sequencing, Attrition Rates, and Survival Outcomes in Multiple Myeloma: A Retrospective Study over Four Decades
3374 - Survival Improvement of Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma in Two Consecutive Randomized Phase III Trials: Long-Term Follow up of GEM05 and GEM12 Trials

Blaeschke, F.

- Knockin Sequences to Program Durable Cell Therapies Acting Against Leukemia Cells

Blaha, O.

664 - Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database
736 - Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2)

Blahovcova, P.

1697 - The Survival Improvement of Transplant-Eligible Primary CNS Lymphoma Patients within Last 15 Years
1711 - PCNSL Patients Treated with the Matrix Regimen in the Real World Have Similar Outcome to Those in the IELSG 32 Trial
3012 - Intensified Immunochemotherapy with Autologous Stem Cell Transplantation for Mantle Cell Lymphoma - Could It Still be Considered the Standard of Care?

Blair, A. B.

1204 - ATHN Transcends Hemophilia Natural History Arm: Baseline Characteristics, Adverse Events, and Self-Reported Health Status of Individuals with Hemophilia A and B

Blair, M. C.

4043 - Chemical Modulation of ELF1 Binding to RUNX1 Target Genes Leads to Increased Hematopoietic Stem Cell Self-Renewal

Blair, R.

1323.1 - Trial in Progress: A Phase I/II Study of the JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure

Blais, F.

5068 - Validitation of the Rowland Universal Dementia Assessment Scale (RUDAS) for the Detection of Cognitive Impairment Among Adults with Sickle Cell Disease

Blaise, D.

67 - Rapcabtagene Autoleucel (YTB323) in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Phase II Trial Clinical Update
464 - Autologous and Allogeneic Stem Cell Transplantation for Major T-Cell Lymphoma Entities: An Analysis of the EBMT Lymphoma Working Party
505 - Non-T-Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation from Unrelated and Matched Sibling Donors in Patients with Secondary Acute Myeloid Leukemia in First Complete Remission: A Study from the ALWP/EBMT
508 - Younger Haploidentical Versus Older Matched Sibling Donors in Acute Lymphoblastic Leukemia: A Study from the ALWP of EBMT
693 - No Differences in Transplant Outcomes with Post-Transplant Cyclophosphamide in One Antigen Mismatched Unrelated Donor Compared to Matched Unrelated Donor Recipients Receiving Antithymocyte Globulin in Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT
749 - Outcome of Hematopoietic Stem Cell Transplantation for Follicular Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
2180 - Better Outcome Following Younger Haploidentical Donor Versus Older Matched Unrelated Donor Transplant for Patients with Acute Myeloid Leukemia in First Remission: A Study from the Global Committee and Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
2185 - Improved Post-Transplant Outcomes over Time for Older Patients with Acute Lymphoblastic Leukemia in First Complete Remission. a Study from the EBMT Acute Leukemia Working Party
2190 - Peripheral Blood Stem Cell Versus Bone Marrow Graft for Non-T-Depleted Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Patients with Secondary Acute Myeloid Leukemia in First Complete Remission: A Study from the ALWP/EBMT
2193 - Optimizing Haploidentical Transplant for Adults with Acute Lymphoblastic Leukemia: The Role of Donor and Graft Selection. a Study from the ALWP of the EBMT
3027 - Hematopoietic Stem Cell Transplantation for Marginal Zone Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
3456 - Impact of Fludarabine Dosage on Outcomes in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy: A Retrospective Study on Behalf of the Ctiwp of the EBMT
3559 - Impact of Donor Type on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis
3562 - Similar Transplant Outcomes for Haplo and MUD Allo-Hcts in AML Patients Achieving CR2: A Study Analyzing 4030 Allo-HCT Recipients from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
3570 - Ptcy Overcomes HLA Mismatch in Unrelated Donor Transplant for Acute Lymphoblastic Leukemia: A Study from the ALWP of the EBMT
4895 - Separation of Gvl Effects from GvHD with Ptcy-Based Gvhd Prophylaxis in Mmud Transplantation: A Study from the ALWP of the EBMT
4944 - Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Haploidentical Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Blake, A.

1331 - Outcomes of Germline Genetic Testing in Children with Hematologic Malignancies Undergoing Allogeneic Transplantation

Blake, A.

1927.2 - A Decentralized Phase II Open-Label Trial Assessing the Safety and Efficacy of Dapagliflozin in Renal AL Amyloidosis (FLORAL)

Blake, D.

4373 - Generation of a Patient Derived T-Cell Prolymphocytic Leukemia Xenograft Model to Evaluate Pre-Clinical Treatment with Small Molecule Inhibitors In Vivo

Blake, D.

4807 - Obesity Attenuates CAR T-Cell Function in Pediatric B-Cell Acute Lymphoblastic Leukemia

Blake, L.

1029 - CAR-T Cell Therapy in Advanced Myeloma with Extramedullary Disease – an In Vivo Imaging and Molecular Monitoring Study (CARAMEL): First Results of Cu-64 Radiolabelled Nanoparticle PET-CT and PET-MRI

Blake, M. L.

4832 - Gamma Secretase Inhibition May Mitigate the Impact of Low BCMA Target Density in Relapsed/Refractory Multiple Myeloma: Results from a Comparative Analysis of Two Phase 1 Clinical Trials

Blakemore, S. J.

367 - Targeting Lymphoma Associated Myeloid-Monocytic Cells through CSF1R Blockade Enhances CAR-T Cell Response in Aggressive B Cell Lymphoma

Blampey, Q.

752 - Amplification of Von Willebrand Factor-Positive CALR^mut Disease-Initiating Hematopoietic Stem Cells Is Associated to the Activation of the PERK/EiF2a Branch of Unfolded Protein Response

Blanc, L.

163 - Heterogeneity of the Erythromyeloblastic Island (EMBI) Niche during Baseline and Stress Erythropoiesis
195 - Hematopoietic Stem Cells Supporting Fetal Erythropoiesis Are Differentially Regulated By Small and Large Ribosomal Subunits
536 - HEXIM1 Regulates Early Erythropoiesis and Participates in Multiple Complexes in Erythroid Cells
808 - Serine Threonine Protein Kinase 25 (STK25) Is a New Mediator of Myelopoiesis and Myeloid Cell Effector Function(s) during Injury and Inflammation
1076 - Dexamethasone Targets E2F4 to Induce Erythroid Progenitor Renewal
2455 - Comprehensive Analysis of Changes in the Proteome during Maturation of Nascent Human Bone Marrow Reticulocytes into Red Cells
2458 - The Dominant Negative Acting VPS4A^E228Q Mutation Causes Dyserythropoiesis in Human iPSC-Derived Erythroblast Cultures That Phenocopies Cimdag Syndrome-Associated Anemia
1173.1 - Delivering Transcutaneous Auricular Neurostimulation to Reduce Heavy Menstrual Bleeding in Von Willebrand Disease Patients

Blanc, S.

2353 - Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Utilization and Clinical Outcomes Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
3253 - Treatment-Emergent Cardiovascular Events Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Treated with Bruton’s Tyrosine Kinase Inhibitors (BTKi)

Blanc-Durand, P.

575 - Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase 3 Gained Study Conducted By Lysa
4505 - Health-Related Quality of Life after Axi-Cel As a Second-Line Therapy in Patients with High-Risk Relapsed/Refractory Large B-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Results of the Alycante Phase II Trial

Blanchard, M. J.

365 - Clinical Value of Peripheral Residual Disease (PRD) and Measurable Residual Disease (MRD) in Newly Diagnosed Elderly Patients in the GEM2017FIT Trial
489 - Reevaluating the IMWG Multiple Myeloma Complete Response Criterion in the Era of Mass Spectrometry: A Critical Analysis
678 - GEM2017Fit Phase 3 Trial in Fit Elderly Patients (Aged 65-80) with Newly Diagnosed Myeloma: Impact of Daratumumab at Induction and/or Consolidation
3349 - Clinical, Biological and Prognostic Characterization of Multiple Myeloma According to the Presence of Circulating Plasma Cells
3374 - Survival Improvement of Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma in Two Consecutive Randomized Phase III Trials: Long-Term Follow up of GEM05 and GEM12 Trials

Blanchard, T.

4792 - EZH1/2 Inhibition Improves the Anti-Tumor Efficacy of CAR and TCR T-Cell Based Therapies Against Multiple Liquid and Solid Tumors

Blanckaert, K.

3840 - Cold Autoimmune Hemolytic Anemia Secondary to Mycoplasma Pneumoniae Infection in Adults: Results from a Large French Observational Study (MYCOLD study)

Blanco, A.

1935 - Ultra-Deep Sequencing of TP53 in Multiple Myeloma: Double-Hit Prevalence and Clinical Phenotype
2803 - Single Center Experience Combining Multiple Tools for Genetic Diagnosis of B-Cell Acute Lymphoblastic Leukemia

Blanco, E.

3491 - Clinical Impact of Colonization By Multi-Drug Resistant Organisms in Stem Cell Transplantation

Blanco, G.

74 - Eradication of the CLECL1+ CLL Subset That Is Prone to Carrying Novel Genomic Mutations and Promoting a Pro-Tumor Microenvironment By a Series of New Monoclonal Antibodies Reactive with Distinct Target Epitopes
1851 - Normal B Cells in MBL Are Biased Toward Antigen-Experienced B Cells, with Increased Percentages of DN1 Cells in IGHV-Mutated MBL and ABC/DN2 Cells in IGHV-Unmutated MBL Suggesting Distinct Follicular/Extrafollicular Maturation Pathways

Blanco Juan, A.

1708 - Primary Mediastinal B Cell Lymphoma (PMBCL): A Multicentric Observational Study of Spanish Lymphoma Group Geltamo

Blanco-Gomez, A.

2773 - BVX001, a Bispecific ADC Targeting CD7-Positive AML with Favorable Toxicity Profile, Exhibits Significant Efficacy in Primary Patient Samples and PDX-Models

Bland, N.

1390 - Belvarafenib Inhibits the Growth of RAS-Mutant Acute Myeloid Leukemia Cell Lines in Vitro and Drives Adaptive Resistance In Vivo

Blaney, P.

766 - Whole Genome Sequencing Reveals Lower Apobec-Mutational Activity in Multiple Myeloma Patients with African Ancestry Compared with Those Having European Ancestry
857 - A Multiomic Analysis of Waldenstrom's Macroglobulinemia Identifies Three Subtypes of Disease Based on Impaired Plasma Cell Differentiation
4636 - Bone Marrow Fibroblasts at the Single-Cell Resolution Level in Multiple Myeloma
4655 - Mutationally Enriched Regions of the Non-Coding Genome Harbor Functionally Impactful Mutations That Dysregulate Key Genes Involved in Multiple Myeloma Pathogenesis

Blank, A.

644 - CD19-CD28 (RO7443904) Combination with Glofitamab Enhances T-Cell Proliferation and Effector Function in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)

Blankenfeld, M.

2050 - Potent Target-Specific Efficacy of CAR T Cells Directed Toward the AML and KMT2A-Rearranged Specific Antigen CLEC2A
3413 - Discovery and Immunotherapeutic Targeting of the Tumor-Specific Target LAMP5 in Acute Myeloid Leukemia
3417 - Effective Dual Targeting of PRAME and WT1 with CD33-Gated ARTEMIS^® Antibody-TCR Platform in Acute Myeloid Leukemia
4793 - Preclinical Efficacy of CD276 (B7-H3) CAR T in Acute Myeloid Leukemia

Blanquer Blanquer, M.

4401 - Impact of Bone Marrow Evaluation Using Bone Marrow Biopsy, Flow Cytometry, and PET/CT in B-Cell Non-Hodgkin Lymphomas

Blans, C.

4996 - Artificial-Intelligence Driven Quantification of Sickle Red Blood Cell Morphology As an Objective Disease Marker

Blaser, B. W.

275 - ALL-R: An Anchoring Score to Predict Relapse in Acute Lymphoblastic Leukemia (ALL) Using a Zebrafish Patient-Derived Xenograft Model
1300 - Mesenchymal Stromal Cell Expansion in FLT3-ITD+ Zebrafish Treated with Gilteritinib
2432 - Real-World Experience of Venetoclax Target Dosing with Concomitant Posaconazole in Adult Patients with Acute Myeloid Leukemia
4066 - Decoding Transcription Factor Dependent Enhancer-Gene Regulatory Networks That Define Hematopoietic Niche Function
4067 - Hepatocyte Growth Factor Is Overexpressed in AML and Remodels the Mesenchymal Stromal Cell Niche

Blasi, F.

1696 - Post-Transplant Lymphoproliferative Disorders (PTLD) in a Referral Center

Blasutig, S.

759 - Richter Syndrome-Associated Genetic Lesions in TP53 and the Cell Cycle Inhibitors CDKN2A and CDKN2B Induce Transformation of a CD5+ B Cell Subset Characterized By a Restricted IGHV Repertoire, Autoreactivity and BCR Dependence

Blatt, P.

4498 - Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Blau, C. A.

2384 - Evaluating Multiple Myeloma Treatment and Clinical-Decision Making with Real-World Data
5043 - Study Assessing the All4Cure Health Technology Intervention on Patient Activation in Multiple Myeloma

Blau, I. W.

84 - Impact of Clonal Heterogeneity in Newly Diagnosed, Transplant-Eligible Multiple Myeloma – Subgroup Analysis of the GMMG HD6 Phase III Trial
708 - Single Vs. Tandem Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Real-World Multi-Center Study from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)
769 - Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
1963 - Quality of Life in the Multicenter, Randomized, Phase 3 GMMG-HD6 Trial Applying Elotuzumab, Lenalidomide, Bortezomib and Dexaemethason in Patients with Newly-Diagnosed Multiple Myeloma
2185 - Improved Post-Transplant Outcomes over Time for Older Patients with Acute Lymphoblastic Leukemia in First Complete Remission. a Study from the EBMT Acute Leukemia Working Party
3560 - Impact of FLT3 Inhibitor Maintenance Therapy on Post-Transplant Outcomes in FLT3-Mutated AML Patients: A Real World Analysis from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)
4945 - Prognostic Impact of t(9;11) and Del(7q) As Intermediate-Risk Abnormalities in AML Following Allo-Transplant: Insights from the ELN 2022 Classification – an EBMT ALWP Study
5140 - Long-Term Follow-up Analysis of Progression-Free and Overall Survival in Newly Diagnosed Multiple Myeloma Patients from the GMMG Myeloma Registry Following the Randomized Phase III GMMG-HD6 Trial

Blau, S.

5043 - Study Assessing the All4Cure Health Technology Intervention on Patient Activation in Multiple Myeloma

Blaus, A.

4846.1 - A Phase 1 Study of NKX019, an Allogeneic Chimeric Antigen Receptor Natural Killer (CAR-NK) Cell Therapy in Patients with Systemic Lupus Erythematosus

Blaylark, R.

5004 - Multi-Disciplinary Care Model for Transition and Re-Transition after Gene Therapy in Sickle Cell Disease

Blazar, B. R.

3516 - Five-Year Outcomes of the “Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease (GVHD) Prophylaxis: A Randomized Controlled Trial” (‘ABA2’)

Blazevic, M.

4665 - CD31 and JAM-a Expressing Circulating Tumor Plasma Cells As Prognostic Biomarkers for Multiple Myeloma Disease

Blazos, C.

2256 - Relationship between Frequency of Treatment Administration, Adherence to Treatment, and Quality of Life in Patients with Hemophilia a or Hemophilia B, with or without Inhibitors: A Real-World Survey
3973 - Unmet Needs, Factor Consumption, and Healthcare Resource Use Among People with Hemophilia a: Real-World Analysis of the Adelphi Hemophilia Disease Specific Programme^TM
5078 - Real-World Experience with Emicizumab for Hemophilia a from the Physician Perspective Based on Survey Data
5082 - Treatment Adherence, Satisfaction and Quality of Life of Adult Patients with Severe Haemophilia a: Results from a Real-World Survey of Physicians and Patients

Bleakley, M.

901 - Memory CD4⁺ T Cells Recognize Divergent HLA-DP Immunopeptidomes and Contribute to Leukemia Control after Allogeneic HCT
4771 - Identification of Microbiota-Reactive CD4+ T Cells in the Post-Transplant Setting

Bledsoe, J. R.

418 - CXCR4 Antagonism Corrects Peripheral Neutropenia and Mature Neutrophil Accumulation in Bone Marrow in a Pharmacological Mouse Model of CXCR2 Loss-of-Function

Bledsoe, S.

999 - A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib

Bleul, S.

856 - Modulation of the Tumor Microenvironment By CCL19 in Primary CNS Lymphomas
1583 - Guiding Treatment and Clinical Management of Patients with CNS Lymphomas By Minimal-Invasive Detection of Circulating Tumor DNA in Cerebrospinal Fluid
4374 - The Effect of Ibrutinib on the Myeloid Cell Compartment in Central Nervous System Lymphoma Slice Cultures

Blewett, T.

2031 - Early MRD Detection after CAR-T Associated with Poor Outcome in Patients with Large B-Cell Lymphoma

Blisset, R.

5037 - Estimating the Impact on Survival of Not Receiving CAR T Therapy Despite Being Eligible in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Patients in Germany

Bliven, S. P.

111 - Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study
4839 - Influence of Siltuximab for CAR T-Cell Related CRS/Icans on CAR T-Cell Reconstitution, Function, and Clinical Outcomes

Blixt, L.

4634 - Severity of COVID-19 in Individuals with Chronic Lymphocytic Leukemia throughout the Pandemic in Sweden: A Nationwide Multiple Register Cohort Study Conducted from 2020 to 2023

Blobel, G. A.

412 - A Novel Genome-Scale CRISPR-Cas12a Screen Identifies Ptpa As a Fetal Hemoglobin Regulator Via BCL11A
537 - LDB1 Establishes Multi-Enhancer Networks to Regulate Erythroid Gene Expression
2740 - Defining Oncogenic Transcriptional Networks Regulated By LDB1 in T-Cell Acute Lymphoblastic Leukemia

Bloch, C.

1117 - Autoimmune and Inflammatory Diseases in Children with Sickle Cell Disease: A French Multicenter Observational Study on Diagnostic and Therapeutic Issues

Blocher, J.

5195 - Predictors of Individual Symptom Scores in Myeloproliferative Neoplasms: A Real-World Retrospective Cohort Study

Block, T.

671 - A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma

Blocka, J.

1898 - Single-Cell RNA Sequencing of Circulating Myeloma Cells: Clinical Implications in Times of Immunotherapies

Bloemenkamp, K. W.

129 - Postpartum Hemorrhage in Hemophilia a and B Carriers after Enhanced Prophylactic Clotting Factor Suppletion: The Pregnancy and Inherited Bleeding Disorders Study (PRIDES)
1208 - The Influence of Postpartum Hemorrhage on the Quality of Life Among Pregnant Hemophilia a and B Carriers: The Pregnancy and Inherited Bleeding Disorders Study (PRIDES)
2595 - Postpartum Hemorrhage in Women with Von Willebrand Disease after Enhanced Prophylactic Clotting Factor Suppletion: The Pregnancy and Inherited Bleeding Disorders Study (PRIDES)
2601 - The Influence of Postpartum Hemorrhage on Patient Reported Outcomes Among Women with Von Willebrand Disease: The Pregnancy and Inherited Bleeding Disorders Study (PRIDES)

Blom, B.

2011 - Long-Lasting AML-Specific Antibody Responses after Allogeneic Hematopoietic Progenitor Cell Transplantation

Blombery, P.

51 - Venetoclax-Based Measurable Residual Disease Directed Therapy in Acute Myeloid Leukemia Is Associated with Emergent TP53 Microclones in Remission
303 - Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve Severe Aplastic Anemia: Results of the Diaamond-Ava-First Trial
582 - A Randomized Phase 2, Investigator-Led Trial of Glofitamab-R-CHOP or Glofitamab-Polatuzumab Vedotin-R-CHP (COALITION) in Younger Patients with High Burden, High-Risk Large B-Cell Lymphoma Demonstrates Safety, Uncompromised Chemotherapy Intensity, a High Rate of Durable Remissions, and Unique FDG-PET Response Characteristics
653 - DNA Damage Repair Pathway Variants Are Frequent in Patients Undergoing CAR-T Cell Therapy for Lymphoma and Associated with Increased Risk of Myeloid Neoplasia Post Cytotoxic Therapy
1318 - Cellular and Cell-Free Genomic Characterization of Patients Receiving Avatrombopag and Immunosuppressive Therapy for Treatment-Naïve Severe Aplastic Anemia
1721 - Interim Safety Analysis of ALLG-Pacific (NHL35): An Open Label Phase II Study of Pembrolizumab and Chemo-Immunotherapy As First-Line Therapy for Primary Mediastinal B-Cell Lymphoma
4410 - Obinutuzumab, Lenalidomide and Venetoclax for the Initial Treatment of Patients with Advanced-Stage Follicular Lymphoma: Primary Analysis of an Investigator-Initiated Phase Ib/II, Multicenter Study (LEVERAGE)
4613 - Clonal Hematopoiesis in Patients with Chronic Lymphocytic Leukemia Treated with Fixed-Duration Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Insights from the Randomized CLL14 Trial
5015 - Evaluating a Multidisciplinary Model of Care for Inherited Bone Marrow Failure and Predisposition to Hematological Malignancy

Bloom, E.

547 - Critical Bleeding in Adults and Children with Immune Thrombocytopenia: A Multicentre Cohort Study
795 - Pediatric Autoimmune Hemolytic Anemia Is Associated with a High Incidence of an Underlying Immune Disorder and High Mortality Rate

Bloor, A.

585 - IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax: Report of the UK NCRI FLAIR Study
925 - The Influence of HLA Matching of the Winning and Losing Units in Relapse of Patients Receiving Double Cord Blood Transplantation for Acute Leukemia or Myelodysplastic Syndrome
3070 - Autologous Hematopoietic Stem Cell Transplantation in Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
3496 - Prediction Model to Evaluate Engraftment Kinetics Following Stem Cell Transplantation

Blouet, A.

3167 - Outcome of Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms Ineligible for Intensive Chemotherapy or Allogeneic Hematopoietic Cell Transplantation Treated By Azacitidine Alone or in Combination – a FIM Study

Bloye, G.

2830 - A Non-Canonical Lymphoblast in Refractory Childhood T-Cell Acute Lymphoblastic Leukemia

Blue, B.

896 - Comprehensive Analysis of Pre-Treatment Biomarkers Associated with Toxicity and Durable Responses in Idecabtagene Vicleucel Therapy for Relapsed/Refractory Multiple Myeloma
1906 - De Novo Resistance and Relapse from Daratumumab Monotherapy in NDMM Is Associated with Immune Evasion and Immunosuppression
1995 - Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Final Results of a Phase II Study
2004 - Predictive Markers for Outcomes after Disease Progression Post BCMA-Directed CAR T-Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma
2383 - A Patient Perspective on Actionable Steps to Address Disparities in Healthcare Among US Patients with Multiple Myeloma
3021 - Clinical Characteristics and Outcomes of Patients with MYD88 Positive Waldenström Macroglobulinemia: A Single Center Retrospective Analysis
3337 - Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab
3784 - Single Center Real World Experience of Talquetamab in Patients with Relapsed and Refractory Multiple Myeloma
3785 - Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
4692 - Patterns of Progression and Outcomes in Multiple Myeloma after Anti-BCMA CAR T-Cell Therapy
4740 - Activity and Safety of Venetoclax (VEN)-Based Treatment in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (R/R MM)
5165 - Meaningful Change in Patient-Reported Outcomes after CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma in Standard of Care: Differences By Race and Ethnicity
5168 - Effect of Talquetamab on Responses in Patients with Relapsed and Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies
- CRTI

Blum Dominguez, M. A.

1708 - Primary Mediastinal B Cell Lymphoma (PMBCL): A Multicentric Observational Study of Spanish Lymphoma Group Geltamo

Blum, J.

2998 - Epcoritamab Induces in Vitro-Derived Terminally Differentiated Exhausted T Cells to Kill B Cells

Blum, J.

416 - CEBPA Regulates Molecular Kinetics of RNA Polymerase I in Myeloid Progenitors

Blum, K. A.

110 - Representation of Minorities in Therapeutic Clinical Trials – a 15-Year Review of Lymphoma Cooperative Group Studies (Alliance A152123)
459 - A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma
570 - Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma
831 - Disrupting IL10 Signaling Overcomes Compound Copy Number Variation-Driven Clinical Resistance to CDK4/6 and BTK Inhibition in Mantle Cell Lymphoma
1717 - Clinical Features and Outcomes of Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Single-Center Analysis
2347 - Acuity of Illness at Initial Presentation Mediates Early Mortality in Adolescent and Young Adult Leukemia

Blum, S.

4061 - Single-Cell Transcriptomic and Spatial Characterization of Multipotent Stromal Cells in Homeostatic,Remodeled, and In Vitro Expanded Human Bone Marrow

Blum, S.

3452 - Euplagia-1: A Phase 1/2 Trial of GLPG5201, a Fresh Stem-like Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, in Patients with Relapsed/Refractory CLL and RT

Blum, W.

733 - Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial
1008 - IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results
1514 - Time to Response and Overall Survival in Patients with mIDH1 Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib
1564 - Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with NPM1 Mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial
2886 - Combination of Olutasidenib and Azacitidine Induces Durable Complete Remissions in mIDH1 Acute Myeloid Leukemia: A Multicohort Open-Label Phase 1/2 Trial
2921 - BRAF-Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML
3521 - Intermediate Dose Post-Transplant Cyclophosphamide Is Associated with Faster Engraftment and Similar Other Outcomes When Compared with Full Dose Post-Transplant Cyclophosphamide Among Patients Undergoing Allogeneic Transplantation: A Single Center Retrospective Analysis
4324 - Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age
4325 - IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy
2883.4 - A Phase 1, Open-Label, Dose Escalation and Dose Expansion, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Lomonitinib (ZE46-0134) in Adults with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia
2907.2 - A Randomized Phase 2 Trial of 28-Day (Arm A) Versus 14-Day (Arm B) Schedule of Venetoclax + Azacitidine in Newly Diagnosed Acute Myeloid Leukemia Patients ≥ 60 Years

Blumberg, N.

4741 - Hyperbaric Oxygen (HBO) Effects on Blood Count Recovery and Post Transplant Outcomes Following High-Dose Therapy and Autologous HSPC Transplantation for Multiple Myeloma: Final Analysis of the Multicenter Phase II Randomized Clinical Trial

Blumenberg, V.

3415 - Characterizing Environmental Adaption and Virulence of Gut Microbiome Enterococcus Spp. from Patients Receiving CD19-Targeted CAR-T Cell Therapy
3425 - Divergent Population Dynamics and Gene Signaling in Monocytes Distinctly Influence Responses to CD19-Targeted CAR T-Cells in Relapsed/Refractory B-NHL

Blunk, B.

2300 - Comparison of 15- Vs. 30-Day Remote Patient Monitoring for Outpatient Chimeric Antigen Receptor T-Cell Therapy (CAR-T) across a Large Health System
3734 - The Patient Journey and Treatment Outcomes Comparing Inpatient Versus Outpatient Axicabtagene Ciloleucel in Non-Hodgkin’s Lymphoma (NHL) - a Large, Multicenter Study

Blunt, D. N.

1727 - Durvalumab and Acalabrutinib for Relapsed/Refractory (r/r) High-Grade B-Cell Lymphoma: MoST15, Open Label Phase II Sub-Study of the Molecular Screening and Therapeutics in Leukaemia and Lymphoma (MoST-LLy) Framework

Blüthgen, N.

1351 - Parallel Sequencing of Transposons and Transcriptomes in Single Cells for Genome-Wide Cancer Gene Discovery

Blyden, G. T.

3875 - Further Validation of Flow Adhesion of Whole Blood to P-Selectin (FA-WB-PSEL) to Assess Targeted P-Selectin Therapies in Sickle Cell Disease (SCD)

Blydt-Hansen, I.

1091 - Iron and B12 Deficiency Has Rarely Been Considered in Studies Defining Hemoglobin Concentration Reference Intervals in Pregnancy: A Systematic Review

Bo-Subait, S.

3672 - Addressing Patient Representation in Hematopoietic Cell Transplant Clinical Trials: Insights Gained through the Access Trial

Boadi-Acheampong, N. A.

1017 - Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants

Boals, M.

2704 - Prospective Genomic Study for Optimizing Clonal Hematopoiesis Surveillance in Bone Marrow Failure Syndromes and Related Cytopenia

Boardman, A. P.

501 - Dual-Vector-Transduction with Single-Step Magnetic Selection (Zip-sort) Increases Transgenic Payloads to Enhance CAR T Cell Activity
569 - Pembrolizumab Maintenance Instead of Autologous Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma in Complete Response after Pembrolizumab, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin
781 - Barriers to Immune Effector Cell Therapy: Rapid Disease Progression, Concern for Toxicity, and Lack of Appropriate Trials Drive Non-Receipt after Referral at a Large Academic Center
1707 - High Grade B-Cell Lymphoma with MYC/BCL6-Rearrangements (R) May Have Inferior Outcomes Compared to BCL2-R Disease
1746 - Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study
2030 - Effector Differentiation and Exhaustion Attenuate on-Target, Off-Tumor Toxicity of CD24 CAR T Cells
2336 - Real-World Outcomes of Frontline Polatuzumab and Impact of Frailty in Older Adults with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
2369 - When Can We Define Cure after CAR-T Therapy in LBCL? Insights from Serial Landmark Analyses
3028 - Matching-Adjusted Indirect Comparison (MAIC) of Efficacy and Safety Outcomes for Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for the Treatment of Third-Line or Later (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
3053 - Final Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma
3128 - A Proof-of-Principle of Split-Course Bridging Radiotherapy (SC-BRT) Prior to CAR T-Cell Therapies for Relapsed or Refractory B-Cell Lymphomas: A Phase 1a Pilot Cohort
3752 - Comparative Real-World Outcomes of Commercial CD19-Directed CAR T-Cell Therapies in Large B-Cell Lymphoma
4429 - Improved Outcomes for Primary Refractory Classical Hodgkin Lymphoma: A Retrospective Analysis
4434 - Pembrolizumab and Involved Site Radiation Therapy Alone As an Alternative to Transplant in Patients with Localized Failure Following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study
4451 - Angioimmunoblastic Versus Non-Angioimmunoblastic Nodal T-Follicular Helper Cell Lymphomas: Single Center Retrospective Analysis on 208 Cases
4474 - A Prospective Geriatric Assessment (GA) Study Predicting Toxicities in Older Adults (OA) with Non-Hodgkin Lymphoma (NHL): Timed up and Go Test (TUG) Time Emerges As a Functional Vital Sign
4485 - Sequential R-CHOP/(R)-ICE and Dose-Adjusted EPOCH-R Are Both Appropriate Frontline Treatments for Newly Diagnosed Primary Mediastinal B-Cell Lymphoma: Results of a Retrospective Analysis

Boaro, M. P.

290 - Oxygen Gradient Ektacytometry Is Associated with Markers of Hemolysis and Inflammation in a Large Sickle Cell Disease Cohort within the GenoMed4ALL Project
1138 - Data Driven Research through the European RADeep Registry and the Use of Artificial Intelligence Towards Personalized Medicine in Sickle Cell Disease

Boateng-Antwi, K. A. M.

3473 - In Vivo Persistence and Function of CAR19 T-Cell Products for Pediatric B-Cell Acute Lymphoblastic Leukemia Are Impacted By Media, Cytokine Supplementation and Metabolite Bioavailability during Ex Vivo Manufacturing

Boaventura, I.

796 - Post-Partum Hemorrhage in Sub-Saharan Africa: A Prospective, Multi-Faceted Intervention Study in Metropolitan Mozambique

Boban, A.

715 - Annualized Bleeding Rates in Patients with Hemophilia a or B and Inhibitors with and without Target Joints at Baseline: Results from the Concizumab Phase 3 Explorer7 Study

Bobba, S.

997 - Hematological Improvement and Other Clinical Benefits of Elritercept As Monotherapy and in Combination with Ruxolitinib in Participants with Myelofibrosis from the Ongoing Phase 2 Restore Trial
1825 - Improvements in Hematological Parameters and Quality of Life (QOL) with Elritercept (KER-050): Results from an Ongoing Phase 2 Trial in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS)
4591 - Hematologic Improvement and Fatigue Reduction with Elritercept (KER-050) in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS) with Non-Transfusion Dependent Anemia: New Analyses from an Ongoing Phase 2 Trial
3228.1 - Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)

Bobbili, P. J.

1801 - Overall Survival and Duration of Treatment in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib Versus Midostaurin or Best Available Therapy in a Real-World Setting
3770 - Patient-Reported Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma in Real-World Clinical Practice: A Prospective, Multi-Site Observational Study – Interim Results

Bobée, V.

4353 - Clonal Dominance in Follicular Lymphoma: A Predictor of Poor Prognosis and Histological Transformation

Bobek, O.

4502.4 - Trial in Progress – Alliance A051901 – Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed By Lenalidomide and Nivolumab Maintenance in Primary Central Nervous System Lymphoma (PCNSL)

Bobillo, M. S.

470 - Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
523 - Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above
526 - Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Bobin, A.

4756 - High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)
4765 - Prognostic Value of Positron Emission Tomography/Computed Tomography in Multiple Myeloma Patients Treated with Ide-Cel CAR-T Cell Therapy: Preliminary Results of a Real-World IFM Study from the Descar-T Registry (CAR MY PET)

Bobruff, Y.

512 - Durable Clinical Benefits with Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia

Boccacci, R.

65 - Identification of Genomic Structural Variants (SVs) with Adverse Prognostic Significance in Normal-Karyotype (nk) Acute Myeloid Leukemia (AML) Patients

Boccadifuoco, U.

3904 - Circulating Erythroblasts Are Associated with Specific Characteristics in Adult Patients with Sickle Cell Disease: The Drepablast Study

Boccadoro, M.

487 - Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study
494 - Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial
674 - Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial
676 - Results of the Phase II Randomized Trial EMN15/HOVON147: Carfilzomib-Lenalidomide-Dexamethasone Vs Lenalidomide-Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma
898 - Early Relapse in Patients with Newly-Diagnosed Multiple Myeloma: A European Myeloma Network/Harmony Alliance Analysis Including 10843 Patients
2000 - Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)
2226 - Development and Validation of Novel Machine Learning-Based Risk Scores for Multiple Myeloma: Insights from the Harmony Alliance Big Data Platform

Bocchetta, S.

73 - Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated By Epigenetic Plasticity of Residual Disease and By-Pass Signaling Via MAPK Pathway
854 - A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Ctdna
1367 - Mouse Model of Splenic Marginal Zone Lymphoma to Decipher the Pathogenetic Implications of NOTCH2 and KLF2 Mutations
1578 - Clonal Hematopoiesis in Diffuse Large B-Cell Lymphoma: Clinical and Molecular Correlations
2960 - Non-Coding Mutations of BCL6 in Classical Hodgkin Lymphoma
4354 - Circulating Tumor DNA for Primary Mediastinal B-Cell Lymphoma Genotyping: A Prospective Multicenter Study

Bocchia, M.

835 - Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820
995 - FATE and Role of Peripheral Blood CD26+ Leukemia STEM CELLS at Diagnosis in Chronic Myeloid Leukemia Patients: FINAL Results of Prospective Flowers Study
1574 - Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML
1772 - Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50 – 60 Years: A “Campus CML” Study
1778 - Treatment-Free Remission in CML Patients Discontinuing Post-First Line Therapy
2690 - Methodology and Clinical Significance of Longitudinal UBA1 Clonal Burden Evaluation in Vexas Syndrome
2836 - Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial
2891 - Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia
3155 - CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or ≤ 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study
3162 - Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: Observational Study of 673 Patients in Italy
4532 - Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact Project, a CML Campus Study

Boccia, R.

2080 - Safety and Tolerability of BCMA-Directed mRNA CAR T-Cell Therapy in Multiple Myeloma and Autoimmune Disease

Boccia, R. V.

861 - Iopofosine I 131 in Previously Treated Patients with Waldenstrom Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaM)

Boccieri, E.

3561 - Outcomes of Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia Given Blinatumomab As Last Consolidation Treatment before Allogeneic Hematopoietic Cell Transplantation
4830 - CD7.Pebl-CART for Patients with Relapsed/Refractory (r/r) T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Boccomini, C.

339 - Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from "FOLL12" Phase III Trial of the Fondazione Italiana Linfomi
1577 - TP53, CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial
3042.1 - Mosunetuzumab and Zanubrutinib in Relapsed/Refractory Follicular Lymphoma Patients (MOZART): A Phase II, Chemo-Free Trial from Fondazione Italiana Linfomi (FIL)

Boccucci, J.

523 - Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above
4200 - NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival

Bochenek, V.

173 - A Novel Direct Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease – In Vivo Efficacy of Ilx-002 in Humanized Mice

Bochenek, V.

1231 - Platelet Factor 4 Enhances Endothelial Cell Antimicrobial Activity in Vitro and Promotes Bacterial Clearance In Vivo, Improving Sepsis Outcomes
2528 - Why Do Peptidyl Arginine Deiminase (PAD) 4-Deficient Mice Have Improved Survival Following Cecal Ligation and Puncture (CLP) Sepsis? Implications for the Role Neutrophil Extracellular Trap (NETs) in Immune Homeostasis
3986 - Platelet Factor 4 (PF4) Binding to Neutrophil Extracellular Traps (NETs) and Von Willebrand Factor (vWF) Improves Bacterial Capture and Killing in an Electrostatic Charge-Dependent Manner

Bochicchio, M. T.

1574 - Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML
2891 - Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Bociek, R. G.

2368 - Impact of Icans on Long-Term Neurocognitive Function in Patients with Diffuse Large B-Cell Lymphoma Receiving CAR T-Cell Therapy
3126 - A Prospective Clinical Trial of Boom-Boom Radiation As Bridging Therapy for Patients with Large B-Cell Lymphoma Undergoing Treatment with Lisocabtagene Maraleucel (Liso-cel) Therapy

Bock, A. M.

1864 - Real-World Comparison of BCL2 Inhibitor and BTK Inhibitor Therapy in the Front-Line Treatment of CLL Including Patients with Del(17p)/TP53 Mutation
2977 - Subtype-Specific Mechanisms of Treatment Resistance and Relapse in Diffuse Large B Cell Lymphoma (DLBCL)
4434.2 - CTEP 10590, NORM: Nodular Lymphocyte Predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase II Trial with Either Rituximab or Mosunetuzumab

Bock, T.

2028 - Prediction of Therapeutic Potential of CD19 CAR-T Cells for LBCL By Histone Mark Analyses of Core Epigenetic Programming

Böckle, D.

1583 - Guiding Treatment and Clinical Management of Patients with CNS Lymphomas By Minimal-Invasive Detection of Circulating Tumor DNA in Cerebrospinal Fluid

Bodach, M.

229 - Pathogenesis and Clinical Relevance of Diffuse Large B-Cell Lymphoma Proteogenotypes

Bodanapu, G.

3341 - Risk Factors for Suboptimal Treatment in Patients with Newly Diagnosed Multiple Myeloma across US Healthcare Systems
5169 - Evaluation of Socioeconomic Barriers Impacting Patients with Newly Diagnosed Multiple Myeloma

Bodanapu, G.

287 - Development of a Risk Prediction Model for 6-Month Early Mortality in Patients with Systemic Light Chain Amyloidosis Treated with Daratumumab-Based Frontline Therapy

Boddicker, N. J.

397 - Prevalence, Genetic Predispositions and Clinical Consequences of Non-CLL-Type MBL: Screening in 10,330 Individuals
2967 - Role of Clonal Hematopoiesis (CH) in Lymphoma: Prevalence and Clinical Impact in Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL)
4616 - Serum Immunoglobulins Are an Independent Prognostic Marker of Time to First Therapy in Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) and Monoclonal B-Cell Lymphocytosis (MBL)

Boddu, P.

1075 - Cytoplasmic Intron Retention As a Regulatory Mechanism of Mitochondrial Homeostasis in Erythroid Cells
1812 - Tet2 Loss in Hematopoietic Stem Cells Triggers Chromatin Reorganization through DNA Methylation Shifts
1813 - SF3B1 Mutations Lead to Changes in Fine-Scale Chromatin Organization through Impaired Transcription
2732 - A Unified Post-Transcriptional Mechanism Regulates Intron Retention in Splicing Factor-Mutant MDS

Boddu, R.

3938 - Randomised Controlled Trial of High Dose Dexamethasone and Methylprednisolone in Immune Thrombocytopenia (HDMI Trial)

Bode, A.

2311 - Opioid Overdose in Patients with Sickle Cell Disease, Outcomes Among Hospitalized Patients in the United States: A Nationwide Analysis

Bodelon, S.

1642 - Zanubrutinib Is Effective in the Treatment of Patients with Waldenström's Macroglobulinemia and Bing-Neel Syndrome: A Retrospective Multicenter Study

Bodet, D.

2814 - How to Administer Pegaspargase during Induction Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents? Results of the Caall-F01, a Multicentre Randomized Clinical Trial from the French Pediatric Cancer Society (SFCE)

Bodivit, G.

2608 - Red Blood Cell-Derived Particles Induce Endothelial Damage Via the Alternative Complement Pathway

Bodmer, N.

309 - A Reduced Daunorubicin Dose during Induction Is Equally Effective As Standard Dose in Children with Acute Lymphoblastic Leukemia (ALL) and Favorable Prognostic Features: Long-Term Results of the Phase 3 Trial AIEOP-BFM ALL 2009
730 - Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy

Bodnar, S.

1970 - Enhanced Detection of Pathogenic Germline Variants in Plasma Cell Disorders: Impact of a Targeted Genetic Counseling Referral Pathway
3329 - Delayed Neutrophil Recovery Following BCMA-Directed CAR-T Correlates with Poor Outcomes and Is Associated with a Cytokine Signature of Persistent Inflammation and T Cell Checkpoint Activation

Bodo, I.

139 - Obinutuzumab in Rituximab Refractory or Intolerant Immune-Mediated Thrombotic Thrombocytopenic Purpura

Bodo, J.

2920 - Distinct Phenotypes of Myeloid Neoplasia Associated with Truncating C-CBL Mutations

Boechenek, M.

124 - T-Cell Transcriptomic Signatures in Adults with Primary Untreated Immune Thrombocytopenia Segregate By Age, Revealing Distinct Druggable Pathways

Boeckh, M.

2146 - CMV Specific T Cell Polyfunctionality after HCT: A Detailed Analysis of the Impact of Steroid Exposure, Immunosuppressive Regimens and Viral Reactivation

Boedicker, D.

1919 - Diagnostic Test Accuracy of Cardiac Imaging for AL Amyloidosis: A Systematic Review and Meta-Analysis
1920 - Diagnostic Test Accuracy of Bone Scintigraphy in the Diagnosis of Attr Amyloidosis: A Systematic Review and Meta-Analysis
1925 - Diagnostic Test Accuracy of Serum and Urine Immunofixation and Free Light Chains in the Diagnosis of Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
1926 - Diagnostic Test Accuracy of Cardiac Biomarkers for Light Chain Amyloidosis: A Systematic Review and Meta-Analysis

Boegeholz, J.

565 - Ultrasensitive Circulating Tumor DNA MRD Status Predicts Treatment Failure & Complements PET/CT throughout Treatment for Early and Advanced Stage Classic Hodgkin Lymphoma
648 - Non-Invasive Characterization and Early Detection of Post-Transplant Lymphoproliferative Disorders
853 - Distinct Molecular Aberrations of Classic Hodgkin Lymphoma in Older Adults Identified By Comprehensive Genomic Profiling

Boehm, H.

1221 - Evaluation of Pharmacokinetics, Efficacy and Safety of a New Human Fibrinogen Concentrate in Patients with Congenital Fibrinogen Deficiency

Boehm, M.

807 - The Ectopyrase CD73 Is a Critical Checkpoint in Thromboinflammation

Boehme, V.

4498 - Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Boehner, C. J.

1019 - A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome
1894 - Novel Non-Coding Candidate Drivers of Multiple Myeloma Linked to Plasma Cell Tumor Biology and B Cell Development
1903 - Comprehensive Characterization of the Plasma Proteome of Multiple Myeloma and Its Precursor Conditions and Identification of a Proteomic Signature to Improve Risk Prediction of Disease Progression
4637 - Single-Cell Profiling of ~1.7 Million Plasma Cells across >250 Individuals Reveals Transcriptional Signatures of Progression and Clonal Expansion in Multiple Myeloma and Its Precursor Stages

Boelens, J. J.

2175 - T- and B-Cell Subset Reconstitution As Predictor of Relapse in Pediatric and Young Adult Allo-Hematopoietic Cell Transplantation Patients
4953 - Cerebral Hemodynamics Improve in Adults with Sickle Cell Disease after Gene Therapy

Boelig, R. C.

299 - Impact of Protease Activated Receptor 4 Genotype on Response to Aspirin and Perinatal Outcomes in High Risk Pregnancies

Boeltz, S.

684 - Update on Monocentric CD19-CAR T-Cell Therapy in 30 Patients with Autoimmune Disease

Boer, J. M.

1459 - Challenging Conventional Diagnostic Methods By Comprehensive Molecular Diagnostics: Results of a Nationwide Prospective Comparison in Children with Acute Lymphoblastic Leukemia
4228 - The Leukemic Microenvironment Represses Blinatumomab-Dependent Killing in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia

Boerner, J.

1540 - Clonal Evolution of TP53 Configurations with Treatment Predict Prognosis in Myeloid Neoplasms
4254 - Longitudinal Sequencing to Investigate Clonal Evolution in Myeloid Neoplasms

Boerries, M.

442 - Hematological Phenotypes in GATA2 Deficiency Syndrome Arise from Secondary Injuries and Maladaptation to Proliferation
1298 - SPARC Stabilizes Integrin α4-VCAM-1 Interactions and Is Regulated By Intracellular Rac in NPM1-Mutated AML
4119 - STAT5-Activating Oncogenes Drive Oncostatin M Production Causing T Cell Exhaustion and Suppressive Myeloid Cell Recruitment
4365 - Identification of Ikaros As Novel Interaction Partner of Cyclin D1/CDK4 in MCL

Boersma, R.

4380 - Immunosuppressed Tumor Microenvironment in MYC-Rearranged High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas, Not Otherwise Specified

Boersma, R.

1588 - Cell-Free DNA Genomic and Fragmentomic Features for Early Outcome Prediction in Diffuse Large B-Cell Lymphoma

Boertjes, E.

2718 - DNMT3A Mutations Deregulate the DNA Demethylation Pathway in Acute Myeloid Leukemia

Boesch, A.

3421 - In Vitro and In Vivo Activity of a Lipid Nanoparticle System for the In Vivo Generation of CAR T Cells

Boet, E.

4097 - Deciphering EZH2 Non-Canonical Activities in AML Resistance

Boettcher, I. S.

1524 - Safety and Efficacy of Venetoclax, Cytarabine and Metformin for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia

Boettcher, S.

41 - The Pathogenesis of Therapy-Related Myeloid Neoplasms from TP53-Mutant Clonal Hematopoiesis
193 - Somatic TP53 Mutations Rescue the Hematopoietic Stem and Progenitor Cell Defect at the Expense of Increased Risk for Myeloid Malignancies in ERCC6L2-Associated Inherited Bone Marrow Failure Syndrome
2673 - Mutagenic DNA Lesions in Normal Hematopoietic Stem Cells Persist for Years Causing Distinct Patterns of Mutation
2881 - MP0533 (CD33 x CD123 x CD70 x CD3), a Tetra-Specific CD3-Engaging Darpin for the Treatment of Patients with Relapsed/Refractory AML or MDS/AML: Results of an Ongoing Phase 1/2a Study
4155 - Reactivation of p53 in TP53-Y220C Mutant AML: Mechanism of Action and Mechanism-Based Drug Combinations
4307 - MDS-AML Aggregative Risk Classification System (MARCS): A Novel, Enhanced Risk Stratification System Derived from the Combined Unsupervised Analysis of 7,480 MDS and AML Patients

Bogaanay, L.

944 - Clonal Haematopoiesis with TP53 Mutations Exhibits Abnormal Erythropoiesis and Erythroid Metabolic Stress
1284 - DNMT3A-Mutant Clonal Haematopoiesis Is Associated with Worse Recovery after ST-Elevation Myocardial Infarction Via Increased Inflammation

Bogen, B.

4664 - Characterizing the Multiple Myeloma Bone Marrow Microenvironment at the Single-Cell Level in a Preclinical Model

Boggs, N.

4556 - Updated Efficacy and Safety Results of Patients Receiving Selected 100mg Bezuclastinib Dose and Participating in the Open-Label Extension of Summit: A Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial of Bezuclastinib in Adult Patients with Nonadvanced Systemic Mastocytosis

Boghani, F.

3884 - Hindsight 20/20: The Role of Hemoglobin F in Sickle Cell Retinopathy

Bognar, L.

753 - Identification and Functional Interrogation of Dormant Cancer Stem Cells in JAK2V617F-Driven MPNs

Bognar, T.

4876 - Standard Fludarabine Dosing Results in Overexposure in Young Children Undergoing Hematopoietic Cell Transplantation

Bogner, C.

3238 - Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial

Bogol, V.

1582 - Detection of B Cell Lymphomas By a Simple Epigenetic Blood Test

Bohac, C.

4497 - Plamotamab: First Presentation of Subcutaneous Administration in a Phase 1 Dose Escalation Study in Heavily Pretreated R/R NHL Patients Who Had Prior CAR-T Cell Therapy

Boher, J. M.

1496 - Results of a Phase 1, First-in-Human Study of INA03, an Anti-CD71 Antibody-Drug Conjugate in Patients with Relapsed or Refractory (R/R) Acute Leukemias

Bohers, E.

4353 - Clonal Dominance in Follicular Lymphoma: A Predictor of Poor Prognosis and Histological Transformation
4354 - Circulating Tumor DNA for Primary Mediastinal B-Cell Lymphoma Genotyping: A Prospective Multicenter Study

Bohlaender, F.

1221 - Evaluation of Pharmacokinetics, Efficacy and Safety of a New Human Fibrinogen Concentrate in Patients with Congenital Fibrinogen Deficiency

Bohlander, S. K.

3223 - Clinical Response to Azacitidine in Myelodysplastic Neoplasms Is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor Cells In Vivo

Bohler, S.

442 - Hematological Phenotypes in GATA2 Deficiency Syndrome Arise from Secondary Injuries and Maladaptation to Proliferation

Bohlin, A.

1565 - Resistance to FLT3 Inhibitors in FLT3-Mutated AML Is Associated with CD45RA⁺CD200^-leukemic Cells and Can be Overcome By Combination with SMAC Mimetics
3320 - Outcomes of Relapsed and Refractory Multiple Myeloma with the Evolving Standard of Care

Böhmer, L. H.

4380 - Immunosuppressed Tumor Microenvironment in MYC-Rearranged High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas, Not Otherwise Specified

Bohn, J. P.

4618 - Efficacy and Safety of Acalabrutinib Treatment in Very Old (≥80y) and/or Frail Patients with Chronic Lymphocytic Leukemia (CLL) – Primary Endpoint Analysis of the Phase II CLL-Frail Trial

Bohnenberger, H.

230 - Exploiting TCF3-Driven Oncogenic Circuits in Burkitt Lymphoma

Bohra, A.

1945 - Development of a Three-Gene-Based Proliferation Score (3GPS) to Predict Proliferation Index in Newly Diagnosed Multiple Myeloma
3319 - A Comparative Study of Plasma Cell Detection By Peripheral Smear and Peripheral Blood Flow Cytometry
3340 - Presence of Circulating Tumor Cells on Peripheral Blood Flow Cytometry at Best Response Predicts Overall Survival in Multiple Myeloma

Boiarsky, R.

4637 - Single-Cell Profiling of ~1.7 Million Plasma Cells across >250 Individuals Reveals Transcriptional Signatures of Progression and Clonal Expansion in Multiple Myeloma and Its Precursor Stages

Boibessot, C.

4136 - CD74 Antibody Conjugated to an MCL1 Inhibitor (S227928) Combines Synergistically with Venetoclax to Enhance Killing of Acute Myeloid Leukemia

Boichuk, I.

5156 - Teclistamab in Relapsed and Refractory Multiple Myeloma Patients – Czech Multi-Center Real World Evidence Analysis

Boiko, J. R.

905 - Donor XCR1⁺ and CD11b⁺ Dendritic Cells Determine the Severity of Th1 and Th17-Dependent Acute Gvhd within the Gastrointestinal Tract

Boileau, M.

188 - In Vivo barcoded CRISPR-Cas9 Screen Identifies Ncoa4-mediated Ferritinophagy As a Dependence in Tet2-Deficient Haemopoiesis
4060 - Loss of Negative Metabolic Feedback Drives TET2 Mutant Inflammation

Boiocchi, L.

671 - A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma

Boise, L. H.

249 - Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax
251 - DNA Methylation Analysis of Commpass Reveals Distinct Epigenetic Programs of High-Risk Disease
1359 - Ectopic NSD2 Remodels H3K36me2 and DNA Methylation to Promote Oncogenic Gene Expression in Multiple Myeloma
1892 - Tumor Intrinsic and Antigen-Independent Resistance Mechanisms to Bispecific T Cell Engagers in Multiple Myeloma
4635 - The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma
4663 - Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2

Boissel, N.

227 - Secondary Genetic Alterations and Measurable Residual Disease in Core Binding Factor Acute Myeloid Leukemia - a Study from the Acute Leukemia French Intergroup
731 - Determinants of Isolated CNS Relapse in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia. from Graall-2005 to -2014 Trials
1433 - Characteristics and Outcome Determinants in Children, Adolescents and Young Adults Who Failed Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia
1434 - Switch of Asparaginase Formulation Based on Antibody Monitoring in Adults with Philadelphia-Negative Adult Lymphoblastic Leukemia. Results of the Graall-2014 Trial
2814 - How to Administer Pegaspargase during Induction Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents? Results of the Caall-F01, a Multicentre Randomized Clinical Trial from the French Pediatric Cancer Society (SFCE)
2881 - MP0533 (CD33 x CD123 x CD70 x CD3), a Tetra-Specific CD3-Engaging Darpin for the Treatment of Patients with Relapsed/Refractory AML or MDS/AML: Results of an Ongoing Phase 1/2a Study
3450 - WU-CART-007 (WT-7), an Allogeneic CAR T-Cell Targeting CD7 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Phase 2 Results
4311 - IL-1RAP Is a Targetable Surface Antigen in Relapsed/Refractoy AML
2883.2 - Resolve AML 001: An Adaptive Open-Label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of Cctx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients with r/r AML

Boiten, H. J.

3906 - Comprehensive Analysis of Diagnosis, Treatment and Outcome in a Retrospective Cohort of HES Patients in the South-West of the Netherlands between 2000-2020

Bojanini, L.

1677 - Long-Term Outcomes with Mogamulizumab Alone or in Combination with Other Therapies for the Treatment of Cutaneous T-Cell Lymphoma

Bojarczuk, K.

230 - Exploiting TCF3-Driven Oncogenic Circuits in Burkitt Lymphoma

Boje, A. S.

914 - A Novel Platform Technology for the Development of NK Cell-Based Cellular Immunotherapies
4173 - Preclinical Development of a Novel Humanized and Fc-Engineered Antibody-Drug Conjugate for the Therapy of T-Cell Acute Lymphoblastic Leukemia

Bojesen, S. E.

1087 - Risk of Fractures in Individuals with Hemochromatosis HFE C282Y Homozygosity and in Individuals with Low or High Levels of Plasma Iron, Transferrin Saturation, or Ferritin: A Prospective Study of 142,146 General Population Individuals
3334 - Absolute Risk of Multiple Myeloma Is Quite Modest in Individuals with Incidentally Discovered Vertebral Fractures: A Prospective Cohort Study of 9,065 CT-Scanned Danish General Population Individuals with Independent Validation in a UK General Population Cohort

Bokemeyer, C.

3792d - Activity of CAR-T Cells and Bispecific Antibodies in Multiple Myeloma with Extramedullary Involvement

Bokhari, S. W.

3324 - Impact of Pre-Transplant Depth of Response on Outcomes in Patients with Multiple Myeloma: A Report on Behalf of Pakistan Blood and Marrow Transplant Group

Boklan, J.

2691 - Outcomes of Immunosuppressive Therapy in Children Less Than Three Years of Age with Idiopathic Severe Aplastic Anemia: A North American Collaboration

Bokobza, S.

1609 - Lacutamab in Patients with Relapsed and/or Refractory Sézary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial

Bokun, A.

2362 - Real-World Treatment Patterns and Clinical Outcomes Among Patients with Diffuse Large B-Cell Lymphoma in a US Healthcare Claims Database

Bolanos, L. C.

4572 - The Zymogen Form of Caspase-1 Is Required to Finetune Excessive Cell-Intrinsic Inflammation in Myelodysplastic Syndromes

Bolaños, T. A.

901 - Memory CD4⁺ T Cells Recognize Divergent HLA-DP Immunopeptidomes and Contribute to Leukemia Control after Allogeneic HCT

Bolanos-Meade, J.

1042 - Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis
3551 - Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy

Bolarinwa, A.

1981 - Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience
4635 - The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma
4716 - Evaluating the Interaction between Baseline Risk Stratification, Post-Transplant Measurable Residual Disease, and Long-Term Outcomes in Multiple Myeloma
4728 - Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes

Bolarinwa, D.

3792b - Evaluating Barriers to Enrolment into Multiple Myeloma (MM) Clinical Trials: Results from Health Care Professionals and Patient Survey from the UK Myeloma Research Alliance Equity, Diversity and Inclusivity (EDI) Working Group

Bold, M. S.

2283 - Impact of COVID-19 on Multidisciplinary Lymphoma Tumor Boards: An Analysis of Practice and Care Changes

Bolda, F.

2142 - Improvement of Survival By Use of New Tecniques of Manipulation after Haploidentical Hematopoietic Stem Cell Transplantation: Report of 230 Transplants in Paediatric Patients with Primary Immunodeficiencies and Oncological Diseases

Boldin, M.

348 - Deficit of microRNA (miR)-142 Promotes Transformation of Clonal Myeloid Disorder into Acute Myeloid Leukemia (AML)
2944 - Acquired microRNA (miR)-142 Deficit Drives Immune Escape in Acute Myeloid Leukemia (AML)

Boldorini, R.

854 - A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Ctdna
2960 - Non-Coding Mutations of BCL6 in Classical Hodgkin Lymphoma
2980 - Integration of [¹⁸f]FDG-PET Radiomics with Liquid Biopsy Improves Outcome Prediction in Newly Diagnosed DLBCL Patients

Boldt, A.

1877 - The Differences between Ide-Cel and Cilta-Cel in Relapsed Myeloma at Single Cell Resolution

Bole, D.

2232 - Targeted Non-Viral Gene Delivery through Transcutaneous Ultrasound Enables Robust, Redosable, Titratable, and Durable FVIII and FIX Gene Expression in the Liver in Murine Models

Bolea, L.

3491 - Clinical Impact of Colonization By Multi-Drug Resistant Organisms in Stem Cell Transplantation

Bolen, C. R.

4382 - Highly Heterogeneous Cellular Composition and Neighborhood Architecture within the Follicular Lymphoma Tumor Microenvironment

Boles, A.

4132 - Activating STAT3 Mutations Drive CD38 Expression in T-Large Granular Lymphocytic Leukemia

Boletta, A.

765 - The Mitochondrial Protease Clpp Is a Metabolic Vulnerability and an Immunogenic Trigger Against Multiple Myeloma

Bolis, S.

339 - Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from "FOLL12" Phase III Trial of the Fondazione Italiana Linfomi

Bolkun, L.

2854 - The Premature Reduction of Venetoclax in an Initial Cycle of Ven-AZA Regimen for Unfit AML Patients Leads to Shortened Overall Survival - a Retrospective Study of Polish Adult Leukemia Group (PALG)

Böll, B.

631 - IDH2 Mutations from Clonal Hematopoiesis and Acquired IKZF1 Deletions Define a Novel B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma
840 - Update on GMALL Trial 08/2013 Shows Durable Favorable Outcome of Newly Diagnosed Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) with Imatinib, Dose-Reduced Induction Followed By Stem Cell Transplantation
1440 - Single-Agent Subcutaneous Blinatumomab for Advanced B-Cell Acute Lymphoblastic Leukemia: Long-Term Follow-up from a Phase 1b Dose Expansion Cohort
3054 - Brentuximab Vedotin, Cyclophosphamide, Doxorubicin and Prednisone (B-CAP) First-Line Treatment of Advanced-Stage Hodgkin Lymphoma: Final Results of the GHSG-NLG Phase II Bvb Trial

Bollag, G.

1908 - OPN-6602, an Orally Bioavailable EP300/CBP Bromodomain Inhibitor, Targets Multiple Myeloma through Suppression of IRF4 and MYC

Bollard, C. M.

2067 - A Phase 1 Dose Escalation and Expansion Trial of Third-Generation CD19-Directed CAR T-Cells Incorporating CD28 and Toll-like Receptor 2 (TLR2) Co-Stimulation for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (ENABLE-1)

Bollard, J.

3149 - Retrospective Study to Compare Treatment Outcomes of Asciminib Vs. Ponatinib in 99 Patients with T315I Mutated Chronic Myeloid Leukemia

Bolli, N.

2928 - Intrinsic and Microenvironmental Determinants of AML Response to HMA-Venetoclax Therapy at the Single-Cell Transcriptomic Level
3158 - ASXL1 Mutations at Diagnosis Did Not Impact on the Depth of Molecular Response (MR) and on Treatment-Free Remission (TFR) Eligibility in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Receiving either Nilotinib (NIL) First-Line or Imatinib (IM) with Early Switch to NIL in Case of No Optimal Response in the SUSTRENIM Clinical Trial
4550 - Prognostic Insights on PRE-Fibrotic Primary Myelofibrosis: A Clinical-Pathological Perspective in 762 Patients
4642 - Immune and Tumor Mediators of Resistance to Daratumumab-IMiDs Based Therapies in Relapsed Multiple Myeloma

Bologna, S.

474 - Post-Therapeutic Tumor Losses of B-Cell Receptor Components CD20/CD19, a New Challenge in the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Bolognini, S.

4023 - Fibrinogen and D-Dimer Predict Venous Thromboembolism (VTE) in a Prospective Observational Cohort of Metastatic Breast Cancer Patients

Bolomsky, A.

763 - Proteogenomic Screens Identify Plasma Cell Specific Vulnerabilities to Halt Oncogenic Transcription in Multiple Myeloma

Bolon, Y. T.

692 - Immunopeptidome Divergence between Mismatched HLA Haplotypes and Survival after Haploidentical HCT: A Retrospective Study from the CIBMTR
3672 - Addressing Patient Representation in Hematopoietic Cell Transplant Clinical Trials: Insights Gained through the Access Trial

Bolshakov, E. S.

3610 - Novel Plasma Cell-Free RNA-Based Liquid Biopsy Approach for CLL
4377 - Radiation Therapy and Monocyte Activation in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy

Bolshakova, A. A.

3038 - Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma

Bolton, K.

1285 - Predictive Modeling of Clonal Hematopoiesis across Diverse Cohorts
- Introduction of Germline Context for Clonal Hematopoiesis
- Moderator Introduction

Boluda, B.

1552 - Enhanced Validation of the FLT3-like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in FLT3-ITD Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial
4986 - A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML

Boluda, B.

1512 - Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3-ITD Negative AML
2895 - Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3-ITD–Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial

Bolyard, A. A.

2530 - Genotype-Phenotype Correlations in Patients with Severe Chronic Neutropenia Harboring ELANE Mutations: A Long-Term Study of the Severe Chronic Neutropenia International Registry

Bomba, S. E.

2445 - Educational Impact of Live and Online Enduring CME Activities Presented at the 65^th ASH Annual Meeting on Hematology/Oncology Specialists Evaluated Using Pre-/Post-Education Assessments
2446 - The Effects of an Online Curriculum Based Approach to CME on Hematologist/Oncologists’ Ability to Treat Patients with BTK Inhibitors for Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Bombaci, F.

475 - Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study

Bomben, R.

75 - High IGHV Intraclonal Diversification Identifies CLL with Good Prognosis, Features of Anergy and Specific T-Cell Profiles
339 - Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from "FOLL12" Phase III Trial of the Fondazione Italiana Linfomi
453 - B Cell Receptor Silencing Reveals Origin and Impacts Treatment of High-Grade B Cell Lymphomas with MYC and BCL2 Rearrangements
1577 - TP53, CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial
2975 - Dissecting Diffuse Large B Cell Lymphoma Heterogeneity: New Insights from a State-Specific Molecular Characterization
4362 - Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)

Bompiani-Myers, K.

358 - Combination with Cytotoxic Therapy and Checkpoint Blockade Overcomes Primary Resistance to BCMA Bispecific Antibody Therapy and Leads to Durable Remission of Vk*MYC Multiple Myeloma

Boms, M.

4839 - Influence of Siltuximab for CAR T-Cell Related CRS/Icans on CAR T-Cell Reconstitution, Function, and Clinical Outcomes

Bomsztyk, J.

890 - Defining a New “Mayo Stage IIIc” Ultra Poor Risk Category in Systemic AL Amyloidosis: Incorporating Echocardiographic Global Longitudinal Strain to the European Modified Mayo Staging System

Bona, K.

402 - Pediatric RISE: Development of a Poverty-Targeted Cash Support Intervention for Pediatric Cancer
531 - Real-World Generalizability of Clinical Trial Cytomolecular Features By Race and Ethnicity in Pediatric Acute Myeloid Leukemia (AML)
3649 - Household Material Hardship and Inpatient Days in Dana-Farber Cancer Institute (DFCI) Acute Lymphoblastic Leukemia (ALL) Consortium Trial 16-001
3750 - Public Insurance As a Proxy Measure of Household Poverty-Exposures Among Children with Hematologic Malignancies
5130 - Food Insecurity and Cardiovascular Risk Among Survivors of Pediatric Hematologic Malignancies

Bona, R. D.

157 - Preventing Long-Term Neurologic Disability in Hemophilia (A): Cost-Effectiveness of Emicizumab Prophylaxis for the Prevention of Intracranial Hemorrhage in Infants with Severe Hemophilia (A)
1175 - Correlation of Low Variant Allele Frequency STAT3 Gain-of-Function Mutations and T-Cell Clonality with Cyclic Thrombocytopenia
2584 - Characterizing an Underdiagnosed Condition: Hemophilia in Females

Bonadies, N.

3207 - Preliminary Safety and Efficacy of Luspatercept Initiated at Maximum Approved Dose in Patients with Transfusion Dependent Anemia Due to Very Low, Low and Intermediate Risk MDS with Ring Sideroblasts: First Results of the Lusplus Trial

Bonadonna, P.

3164 - Ultra-Sensitive KIT testing Uncovers Previously Undetected KIT mutations in Patients with Indolent Systemic Mastocytosis: Results from the Pioneer Trial

Bonal, D. M.

64 - Deciphering the AML Niche: RNA Sequencing and Spatial Transcriptomics Reveal Diverse Transcriptomic Landscapes in Responders Vs. Non-Responders
754 - Engrafted JAK2V617F Clone Hijacks Resident Non-Mutated Hematopoietic System to Drive Myeloproliferative Neoplasm

Bonanad Boix, S.

141 - Recombinant ADAMTS13 Prophylaxis in Pediatric Patients with Congenital Thrombotic Thrombocytopenic Purpura: Results from the Phase 3 Randomized, Crossover Study and the Phase 3b Continuation Study

Bonato, A.

759 - Richter Syndrome-Associated Genetic Lesions in TP53 and the Cell Cycle Inhibitors CDKN2A and CDKN2B Induce Transformation of a CD5+ B Cell Subset Characterized By a Restricted IGHV Repertoire, Autoreactivity and BCR Dependence

Bond, C.

2045 - A Layered Cloaking Strategy to Generate Allogeneic iPSC-Derived CD8 T-Cells That Evade NK Clearance
4806 - A Regulated Cytokine Engineering Strategy to Augment in Vitro and In Vivo persistence of Allogeneic iPSC Derived CD8 T-Cells

Bond, D. A.

459 - A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma
746 - MRD-Driven Time-Limited Therapy of Acalabrutinib and Lenalidomide Plus Rituximab (ALR) or Obinutuzumab (ALO) in Patients with Treatment-Naïve Mantle Cell Lymphoma: Phase 2 Trial Outcomes with MRD and cfDNA Analyses
1719 - Nivolumab in Combination with Dose Adjusted (DA) R-EPOCH for First-Line Treatment of Large B-Cell Lymphoma: Results from a Phase II Trial
3245 - A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL
3446 - Association between Post-CART Terminal Complement Complex Levels and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
3737 - Impact of Baseline Osseous Involvement on Outcomes in Patients with Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom’s Macroglobulinemia (WM)
3747 - Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy Is Associated with Inferior Survival for Patients with Relapsed or Refractory Large B-Cell Lymphoma
4415 - A Phase I/II Study of Tazemetostat Combined with Abbreviated Rituximab/Bendamustine Therapy for High Tumor Burden Follicular Lymphoma in Frontline Treatment: A Big Ten Cancer Research Consortium Study
4460 - Patterns of Use and Outcomes of Novel Agents in Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Single-Center Retrospective Analysis
4507 - Steroid Prophylaxis in Patients Receiving CAR T-Cell Therapy for Relapsed and Refractory Non-Hodgkin Lymphoma
5099 - Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy
4422.1 - A Phase 1 Study of AC676, a Novel BTK Chimeric Degrader, in Patients with B-Cell Malignancies

Bond, J.

4161 - Using Structure-Based Modeling to Identify Effective Drug Combinations in RAS-Mutant Acute Myeloid Leukemia

Bondielli, G.

1854 - Treatment with Venetoclax Positively Modulates Immunological Parameters and T-Cell Features in Patients with Chronic Lymphocytic Leukemia

Bone, K.

3459 - Cytogenetic Abnormalities Following CAR T Cell Therapy for B-Cell Malignancies

Bonfim, C.

374 - Critical Care Support in Infants Post-Allogeneic HCT: Large Single-Center Cohort Experience
1158 - Cultured Thymus Tissue Implantation for Congenital Athymia Post FDA Approval: Auto-Immunity and Novel Genetic Mutations

Bongarzoni, V.

4699 - Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials
5153 - Pomalidomide, Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Lenalidomide and Anti-CD38 Monoclonal Antibodies: A Multicentric Italian Retrospective Study

Bonham, V. L.

1068 - A Holistic Approach to Sickle Cell Disease Severity Using Patient-Reported Outcomes

Boni, C.

4090 - Eif6 Dosage Alleviates Activation of the Tp53 Pathway in Sbds-Deficient Cells: A Mechanism for Somatic Genetic Rescue in Shwachman-Diamond Syndrome

Bonifacino, A.

516 - CD117 Antibody Conditioning and Multiplex Base Editing Enable Rapid and Robust Fetal Hemoglobin Reactivation in a Rhesus Autologous Transplantation Model

Bonifacio, G.

733 - Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial

Bonifacio, M.

4569.1 - Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis

Bonifacio, M.

113 - Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia
245 - Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition
835 - Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820
992 - Molecular Outcome of Chronic Myeloid Leukemia Affected Patients Not in Deep Molecular Response: The “Others” from the Gimema Labnet Network
1772 - Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50 – 60 Years: A “Campus CML” Study
1778 - Treatment-Free Remission in CML Patients Discontinuing Post-First Line Therapy
2836 - Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial
3155 - CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or ≤ 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study
3158 - ASXL1 Mutations at Diagnosis Did Not Impact on the Depth of Molecular Response (MR) and on Treatment-Free Remission (TFR) Eligibility in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Receiving either Nilotinib (NIL) First-Line or Imatinib (IM) with Early Switch to NIL in Case of No Optimal Response in the SUSTRENIM Clinical Trial
3162 - Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: Observational Study of 673 Patients in Italy
4532 - Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact Project, a CML Campus Study
4535 - Probability of Switch of TKIs Treatment According to Baseline Features in a Large Chronic Myeloid Leukemia (CML) Population: Italian CML Network

Bonifant, C. L.

2817 - Role of B Cell Recovery in Relapse Risk and CD19 Phenotype Following Real-World Use of Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia: A Multi-Institutional Retrospective Study

Bonifay, V.

1949 - Clonotypic Peptide Mass Spectrometry to Define Functional Cure in Patients with Multiple Myeloma Undergoing Maintenance Cessation

Bonifazi, F.

1132 - Analysis of the Pilot Study of the International Hemoglobinopathy Research Network (INHERENT)

Bonifazi, F.

2126 - Evidence-Based Choice of Conditioning Regimen for Hematopoietic Stem Cell Transplantation (HSCT) in Acute Leukemia: The Italian Cellular Therapy and Stem Cell Transplant Group (GITMO) Guidelines
2893 - Venetoclax and Azacitidine for Relapse Prevention in NPM1-Mutated Acute Myeloid Leukemia in Molecular Failure: Results from the Ongoing Gimema AML2521 Phase 2 Trial
4786 - High Ferritin and C-Reactive Protein Levels Result in Poor Clinical Outcome in R/R Large B-Cell Lymphoma Patients Despite Significant Anti-CD19 CAR-T Cell In Vivo Expansion
4895 - Separation of Gvl Effects from GvHD with Ptcy-Based Gvhd Prophylaxis in Mmud Transplantation: A Study from the ALWP of the EBMT

Bonig, H.

433 - Hematopoietic Differentiation from Single Codon Perspective

Bonilla, G. M.

1354 - AML Stem Cell Clearance By Inhibiting Selenoprotein Biosynthesis That Causes Cgas-Sting Activation and Ferroptosis

Bonini, C.

607 - Tisagenlecleucel for the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: An Interim Report of the European Post-Authorisation Safety Study Conducted By EBMT

Bonkovsky, H. L.

1089 - Results from the Aurora Study: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Bitopertin in Erythropoietic Protoporphyria

Bonnafous, C.

1609 - Lacutamab in Patients with Relapsed and/or Refractory Sézary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial

Bonnal, R.

453 - B Cell Receptor Silencing Reveals Origin and Impacts Treatment of High-Grade B Cell Lymphomas with MYC and BCL2 Rearrangements

Bonnal, R.

2834 - CD19 CAR T Cells Drive a Remodeling of the Immune Microenvironment Associated with T-Cell Dysfunction in Acute Lymphoblastic Leukemia

Bonnard, A.

2522 - Effect of Rituximab on Spleen and Blood B-Cell Subpopulations in Allo-Immunized Children with Sickle Cell Anemia

Bonneau-Lagacherie, J.

1592 - Circulating Cell-Free DNA in Classical Hodgkin Lymphoma in Children, Adolescents and Young Adults. Results from the Holy Study, a French Ancillary Study of Euronet PHL-C2 Protocol

Bonner, A.

3130 - Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Second-Line (2L) Treatment of Patients (pts) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL): Update with 34 Months of Liso-Cel Follow-up

Bonner, E. A.

344 - MDS-Associated SF3B1 Mutations Promote Aberrant Hematopoietic Cell Fate Choice By Disrupting Mediator Kinase Module Component CDK8

Bonnet, C.

575 - Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase 3 Gained Study Conducted By Lysa

Bonnet des Claustres, M.

2793 - APR-246 Overcomes Resistance to Asparaginase in Lymphoid Malignancies By Targeting Metabolic Cell Vulnerabilities

Bonnet, S.

731 - Determinants of Isolated CNS Relapse in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia. from Graall-2005 to -2014 Trials

Bonneville, E. F.

4894 - Decreased Chronic GvHD with Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelofibrosis Allografted with Unrelated Donor: A Study from the Chronic Malignancies Working Party of the EBMT
4907 - The Use of MSCs in Steroid-Refractory Acute GvHD in Europe: A Survey from the EBMT Cellular Therapy & Immunobiology Working Party

Bonney, D.

4206 - Bridging Pediatric B-Cell Acute Lymphoblastic Leukemia (ALL) Patients to CAR-T Cell Therapy: A National Perspective

Bono, C.

339 - Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from "FOLL12" Phase III Trial of the Fondazione Italiana Linfomi
4362 - Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)

Bonolo De Campos, C.

3271 - The Immune Inhibitory Hematopoietic Adaptor Protein Hacs1(Sly2) Suppresses the Proinflammatory Macrophage Function Contributing to Multiple Myeloma Progression
3338 - Cell-Free DNA Whole Genome Sequencing for Non-Invasive MRD Detection in Multiple Myeloma

Bonometti, A.

105 - Enhancing Personalized Prognostic Assessment of Myelodysplastic Syndromes through a Multimodal and Explainable Deep Data Fusion Approach (MAGAERA)
1681 - Bendamustine in Combination with Gemcitabine and Vinorelbine As Salvage Regimen for Relapsed or Refractory Peripheral T-Cell Lymphomas: A Retrospective Single Center Experience
3597 - The “David Vs Goliath” Study: Application of Large Language Models (LLM) for Automatic Medical Information Retrieval from Multiple Data Sources to Accelerate Clinical and Translational Research in Hematology
3598 - Artificial Intelligence-Powered Digital Pathology to Improve Diagnosis and Personalized Prognostic Assessment in Patient with Myeloid Neoplasms
4989 - An Artificial Intelligence-Based Federated Learning Platform to Boost Precision Medicine in Rare Hematological Diseases: An Initiative By GenoMed4all and Synthema Consortia

Bonon Assis, T. O.

3692 - Impact and Aggravating Factors of Chronic Pain in Sickle Cell Disease: Results of the Analysis of Promis® Questionnaires and the Metabolomic Profile of Brazilian Adult Patients

Bonotis, P.

2358 - Improving Quality of Life Based on Electronic Patient Reported Outcomes in Patients with CLL and MDS: The Mypal Study

Bonuomo, V.

1778 - Treatment-Free Remission in CML Patients Discontinuing Post-First Line Therapy

Bonuomo, V.

3162 - Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: Observational Study of 673 Patients in Italy

Bonzheim, I.

859 - Bortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First – Line Treatment for Waldenström’s Macroglobulinemia: Results of the Multicenter Phase II trial (ECWM-2) of the European Consortium for Waldenström’s Macroglobulinemia

Boo, Y. L.

3529 - Haploidentical Transplant Using Selective Ex-vivo TCR-Αβ Depleted and Upfront Memory T-Cell Add-Back Is Associated with Lower Chronic Gvhd and More Favorable Gvhd-Free/Relapse-Free Survival As Compared to Matched Related and Unrelated Donor Transplant for Adults with Hematological Malignancies

Boocock, D. J.

2911 - Multi-Omic Analyses of TP53-Mutated Acute Myeloid Leukemia Identify Prognostic Metabolic Signatures

Bookens, S.

4804 - Engineered T Regulatory Cells for Malignancy Associated Vascular Inflammation

Booker, N.

3687 - Exploring What Makes Sickle Cell Patients Feel Cared for & Opportunities for Improvement through a Qualitative Lens

Bookhart, B.

697 - Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients with Pulmonary Embolism and Right Ventricular Dysfunction

Boon, L.

3402 - Allogeneic Hematopoietic Cell Transplantation Promotes Atherosclerosis in Mice Driven By Donor CD8+ T Cells

Boonstra, P.

3379 - Phase 2 Study Using Minimal Residual Disease-Driven Adaptive Strategy in Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy – First Report from the Maestro Trial

Boonstra-Schelfhorst, M.

3108 - Brigatinib Monotherapy in Children with R/R ALK+ ALCL, IMT, or Other Solid Tumors: Updated Results from the Brigaped (ITCC-098) Phase 1 Dose-Escalation Study

Boorgula, M. P.

3273 - Multiple Myeloma Persister Cells Surviving Bispecific Antibodies and CAR-T Cells Exhibit New CD45+ Expression

Boot, J.

4445 - Delays to Diagnosis of Peripheral T-Cell Lymphoma and Clinical Utility of Molecular Profiling: A UK Multicentre Real-World Study

Booth, C.

2281 - Patient Preferences on Clinical Decision-Making in Myeloma: A 747-Patient Survey

Booth, C.

1051 - Ex Vivo Lentiviral Hematopoietic Stem Cell (HSC) Gene Therapy May Represent a Curative Therapy for the Life-Threatening Inborn Error of Immunity Severe Combined Immunodeficiency Due to Adenosine Deaminase (ADA) Deficiency (ADA-SCID)
3639 - International Clinical Consensus on Leukocyte Adhesion Deficiency-I: A Modified Delphi Analysis
5079 - Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Outcomes in Leukocyte Adhesion Deficiency Type -I

Booth, L.

2550 - A Freeze-Dried Platelet-Derived Hemostat Decreases Bleeding in a Novel Murine Model of Type 1 Hermansky-Pudlak Syndrome

Boothby, A.

22 - Anti-HLA Antibody Specificities Are Differentially Associated with Immune Platelet Transfusion Refractoriness in Patients at Lower Calculated Panel Reactive Antibody (cPRA) Levels
124 - T-Cell Transcriptomic Signatures in Adults with Primary Untreated Immune Thrombocytopenia Segregate By Age, Revealing Distinct Druggable Pathways
3919 - Expanding the Role of SH2B3: T Cell Large Granular Lymphocytosis (LGL) and Common Variable Immune Deficiency in the Setting of Biallelic SH2B3 Mutations

Boquimpani, C.

4526 - Asciminib Shows High Efficacy and Favorable Tolerability at 80 Mg Once Daily and 40 Mg Twice Daily in Patients with Chronic Phase Chronic Myelogenous Leukemia Previously Treated with 2 or More Tyrosine Kinase Inhibitors: Primary Analysis from the ASC4OPT Study

Borate, U.

Borbaran Bravo, N. A.

417 - Autosomal Recessive COPZ1 Mutations Cause Isolated Severe Neutropenia or Complex Syndrome with Severe Neutropenia

Borchert, C.

1831 - Progression of Myelodysplastic Syndromes in the MDS Natural History Study (MDS NHS)
4597 - Association between Smoking Intensity, Genetic Mutations, and Disease Progression in Myelodysplastic Syndromes

Borchiellini, A.

710 - A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3

Borchmann, P.

367 - Targeting Lymphoma Associated Myeloid-Monocytic Cells through CSF1R Blockade Enhances CAR-T Cell Response in Aggressive B Cell Lymphoma
566 - Metabolic Tumor Volume after Two Cycles of Chemotherapy in Patients Treated for Advanced-Stage Hodgkin Lymphoma: Analysis of the German Hodgkin Study Group Phase III HD18 and HD21 Trials
568 - PET-Guided Brecadd in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma: Results of the Phase 2 Part of the GHSG HD21 Trial
1662 - Patient-Reported Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classical Hodgkin Lymphoma Treated with BrECADD and eBEACOPP in the HD21 Trial
2346 - Estimation of Health State Utility Values for Patients Undergoing First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the HD21 Trial
3044 - Serum TARC Dynamics Correlate with Clinical Response and Metabolic Tumor Volume during Anti-PD1-Based First-Line HL Treatment in the GHSG Phase II Nivahl Trial
3050 - Patterns of Disease in Early Stage Favorable Hodgkins Lymphoma
3054 - Brentuximab Vedotin, Cyclophosphamide, Doxorubicin and Prednisone (B-CAP) First-Line Treatment of Advanced-Stage Hodgkin Lymphoma: Final Results of the GHSG-NLG Phase II Bvb Trial
4355 - Lymphovista HL - a Validated Assay for Genotyping and MRD Assessment in Hodgkin Lymphoma
4387 - Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up
4426 - Impact of Treatment-Related Morbidity on Health-Related Quality of Life in Patients with Advanced-Stage Classical Hodgkin Lymphoma Receiving Multiagent Therapy: Findings from the HD21 Study
4428 - Abscopal Effect of Radiotherapy and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Results of the International GHSG Phase II Aern Trial
1674.2 - PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies

Borchmann, S.

367 - Targeting Lymphoma Associated Myeloid-Monocytic Cells through CSF1R Blockade Enhances CAR-T Cell Response in Aggressive B Cell Lymphoma
4355 - Lymphovista HL - a Validated Assay for Genotyping and MRD Assessment in Hodgkin Lymphoma

Borda Molina, A.

1943 - Prognostic Impact of Measurable Residual Disease Evaluated By Next Generation Flow and PET-CT in Clinical Practice at Fundación Santa Fe De Bogotá Hospital, Colombia

Bordeleau, L.

4878 - Patient Characteristics and Outcomes of Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease in Allogeneic Stem Cell Transplant Patients - a Multicenter Canadian Study

Borden, S.

2287 - Supportive Care Utilization in Patients with Multiple Myeloma—a Single Center Retrospective Study
4702 - Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes

Borderon, L.

752 - Amplification of Von Willebrand Factor-Positive CALR^mut Disease-Initiating Hematopoietic Stem Cells Is Associated to the Activation of the PERK/EiF2a Branch of Unfolded Protein Response

Borducchi, D. M.

983 - Refining Prognostication in Peripheral T Cell Lymphoma (PTCL): A Risk-Adapted Prognostic Model for Patients with Limited-Stage PTCL
1687 - Clinical Features, Therapy Patterns and Survival Outcomes of Limited-Stage Peripheral T-Cell Lymphomas: A Cross-Continental Study

Borel, C.

4903 - Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe

Borelli, G.

2093 - Comparison of Cryopreserved Versus Non-Cryopreserved Strategies for Autologous Stemcell Transplantation in Multiple Myeloma in Two Centers in Uruguay

Borg, J.

2722 - STAT3-VDAC1 Axis Modulates Mitochondrial Function and Plays a Critical Role in the Survival of Leukemic Stem Cells

Borgel, D.

3839 - Protein S Enhances the Phagocytosis of Phosphatidylserine-Positive Erythrocyte: Implications for the Erythrocytes Turnover

Borges, C. M.

3421 - In Vitro and In Vivo Activity of a Lipid Nanoparticle System for the In Vivo Generation of CAR T Cells

Borges, P.

1059 - Multimodal Spatial Transcriptomic Profiling Elucidates Niche-Specific Dynamics in Medullary and Extramedullary Acute Myeloid Leukemia
4818 - Cord-Derived Invariant Natural Killer T Cells As Novel Cell Therapy to Improve the Outcome of Hematopoietic Stem Cell Transplantation

Borghero, C.

4949 - Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Neoplasms with Accompanying Paroxysmal Nocturnal Hemoglobinuria – a Study on Behalf of Cmwp and Saawp of the EBMT

Borgonia, D.

126 - NT-I7, a Long-Acting Interleukin-7 Molecule, Promotes T Cell Reconstitution Following Radiation Injury through Thymic-Dependent and Independent Pathways

Borhan, R.

2250 - Bridging the Gap for Sickle Cell Disease Patient Data in Sub-Saharan Africa By Expanding Access to Specialty Biomarkers and Clinical Trials

Borhany, M.

3324 - Impact of Pre-Transplant Depth of Response on Outcomes in Patients with Multiple Myeloma: A Report on Behalf of Pakistan Blood and Marrow Transplant Group

Borie, D.

2073 - CD19-Directed CAR T Cell Therapy in 4 Patients with Refractory Multiple Sclerosis

Bories, C.

731 - Determinants of Isolated CNS Relapse in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia. from Graall-2005 to -2014 Trials
2424 - Treatments and Outcomes of Adult Patients with AML in the Real-Life – First Report of the French Observational ALFA-PPP Study

Bories, J. C.

4760 - Immunological Predictive Markers of Response to Idecabtagene Vicleucel Therapy in Multiple Myeloma : A Real-World Experience from St Louis Hospital (France)

Bories, P.

215 - Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations
1496 - Results of a Phase 1, First-in-Human Study of INA03, an Anti-CD71 Antibody-Drug Conjugate in Patients with Relapsed or Refractory (R/R) Acute Leukemias
4765 - Prognostic Value of Positron Emission Tomography/Computed Tomography in Multiple Myeloma Patients Treated with Ide-Cel CAR-T Cell Therapy: Preliminary Results of a Real-World IFM Study from the Descar-T Registry (CAR MY PET)

Bories, P.

738 - Engaging Innate Immunity By AFM28, an Innate Cell Engager (ICE^®) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study
1976 - Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible or with No Immediate Intent for Transplant: Long-Term Efficacy and Safety in a Phase 1b Study
2881 - MP0533 (CD33 x CD123 x CD70 x CD3), a Tetra-Specific CD3-Engaging Darpin for the Treatment of Patients with Relapsed/Refractory AML or MDS/AML: Results of an Ongoing Phase 1/2a Study
3018 - Golcadomide (GOLCA) ± Rituximab (RTX) Demonstrates Durable Efficacy and Is Well Tolerated in Patients (pts) with Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Results from the Phase 1/2 CC-99282-NHL-001 Study
3129 - A Real-World Weighted Comparison of Tisagenlecleucel and Axicabtagene Ciloleucel CAR T Cells in Relapsed or Refractory Diffuse Large B Cell Lymphoma Aged 75 Years and Older : A Lysa Study from the Descar-T Registry
3370 - First Results from the Dose Escalation Part of the Phase 1 Study of KTX1001, an Oral, First-in-Class, Potent Inhibitor of MMSET/NSD2 for Relapsed/Refractory Multiple Myeloma (RRMM)

Borin, C.

204 - Hnrnpc and m⁶a RNA Methylation Control Oncogenic Transcription and Metabolism in T-Cell Leukemia

Borin, L.

3800 - Myelodysplastic Neoplasms Patients’ and Caregivers’ Unmet Needs and Their Impact on Their Quality of Life and Symptoms

Borin, L. M.

1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features

Borisenkova, E.

3332 - The Impact of Circulating Plasma Cells on Overall Survival (OS) in Patients with Newly Diagnosed Multiple Myeloma (MM) - Results of a Multicenter Study

Borisenkova, E.

4614 - Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax

Borisov, V.

3425 - Divergent Population Dynamics and Gene Signaling in Monocytes Distinctly Influence Responses to CD19-Targeted CAR T-Cells in Relapsed/Refractory B-NHL

Borja Montes, O.

2311 - Opioid Overdose in Patients with Sickle Cell Disease, Outcomes Among Hospitalized Patients in the United States: A Nationwide Analysis

Borji, M.

379 - Heterogeneity of PD-1⁺regulatory T Cells after Low-Dose IL-2 Therapy for Patients with Chronic Graft-Versus-Host Disease
910 - A Clonally Expanded Nodal T Cell Population Diagnosed As T Cell Lymphoma after CAR-T Therapy

Borkhardt, A.

1160 - Immune Training Enhances Anti-Viral Responses and Improves Outcomes in Pax5^-/+ Mice Susceptible to Chronic Infection
3563 - Addition of Anti-T-Lymphocyte-Globuline As Graft Versus Host Disease Prophylaxis for Matched Unrelated Donors Equalizes Outcomes with Matched Sibling Donors: Results from the AML SCT-BFM 2007 Trial

Borlenghi, E.

113 - Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia
835 - Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820
838 - Immunomodulatory Effect of Dasatinib Plus Blinatumomab Versus Ponatinib Plus Blinatumomab in Newly Diagnosed Ph⁺ Acute Lymphoblastic Leukemia Patients
1523 - Disease Course and Treatment Patterns of Acute Myeloid Leukemia with FLT3 Mutations and Myeloid Sarcoma Reveal High Efficacy of Gilteritinib: A Multicentric Retrospective Study
1574 - Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML
2836 - Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial
2849 - CPX-351 Induces High Rate of Complete Remission in the New ICC/ELN 2022 Adverse-Risk Entity ‘AML with MDS-Related Gene Mutations’: Evidence from a Large Real-World Italian Study
2863 - Venetoclax and Hypomethylating Agents Confirmed to be Standard Therapy in De Novo and ELN17 Not Adverse Acute Myeloid Leukemia Patients, Unfit for Chemotherapy According to SIE/Sies/GITMO Criteria. a Multicentric Real-Life Study on 379 Patients, By the Hematological Network Rete Ematologica Lombarda (REL)
4473 - Impact of MYC Alterations in De Novo and Transformed Large B-Cell Lymphoma: An Italian Single Center Experience
5188 - Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results

Born, P.

1877 - The Differences between Ide-Cel and Cilta-Cel in Relapsed Myeloma at Single Cell Resolution

Bornhaeuser, M.

1822 - Supervised Machine Learning Predicts Transformation Risk and Key Features throughout the Patient Journey in Myelodysplastic Neoplasms
2948 - HLA‑DR Expression on Leukemic Progenitor Cells before Allogeneic Hematopoietic Cell Transplantation Adds Prognostic Value in the Presence of MRD

Bornhauser, B.

314 - Role of Stem-like Cells in Chemotherapy Resistance and Relapse in Pediatric T Cell Acute Lymphoblastic Leukemia (T-ALL)
318 - Drug Sensitivity and Treatment Response Are Modulated By the Cell of Origin, the Underlying Gene Fusion, and Patient Age in KMT2A-Rearranged BCP-ALL

Bornhäuser, M.

776 - Follow-up of the Randomized ASAP Trial Shows No Survival Advantage for Patients with Poor Responsive or Relapsed AML Who Received Intensive Salvage Chemotherapy for Remission Induction Prior to Allogeneic Transplantation Compared to Immediate Allogeneic Transplantation
944 - Clonal Haematopoiesis with TP53 Mutations Exhibits Abnormal Erythropoiesis and Erythroid Metabolic Stress
1057 - Synthetic Bone Marrow Smears Are a Privacy-Preserving Substitute for Developing Accurate Leukemia Classification Models in Hematological Microscopy
1563 - ACSL4-Associated Lipid Metabolism Is a Distinct Therapeutic Vulnerability in KMT2A-Rearranged Acute Myeloid Leukemia
2179 - Outcome after Allogeneic Stem Cell Transplant in Adults with Inherited Myeloid Malignancies – a Multicenter Retrospective Analysis on Behalf of the German Cooperative Transplant Study Group
2211 - Age-Stratified Game-Theory-Informed Machine Learning of Molecular Alterations Unveils Prognostic Divergence in 3062 Pediatric and Adult Acute Myeloid Leukemia Patients
2917 - Deep Learning Predicts Response to Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia Solely Based on Bone Marrow Smear Image Data
2934 - The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients
3554 - Impact of Allogeneic Hematopoietic Cell Transplantation Post-Sars-Cov-2 Infection: A Retrospective Analysis By the German Cooperative Transplant Study Group
3558 - Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques
4337 - Clonal Dynamics of Leukemic and Clonal Hematopoiesis Mutations Predict Relapse in Single Cell MRD Analysis of AML in First Complete Remission
4907 - The Use of MSCs in Steroid-Refractory Acute GvHD in Europe: A Survey from the EBMT Cellular Therapy & Immunobiology Working Party
4975 - Autonomous Region-of-Interest Detection, Cell Segmentation and Cell Classification in Bone Marrow Cytomorphology Using Deep Learning
1527.1 - Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1-Mutated AML – the SAL/AMLCG Vincent Trial

Borogovac, A.

459 - A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma
3636 - Uncovering Root Causes Underlying Gaps in the Evaluation and Integration of the Latest Clinical Evidence in Congenital Thrombotic Thrombocytopenic Purpura: Key Findings from a National Hematology Care Team Survey
1742.1 - A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Boros, S.

3793 - Real-World Comparison of Outcomes of Patients Treated with HMA Monotherapy Versus HMA-Ven – Insights from 1634 Patients Included within the Austrian Myeloid Registry of the AGMT Study Group

Borowitz, M. J.

2797 - Examining Disparities By Race, Ethnicity, and Socioeconomic Factors in Children and Young Adults with Relapsed Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
2813 - Utility of a Second Interim Maintenance Phase to Improve Outcomes for Pediatric Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group

Borrill, R.

3455 - Reproducible Transient, Significant, Early Donor-Derived T-Cell Expansion, Induced By Pooled Granulocyte Transfusion, during Mismatch T-Cell Replete Cord Blood Transplant - an Optimal Platform for Allogeneic Graft Versus Leukaemia: Results of a Prospective Phase I/II Clinical Trial

Borsatti, E.

854 - A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Ctdna
2960 - Non-Coding Mutations of BCL6 in Classical Hodgkin Lymphoma

Borsotti, C.

3956 - Role of Factor VIII As a Regulator of Angiogenesis and Promoter of Endothelial Barrier Stability

Borsotti, C.

2571 - Extracoagulative Role of FVIII: Impact on in Vitro and In Vivo Murine Bone Cell Differentiation and Function

Borsotti, C.

3991 - Role of Factor VIII in Angiogenesis, Vessel Stability and the Regulation of Extracellular Matrix Proteins

Borst, A. J.

- Targeted Medical Therapies for Vascular Anomalies

Borthakur, G.

Borthakur, G.

1816 - Distinct Impact of Platinum Chemotherapies on the Fitness and Genome of Hematopoietic Stem Cells and the Risk of Therapy-Related Myeloid Neoplasms

Bortolotti, M.

3844 - Mixed Type Autoimmune Hemolytic Anemia: A Single Center Observational Study
4076 - Aplastic Anemia in the Elderly: Treatment Patterns and Outcomes from an International Observational Study

Bortoluzzi, S.

65 - Identification of Genomic Structural Variants (SVs) with Adverse Prognostic Significance in Normal-Karyotype (nk) Acute Myeloid Leukemia (AML) Patients

Bortucchi, D.

1692 - The Number of Extranodal Sites Matters! a Proposal for a Feasible Prognostic Model in Nodal PTCL. a Collaborative Study grupo De Estudio Latino-Americano De Linfoproliferativos (GELL) & T-Cell Brazil Project (TCBP)
3064 - Central Nervous System Involvement in Aggressive ATLL: Can We Predict the Risk in a Devastating Complication? Epidemiology and Clinical Features from Latin America. a Collaborative Study from Grupo De Estudio Latino-Americano De Linfoproliferativo (GELL) & T-Cell Brazil Project (TCBP)

Boruchov, D.

617 - Community Health Worker Engagement with Adolescents and Young Adults with Sickle Cell Disease: Findings from the Comets Study
1066 - Community Health Worker and Mobile Health Programs to Help Young Adults with Sickle Cell Disease Transition to Using Adult Healthcare Services -- the Comets Study; Results from Patient-Reported Outcomes at 6 Months

Bos, J.

1112 - Iron Deficiency in HbSC Disease Is Associated with Less Sickle Cell Disease-Related Complications – a Rationale for Repetitive Phlebotomy As Disease Modifying Therapy
3831 - Satisfy: A Eurobloodnet Multicenter, Single-Arm Phase 2 Trial of Mitapivat in Adult Patients with Erythrocyte Membranopathies and Congenital Dyserythropoietic Anemia Type II – Results from the 8-Week Dose-Escalation Period

Boscaro, E.

113 - Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia

Bosch, F.

988 - Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study
1646 - Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma

Bosch, F.

597 - Donor Cell-Derived Hematologic Neoplasms: Role of Germline Predisposition and Clonal Hematopoiesis
666 - Newly Developed Prognostic Score for Myelodysplastic Syndrome (MDS) with Isolated 5q Deletion (IPSS-del(5q))
886 - BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
990 - Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072
1616 - EO2463 Peptide Immunotherapy in Patients with Indolent NHL: A Phase 1 Exploration of a Response Biomarker for EO2463 Monotherapy and EO2463 in Combination with Lenalidomide/Rituximab
1658 - Immunotherapy May be Preferable to Chemotherapy As Second-Line Treatment for POD24 Follicular Lymphoma (FL) Patients
1698 - Clinical Characteristics and Outcomes of Patients with Localized Stage High-Grade B-Cell Lymphoma (HGBCL) with or without MYC and BCL2 and/or BCL6 Rearrangements: A Retrospective Study from the Spanish Group Geltamo
1935 - Ultra-Deep Sequencing of TP53 in Multiple Myeloma: Double-Hit Prevalence and Clinical Phenotype
2708 - Genomic Instability in Early-Onset Myelodysplastic Syndrome Patients Harboring Rare Germline Variants in NHEJ DNA Repair Genes
2803 - Single Center Experience Combining Multiple Tools for Genetic Diagnosis of B-Cell Acute Lymphoblastic Leukemia
3009 - Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma
3214 - The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms
4012 - Reduce Dose of Apixaban Vs. Standard of Care for Secondary Prevention in Cirrhotic Patients with Chronic Portal Vein Thrombosis
4186 - Clinical Outcomes of Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Autologous Chimeric Antigen Receptor T-Cell Therapy: A Meta-Analysis of 1,154 Patients Included in Clinical Trials
4395 - EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study
4619 - Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study

Bosch, M.

1935 - Ultra-Deep Sequencing of TP53 in Multiple Myeloma: Double-Hit Prevalence and Clinical Phenotype

Bosch, M.

1658 - Immunotherapy May be Preferable to Chemotherapy As Second-Line Treatment for POD24 Follicular Lymphoma (FL) Patients

Bosch, N.

2241 - Validation of ICD-10 Codes for Identifying Acute Chest Syndrome in Patients with Sickle Cell Disease

Bosch-Vilaseca, A.

1027 - Early Safety and Efficacy of CAR-T Cell Therapy in Precursor Myeloma: Results of the CAR-PRISM Study Using Ciltacabtagene Autoleucel in High-Risk Smoldering Myeloma
1045 - Feasibility, Safety and Efficacy of Oral Maintenance Therapy with Venetoclax Plus Decitabine/Cedazuridine after Venetoclax Plus FluBu2 for High Risk MDS/AML Undergoing RIC Allo-HCT

Boschert, T.

1890 - Tumor Reactive T Cells Drive Clinical Responses to Multiple Myeloma

Boscoe, A.

3696 - Clinical Monitoring Practices Among Adult Patients with Pyruvate Kinase Deficiency Who Have Never Been Transfused

Bose, P.

4569.1 - Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis

Bose, P.

219 - A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update
483 - Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis
655 - Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients
657 - A Phase 1b Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia
658 - Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study
999 - A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib
1760 - Temporal Dynamics of Bone Marrow Fibrocytes in the Progression of Primary Myelofibrosis
1800 - Adolescents and Young Adults (AYA) with Myeloproliferative Neoplasms (MPNs): Analysis of Patient Outcomes and Impact of High-Molecular Risk Mutations
1807 - Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocytopenia and Polycythemia Vera: Final Analysis Focused on the Two Diseases
1855 - Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10^-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL
2857 - Incidence, Characteristics, and Outcomes of Patients with Newly Diagnosed, De Novo KIT-Mutated Non-Core Binding Factor Acute Myeloid Leukemia without Systemic Mastocytosis
3142 - Evaluation of the Lethal Activity and Its Mechanism of Tasquinimod in Advanced Myeloproliferative Neoplasm (MPN) in Blastic Phase
3178 - Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor–Naïve Patients with Myelofibrosis
3179 - Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor
3817 - Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods
4556 - Updated Efficacy and Safety Results of Patients Receiving Selected 100mg Bezuclastinib Dose and Participating in the Open-Label Extension of Summit: A Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial of Bezuclastinib in Adult Patients with Nonadvanced Systemic Mastocytosis
4601 - A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome
1808.1 - Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-Label, Phase 3 Trial
3147.1 - A Multicenter, Open-Label, Phase 1 Clinical Trial of AJ1-11095 Administered As Oral Monotherapy in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed By a Type I JAK2 Inhibitor (JAK2i)
3191.2 - Odyssey: A Phase 2 Open-Label Study of Momelotinib in Combination with Luspatercept in Patients with Transfusion-Dependent Myelofibrosis

Bose, R.

2287 - Supportive Care Utilization in Patients with Multiple Myeloma—a Single Center Retrospective Study
5194 - Outcomes with Real-World Use of Azacitidine and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Are Comparable to Long-Term Viale-a Results

Boselli, D.

458 - PET-Directed Therapy with ABVD Vs. Bv+AVD Followed By Nivolumab in Patients with Early Stage Hodgkin Lymphoma: A Propensity Score Matched Analysis of CALGB50604 and ACCRULY1601
5194 - Outcomes with Real-World Use of Azacitidine and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Are Comparable to Long-Term Viale-a Results

Bosi, A.

65 - Identification of Genomic Structural Variants (SVs) with Adverse Prognostic Significance in Normal-Karyotype (nk) Acute Myeloid Leukemia (AML) Patients

Bosi, A.

1696 - Post-Transplant Lymphoproliferative Disorders (PTLD) in a Referral Center

Bosi, C.

3800 - Myelodysplastic Neoplasms Patients’ and Caregivers’ Unmet Needs and Their Impact on Their Quality of Life and Symptoms

Bosler, D. S.

2868 - Outcomes of Blast-Phase MPN and JAK2, MPL, and CALR Mutated de Novo AML Compared to AML with Wild-Type JAK2, MPL, and CALR Genes: A Propensity Score-Adjusted Cohort Study

Bosler, D. S.

1328 - Genomic Landscape of Germline RUNX1 variants in Adult Myeloid Neoplasia According to Functional Impact
3153 - Impact of Non-ABL1 Mutations on Outcomes in Patients with Chronic Myeloid Leukemia

Bosma, G.

4266 - Efficacy and Molecular Predictors of Response and Survival for Venetoclax/Azacitidine Therapy in Relapsed or Refractory Acute Myeloid Leukemia

Boss, I. W.

4585 - Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab

Bossi, E. G.

3945 - Platelet Laboratory Markers of Failure of First-Line Treatments in Immune Thrombocytopenia (ITP)

Bosworth, A.

14 - Clonal Hematopoiesis and Venous Thromboembolism Risk in Lymphoma Patients Surviving Autologous Transplantation
403 - Self-Rated Health Is an Independent Predictor of Subsequent Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Myeloid Malignancies: A BMTSS Report
947 - Clonal Hematopoiesis Is Associated with Non-Myeloid Subsequent Malignant Neoplasms after Autologous Hematopoietic Cell Transplantation
2338 - Self-Rated Health Is an Independent Predictor of Subsequent Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Lymphoid Malignancies: A BMTSS Report
2411d - Long-Term Health Outcomes in Older (≥60 Years) Blood or Marrow Transplantation (BMT) Recipients: A Report from the Blood or Marrow Transplant Survivor Study (BMTSS)
3715 - Individual- and Area-Level Socioeconomic Disadvantage and Risk of Death Due to Chronic Health Conditions Among Autologous Blood or Marrow Transplant (autoBMT) Recipients for Lymphoma: A BMT Survivor Study (BMTSS) Report
4924 - Social Vulnerability Is an Important Predictor of Cardiovascular Disease Risk after Allogeneic Hematopoietic Cell Transplantation
5036 - Predictors of Risky Health Behaviors Among Blood or Marrow Transplant (BMT) Survivors of Lymphoid Malignancies – a BMT Survivor Study (BMTSS)
5053 - Predictors of Risky Health Behaviors Among Blood or Marrow Transplant (BMT) Survivors of Myeloid Malignancies – a BMT Survivor Study (BMTSS)
5146 - Self-Rated Health Is an Independent Predictor of Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Plasma Cell Disorders: A BMTSS Report

Botella, C.

962 - Prognostic Impact of the Genetic Risk at Baseline Associated to the MRD Clearance in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. Preliminary Results of Pethema LAL19 Trial
1437 - Similar Outcome of Adolescents and Young Adults (AYA) and Older Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) without Philadelphia Chromosome (Ph-) Included in the Pethema LAL-2019 Trial
1512 - Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3-ITD Negative AML
1552 - Enhanced Validation of the FLT3-like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in FLT3-ITD Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial
2895 - Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3-ITD–Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial
4986 - A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML

Botella, C.

320 - Treatment Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Data from the Pethema and PALG Epidemiologic Registry
4328 - Single-Cell Multiomics Data-Driven Measurable Residual Disease (MRD) Assessment Using Multidimensional Flow Cytometry (MFC) in Acute Myeloid Leukemia (AML)

Botella, I.

4566 - Diagnostic Challenges in Patients with Clinical Suspicion of Myeloproliferative Neoplasms and JAK2V617F≤1%

Bothmer, A.

515 - In Vivo HSC Gene Editing for Correction of the Sickle Cell Mutation Using RNA Gene Writers
2197 - Delivery of Gene Writers In Vivo to Hematopoietic Stem Cells and T Cells Using Targeted and Untargeted Lipid Nanoparticles (LNP)

Bott, A.

4498 - Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Botta, C.

4699 - Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Bottalico, S.

1086 - Toward the Creation of Diagnostic Algorithms for Congenital Hemolytic Anemia Using Advanced Parameters from Modern Hematology Analyzers

Böttcher, M.

4521 - A Study on Experimentally Induced Thrombus Formation in JAK2-V617F and Calr-del52 Mouse Models Using Ligation of the Inferior Vena Cava (IVC)

Bottelli, C.

82 - Early Identification of Functional High Risk Multiple Myeloma Patients after Transplant with Diffusion-Weighted Whole-Body MRI: Predictive Role of Fat Fraction in Addition to RAC Score

Botti, S.

2126 - Evidence-Based Choice of Conditioning Regimen for Hematopoietic Stem Cell Transplantation (HSCT) in Acute Leukemia: The Italian Cellular Therapy and Stem Cell Transplant Group (GITMO) Guidelines

Botto, B.

1663 - Outcomes of Patients with Hodgkin Lymphoma Receiving Brentuximab Vedotin (BV) As Maintenance Therapy after ASCT According to Previous Exposure to BV. a Retrospective Analysis of the EBMT Lymphoma Working Party in Collaboration with Geltamo, FIL, Lysarc, and Turkish Lymphoma Group
3131 - Outcomes of CAR T-Cells Therapy in High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas: A Weighted Comparison Analysis from CAR-T SIE Study
4786 - High Ferritin and C-Reactive Protein Levels Result in Poor Clinical Outcome in R/R Large B-Cell Lymphoma Patients Despite Significant Anti-CD19 CAR-T Cell In Vivo Expansion

Bottomly, D.

1566 - Combination with Palbociclib Overcomes Venetoclax Resistance Mechanisms and Outperforms Single Agent Efficacy in Acute Myeloid Leukemia

Bottos, A.

865 - Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study
1631 - Glofitamab Induces High Response Rates and Durable Remissions in Patients (Pts) with Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL), Including Those with a Poor Prognosis: Subgroup Results from a Phase I/II Study
2990 - Evaluation of Anti-Tumor Activity and Impact on T Cell Activation of Glofitamab in Combination with Gemcitabine and Oxaliplatin (Glofit-GemOx)
4356 - Early Assessment of Circulating Tumor (ct)DNA and Analysis of TP53 mutations in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma Treated with Glofitamab Monotherapy
4382 - Highly Heterogeneous Cellular Composition and Neighborhood Architecture within the Follicular Lymphoma Tumor Microenvironment

Bou-Maroun, L.

2317 - Complementary and Alternative Medicine (CAM) Use Reported Among Individuals with Immune Thrombocytopenia (ITP): Data from the ITP Natural History Study Registry

Bouabdallah, K.

239 - Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy: A Descar-T Study By Lysa Group
575 - Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase 3 Gained Study Conducted By Lysa
1596 - Predictive Power of Early, Sequential Minimal Residual Disease and Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Monitoring in Young Patients with Mantle Cell Lymphoma in the Lyma Trial: A Lysa Study
1657 - 5-y Follow-up of Combination of Ibrutinib, Obinutuzumab and Venetoclax for Patients with Newly Diagnosed Mantle Cell Lymphoma, the Oasis Trial
3029 - Comparative Efficacy of Zanubrutinib Plus Obinutuzumab Versus Last Prior Treatment in Relapsed/Refractory Follicular Lymphoma: Growth Modulation Index Analysis from ROSEWOOD Study
4354 - Circulating Tumor DNA for Primary Mediastinal B-Cell Lymphoma Genotyping: A Prospective Multicenter Study
4489 - Outcomes By Refractory Status and Prior Therapies Received in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

Boucaud, F.

579 - Golcadomide (GOLCA) Plus R-CHOP Has High Minimal Residual Disease (MRD) Negativity across High-Risk, Untreated Aggressive B-Cell Lymphoma (a-BCL)
1742.2 - Golseek-1: A Phase 3, Double-Blind, Randomized Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Vs R-CHOP in Patients with Previously Untreated, High-Risk, Large B-Cell Lymphoma

Boucher, A. A.

4999 - Exploring the Patient Perspective of Gene Therapy for Sickle Cell Disease
5004 - Multi-Disciplinary Care Model for Transition and Re-Transition after Gene Therapy in Sickle Cell Disease
5062 - Comparing Emergency Department and Infusion Clinic Outcomes Among Individuals with Sickle Cell Disease Seeking Care for Vaso-Occlusive Crises
- General Session 3: Incorporating Health Equity Education in UME/GME Curriculum
- Lifespan Hematology

Boucher, A. C.

1376 - Loss of Cystathionine-β-Synthase Activity Results in Increased Oxidative Phosphorylation and Cytarabine Resistance in Myeloid Leukemia Associated with Down Syndrome
2731 - Multi-Pronged Effects of Cohesin Mutations in the Myeloid Leukemia of Down Syndrome

Boucher, J.

4826 - Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic Transplantation

Boucher, R.

120 - Prospective Cohort Study of Non-COVID Infection in Patients with AML/MDS Undergoing Treatment: Implications for Practice
3186 - Interim Analysis of Promise, a Clinical Study Combining the BET Inhibitor OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis Experiencing an Inadequate Response to Ruxolitinib

Bouchla, A.

1083 - High Incidence of Thalassemia Traits Among Myelodysplastic Syndrome Patients May Mask Macrocytic Anemia but Not the Enhanced Proteasome Proteolytic Activity

Bouck, J. R.

394 - Neurocognitive Screening and Neighborhood Impact for Children and Adolescents with Sickle Cell Disease

Boudjemaa, S.

1592 - Circulating Cell-Free DNA in Classical Hodgkin Lymphoma in Children, Adolescents and Young Adults. Results from the Holy Study, a French Ancillary Study of Euronet PHL-C2 Protocol

Boudreau, J.

697 - Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients with Pulmonary Embolism and Right Ventricular Dysfunction

Bouffard, A. A.

2025 - Novel CD2-Targeting Trispecific Immune Effector Cell Engager (TRIEC) Coupled with CD19 CAR-T Overcomes Resistant B-Cell Lymphoma

Bouhier-Leporrier, K.

1289 - Emergence of DNA Damage Repair Clonal Hematopoiesis after Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors

Bouhlal, J.

329 - Genomic Subtypes of AML Define Sensitivity to NK Cell Cytotoxicity
913 - Comprehensive Drug Profiling and CRISPR Screening Reveal Essential Pathways for NK Cell Cytotoxicity
4814 - Bone Marrow Stromal Cells Hamper Leukemia Cell Induced NK Cell Activation and Cytotoxicity

Bouillié, M.

2793 - APR-246 Overcomes Resistance to Asparaginase in Lymphoid Malignancies By Targeting Metabolic Cell Vulnerabilities

Boulanger, M. C.

3697 - Impact of Obesity on Anticoagulation Dosing and Clinical Outcomes in Pediatric Patients with Venous Thrombo-Embolism

Bouligny, I. M.

446 - Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine
734 - A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
3212 - A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome
4601 - A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome

Boulil, Z.

4010 - Insights and Characteristics of Pediatric Central Venous Catheter Malfunction and Catheter-Associated Deep Vein Thrombosis: A Subanalysis of the Circle Study

Boultwood, J.

878 - TGF-β1-SMAD2 Axis Regulates Hematopoiesis and β-Globin Gene Expression Via Super-Enhancer Associated Chromatin Reorganization

Bourck, V.

3634 - From Theory to Therapy: Evaluating Canadian Hemophilia Treatment Centres' Readiness for Gene Therapy Implementation

Bourdelier, E.

290 - Oxygen Gradient Ektacytometry Is Associated with Markers of Hemolysis and Inflammation in a Large Sickle Cell Disease Cohort within the GenoMed4ALL Project

Bourdine, A.

2540 - Circulating T Follicular Helper Cells in Pediatric Immune Cytopenias

Bourgeois, W.

724 - Discerning the Landscape of Menin Inhibitor Resistance

Bourgoin, M.

1378 - Dasatinib Overcomes AML Resistance to BCL2 Inhibition By Indirectly Inhibiting MCL1: From Ex Vivo drug Sensitivity/Resistance Profiling to a Phase II Clinical Trial: A Hemato-BIO Study

Bourhis, J. H.

3483 - Sequential Intensified Conditioning Regimen Allogeneic Transplantation in Younger Adult Patients with Adverse-Risk Acute Myeloid Leukemia: A Multi-Center Prospective Study from the Acute Leukemia French Intergroup on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
4909 - Cyclosporine Versus Cyclosporine Plus Mycophenolate Mofetil in Reduced Intensity Allogeneic Stem Cell Transplantation for Intermediate-Risk AML: A Multi-Center Randomized Study from the Acute Leukemia French Intergroup, on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Bourquin, J. P.

309 - A Reduced Daunorubicin Dose during Induction Is Equally Effective As Standard Dose in Children with Acute Lymphoblastic Leukemia (ALL) and Favorable Prognostic Features: Long-Term Results of the Phase 3 Trial AIEOP-BFM ALL 2009
314 - Role of Stem-like Cells in Chemotherapy Resistance and Relapse in Pediatric T Cell Acute Lymphoblastic Leukemia (T-ALL)
318 - Drug Sensitivity and Treatment Response Are Modulated By the Cell of Origin, the Underlying Gene Fusion, and Patient Age in KMT2A-Rearranged BCP-ALL
730 - Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy
968 - Favourable Outcomes in Newly Diagnosed Paediatric AML with Gemtuzumab Ozogamicin and Risk-Stratified Therapy: Results from the International Phase III Myechild 01 Trial

Bouscary, D.

2286 - Reducing Infection Risks of Anti-BCMA Bispecific Antibodies in Multiple Myeloma: In-Hospital Vs. Hospital-at-Home Treatment
2793 - APR-246 Overcomes Resistance to Asparaginase in Lymphoid Malignancies By Targeting Metabolic Cell Vulnerabilities
4343 - Inflammatory Waldenström Macroglobulinemia Is Associated with Clonal Hematopoiesis: A Multicentric Cohort
5141 - Infection Risk and Efficacy of Anti-BCMA Bispecific Antibodies in Multiple Myeloma: A Real-World Propensity Score-Matched Study

Bousiou, Z.

1163 - Long-Term Safety and Efficacy of Autologous Hematopoietic Cell Transplantation for Patients with Progressive Systemic Sclerosis
3408 - Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) and Growth Differentiation Factor-15 (GDF-15) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients
3484 - Long-Term Safety and Efficacy of Treosulfan-Based Conditioning Regimens of Allogeneic Hematopoietic Cell Transplantation
4778 - Genetic Susceptibility in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease

Bouska, A.

456 - An Llmpp Study: Genomic Characterization of Novel PTCL- Biological Subtypes Reveal Distinctive Therapeutic Vulnerabilities
1357 - Tet2 Loss and IDH2^R172K Mutation Develop T_FH-Cell-like Lymphoma with Restricted T_H1 Differentiation Program and Cognate Interaction with B Cells
1360 - RHOA^G17V Mutation Exhibits Markedly Different Functions in the Presence of TET2 Loss in T-Cells

Boussi, L.

445 - Outpatient Vs Inpatient Hidac Consolidation for AML: The MSKCC Experience
465 - Development of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium
781 - Barriers to Immune Effector Cell Therapy: Rapid Disease Progression, Concern for Toxicity, and Lack of Appropriate Trials Drive Non-Receipt after Referral at a Large Academic Center
1508 - Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed By Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid Leukemia
1556 - Adult AML Patients with NUP98 Fusions Are Frequently Therapy-Related, and Are Associated with Monocytic Differentiation, Recurring Mutations in NRAS, DNMT3A and WT1 and Poor Outcome
2847 - Patients with AML and an IDH2-R172 Mutation Exhibit a Unique Response to Intensive Induction Chemotherapy, Suggesting Futility of Mid-Cycle Bone Marrow Biopsy and Caution When Considering Re-Induction
2947 - The Prognostic and Predictive Value of RUNX1 Mutations in Newly Diagnosed Acute Myeloid Leukemia – an International Multicenter Cohort Study
4267 - Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics
4281 - Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients with Chromosome 5 and 7 Abnormalities

Boussiotis, V. A.

123 - Loss of LDH-a Accelerated CD8⁺ T Memory Cell Differentiation but Impairs Anti-Tumor Responses
1144 - Combined Ablation of PD-1 and Pparγ Synergistically Promotes M1-like Macrophage Polarization and Proinflammatory Differentiation

Boutakoglou, E.

2529 - Malignant Transformation in Relationship to Clonal Hematopoiesis in CIN

Boutboul, D.

1915 - Latent Nuclear Antigen Flow-FISH Improves the Detection of Circulating Viroblasts during KSHV/HHV-8-Associated Multicentric Castleman Disease Flares
1917 - Characteristics of Autoimmune Hemolytic Anemia Associated with Khsv/HHV-8 Multicentric Castleman Disease
3124 - CAR T-Cells Treatment for Relapsed/Refractory B-Cell Lymphoma Is Effective and Safe in People Living with HIV (PLWH): A Lysa Study from the Descar-T Registry

Boutilier, A. J.

4386 - Macrophages in Waldenstrom Macroglobulinemia: Implications for the Tumor Microenvironment

Boutin, A. B.

2674 - Clinical Efficacy of Erythroid Stimulating Agent (ESA) and Luspatercept (LUSPA) in Vexas Syndrome with or without Myelodysplastic Syndrome (MDS) : A Multicenter Retrospective Study By the Frenvex Group

Boutin, M.

4483 - Outcomes in Older Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

Bouvier, A.

58 - Real-World Multicenter Evaluation of Venetoclax and Azacitidine for Molecular Relapse after First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Filo Study

Bouvier, C.

3149 - Retrospective Study to Compare Treatment Outcomes of Asciminib Vs. Ponatinib in 99 Patients with T315I Mutated Chronic Myeloid Leukemia

Bouwens, B.

2603 - Citrullination in the C-Terminus of Tissue Factor Pathway Inhibitor-Alpha Impairs the Inhibition of Factor V Activation, and the Synergy with Protein S in Factor Xa Inactivation
3994 - Citrullination of TFPI By PAD4 Impairs Its Natural Anticoagulant Activity Towards Factors Xa, VIIa and Tissue Factor, and Reduces Binding to Its Cofactor Protein S

Bouyssi-Kobar, M.

3901 - Mapping Total Cortical Volume of Children and Adolescents with Sickle Cell Disease Against Normative Growth Trajectories: First Baseline Results of the Brick Study

Bouzani, M.

1742.2 - Golseek-1: A Phase 3, Double-Blind, Randomized Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Vs R-CHOP in Patients with Previously Untreated, High-Risk, Large B-Cell Lymphoma
4502.1 - Phase 3, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared with Rituximab Plus Gemcitabine and Oxaliplatin in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Bovay, A.

2729 - Chromatin-Based Cellular Dependency of HOXA9/MEIS1-Driven Acute Myeloid Leukemia

Boveri, E.

4400 - Persistence of Monotypic Plasma Cells after Chemoimmunotherapy in Patients with Waldenström Macroglobulinemia: A Matter of Time?

Bovet, J.

718 - Safety and Efficacy of Mim8 Prophylaxis Administered Once Every Two Weeks for Patients with Hemophilia A with or without Inhibitors: Interim Analysis of the FRONTIER4 Open-Label Extension Study

Bowcock, S.

385 - Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma – an Economic Evaluation of the Fitness Trial
673 - IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial

Bowen, D. T.

3146 - RUX-AZA Response in AP/BP-MPN Is Driven By Release of the Differentiation Block in Mutant HSPCs: A Single-Cell Multi-Omic Analysis of Responders on the Phase Ib Phazar Study

Bower, K.

2181 - Comparative Analysis of Donor and Conditioning Intensity in the MRD and Ptcy Era in Philadelphia + Acute Lymphoblastic Leukemia (Ph+ ALL). a 12-Year Span Report of 119 Center CIBMTR Report

Bower, K.

4881 - Low Risk of Relapse and Favorable Survival after Allogeneic Transplantation with Fludarabine and Melphalan Conditioning for Measurable Residual Acute Myeloid Leukemia

Bower, L.

4954 - Durable Clinical Benefits with Exagamglogene Autotemcel for Severe Sickle Cell Disease

Bowers, E.

3468 - Phase 1 Trial of CD30-Directed, CCR4 Co-Expressing Chimeric Antigen Receptor T-Cells in Patients with CD30⁺ Cutaneous T-Cell Lymphomas Refractory to Brentuximab Vedotin

Bowhay-Carnes, E.

5080 - Real-World Experience with Combination Therapy of Fostamatinib and Thrombopoetin Receptor Agonists (TPO-RAs) for Treatment of Immune Thrombocytopenia (ITP): Patient-Reported Outcomes

Bowles, K.

1641 - A Prospective Analysis of Outcomes Following Successive Lines of Treatment in Mantle Cell Lymphoma in an Unselected Previously Untreated Population: The UK MCL Biobank
1802 - Efficacy and Tolerability of Trametinib in Adults with Histiocytic Neoplasms
1893 - Age-Associated Macrophage Polarization to an M2 Phenotype Drives Myeloma Proliferation in the Aged Bone Marrow By Loss of Tumor-Associated Phagocytosis
3354 - Extended Intensified Consolidation and Maintenance Improve Ultra High-Risk Multiple Myeloma Patient Outcome – Long-Term Follow-up of the Ukmra Optimum/Muknine Trial
4113 - Repolarisation of M2 Macrophages Via Cgas-Sting Activation Enhances Phagocytosis of Acute Myeloid Leukaemia

Bowman, K.

2786 - Protein Degrader WH25244 Eliminates Venetoclax Resistance Factors: Mutant or Hyperphosphorylated BCL2, and BCL-XL

Bowman, M. S.

1334 - Super-Jump: State Intent Inference and Lineage Tracking through Semi-Supervised Jump Diffusion Modeling in Normal Hematopoiesis and Acute Myeloid Leukemia
1343 - Distinct Cell-Intrinsic and Extrinsic Consequences of TLR2 Activation Drive Pleiotropic Effects in AML Affecting Overall Survival
2200 - Selection for an HIV-Resistant Immune System By Base-Edited CD45 CAR-T Cell Therapy

Bowman, R. L.

66 - Single-Cell Multi-Omic Analysis of KMT2A-Rearranged Pediatric Acute Leukemia Clonal Evolution
1334 - Super-Jump: State Intent Inference and Lineage Tracking through Semi-Supervised Jump Diffusion Modeling in Normal Hematopoiesis and Acute Myeloid Leukemia
1343 - Distinct Cell-Intrinsic and Extrinsic Consequences of TLR2 Activation Drive Pleiotropic Effects in AML Affecting Overall Survival
1536 - Early Drivers of Clonal Hematopoiesis Shape the Subsequent Evolutionary Trajectories of De Novo AML
2200 - Selection for an HIV-Resistant Immune System By Base-Edited CD45 CAR-T Cell Therapy
2713 - Codon-Specific Differences in RAS Mutations in AML and Differential Response to Therapeutic Agents
2921 - BRAF-Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML
2939 - Combined Human and In Vivo Analyses Implicate the Critical Importance of Acute Myeloid Leukemia Associated CD8 T Cells and Identifies Their Molecular Dysfunction

Bowman, T. V.

1811 - Elucidating the Interplay between ddx41 and cux1 mutations in Hematopoiesis in Danio Rerio
4576 - Heterozygous ddx41 Mutation Drive Age-Dependent Hematopoietic Stem and Progenitor Cell Dysfunction

Bowser, B.

369 - Autologous CD33CART for Children and Adolescents/Young Adults with Relapsed/Refractory AML: Phase 1/2 Clinical Trial Correlative Biology Analyses Demonstrate Potent in Vitro, In Vivo, and Ex Vivo Anti-Leukemia Activity

Boxer, M. B.

2614 - Phase 1, 3-Sequence Interaction Study of Intravenous Vlx-1005 and Argatroban Shows a Favorable Safety, Pharmacokinetic and Pharmacodynamic Profile in Healthy Volunteers

Boxer, S.

2132 - Efficacy of Recombinant Human Erythropoietin in Enhancing Erythroid Hematopoietic Recovery after Allogeneic Hematopoietic Stem Cell Transplantation: A Meta-Analysis

Boya, R. K.

3755 - Real World Data of Novel Talicabtagene Autoleucel (humanized CD19 CAR-T) from India; Ensuring Equitable Access with Excellent Safety and Efficacy Profile

Boyadzhiev, H.

114 - Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma
3383 - Idecabtagene Vicleucel (ide-cel) Shows Similar Efficacy and Toxicity in Patients with Multiple Myeloma Aged 70 and Older Compared to Younger Patients: A Multicenter Cohort Study
3818 - Outcomes of Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Multicenter Real-World Analysis
4759 - Efficacy of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma and Prior Central Nervous System Manifestation: A Retrospective Real-World Analysis

Boyapati, A.

3265 - Characterization of Linvoseltamab’s BCMA Binding Epitope and Efficacy Against BCMA Mutations in Relapsed/Refractory Multiple Myeloma
3310 - Soluble BCMA Dynamics in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1
3369 - Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study

Boyce, D. R.

4182 - CNS Involvement in Adult Patients with B-Cell Acute Lymphoblastic Leukemia

Boyd, A.

2076 - CD123-CAR T Cells Manufactured in the Presence of Dasatinib Induce High Grade CRS and/or IEC-HS without Improving Efficacy in Pediatric Patients with Recurrent/Refractory Leukemia

Boyella, P. K.

3755 - Real World Data of Novel Talicabtagene Autoleucel (humanized CD19 CAR-T) from India; Ensuring Equitable Access with Excellent Safety and Efficacy Profile

Boyer Chammard, A.

Boyer, D.

1528 - Identification of Novel Genes Underlying Human AML Expansion at Relapse from Chemotherapy

Boyer, F.

3133 - Increased Thromboinflammation Is Associated with High Thrombotic Risk in Patients with Myeloproliferative Neoplasms: A Multicentric Study of 394 Cases By the French Intergroup of Myeloproliferative Neoplasms (FIM)
3167 - Outcome of Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms Ineligible for Intensive Chemotherapy or Allogeneic Hematopoietic Cell Transplantation Treated By Azacitidine Alone or in Combination – a FIM Study

Boyer, L.

2511 - Evaluation of Sleep Apnea in Adult Sickle Cell Disease; About 107 SS and Sβ°Thal Patients
3890 - Protection Against Coronary Atherosclerosis in High Cardiovascular Risk Sickle Cell Disease Patients: A Beneficial Role of Intravascular Hemolysis?

Boyer, M.

577 - Final Analysis of the Safety and Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma
1873 - Reduction of Tumor Lysis Syndrome Risk after Debulking with Obinutuzumab in Patients Treated with Venetoclax–Obinutuzumab in the Randomized Phase 3 CRISTALLO Trial
3237 - CRISTALLO: Results from a Phase III Trial of Venetoclax–Obinutuzumab Versus Fludarabine, Cyclophosphamide and Rituximab or Bendamustine–Rituximab in Patients with Untreated Chronic Lymphocytic Leukemia without Del(17p) or TP53 Mutations

Boyiadzis, M.

1504.2 - Trial in Progress: A Multicenter, Open Label, Randomized, Phase 2 Study of Venetoclax and Azacitidine Plus Cusatuzumab Versus Venetoclax and Azacitidine Alone in Newly Diagnosed AML Patients Who Are Not Candidates for Intensive Therapy

Boyle, E. M.

669 - Tumour-Intrinsic Features Shape T-Cell Differentiation through Myeloma Disease Evolution
1909 - A Novel Segmentation-Based Purity-Informed Approach Accurately Detects Total Copy Number and Its Subclonal Fraction in Myeloma Targeted Panel Sequencing Data
3333 - Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial
3792b - Evaluating Barriers to Enrolment into Multiple Myeloma (MM) Clinical Trials: Results from Health Care Professionals and Patient Survey from the UK Myeloma Research Alliance Equity, Diversity and Inclusivity (EDI) Working Group
3895 - Observational Data on Parvovirus B19 Cases in Patients with Red Cell Disorders in the United Kingdom from 2023-2024

Boyle, M.

742 - A Novel Genetics-Based Classification of Advanced Follicular Lymphoma Identifies Prognostic Subgroups Following Bendamustine-Rituximab Immunochemotherapy
855 - CSF2RB Mutations Result in Cytokine-Dependent Gain-of-Function Phenotypes in Classic Hodgkin Lymphoma
2966 - Multiomic Profiling Reveals Pleiotropic Effects of Somatic IRF4-C99R Mutations in Primary Mediastinal Large B-Cell Lymphomas

Boynton, K.

3969 - Strategies for Increasing Racial and Ethnic Diversity in Hemophilia Clinical Trials and Their Outcomes

Bozek, K.

367 - Targeting Lymphoma Associated Myeloid-Monocytic Cells through CSF1R Blockade Enhances CAR-T Cell Response in Aggressive B Cell Lymphoma

Bozic, I.

3233 - The Impact of Therapeutic Selective Pressure on the Evolutionary Landscape of Chronic Lymphocytic Leukemia

Bozkaya, D.

131 - Real-World Experience of Switching to Prophylactic Efanesoctocog Alfa in Patients with Moderate and Severe Hemophilia a: An Analysis of the Adelphi Hemophilia Wave III Disease Specific Programme
719 - Association between Hemophilia Joint Health Score and Quality of Life Using Results from the Xtend-1 Efanesoctocog Alfa Phase 3 Trial
3967 - Real-World Patterns of Additional Factor Treatment Use Among Hemophilia a Patients on Regular Prophylaxis in the United States: Results from the Picnichealth Database
3973 - Unmet Needs, Factor Consumption, and Healthcare Resource Use Among People with Hemophilia a: Real-World Analysis of the Adelphi Hemophilia Disease Specific Programme^TM

Bozkir, H. O.

1490 - Outcomes of Acute Promyelocytic Leukemia (APL) during Pregnancy: A Systematic Review of Outcomes

Bozzetti, C.

631 - IDH2 Mutations from Clonal Hematopoiesis and Acquired IKZF1 Deletions Define a Novel B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma
1458 - C/EBP Family Member Gene Fusions and Cooperating Genomic Events Define Two Distinct Molecular Sub-Groups in Adult B Precursor ALL

Bozzi, S.

131 - Real-World Experience of Switching to Prophylactic Efanesoctocog Alfa in Patients with Moderate and Severe Hemophilia a: An Analysis of the Adelphi Hemophilia Wave III Disease Specific Programme
3973 - Unmet Needs, Factor Consumption, and Healthcare Resource Use Among People with Hemophilia a: Real-World Analysis of the Adelphi Hemophilia Disease Specific Programme^TM

Bozzo, J.

2249 - Screening for Cognitive Impairment and Depression in Sickle Cell Disease: How Are We Doing?
5009 - Implementation of American Society of Hematology (ASH) Neuro-Related Guidelines at a Sickle Cell Center: How Are We Doing?

Brabenec, R.

4796 - Dissection of Single-Cell Landscapes for the Development of Chimeric Antigen Receptor T Cells in Hodgkin Lymphoma

Brabson, J. P.

4051 - Vitamin A Directly Enhances TET2 Activity and Suppresses Clonal Hematopoiesis

Bracht, T.

901 - Memory CD4⁺ T Cells Recognize Divergent HLA-DP Immunopeptidomes and Contribute to Leukemia Control after Allogeneic HCT

Bracken, A.

4121 - A Novel Form of AEBP2-Containing PRC2.2 Is a Genetic Dependency in Germinal Centre B-Cell Lymphoma and Its Targeting Can Overcome Acquired Resistance to EZH2 Inhibition

Bradbury, C. A.

710 - A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3

Bradford, D.

1062 - Overcoming Immune Escape Via Targeting Akt-Wnt/β-Catenin By Artificial-Intelligence-Powered Peptide-Producing mRNAs

Bradford, K.

2054 - Discovery of JNJ-89853413, a First-in-Class CD33xVδ2 T-Cell Engager for the Treatment of Acute Myeloid Leukemia

Bradley, M. D.

3220 - Robust Copy Number Alteration Detection (RCNA): A Novel Algorithm for Detecting Copy-Number Alterations for Targeted Gene Sequencing Experiments

Bradley, R. K.

343 - Mis-Splicing Derived Neoantigens and Cognate T Cell Receptors in Splicing Factor Mutant Myeloid Neoplasms
3422 - TNFα Apoptotic Signaling By Antigen-Engaged CAR T-Cells Mediates Clearance of Target Antigen-Negative Acute Myeloid Leukemia

Bradley, T.

655 - Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients
998 - Trial Update from IMproveMF, an Ongoing, Open-Label, Dose-Escalation and -Expansion, Phase 1/1B Trial to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Novel Combination of Imetelstat with Ruxolitinib in Patients with Intermediate-1, Intermediate-2, or High-Risk Myelofibrosis (MF)
1787 - Outcomes of Patients with IDH1/2 Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Era of IDH Inhibitors
1821 - A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-Risk, Non-Del(5q) Patients with Myelodysplastic Syndromes: Phase Ib Results
3179 - Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor
3679 - Differences in Treatment Decision-Making in Frontline Management of Lower-Risk Myelodysplastic Syndromes between Academic and Community Practice Settings: Results from a Nationwide Survey

Bradley, T.

1808.2 - POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Brady, B.

3976 - Safety and Outcome of Early Start of Emicizumab in Neonates and Infants with Severe Hemophilia Α, a Real-World Experience

Brady, C.

2712 - TET2 and TP53 Mutations Cooperate in Leukemia Development and Modulate the Response to Inflammation

Brady, Z.

31 - Genetic Determinants of Hypercoagulability in Complement and Hemostatic Systems Shape the Thrombotic Risk of Paroxysmal Nocturnal Hemoglobinuria
35 - First Results of High Throughput Pipeline for Serotypic and TCR Clonotypic Specificities in Aplastic Anemia and Large Granular Lymphocyte Leukemia Uncovering Antigenic Peptides Relevant to Disease Etiology
1254 - Budd-Chiari Syndrome: Pathogenetic Factors and Completeness of Screening for Paroxysmal Nocturnal Hemoglobinuria
1328 - Genomic Landscape of Germline RUNX1 variants in Adult Myeloid Neoplasia According to Functional Impact
1688 - Low-Count T-/NK-Large Granular Lymphocytic Leukemia: A Nosologically Distinct Disease Subtype at the Crossroads between Lymphoproliferation, Autoimmunity and Immunodeficiency
2224 - Unraveling Immunogenomic Features Germane to Pathobiology of Myelodysplastic Syndromes
2675 - Dysregulation of the Ubiquitination Pathway: Insights on Autoinflammatory Conditions and Inborn Errors of Immunity in Bone Marrow Failure Disorders
2943 - Geno-Transcriptomic Topography of Clonal Drivers in Trisomy 8 Myeloid Malignancies
4084 - An Immunogenetic Perspective on Bone Marrow Failure Syndromes: The KIR-HLA System
4085 - Counterpoising Immune Pressure and Privilege: Paroxysmal Nocturnal Hemoglobinuria Evolutionary Dynamics
4096 - Genetic and Molecular Dynamics of DDX41-variants: Insights on the Variant Effect Prediction
4980 - Novel Machine Learning Approaches Tailored to Protein Configuration Predict Drug Vulnerabilities in Myeloid Neoplasia

Braendstrup, P.

3099 - Outcome of T-Cell/Histiocyte-Rich Large B-Cell Lymphoma in Denmark 2008-2022

Braess, J.

2934 - The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients

Bragado-Garcia, I.

3414 - Enhancing CAR-T Cell Therapy for Non-Hodgkin Lymphoma through Gut Microbiota and Butyrate

Bragasin, E. I.

3566 - Clinical Impact of Pretransplant Blinatumomab in Predominantly Hispanic Adults with B-Cell Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Brägelmann, J.

367 - Targeting Lymphoma Associated Myeloid-Monocytic Cells through CSF1R Blockade Enhances CAR-T Cell Response in Aggressive B Cell Lymphoma

Braggio, E.

249 - Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax
397 - Prevalence, Genetic Predispositions and Clinical Consequences of Non-CLL-Type MBL: Screening in 10,330 Individuals
592 - Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma
2744 - The Mutational Landscape of Extramedullary Multiple Myeloma Reveals Novel Biologic Insights and Potential Therapeutic Targets for Exploration
3269 - A Proteogenomic Approach to Identify Potential Drivers of Hyperdiploid Multiple Myeloma
4616 - Serum Immunoglobulins Are an Independent Prognostic Marker of Time to First Therapy in Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) and Monoclonal B-Cell Lymphocytosis (MBL)
4635 - The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma

Braggio, M.

3858 - Exploring Muscular Senescence in Transfusion-Dependent Thalassemia without Cardiac Iron Overload: Roles of FGF21, ICAM1 and Post-Exercise Pulmonary Congestion

Braghetta, P.

2452 - 3D Silk-Based Bone Marrow Models Identify Autophagy As a Critical Mechanism in Red Blood Cell Production

Braglia, L.

2975 - Dissecting Diffuse Large B Cell Lymphoma Heterogeneity: New Insights from a State-Specific Molecular Characterization

Brahma, S.

2728 - PTBP1, an RNA Binding Protein and Splicing Regulator, Binds RUNX1 and Co-Localizes at Target Gene Promoters in Leukemia

Brahmbhatt, J.

2570.1 - Intravenous Efgartigimod for the Treatment of Primary Immune Thrombocytopenia in Adults: A Planned, Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study with Open-Label Period (ADVANCE NEXT)

Braida, A.

75 - High IGHV Intraclonal Diversification Identifies CLL with Good Prognosis, Features of Anergy and Specific T-Cell Profiles

Braier, J.

3909 - Treatment Strategies and Outcomes of the Rare Histiocytic Disorders: Long-Term Results of the International Rare Histiocytic Disorders Registry (IRHDR)

Braish, J.

3209 - Phase I/II Combination Study of Azacitidine and Venetoclax Post Hypomethylating Agents Failure in High Risk MDS and CMML

Braitsch, K.

3513 - Omitting Ciprofloxacin Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation Does Not Result in Inferior Outcomes

Brake, M.

18 - Use of Large-Scale Genomic Datasets to Identify Additional Modifiers of Thrombosis Risk Among 26,436 Carriers of the Factor V Leiden and Prothrombin G20210A Mutations
- CD200R1 and IL-17 Axis in Cancer Associated Thrombosis

Brakhane, M.

875 - Monocyte-Driven Aberrant Inflammation in Myeloproliferative Neoplasms Is Regulated By Galectin-1
1169 - Altered Calcium Signaling Via STIM1 Drives Aberrant Megakaryopoiesis and Myelofibrosis

Bramanti, S.

607 - Tisagenlecleucel for the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: An Interim Report of the European Post-Authorisation Safety Study Conducted By EBMT
1681 - Bendamustine in Combination with Gemcitabine and Vinorelbine As Salvage Regimen for Relapsed or Refractory Peripheral T-Cell Lymphomas: A Retrospective Single Center Experience
2190 - Peripheral Blood Stem Cell Versus Bone Marrow Graft for Non-T-Depleted Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Patients with Secondary Acute Myeloid Leukemia in First Complete Remission: A Study from the ALWP/EBMT
2269 - A SWOT-Consensus for CAR-T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection
3131 - Outcomes of CAR T-Cells Therapy in High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas: A Weighted Comparison Analysis from CAR-T SIE Study
3565 - Allogeneic Stem Cell Transplantation As Consolidation Therapy in Patients with Relapsed-Refractory B-Cell Lymphoma Exposed to Bispecific Antibodies: A Study on Behalf of Grupo Español De Transplante y Terapia Celular (GETH-TC)
4786 - High Ferritin and C-Reactive Protein Levels Result in Poor Clinical Outcome in R/R Large B-Cell Lymphoma Patients Despite Significant Anti-CD19 CAR-T Cell In Vivo Expansion
4947 - Effect of Consolidation with Allogeneic Hematopoietic Cell Transplant Versus No Consolidation in Patients with Non-Hodgkin Lymphomas Treated with Bispecific Antibodies

Brambillasca, S.

334 - B Cell Receptor Inactivation Boosts NK Cell Killing of MYC-Driven Lymphomas

Brammer, J. E.

980 - Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization
982 - Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort
1719 - Nivolumab in Combination with Dose Adjusted (DA) R-EPOCH for First-Line Treatment of Large B-Cell Lymphoma: Results from a Phase II Trial
3061 - Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial
3446 - Association between Post-CART Terminal Complement Complex Levels and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
3747 - Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy Is Associated with Inferior Survival for Patients with Relapsed or Refractory Large B-Cell Lymphoma
4132 - Activating STAT3 Mutations Drive CD38 Expression in T-Large Granular Lymphocytic Leukemia
4433 - Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors
4438 - Final Results of a Phase II Study of Brentuximab Vedotin and Lenalidomide in Relapsed and Refractory T-Cell Lymphomas
4460 - Patterns of Use and Outcomes of Novel Agents in Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Single-Center Retrospective Analysis
4507 - Steroid Prophylaxis in Patients Receiving CAR T-Cell Therapy for Relapsed and Refractory Non-Hodgkin Lymphoma

Bramson, E.

976 - Metabolic Determinants of Ferroptosis in B-Cell Lymphoma

Bran, J.

2076 - CD123-CAR T Cells Manufactured in the Presence of Dasatinib Induce High Grade CRS and/or IEC-HS without Improving Efficacy in Pediatric Patients with Recurrent/Refractory Leukemia

Branagan, A. R.

79 - Previous HDM/ASCT Adversely Impacts PFS with BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma
1647 - Two-Year Follow-up after Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia
2972 - Discovery of Undocumented, Cancer-Specific and Pro-Inflammatory Isoforms of WNK2 That Are Highly Expressed in MYD88 Mutated Waldenström’s Macroglobulinemia and Represent Novel Therapeutic Targets.
3011 - A Phase II Study of Pirtobrutinib and Venetoclax in Previously Treated Patients with Waldenström Macroglobulinemia: An Interim Analysis
3339 - Clonal Hematopoiesis of Indeterminate Potential Does Not Impact Overall Survival in Multiple Myeloma

Brancaleoni, V.

1069 - Evaluating the Clinical Impact of Hemoglobinopathy and Hereditary Red Blood Cell Disorder Co-Inheritance in a Cohort of 315 Patients
2465 - Not so Rare, Not so Mild Disease: Defects of Flippase Activity Due to ATP11C Mutations. Description of Three New Cases

Brancamp, R. L.

1244 - Real World Data on the Utility of P-Selectin Expression Assay; Correlation of Test Results and Disease Expression

Branchaud, B.

2422 - Treatment Experience of Patients with Acute Myeloid Leukemia in the Era of Novel Therapies: A Longitudinal Electronic Patient-Reported Outcomes Study

Branchford, B. R.

296 - Mechanical Thromboprophylaxis and Hospital-Acquired Venous Thromboembolism: A Report from the Children’s Healthcare Advances in Thrombosis Consortium
1257 - Anticoagulation Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
2633 - Thrombolytic Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis

Branco, H.

2933 - Genetic Classification of Acute Myeloid Leukemia By Differential Long Noncoding RNA Expression

Brancolini, A.

1754 - Clinical Implications of Plasma-Derived Extracellular Vesicles in Myeloproliferative Neoplasms: Unveiling Inflammatory Potential and Biomarkers for Cancer Treatment

Brand, M.

2657 - YY1-Mediated PcG Regulation Dictates Hematopoietic Stem Cell Fate

Brandao, L. R.

295 - Efficacy and Safety of Apixaban for Pediatric Patients Requiring Anticoagulation for Treatment of Venous Thromboembolism
1257 - Anticoagulation Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
2633 - Thrombolytic Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis

Brandely-Piat, M. L.

2286 - Reducing Infection Risks of Anti-BCMA Bispecific Antibodies in Multiple Myeloma: In-Hospital Vs. Hospital-at-Home Treatment

Brandemarte, A.

519 - Clinical Management Bundle for Patients with Sickle Cell Disease: Improving Completion of Age-Specific Screening Tests and Disease-Modifying Therapy Use

Brander, D. M.

3245 - A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL
3662 - Systems-Based Care Improvements to Optimize BTK Inhibitors in Chronic Lymphocytic Leukemia Vary in the Community Setting
4622 - LP-168 (Rocbrutinib), a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton’s Tyrosine Kinase: Updates on the Phase 1 Trial and Initial Results of the CLL Gatekeeper Mutation Cohort
4633 - Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004
5099 - Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy

Brander, T.

1970 - Enhanced Detection of Pathogenic Germline Variants in Plasma Cell Disorders: Impact of a Targeted Genetic Counseling Referral Pathway

Brandes, A. H.

502 - Vivovec™ Surface-Engineered Lentiviral Particles Mediate In Vivo CAR T Generation with Potent and Highly Durable Activity in Non-Human Primates
2046 - Nonclinical Toxicology, Biodistribution, and Pharmacokinetics of UB-VV111, an In Vivo Anti-CD19 CAR T Cell Therapy

Brandon, J.

2647 - Platelet Quality and Function Variability across Collection Platforms and during Storage: Findings from the Ongoing Chilled Platelet Study in Vitro (CHIPSiv)

Brandow, A. M.

2240 - Preparing for the Future: Themes in Transition Readiness for Individuals with Sickle Cell Disease Using the ASH Transition Readiness Assessment Tool
2303 - Comprehensive Assessment of Adequate Nutrition in Children and Adults with Sickle Cell Disease As Determined By Dietary Guidelines for Americans
2309 - Pain-Specific Patient-Reported Outcomes Are Worse in Adults Compared to Children with Sickle Cell Disease
2313 - High Concordance between Investigator-Verified Diagnosis and Manual Data Abstraction for Sickle Cell Diagnosis Type: An ASH Research Collaborative Data Hub Validation Study
3893 - Individuals with Sickle Cell Disease Have Decreased Intestinal Microbial Diversity Compared to Healthy Related and Unrelated Black Individuals without Sickle Cell Disease
- Beyond IV Push: Alternative Methods for Management of Acute Pain in SCD

Brandsma, E.

4996 - Artificial-Intelligence Driven Quantification of Sickle Red Blood Cell Morphology As an Objective Disease Marker

Brandstadter, J. D.

43 - The Follicular Lymphoma and Chronic Lymphocytic Leukemia Proliferative Microenvironment at Single-Cell Resolution
1155 - Myofibroblast to T-Zone Reticular Cell Ratio Identifies Unicentric Castleman Disease Lymph Nodes
1156 - The Development of Diagnostic Criteria and Utilization of Excisional Lymph Node Biopsies Shorten Time to Diagnosis for Idiopathic Multicentric Castleman Disease
3923 - Lymph Node Transcriptomics in Idiopathic Multicentric Castleman Disease (iMCD) Identifies Pathogenic Mechanisms and Biomarkers Including Increased Clusterin Expression

Brandt, M.

1513 - Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up

Brandwein, J.

213 - Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia
218 - 10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years
1506 - Real-World Experience with CPX-351 for Secondary Acute Myeloid Leukemia: Comparison with FLAG-IDA in a Propensity Score Matching Analysis

Brandwein, N.

3022 - Comparing Antihistamine Premedication Regimens for Preventing Rituximab-Associated Infusion Reactions in Hemato-Oncology Patients: A Retrospective Analysis

Branford, S.

476 - Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is Rare
991 - Strong Association between Cancer Gene Variants at Diagnosis, Especially ASXL1, and Emergence of Kinase Domain Mutation-Driven Resistance in CML Patients Despite Frontline Treatment with More Potent BCR::ABL1 Inhibitors
993 - Increased Inflammatory Cytokines in Plasma Are Associated with Sustained Treatment-Free Remission in Chronic Myeloid Leukaemia
996 - Longitudinal Clonal Tracking Reveals That Early and Sensitive Detection of Blood Cancer-Related Gene Variants in Patients with Chronic Myeloid Leukemia Predicts Treatment Failure
2715 - Imatinib-Sensitive Chronic Myeloid Leukaemia Is Associated with mtDNA Mutations and Reduced Oxphos Capacity
4928 - Clonal Architecture of Donor-Derived Leukemia/Clonal Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplant

Brant, I.

1074 - RBC eNOS Regulates O₂ Delivery Phenotype during Circulatory Transit Via Control of Intracellular pH
2453 - Oxygen Responsive Myosin Activation Governs Oscillatory Piezo1 Signaling in RBCs during Circulatory Transit

Brantley, A.

5088 - Role of Social Determinants of Health on Infection-Related Hospitalizations in Pediatric Hematopoietic Stem Cell Transplant Patients within the First 100 Days Post-Transplant in an Underserved State

Branzanti, F.

242 - Revised ELN Criteria in Polycythemia Vera Identify an Increased Risk Phenotype for Thrombotic Events Beyond Conventional Risk Stratification. a Multicenter Cooperative Study
245 - Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition
1754 - Clinical Implications of Plasma-Derived Extracellular Vesicles in Myeloproliferative Neoplasms: Unveiling Inflammatory Potential and Biomarkers for Cancer Treatment
3187 - Overall Survival with Momelotinib Vs Best Available Therapy in Patients with Ruxolitinib-Experienced Myelofibrosis: A Matching-Adjusted Indirect Comparison
4550 - Prognostic Insights on PRE-Fibrotic Primary Myelofibrosis: A Clinical-Pathological Perspective in 762 Patients

Brasil, S. A. B.

983 - Refining Prognostication in Peripheral T Cell Lymphoma (PTCL): A Risk-Adapted Prognostic Model for Patients with Limited-Stage PTCL
1687 - Clinical Features, Therapy Patterns and Survival Outcomes of Limited-Stage Peripheral T-Cell Lymphomas: A Cross-Continental Study
1692 - The Number of Extranodal Sites Matters! a Proposal for a Feasible Prognostic Model in Nodal PTCL. a Collaborative Study grupo De Estudio Latino-Americano De Linfoproliferativos (GELL) & T-Cell Brazil Project (TCBP)
3064 - Central Nervous System Involvement in Aggressive ATLL: Can We Predict the Risk in a Devastating Complication? Epidemiology and Clinical Features from Latin America. a Collaborative Study from Grupo De Estudio Latino-Americano De Linfoproliferativo (GELL) & T-Cell Brazil Project (TCBP)
3718 - Uncovering the Epidemiology, Therapy Patterns and Outcomes of MALT Lymphoma in Latin America: A Multinational Retrospective Cohort Study
4413 - Importance of Access Inequality and Biological Prognostic Factors in Mantle Cell Lymphoma Outcomes in Brazil: A Real-World Evidence Study from a Third World Country

Brassard, Y.

5057 - Costs of Healthcare Resource Utilization in the Management of Patients with Higher-Risk Myelodysplastic Syndrome in Canada

Bratrude, B.

3516 - Five-Year Outcomes of the “Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease (GVHD) Prophylaxis: A Randomized Controlled Trial” (‘ABA2’)

Brau Queralt, D.

2230 - Leveraging AI for Predicting Genetic Alterations in Multiple Myeloma through Morphological Analysis of Bone Marrow Aspirates

Brauer, D.

2158 - CT-Based Muscle Quality and Visceral Obesity Prior to Allogeneic Hematopoietic Stem Cell Transplantation Is of Prognostic Relevance in Patients with Acute Myeloid Leukemia
4334 - Measurable Residual Disease Detection of IDH1 or IDH2 Mutations Post but Not Prior to Allogeneic Hematopoietic Stem Cell Transplantation Show High Prognostic Relevance in Patients with Acute Myeloid Leukemia

Brauge, B.

739 - Follicular Dendritic Cells Represent a Therapeutic Vulnerability in Early Follicular Lymphoma

Braulke, F.

4394 - Real World Patient Diagnostic and Treatment Patterns in Marginal Zone Lymphoma (MZL): First Results of the Prospective National MZL Registry of the German Lymphoma Alliance

Braun, A.

2758 - Combined CXCR-4 Inhibition with Novel Agent GPC-100 (burixafor) and Beta 2 Adrenergic Receptor Blockade Enhances Cytarabine Response for Acute Myeloid Leukemia Blasts on Stroma

Braun, B.

723 - CDK8 Inhibition Represses Monocyte-like Gene Expression in Acute Myeloid Leukemia Cells and Antagonizes In Vivo Resistance to FLT3 Inhibition

Braun, B.

4105 - STAG2 Mutations Drive Development of Myelodysplastic Syndromes by Promoting R-Loop-Mediated Genomic Instability and Activation of cGAS-STING

Braun, L. M.

3392 - FLT3-ITD Driven CMTM6 Expression Contributes to Immune Escape of Acute Myeloid Leukemia

Braun, M. A.

2406 - Racial and Socioeconomic Disparities in Patients with Waldenström’s Macroglobulinemia. a SEER Database Analysis

Braun, S.

2876 - ICT01, an Investigational γ9δ2 T Cell Activator, Added to Azacitidine-Venetoclax Achieves Frequent and Early Complete Remissions in Adults with AML Unfit for Intensive Induction Chemotherapy: Interim Results from the Ongoing Open-Label, Randomized Phase 1 Study Eviction

Braun, T. P.

62 - Influence of AML Differentiation State in Risk Stratification of Frontline Therapy with Hypomethylating Agents + Venetoclax in AML
3143 - SETBP1 Regulates Myst Acetyltransferase Complexes to Drive a Leukemogenic Gene Expression Program

Braun, T.

227 - Secondary Genetic Alterations and Measurable Residual Disease in Core Binding Factor Acute Myeloid Leukemia - a Study from the Acute Leukemia French Intergroup
2424 - Treatments and Outcomes of Adult Patients with AML in the Real-Life – First Report of the French Observational ALFA-PPP Study
3241 - Prognosis of the IGLV3-21^R110 Mutation in a Real-Life Chronic Lymphocytic Leukemia Cohort

Braun, T.

2286 - Reducing Infection Risks of Anti-BCMA Bispecific Antibodies in Multiple Myeloma: In-Hospital Vs. Hospital-at-Home Treatment

Braun, T.

3111 - Updated Response and Safety for Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Brauneck, F.

1374 - The PTPN2/PTPN1 Inhibitor Abbv-CLS-484 Augments Immune Responses Against Leukemic Blasts and Impedes Leukemia Cell Proliferation in AML Alone and in Combination with Venetoclax

Brauneck, F.

1397 - CD39 Is Predominantly Expressed in Adverse AML Patients and Blockade By a New Anti-CD39 Nanobody Increases Lysis of AML Blasts

Bräunig, S. S.

4227 - In Situ Spatial mRNA Analysis Implicates Increased TGFB1 and PDGFA1 Expression As Potential Drivers of Fibrosis in Pediatric Acute Lymphoblastic Leukemia

Bräuning, C.

1351 - Parallel Sequencing of Transposons and Transcriptomes in Single Cells for Genome-Wide Cancer Gene Discovery

Bräuning, S.

417 - Autosomal Recessive COPZ1 Mutations Cause Isolated Severe Neutropenia or Complex Syndrome with Severe Neutropenia

Braunschweig, I.

2791 - Venetoclax Alone or in Combination Shows Promising Activity in Preclinical Models and Clinical Cases of Relapsed/Refractory North American Adult T-Cell Leukemia Lymphoma

Braunstein, E. M.

138 - Genetic or Epigenetic CR1 Deficiency Defines Catastrophic Antiphospholipid Syndrome (CAPS) and Response to Complement Inhibition
3173 - High Molecular Risk Mutations (HMR) Drive Progression of CALR-mutated Myeloproliferative Neoplasm (MPN)
4546 - Clinical Outcomes in Patients with Myelofibrosis Treated with Ruxolitinib and Anemia-Supporting Medications

Braunstein, E. M.

3136 - Clinical and Molecular Characterization of Disease Progression in Patients (Pts) with Low-Risk Myelofibrosis (MF) Enrolled in the MOST Study
3145 - Molecular Predictors of Disease Progression to Myelofibrosis (MF) in Patients (Pts) with Polycythemia Vera (PV) Enrolled in Reveal
3813 - Real-World Treatment Patterns and Blood Count Control in Patients with Polycythemia Vera Who Switched from Hydroxyurea to Ruxolitinib

Braunstein, M.

362 - Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial

Braunstein, M. J.

857 - A Multiomic Analysis of Waldenstrom's Macroglobulinemia Identifies Three Subtypes of Disease Based on Impaired Plasma Cell Differentiation
4655 - Mutationally Enriched Regions of the Non-Coding Genome Harbor Functionally Impactful Mutations That Dysregulate Key Genes Involved in Multiple Myeloma Pathogenesis
5155 - Characterization and Comparative Outcomes of Younger Multiple Myeloma Patients

Braunstein, Z.

982 - Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort

Brautman, W.

3862 - Transcriptional Control of Gene Expression By O-Glcnacylation during Erythropoiesis

Braverman, E.

2020 - Deletion of AMPK in Human T Cells Decreases Glycolytic Compensation and Severity of Xenogeneic Gvhd without Impairing GVL Potential

Bravetti, C.

4343 - Inflammatory Waldenström Macroglobulinemia Is Associated with Clonal Hematopoiesis: A Multicentric Cohort

Bravo, P.

2356 - Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)

Bravo-Gonzalez, A.

4463 - Polatuzumab-Vedotin Plus Bendamustine and Rituximab for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis

Bravo-Perez, C.

31 - Genetic Determinants of Hypercoagulability in Complement and Hemostatic Systems Shape the Thrombotic Risk of Paroxysmal Nocturnal Hemoglobinuria
35 - First Results of High Throughput Pipeline for Serotypic and TCR Clonotypic Specificities in Aplastic Anemia and Large Granular Lymphocyte Leukemia Uncovering Antigenic Peptides Relevant to Disease Etiology
1254 - Budd-Chiari Syndrome: Pathogenetic Factors and Completeness of Screening for Paroxysmal Nocturnal Hemoglobinuria
1315 - Using Machine Learning to Predict the Risk of Evolution to Paroxysmal Nocturnal Hemoglobinuria in Patients with Aplastic Anemia
1328 - Genomic Landscape of Germline RUNX1 variants in Adult Myeloid Neoplasia According to Functional Impact
1688 - Low-Count T-/NK-Large Granular Lymphocytic Leukemia: A Nosologically Distinct Disease Subtype at the Crossroads between Lymphoproliferation, Autoimmunity and Immunodeficiency
2224 - Unraveling Immunogenomic Features Germane to Pathobiology of Myelodysplastic Syndromes
2675 - Dysregulation of the Ubiquitination Pathway: Insights on Autoinflammatory Conditions and Inborn Errors of Immunity in Bone Marrow Failure Disorders
2920 - Distinct Phenotypes of Myeloid Neoplasia Associated with Truncating C-CBL Mutations
2943 - Geno-Transcriptomic Topography of Clonal Drivers in Trisomy 8 Myeloid Malignancies
3199 - Could Somatic Gene Rescue Explain Frequency of Compound Heterozygous and Concurrent Receptor Tyrosine Kinase Mutations in Hematological Diseases?
3214 - The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms
4084 - An Immunogenetic Perspective on Bone Marrow Failure Syndromes: The KIR-HLA System
4085 - Counterpoising Immune Pressure and Privilege: Paroxysmal Nocturnal Hemoglobinuria Evolutionary Dynamics
4096 - Genetic and Molecular Dynamics of DDX41-variants: Insights on the Variant Effect Prediction
4104 - Telomere Content Diversity in Myeloid Neoplasia Could Inform on Differential Sensitivity to Telomerase Inhibitors
4436 - Clinically Driven Algorithms Identify Patients with Large Granular Lymphocytic Leukemia at Risk of Significant Cytopenia Requiring Treatment
4573 - Elucidating the Somatic Genetic Rescue Underlying Del(20q) Myeloid Neoplasms
4980 - Novel Machine Learning Approaches Tailored to Protein Configuration Predict Drug Vulnerabilities in Myeloid Neoplasia
- Inborn Errors of Immunity in T-Cell Large Granular Lymphocyte Leukemia

Brawley, C.

497 - Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Dreamm-9 Updated Interim Analysis

Bray, M. R.

1399 - Inhibition of Threonine Tyrosine Kinase Suppressed TP53-mutated Acute Myeloid Leukaemia Via Synergism with Venetoclax and Activation of the Cgas-Sting Pathway
2763 - HPK1 Inhibition and Venetoclax Combination Suppressed AML By Enhancing Cytotoxic T-Cell Response to Leukaemia

Braylan, R. C.

863 - A Randomized Phase 2 Trial of 2nd-Line Cladribine with Concurrent or Delayed Rituximab in Patients with Classic Hairy Cell Leukemia

Breaker, J.

3236 - Comprehensive Characterization of Inflammatory Cytokines in Chronic Lymphocytic Leukemia Highlight Immune Dysregulation and Associates with MRD

Breakey, V. R.

795 - Pediatric Autoimmune Hemolytic Anemia Is Associated with a High Incidence of an Underlying Immune Disorder and High Mortality Rate

Breccia, M.

242 - Revised ELN Criteria in Polycythemia Vera Identify an Increased Risk Phenotype for Thrombotic Events Beyond Conventional Risk Stratification. a Multicenter Cooperative Study
245 - Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition
404 - The Prognostic Value for Survival of Self-Reported Fatigue in Patients with Newly Diagnosed Myelodysplastic Syndromes: An International Prospective Observational Study By the Gimema
992 - Molecular Outcome of Chronic Myeloid Leukemia Affected Patients Not in Deep Molecular Response: The “Others” from the Gimema Labnet Network
1765 - Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial
1772 - Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50 – 60 Years: A “Campus CML” Study
1778 - Treatment-Free Remission in CML Patients Discontinuing Post-First Line Therapy
2427 - Long-Term Safety and Effectiveness of Ponatinib Treatment in Patients with TKI Intolerance: Subgroup Analysis of the Observational Study of Ponatinib Treatment in Patients with CML in Italy (OITI)
3149 - Retrospective Study to Compare Treatment Outcomes of Asciminib Vs. Ponatinib in 99 Patients with T315I Mutated Chronic Myeloid Leukemia
3155 - CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or ≤ 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study
3162 - Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: Observational Study of 673 Patients in Italy
4526 - Asciminib Shows High Efficacy and Favorable Tolerability at 80 Mg Once Daily and 40 Mg Twice Daily in Patients with Chronic Phase Chronic Myelogenous Leukemia Previously Treated with 2 or More Tyrosine Kinase Inhibitors: Primary Analysis from the ASC4OPT Study
4530 - Evaluating the Impact of Cross-over from Imatinib to Nilotinib on the Overall Survival in Chronic Myeloid Leukemia Using Inverse Probability of Censoring Weighting: Results from the Gimema Sustrenim Study
4535 - Probability of Switch of TKIs Treatment According to Baseline Features in a Large Chronic Myeloid Leukemia (CML) Population: Italian CML Network
4550 - Prognostic Insights on PRE-Fibrotic Primary Myelofibrosis: A Clinical-Pathological Perspective in 762 Patients

Brechignac, S.

3241 - Prognosis of the IGLV3-21^R110 Mutation in a Real-Life Chronic Lymphocytic Leukemia Cohort
5141 - Infection Risk and Efficacy of Anti-BCMA Bispecific Antibodies in Multiple Myeloma: A Real-World Propensity Score-Matched Study

Breckenridge, Z.

3464 - Alberta Cellular and Immunotherapy (ACIT) 001, Updated Results of Decentralized Production of Second Generation, Anti-CD19/41BB/CD3z Chimeric Antigen Receptor (CAR) T-Cells in Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) and Aggressive Non-Hodgkin Lymphoma (NHL)

Breda, L.

2195 - An Erythroid-Specific Lentiviral Vector Improves Anemia and Iron Metabolism in a New Model of Xlsa

Breen, W. G.

2283 - Impact of COVID-19 on Multidisciplinary Lymphoma Tumor Boards: An Analysis of Practice and Care Changes

Breeze, C.

4339 - Genome-Wide Meta-Analysis Identifies Multiple Germline Genetic Variants Associated with Increased Risk of Follicular Lymphoma
4358 - Expanded Genome-Wide Association Study (GWAS) Identifies Nine Novel Germline Risk Loci for Waldenström Macroglobulinemia (WM) and Lymphoplasmacytic Lymphoma (LPL)

Brehon, M.

1927.1 - Expanding the Eureka Study: Integrating a Comprehensive Clinical Registry with Molecular Profiling to Advance AL Amyloidosis Research

Breillat, P.

3891 - Unique Nature of Sickle Cell Diastolic Cardiomyopathy: A Tailored Echocardiographic Definition to Refine Prognostic Stratification in Young Adults

Breinholt, M. F.

1594 - NOTCH1 Mutations Are Associated with Therapy-Resistance in Patients with B-Cell Lymphoma Treated with CD20xCD3 Bispecific Antibodies

Breit, K.

3714 - Neurocognitive Decline Among Long-Term Survivors of Pediatric Hodgkin Lymphoma: A Report from the St. Jude Lifetime Cohort

Breitkreutz, L.

2283 - Impact of COVID-19 on Multidisciplinary Lymphoma Tumor Boards: An Analysis of Practice and Care Changes

Breitmeyer, J. B.

1743 - A Phase 1/2 Study of a ROR1-Targeting CAR T Cell Therapy (ONCT-808) in Adult Patients with Relapsed/Refractory (R/R) Aggressive B Cell Lymphomas (BCL)

Brem, E.

4411 - Odronextamab Monotherapy in Previously Untreated Patients with High-Risk Follicular Lymphoma (FL): Results of the Safety Lead-in of the Phase 3 Olympia-1 Study

Bremathas, S.

176 - Allogeneic Transplantation for Sickle Cell Disease Offers High Rates of Cure with Low Incidence of Severe Chronic GVHD in Both Children and Adults: Real World Data from 2010-2021. An Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party
1097 - Donor Trait Status Determines Haematological Outcomes Post-Haemopoietic Stem Cell Transplantation in Transfusion Dependent Thalassaemia Independent of HLA Matching and Chimerism Status
2136 - Age Is a Crucial Determinant of GFRS with Incidence of Severe Chronic GVHD Reducing over Time in Haemopoietic Cell Transplantation for Transfusion Dependent Thalassaemia: Real World Data from 2010-2021. an Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party
2184 - Significant Growth in HCT Use for Haemoglobinopathies in the Last Decade Driven By Sickle Cell Disease across All Ages with Excellent Outcomes: An Analysis of EBMT Haemoglobinopathies Working Party
3518 - Abatacept Abrogates the Risk of Acute GvHD in Both Matched and Mismatched Transplantation for Haemoglobinopathies and Bone Marrow Failure

Bremer, C. T.

479 - Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Kinase Inhibitor (TKI)

Brendel, C.

4767 - Epitope Editing Combined with Extended Schedule Anti-KIT Antibody Treatment Allows Immune-Based In Vivo Selection of Multiplex Genome-Engineered Cells

Brendle-Moczuk, D.

1430 - Increased Environmental Temperature Damages DNA and Is an Emerging Health Risk That Correlates with Rates of Acute Lymphoblastic Leukemia (ALL) in Europe

Brennan, D.

341 - Escalating Doses of AZD0486, a Novel CD19xCD3 T-Cell Engager, Result in High Complete Remissions with Rapid Clearance of Minimal Residual Disease in Patients with Relapsed/Refractory Follicular Lymphoma
868 - Evaluation of AZD0486, a Novel CD19xCD3 T-Cell Engager, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in an Ongoing First-in-Human Phase 1 Study: High Complete Responses Seen in CAR-T–Naive and CAR-T–Exposed Patients
2794 - Exposure-Response Analysis and Quantitative Systems Pharmacology Modeling for Optimal RP2D Selection of AZD0486 in Follicular Lymphoma Patients

Brenner, B.

1748 - Reduction in Platelet Counts May Predict the Development of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma

Brentjens, R.

2070 - CD371-Targeted CAR T-Cells Secreting Interleukin-18 Exhibit Robust Expansion and Disease Clearance in Patients with Refractory Acute Myeloid Leukemia
3406 - Developing an Optimal Fully-Human CD371-Targeting IL-18 Secreting CAR T Cell for the Treatment of Acute Myeloid Leukemia
4802 - Enhancing CAR T Cell Efficacy By Modulating PI3K Signaling Via a Synthetic CD28 Rheostat

Brescia, A. C.

5094 - Real-World Data Shows Increased Incidence of Autoimmune Disease in Survivors of Childhood Lymphoid Malignancies

Bresciani, E.

198 - CD74 Signaling Regulates Inflammatory Stress to Drive Defective Hematopoiesis and Fitness Advantage of Progenitors in RUNX1-Familial Platelet Disorder
798 - Minority Patients in the NIH RUNX1-FPDMM Natural History Study Present Mostly with Large Deletions Affecting RUNX1
1324 - Single Cell Transcriptome Analysis of CD34+ Cells from Patients with RUNX1-Fpdmm at Different Stages of Disease Progression
- Single Cell Transcriptome Analysis of CD34+ Cells from Patients with RUNX1-Fpdmm at Different Stages of Disease Progression

Bresnahan, C.

4408 - Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)

Bresnick, E. H.

725 - Aberrant Stemness Transcription Signature Unveils a Mechanism of Chemotherapy Resistance through Blunting p53-Mediated Response in Acute Myeloid Leukemia
939 - Multiomic Analyses of Erythropoiesis and Anemia Mechanisms Reveal a Signaling Network with Converging Cytokine and Sphingolipid Inflammatory Pathways
1325 - Building a Clinical Genetic GATA2 Variant Curation System with Activity Metrics
4091 - GATA2 Genetic Variant-Induced Pathogenesis: Loss-of-Function and Gain-of-Function Mechanisms

Bresolin, S.

640 - Pursuing Leukemia Stem Cells Definition in Pediatric Acute Myeloid Leukemia
2910 - Novel Promising Therapeutic Strategies for Advancing the Treatment of KMT2A-Rearranged AML

Bresson, L.

1381 - S227928: A Novel Anti-CD74 ADC with MCL-1 Inhibitor Payload for the Treatment of Acute Myeloid Leukemia (AML) and Other Hematologic Malignancies
4136 - CD74 Antibody Conjugated to an MCL1 Inhibitor (S227928) Combines Synergistically with Venetoclax to Enhance Killing of Acute Myeloid Leukemia

Bret, C.

4080 - High Proportion of PNH Type II Neutrophils, I.e. Relative Percentage ≥3%, Is Associated with Thrombosis in Patients Displaying a PNH Clone >1%: Evidence from Analysis of the 5-Year French Nation-Wide Multicenter Observational Study

Brethenoux, C.

3705 - Sentiment Analysis Applied to Digital Conversations Among Warm Autoimmune Hemolytic Anemia (wAIHA) Patients Receiving Rituximab and/or Blood Transfusion

Brethon, B.

310 - Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and Outcomes

Brewer, B.

5133 - Modeling Longitudinal Quality of Life Changes in Patients Diagnosed with Lymphomas: Heatmap Analysis of Electronic Patient-Reported Outcomes (ePRO) Data from the Bison-PRO Quality of Life Study

Brewer, C.

3637 - Standardized Approach to Peri-Operative and Peri-Procedural Chemical Venous-Thromboembolism Prophylaxis

Brewin, J.

2237 - Utilising Patient-Reported Experience Measures to Drive Healthcare Improvements: The Application of Validated PREM Survey Tools in a Haemoglobinopathy Network in South London

Bridges, S.

3338 - Cell-Free DNA Whole Genome Sequencing for Non-Invasive MRD Detection in Multiple Myeloma

Bridoux, F.

892 - Efficacy and Safety of Isatuximab, Pomalidomide and Dexamethasone in Relapsed AL Amyloidosis: Interim Results of the Isamyp Phase 2 Joint Study from the IFM and ALLG
3328 - An International Study of 343 Newly Diagnosed MM Patients with Acute Renal Failure Due to Cast Nephropathy: Assessment of Factors Affecting Renal Response
- Renal Manifestations of MGUS

Brieghel, C.

586 - Mutations in BCOR, CCND2, NRAS and XPO1 Predict Clinical Outcomes upon MRD-Guided Venetoclax Plus Ibrutinib in Relapsed and Refractory Chronic Lymphocytic Leukemia
888 - Quality of Life in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Improves after Minimal Residual Disease-Guided Treatment with Ibrutinib Plus Venetoclax
1860 - Excellent Clinical Outcomes in Deeply Mutated IGHV Chronic Lymphocytic Leukemia upon Fludarabine and Cyclophosphamide Plus Rituximab
3306 - Implementing Revised Reference Intervals for Free Light Chains Improves Risk Stratification of Monoclonal Gammopathy of Undetermined Significance

Brieghel, C.

4609 - Improved Innate Immune Function upon Preemptive Short-Term Acalabrutinib and Venetoclax in Newly Diagnosed CLL Patients with High Risk of Infections: Translational Findings from the Prevent-Acall Clinical Trial

Brien, G. L.

4121 - A Novel Form of AEBP2-Containing PRC2.2 Is a Genetic Dependency in Germinal Centre B-Cell Lymphoma and Its Targeting Can Overcome Acquired Resistance to EZH2 Inhibition

Briercheck, E.

247 - Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma

Briere, J.

575 - Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase 3 Gained Study Conducted By Lysa

Brierley, C.

871 - Development of a First-in-Class CAR-T Therapy Against Calreticulin-Mutant Neoplasms and Evaluation in the Relevant Human Tissue Environment

Brierley, C. K.

3146 - RUX-AZA Response in AP/BP-MPN Is Driven By Release of the Differentiation Block in Mutant HSPCs: A Single-Cell Multi-Omic Analysis of Responders on the Phase Ib Phazar Study

Briest, F.

44 - Tracing Clonal Hematopoiesis and Tumor-Specific Mutations in Hematopoietic Progenitors of B Cell Non-Hodgkin Lymphoma (NHL) Patients

Briggs, J.

3111 - Updated Response and Safety for Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Briggs, R.

4110 - Investigating the Potential of Spliceosome Mutations to be Used As Biomarkers for Directing Immune Checkpoint Blockade Therapies in Myeloid Malignancies

Brignac, M.

2303 - Comprehensive Assessment of Adequate Nutrition in Children and Adults with Sickle Cell Disease As Determined By Dietary Guidelines for Americans
2309 - Pain-Specific Patient-Reported Outcomes Are Worse in Adults Compared to Children with Sickle Cell Disease
3893 - Individuals with Sickle Cell Disease Have Decreased Intestinal Microbial Diversity Compared to Healthy Related and Unrelated Black Individuals without Sickle Cell Disease

Brignier, A.

1433 - Characteristics and Outcome Determinants in Children, Adolescents and Young Adults Who Failed Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia
4343 - Inflammatory Waldenström Macroglobulinemia Is Associated with Clonal Hematopoiesis: A Multicentric Cohort

Brik Simon, D.

2532 - Clinical and Laboratory Characteristics of Pediatric Patients with ACKR1/Darc-Associated Neutropenia

Brill, P.

4757.2 - Trial in Progress: Phase 2 Study of Subcutaneous Isatuximab, Administered By an on-Body Delivery System, in Combination with Weekly Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (SubQSA)

Brillembourg, H.

2084 - The CAR-Hematotox Identifies Patients at High Risk of Infectious/Inflammatory Complications in a Cohort of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Treated with ARI-0001 (Varnimcabtagene Autoleucel)
3423 - M-Easix (Better Than EASIX) Correlates with Specific Endotheliopathy Biomarkers, Predicts Severe CAR-T Cell Toxicities and Discriminates from Sepsis

Brilloff, S.

1563 - ACSL4-Associated Lipid Metabolism Is a Distinct Therapeutic Vulnerability in KMT2A-Rearranged Acute Myeloid Leukemia

Brindel, I.

1321 - Efficacy and Safety of Pegcetacoplan in PNH Patients with Extra-Vascular Hemolysis Under Anti-C5: The Real-Life Experience of the National French Reference Center
4859 - Up-Front Matched Unrelated Donor Transplantation in Pediatric Patients with Idiopathic Aplastic Anemia: A Phase II Feasibility Study, on Behalf of Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC) and French Reference National Center of Severe Aplastic Anemia

Brindisi, M.

104 - Clinical Relevance of the Integrative Analysis of Gut Microbiome and Metabolomics in Myeloid Neoplasms: Correlations with Genomic Profiles, Treatment Response/Complications and Clinical Outcome
105 - Enhancing Personalized Prognostic Assessment of Myelodysplastic Syndromes through a Multimodal and Explainable Deep Data Fusion Approach (MAGAERA)
2221 - A Comprehensive, Artificial Intelligence, Digital Twin Platform Based on Multimodal Real-World Data Integration for Personalized Medicine in Hematology
3137 - Unveiling MED12L: A Potential Novel Orchestrator of Platelet Dysfunction in Myeloproliferative Myeloid Neoplasms
3194 - Single-Cell Multi-Omics Reveals Anticipated Erythroid Differentiation and Transcriptional Regulation in Differentiation Trajectories of SF3B1 - JAK2/MPL Mutated Cells in MDS/MPN-RS-T
3598 - Artificial Intelligence-Powered Digital Pathology to Improve Diagnosis and Personalized Prognostic Assessment in Patient with Myeloid Neoplasms
4981 - Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology
4989 - An Artificial Intelligence-Based Federated Learning Platform to Boost Precision Medicine in Rare Hematological Diseases: An Initiative By GenoMed4all and Synthema Consortia

Bringhen, S.

773 - Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study
1976 - Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible or with No Immediate Intent for Transplant: Long-Term Efficacy and Safety in a Phase 1b Study
2226 - Development and Validation of Novel Machine Learning-Based Risk Scores for Multiple Myeloma: Insights from the Harmony Alliance Big Data Platform

BrinJones, H.

2780 - Preclinical Proof-of-Concept of a Novel mRNA-Based Therapeutic Combination of an FcRH5 Targeted NK Cell Engager and an IL-15 Superagonist for the Treatment of Multiple Myeloma

Brinker, M. T.

2258 - Starting a Blood Bank inside a Private Practice

Brinkman, T.

3714 - Neurocognitive Decline Among Long-Term Survivors of Pediatric Hodgkin Lymphoma: A Report from the St. Jude Lifetime Cohort

Brioli, A.

3383 - Idecabtagene Vicleucel (ide-cel) Shows Similar Efficacy and Toxicity in Patients with Multiple Myeloma Aged 70 and Older Compared to Younger Patients: A Multicenter Cohort Study

Brioli, A.

2007 - Efficacy of Anti-BCMA CAR-T Cell Therapies in Multiple Myeloma Patients with Prior Exposure to Bispecific Antibodies- Results from a Retrospective Multi-Center Registry Analysis

Briones, J.

67 - Rapcabtagene Autoleucel (YTB323) in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Phase II Trial Clinical Update
920 - HSP-CAR30, an Academic Memory-Enriched CART30, for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and CD30⁺ T Cell Lymphoma: Clinical Results of a Phase I/II Trial
3049 - The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin’s Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)
4898 - Efficacy and Safety of Reduced-Doses of Post-Transplant Cyclophosphamide in Matched Peripheral Blood Stem Cell Transplantation, a Multicenter Study

Briones, M.

709 - Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children

Briones, W.

3509 - Terminal Complement Activation in Children with Sinusoidal Obstructive Syndrome after Hematopoietic Cell Transplantation

Brioso Infante, J.

319 - Clinical Features and Outcomes in 228 Patients Diagnosed with Blastic Plasmocytoid Dendritic Cell Neoplasm: A Pethema/PALG Study
320 - Treatment Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Data from the Pethema and PALG Epidemiologic Registry
2894 - Improved Real-World Outcomes of Patients with Acute Promyelocytic Leukemia Treated with First-Line Arsenic Trioxide in Specialized Centers in Portugal through a 24/7 Phone-Based Referral: A Study from the Portuguese Acute Leukemia Group

Briski, R.

666 - Newly Developed Prognostic Score for Myelodysplastic Syndrome (MDS) with Isolated 5q Deletion (IPSS-del(5q))

Brisou, G.

239 - Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy: A Descar-T Study By Lysa Group
528 - Hemophagocytic Lymphohistiocytosis-like Syndrome after Anti-CD19 CAR T-Cells for B-Cell Lymphoma and B-Cell Acute Lymphoblastic Leukemia: A Lysa, Sfce and Graall Study from the Descar-T Registry
740 - A Single Cell Atlas of Follicular Lymphoma across Clinical Stages Defines Tumor B Cell Archetypes, Immune Microenvironment Heterogeneity and Novel Cell States Associated with High-Risk FL
955 - Deciphering the Mechanism of Action of the Novel Celmod, Golcadomide, during Germinal Center B Cell Immune Response and in a Preclinical Mouse Model of Follicular Lymphoma
1597 - Single-Cell Atlas of Diffuse Large B-Cell Lymphoma Reveals Integrated Malignant B Cell and Tumor Microenvironment Characteristics Associated with Clinical Response
3124 - CAR T-Cells Treatment for Relapsed/Refractory B-Cell Lymphoma Is Effective and Safe in People Living with HIV (PLWH): A Lysa Study from the Descar-T Registry
3129 - A Real-World Weighted Comparison of Tisagenlecleucel and Axicabtagene Ciloleucel CAR T Cells in Relapsed or Refractory Diffuse Large B Cell Lymphoma Aged 75 Years and Older : A Lysa Study from the Descar-T Registry
4497 - Plamotamab: First Presentation of Subcutaneous Administration in a Phase 1 Dose Escalation Study in Heavily Pretreated R/R NHL Patients Who Had Prior CAR-T Cell Therapy
4505 - Health-Related Quality of Life after Axi-Cel As a Second-Line Therapy in Patients with High-Risk Relapsed/Refractory Large B-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Results of the Alycante Phase II Trial

Brisson, A.

3839 - Protein S Enhances the Phagocytosis of Phosphatidylserine-Positive Erythrocyte: Implications for the Erythrocytes Turnover

Brissot, E.

508 - Younger Haploidentical Versus Older Matched Sibling Donors in Acute Lymphoblastic Leukemia: A Study from the ALWP of EBMT
596 - Long-Term Outcome of Unrelated Cord Blood Transplantation in Patients with Idiopathic Refractory Severe Aplastic Anemia: A Nationwide Phase 2 Study
693 - No Differences in Transplant Outcomes with Post-Transplant Cyclophosphamide in One Antigen Mismatched Unrelated Donor Compared to Matched Unrelated Donor Recipients Receiving Antithymocyte Globulin in Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT
731 - Determinants of Isolated CNS Relapse in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia. from Graall-2005 to -2014 Trials
851 - Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation in First Remission: On Behalf of the EBMT Acute Leukemia Working Party
2180 - Better Outcome Following Younger Haploidentical Donor Versus Older Matched Unrelated Donor Transplant for Patients with Acute Myeloid Leukemia in First Remission: A Study from the Global Committee and Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
2185 - Improved Post-Transplant Outcomes over Time for Older Patients with Acute Lymphoblastic Leukemia in First Complete Remission. a Study from the EBMT Acute Leukemia Working Party
2188 - Outcome of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia with Wilms Tumor 1 (WT1) Mutation: A Study from the ALWP/EBMT
3562 - Similar Transplant Outcomes for Haplo and MUD Allo-Hcts in AML Patients Achieving CR2: A Study Analyzing 4030 Allo-HCT Recipients from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
4942 - Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party
4944 - Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Haploidentical Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT
4945 - Prognostic Impact of t(9;11) and Del(7q) As Intermediate-Risk Abnormalities in AML Following Allo-Transplant: Insights from the ELN 2022 Classification – an EBMT ALWP Study

Brito, L.

4413 - Importance of Access Inequality and Biological Prognostic Factors in Mantle Cell Lymphoma Outcomes in Brazil: A Real-World Evidence Study from a Third World Country

Brito, M.

1125 - First-Year Outcomes of Newborn Sickle Cell Disease Screening in an Angolan Hospital
1132 - Analysis of the Pilot Study of the International Hemoglobinopathy Research Network (INHERENT)
2522.1 - Learner- Low Dose Aspirin Preterm Trial (Angola). Low Dose Aspirin in Pregnant Women with Sickle Cell Disease When Started in the First Versus Second Trimester– a Clinical Control Study in Angola

Brito, P. L.

2489 - Defining Mechanistic Responses to Different Vaso-Occlusive Triggers in Sickle Cell Disease: A Step Towards Personalized VOC Reversal Strategies

Britos, P. N.

1706 - Unveiling the Burden of Diffuse Large B Cell Lymphoma in Paraguay: A Multicenter Study on Clinical Outcomes and Diagnostic Access

Brittenham, G. M.

23 - Iron Repletion of Iron-Deficient Blood Donors Affects Brain Iron, Myelin, and Neural Network Activation Patterns

Brittle, C.

3786 - Satisfaction and Experiences with Talquetamab: Results from Qualitative Patient and Physician Research

Briukhovetska, D.

4796 - Dissection of Single-Cell Landscapes for the Development of Chimeric Antigen Receptor T Cells in Hodgkin Lymphoma

Brivio, E.

310 - Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and Outcomes

Brix, T.

4242 - “As Treated” Validation of the European LeukemiaNet (ELN) Classification for Adult Acute Myeloid Leukemia (AML) Patients (pts) Treated in a Large AML-Referral Center from 2010-2022

Broadhurst, A.

1272 - Hematopoietic Stem Cell Function and Differentiation Is Regulated By DCAF7 through Polycomb Repressive Complex 1 (PRC1) Modulation

Brocco, C.

3992 - Very Long-Chain Saturated Fatty Acids Are Inversely Correlated with Thrombin Generation and Linked to a Reduced Risk of Coronary Artery Disease and Myocardial Infarction: Preliminary Findings from an Angiographically-Controlled Study

Broccoli, A.

3740 - Immune Checkpoint Inhibitors in Primary Mediastinal B-Cell Lymphoma: A Monocentric Real-Life Experience and Future Potential

Brochier, C.

2486 - Inhibition of the Complement Alternative Pathway Attenuates Hemolysis and Preserves Renal Function in a Mouse Model of Sickle Cell Disease
2644 - Transcriptomic Analysis Shows a Common Multi-Organ Inflammatory/Complement Signature in Hemolysis-Induced Damage
3870 - Complement Activation and Its Implication in the Pathophysiology of Hemolytic Anemia and Aging in Mouse Models of Sickle Cell Disease and Beta-Thalassemia

Brock, J.

1045 - Feasibility, Safety and Efficacy of Oral Maintenance Therapy with Venetoclax Plus Decitabine/Cedazuridine after Venetoclax Plus FluBu2 for High Risk MDS/AML Undergoing RIC Allo-HCT

Bröckelmann, P. J.

367 - Targeting Lymphoma Associated Myeloid-Monocytic Cells through CSF1R Blockade Enhances CAR-T Cell Response in Aggressive B Cell Lymphoma
568 - PET-Guided Brecadd in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma: Results of the Phase 2 Part of the GHSG HD21 Trial
3044 - Serum TARC Dynamics Correlate with Clinical Response and Metabolic Tumor Volume during Anti-PD1-Based First-Line HL Treatment in the GHSG Phase II Nivahl Trial
3050 - Patterns of Disease in Early Stage Favorable Hodgkins Lymphoma
3054 - Brentuximab Vedotin, Cyclophosphamide, Doxorubicin and Prednisone (B-CAP) First-Line Treatment of Advanced-Stage Hodgkin Lymphoma: Final Results of the GHSG-NLG Phase II Bvb Trial
3818 - Outcomes of Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Multicenter Real-World Analysis
4428 - Abscopal Effect of Radiotherapy and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Results of the International GHSG Phase II Aern Trial
4796 - Dissection of Single-Cell Landscapes for the Development of Chimeric Antigen Receptor T Cells in Hodgkin Lymphoma

Brodard, J.

1120 - Transcriptomic Profiling Supports the Phenotypic Classification of Stable-State Sickle Cell Disease Patients

Broder, M. S.

3665 - A Medical Chart Review of Healthcare Costs in Patients with Systemic Amyloid Light Chain Amyloidosis By Mayo 2012 Stage in the United States
5052 - U.S. Expert Consensus on Defining Intolerance to Tyrosine Kinase Inhibitor Treatment in Chronic Phase Chronic Myeloid Leukemia (CML)

Broderick, V.

373 - Significant Incidence of Mixed Donor Chimerism Despite TBI Conditioning in Paediatric B-ALL Patients Bridged to Transplant with Blinatumomab – a Report from the UK and Ireland Paediatric Bone Marrow Transplant/Cellular Therapies Group

Brodersen, L. E.

967 - A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO – a Report from the Children’s Oncology Group
2949 - Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children’s Oncology Group

Brodin, P.

4258 - Outcome of Patients with TP53 Mutated Relapsed/Refractory AML with Lintuzumab-Ac225 in Combination with CLAG-M Following Venetoclax Plus Hypomethylating Agent Therapy

Brodsky, A.

2687 - Phase III Randomized COMMODORE 2 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Naive to Complement Inhibition

Brodsky, R. A.

138 - Genetic or Epigenetic CR1 Deficiency Defines Catastrophic Antiphospholipid Syndrome (CAPS) and Response to Complement Inhibition
1225 - Complement Biosensors Can be Used to Identify Classical Pathway and Alternative Pathway Dysregulation in Complement-Mediated Thrombotic Microangiopathy
4071 - Optimizing Complement Inhibitor Monitoring in PNH and Beyond

Brody, J.

2289 - Demystifying the Delivery and Adverse Event Management of Bispecific Antibodies in the Community Setting
4411 - Odronextamab Monotherapy in Previously Untreated Patients with High-Risk Follicular Lymphoma (FL): Results of the Safety Lead-in of the Phase 3 Olympia-1 Study

Brody, J.

111 - Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study
332 - Prevention of Antigen Escape By Modulation of Off-Target Tumor Killing in T Cells
581 - Fixed-Duration Epcoritamab + R-CHOP Induces High Complete Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Withhigh-Risk Features: Long-Term Results from the Epcore NHL-2 Trial
865 - Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study
1627 - Fixed-Duration Epcoritamab in Combination with Bendamustine + Rituximab for First-Line Treatment of Follicular Lymphoma: Initial Results from Epcore NHL-2 Arm 3
3106 - Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial

Brody, R.

357 - Combined PD-1 and Tim-3 Blockade Improves the in Vitro Anti-Myeloma Activity of T Cells of Patients on Talquetamab

Broeckling, S.

4498 - Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Broemsen, E.

2053 - CAR-T Cell Subsets and Immune Repertoire Are Associated with Immune-Related Adverse Events and Efficacy after CD19 CAR T-Cell Therapy in B Cell Lymphoma

Broen, M. P.

1246 - Imaging Predictors of Intracerebral Hemorrhage in Patients with Brain Tumors Treated with Anticoagulation

Broers, A. E.

464 - Autologous and Allogeneic Stem Cell Transplantation for Major T-Cell Lymphoma Entities: An Analysis of the EBMT Lymphoma Working Party
508 - Younger Haploidentical Versus Older Matched Sibling Donors in Acute Lymphoblastic Leukemia: A Study from the ALWP of EBMT
2185 - Improved Post-Transplant Outcomes over Time for Older Patients with Acute Lymphoblastic Leukemia in First Complete Remission. a Study from the EBMT Acute Leukemia Working Party
3010 - Long Term Outcomes of Hematopoietic Stem Cell Transplantation in Patients with Waldenström’s Macroglobulinemia. Report from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (LWP EBMT)
3558 - Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques
4950 - Outcome of Patients with HTLV-1 Adult T-Cell Leukemia/Lymphoma (ATL) after Allogeneic SCT: Results of the EBMT LWP

Brofferio, A.

807 - The Ectopyrase CD73 Is a Critical Checkpoint in Thromboinflammation

Brogdon, J.

3470 - Cost-Effective Manufacture and Promising Initial Efficacy of huCART19 Cells Manufactured Using the Clinimacs Prodigy Platform

Broge-Reynen, K.

5173 - CNS Status at Diagnosis Can Identify Acute Myeloid Leukemia Patients with Poor Induction Outcomes

Broglie, L.

2412 - Impact of Extramedullary Disease on the Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Acute Myeloid Leukemia - a CIBMTR Analysis
3672 - Addressing Patient Representation in Hematopoietic Cell Transplant Clinical Trials: Insights Gained through the Access Trial
2134.1 - Trial in Progress: Cureaa - a Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia, Blood and Marrow Transplant Clinical Trials Network (BMT CTN) #2207

Broijl, A.

487 - Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study
676 - Results of the Phase II Randomized Trial EMN15/HOVON147: Carfilzomib-Lenalidomide-Dexamethasone Vs Lenalidomide-Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma
2000 - Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)

Bröker, V.

3987 - Tissue Factor Pathway Inhibitor Modulates Endothelial and Vascular Smooth Muscle Cell Functions By Drifting Cellular Phenotypes

Bromage, D.

944 - Clonal Haematopoiesis with TP53 Mutations Exhibits Abnormal Erythropoiesis and Erythroid Metabolic Stress
1284 - DNMT3A-Mutant Clonal Haematopoiesis Is Associated with Worse Recovery after ST-Elevation Myocardial Infarction Via Increased Inflammation

Bromberg, M.

3752 - Comparative Real-World Outcomes of Commercial CD19-Directed CAR T-Cell Therapies in Large B-Cell Lymphoma

Bron, D.

3229 - Extracellular Vesicles from Chronic Lymphocytic Leukemia Cells Promote Leukemia Aggressiveness By Inducing the Differentiation of Monocytes into Nurse-like Cells Via an RNA-Dependent Mechanism

Bron, D.

4929 - Return to Work after Allogeneic HSCT: Further Insights in the Patients-Related Predictive Factors (The SOPRALLO Project)

Broniscer, A.

1381 - S227928: A Novel Anti-CD74 ADC with MCL-1 Inhibitor Payload for the Treatment of Acute Myeloid Leukemia (AML) and Other Hematologic Malignancies

Bronté-Hall, L.

2305 - Voxelotor Therapy Reduces Whole Blood Adhesion to VCAM-1 and P-Selectin, and Shows Modest Improvements in Self-Reported Pain in a Real-World Clinical Setting in a Multi-Center Retrospective Analysis
3875 - Further Validation of Flow Adhesion of Whole Blood to P-Selectin (FA-WB-PSEL) to Assess Targeted P-Selectin Therapies in Sickle Cell Disease (SCD)

Brook, S.

1500 - EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Final Results of Dose Escalation and Optimization Cohorts from a Phase I/IIa Study in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML) or Myelodysplastic Syndrome (MDS)

Brooklyn, C.

781 - Barriers to Immune Effector Cell Therapy: Rapid Disease Progression, Concern for Toxicity, and Lack of Appropriate Trials Drive Non-Receipt after Referral at a Large Academic Center

Brooks, A.

1055 - Site-Specific Insertion of Factor VIII Gene Results in Durable Factor VIII Expression in Nonhuman Primates

Brooks, E.

519 - Clinical Management Bundle for Patients with Sickle Cell Disease: Improving Completion of Age-Specific Screening Tests and Disease-Modifying Therapy Use

Brooks, E.

809 - Targeting PRMT5 in Primary Hemophagocytic Lymphohistiocytosis: A Novel Therapeutic Approach Using a Perforin-Deficient Mouse Model

Brooks, M.

2598 - Impact of Tranexamic Acid Administration on Postpartum Hemorrhage in Women with Von Willebrand Disease Receiving Recombinant VWF at Delivery: The VWD Woman Trial

Brooks, T. R.

111 - Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study
238 - Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis
3247 - Real World Experience with Time Limited Venetoclax and Obinutuzumab (VO) for Frontline Treatment of CLL/SLL with MRD Determination By Clonoseq®
4499 - Loncastuximab Tesirine in Combination with Venetoclax Is Safe and Shows Efficacy in Patients with Relapsed/Refractory Non Hodgkin Lymphoma

Broom, A.

3100 - Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications

Broome, C. M.

805 - ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, Rapidly Controls Inflammation and Improves 2-Month Survival in Treatment-Naïve Malignancy-Associated Hemophagocytic Lymphohistiocytosis
3836 - Part a Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Patients with Warm Autoimmune Hemolytic Anemia (wAIHA): Multicenter, Open-Label, Phase 2b Study
5087 - Challenges in PNH and CAD Management Revealed through Educational Interventions over Three Years
2570.1 - Intravenous Efgartigimod for the Treatment of Primary Immune Thrombocytopenia in Adults: A Planned, Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study with Open-Label Period (ADVANCE NEXT)

Brophy, D.

2590 - Mechanistic Modeling to Support Hemostatic Equivalency of Antithrombin Lowering in People with Hemophilia A or B

Brophy, M. T.

3341 - Risk Factors for Suboptimal Treatment in Patients with Newly Diagnosed Multiple Myeloma across US Healthcare Systems
5169 - Evaluation of Socioeconomic Barriers Impacting Patients with Newly Diagnosed Multiple Myeloma

Brophy, M. L.

3581 - In Vitro and In Vivo Potency Differences between AAVRh74var and AAV5 Vectors Encoding the Same High-Activity Human Factor IX Variant, FIX-R338L, Expression Cassette: Implications for Hemophilia B Gene Therapy

Brophy, M. L.

88 - A Versatile B Cell Engineering Platform Enables Development of B Cell Medicines for Sustained Delivery of Therapeutic Biologics

Broséus, J.

3174 - DNA Methylation Profiling Reveals Multiple Hits in MAPK Pathway in Triple Negative MDS/MPN with SF3B1 Mutation and Thrombocytosis

Broskevicova, L.

1887 - Composition and Fitness of T and NK Cells in Extramedullary Myeloma Tumor Microenvironment
1934 - Depletion of Mature B Cells and of Normal Plasma Cells (PC) behind the Higher Incidence of Infections after Anti-BCMA VS Anti-GPRC5D Bispecific Antibodies (bsAb) in Relapsed Refractory Multiple Myeloma (RRMM)
1962 - Predictive Value of Clonal Plasma Cells in Autografts Assessed By Next Generation Flow Cytometry on Pre-Transplant Bone Marrow MRD in Multiple Myeloma Patients
3270 - Insights into Biological Mechanisms Responsible for Egression of Circulating Tumor Plasma Cells (CTCs) in Multiple Myeloma

Broski, S.

4711 - Radiomics-Based Biomarkers for Risk Stratification in Newly Diagnosed Multiple Myeloma

Brosoff, A.

3128 - A Proof-of-Principle of Split-Course Bridging Radiotherapy (SC-BRT) Prior to CAR T-Cell Therapies for Relapsed or Refractory B-Cell Lymphomas: A Phase 1a Pilot Cohort

Brossart, P.

1504.1 - Trial in Progress: Phase I Trial Evaluating an Immunopeptidome-Defined Multi-Peptide Vaccine Against Acute Myeloid Leukemia Stem and Progenitor Cells

Brossart, P.

1406 - Perforin-Induced Killing in Leukemic Cells Is Driven By NFAT2-Mediated Cytoskeletal Remodeling

Brothers, R.

3885 - OEF Measured with Diffuse Optical Spectroscopies As a Biomarker of Silent Stroke in Pediatric Sickle Cell Anemia

Brothers, S.

829 - Decoding the Pivotal Roles of BCL10 Activating Mutations in DLBCL Drug Resistance and Lymphomagenesis

Brousse, V.

2522 - Effect of Rituximab on Spleen and Blood B-Cell Subpopulations in Allo-Immunized Children with Sickle Cell Anemia
3839 - Protein S Enhances the Phagocytosis of Phosphatidylserine-Positive Erythrocyte: Implications for the Erythrocytes Turnover

Brouwer-Visser, J.

866 - Efficacy and Safety of Odronextamab Monotherapy in Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR T-Cell Therapy: Primary Analysis from the ELM-1 Study

Brouwers, A. H.

1037 - Whole Body CD8⁺ T Cell PET Imaging in Patients with DLBCL before and during Anti-CD19 CAR T Cell Therapy

Brower, J.

4503 - CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Browett, P. J.

217 - A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax +/- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial
476 - Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is Rare

Brown, A. Y.

387 - Feasibility of Multi-Modal Physical Function Data Collection to Assess Treatment Tolerability in Patients with Lymphoma

Brown, A.

2510 - Osteopathic Medical Treatment Improves Pain and Constipation in Children and Adolescents with Sickle Cell Disease

Brown, A.

1006 - Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and Azacitidine
1727 - Durvalumab and Acalabrutinib for Relapsed/Refractory (r/r) High-Grade B-Cell Lymphoma: MoST15, Open Label Phase II Sub-Study of the Molecular Screening and Therapeutics in Leukaemia and Lymphoma (MoST-LLy) Framework
3196 - CBL Variants in Chronic Myelomonocytic Leukemia Exhibit a Complex Sub-Clone Architecture with a High Frequency of RING Domain Mutations Sufficient to Induce GM-CSF Hypersensitivity
3208 - Dynamic Assessment of RBC-Transfusion Dependency (RBC-TD) Improves the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification of MDS
3213 - Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms
4596 - Pathogenic Germline Variants in the DNA Damage Repair Pathway Are Enriched in Patients with Hematologic Malignancies with Prior Exposure to Cytotoxic Therapies Compared to Patients with Multiple Cancers without Prior Exposure

Brown, A.

524 - Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma

Brown, A. K.

69 - CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up
679 - Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL
2064 - CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma

Brown, A. L.

1438 - Understanding the Associations between High-Dose Methotrexate Pharmacokinetics and the Risk of Adverse Events in Children and Adolescents with Down Syndrome Associated High-Risk Acute Lymphoblastic Leukemia
4190 - Evaluation of Methotrexate Pharmacogenomic Variants to Predict Acute Neurotoxicity in Children with Acute Lymphoblastic Leukemia

Brown, B.

3178 - Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor–Naïve Patients with Myelofibrosis

Brown, B. D.

53 - Failure to Execute Caspase Activation Drives Therapy Resistance in TP53 Mutated AML
1534 - Identification of Prognostic Signatures and Potential New Therapies in NPM1 Mutant Adult Acute Myeloid Leukemia Patients Using Proteomics
2942 - Proteomics-Based Approach Recognize Unique Expression Profiles in Adult Acute Monocytic/Monoblastic Leukemia: Implications for Prognostication and Drug Repurposing

Brown, B.

4654 - Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients

Brown, B.

4095 - Robust Immune Reconstitution in Fanconi Anemia Mice Post in Utero Hematopoietic Stem Cell Transplantation

Brown, C.

815 - Long-Term Outcomes of Patients with Isolated Sub-Segmental Pulmonary Embolism Managed without Anticoagulant Therapy
2630 - Management of Upper Extremity Superficial Vein Thrombosis in Patients with Cancer: A Retrospective Observational Cohort Study

Brown, C.

5201 - Impact of an Educational Intervention on Emergency Department Residents' Knowledge and Perceptions of Sickle Cell Disease: A Pilot Study

Brown, C.

4502.2 - Australasian Leukaemia & Lymphoma Group NHL32 Block PCNSL: An Open Label Phase II Study of Pembrolizumab Following Chemoimmunotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma - Trial in Progress

Brown, C.

173 - A Novel Direct Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease – In Vivo Efficacy of Ilx-002 in Humanized Mice

Brown, C.

3885 - OEF Measured with Diffuse Optical Spectroscopies As a Biomarker of Silent Stroke in Pediatric Sickle Cell Anemia

Brown, C.

1245 - Risk Determination in Pediatric Patients for Venous Thromboembolism

Brown, D.

4804 - Engineered T Regulatory Cells for Malignancy Associated Vascular Inflammation

Brown, E.

766 - Whole Genome Sequencing Reveals Lower Apobec-Mutational Activity in Multiple Myeloma Patients with African Ancestry Compared with Those Having European Ancestry

Brown, E. E.

4358 - Expanded Genome-Wide Association Study (GWAS) Identifies Nine Novel Germline Risk Loci for Waldenström Macroglobulinemia (WM) and Lymphoplasmacytic Lymphoma (LPL)
4655 - Mutationally Enriched Regions of the Non-Coding Genome Harbor Functionally Impactful Mutations That Dysregulate Key Genes Involved in Multiple Myeloma Pathogenesis

Brown Frandsen, R.

715 - Annualized Bleeding Rates in Patients with Hemophilia a or B and Inhibitors with and without Target Joints at Baseline: Results from the Concizumab Phase 3 Explorer7 Study
2585 - Unmet Needs of Patients with Hemophilia a/B with or without Inhibitors: Real-World End-of-Study Results from the explorer6 Non-Interventional Study

Brown, G.

4422.1 - A Phase 1 Study of AC676, a Novel BTK Chimeric Degrader, in Patients with B-Cell Malignancies

Brown, H. C.

4169 - Ancestral L-Asparaginases Are Cytotoxic Against ALL Cell Lines with Predicted Reduced Immunogenicity

Brown, H.

1283 - Statin Therapy Is Associated with Reduced Clonal Expansion in TET2 Mutated Clonal Haematopoiesis of Indeterminate Potential

Brown, J.

140 - More Than ADAMTS13: The Impact of Area Deprivation on Major Adverse Cardiovascular Events in Ittp Survivors
144 - Silent Cerebral Infarction Is Progressive during Clinical Remission and Associated with Stroke in Immune TTP Survivors
1238 - Patient Reported Outcomes during Long-Term Follow-up of Atypical Hemolytic Uremic Syndrome in the Era of Terminal Complement Inhibition

Brown, J. R.

1009 - Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial
1865 - Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease
1870 - Outcomes of Therapies Following Discontinuation of Non-Covalent Bruton’s Tyrosine Kinase Inhibitors for Patients with Chronic Lymphocytic Leukemia and Richter Transformation: Results from an International, Multicenter Study
3233 - The Impact of Therapeutic Selective Pressure on the Evolutionary Landscape of Chronic Lymphocytic Leukemia
3249 - Sustained Superiority of Zanubrutinib vs Bendamustine + Rituximab in Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN CLL): 5-Year Follow-Up of Cohort 1 from the SEQUOIA Study
4408 - Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)
4628 - A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter’s Syndrome (RS)

Brown, J. R.

76 - Identifying Novel Drug Vulnerabilities in Specified Molecular Subsets of Chronic Lymphocytic Leukemia
583 - Complex Karyotype, but Not Isolated TP53 mutation, Predicts Overall Survival in Chronic Lymphocytic Leukemia Patients in the Era of Targeted Therapy
587 - Low Variant Allele Frequency (VAF) TP53 Mutation (mut) Is Not a Poor Prognostic Marker in CLL Patients Treated with Targeted Therapy
1669 - Ipilimumab with and without Nivolumab in Patients with Classic Hodgkin Lymphoma with Progression after PD-1 Blockade
1874 - A Phase 2 Study of Zanubrutinib and Venetoclax (ZV) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
4611 - Clonal Evolution during Dual B Cell Receptor Pathway Inhibitor Therapy with Acalabrutinib and Umbralisib in CLL Patients
4617 - Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL
4625 - Treatment Outcomes of Patients Treated with Venetoclax-Obinutuzumab Therapy Vs Btki Therapies in 1L CLL: An International Real-World Study

Brown, J.

421 - Tolerance of Whole Genome Duplication in Megakaryocytes, and Consequences for Their Genome Integrity

Brown, L. A.

1122 - Exploring N-Terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) in Children with Sickle Cell Disease (SCD) and Vaso-Occlusive Pain Episodes (VOE)
1123 - Secretory Phospholipase A₂(sPLA₂) in Patients with Sickle Cell Disease (SCD) Hospitalized for Vaso-Occlusive Pain Episodes (VOE)
2518 - Procalcitonin Elevation in Children with Sickle Cell Disease (SCD) Requiring Hospitalization for Acute Vaso-Occlusive Pain (VOE)

Brown, M.

4837 - Healthcare Resource Utilization and Costs Associated with Managing CRS and ICANS in Patients with Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia Receiving Obecabtagene autoleucel (obe-cel)

Brown, M.

2550 - A Freeze-Dried Platelet-Derived Hemostat Decreases Bleeding in a Novel Murine Model of Type 1 Hermansky-Pudlak Syndrome

Brown, P.

482 - Efficacy and Safety of Fedratinib in Patients with Myelofibrosis and Low Baseline Platelet Counts in the Phase 3 Randomized FREEDOM2 Trial
634 - TCL1A Is Associated with Blinatumomab Response and Immune Activation in Pediatric B-ALL

Brown, P.

650 - Identifying Trial-Eligible High- and High-Intermediate Risk Patients with Diffuse Large B-Cell Lymphoma Using Prognostic Models: A Real-Life Comparative Analysis of IPI, aaIPI and NCCN-IPI from Danish Study Group
1601 - Clonal Hematopoiesis Mutations and Cell-Free DNA Characteristics in Patients with High-Risk Large B-Cell Lymphomas
1638 - Survival in Mantle Cell Lymphoma Patients with a Second Primary Malignancy

Brown, P. D.

654 - Temporal Trends in Relative Survival of Diffuse Large B-Cell Lymphoma in Sweden and Denmark in the Era of Targeted and Cellular Therapies: A Population-Based Binational Study
3099 - Outcome of T-Cell/Histiocyte-Rich Large B-Cell Lymphoma in Denmark 2008-2022

Brown, R.

2016 - Investigating the Role of PPAR Delta in Alloreactive T Cells

Brown, R.

1911 - Assessing the Efficacy and Safety of Reduced Dexamethasone Duration in Newly Diagnosed AL Amyloidosis Versus Standard Therapy

Brown, S.

686 - Phase II Study of Longitudinal Geriatric Assessment with Risk-Adapted Interventions to Reduce Non-Relapse Mortality in Allogeneic Hematopoietic Cell Transplantation for Older Patients with Advanced Myeloid Malignancies
1944 - Impact of Absolute Lymphocyte Count at Pre-Apheresis and Pre-Lymphodepletion on Chimeric Antigen Receptor (CAR)-T Therapy Outcomes in Relapsed Refractory Multiple Myeloma (RRMM)
2369 - When Can We Define Cure after CAR-T Therapy in LBCL? Insights from Serial Landmark Analyses
4509 - CAR T-Cell Therapy for DLBCL with CNS Involvement: Overall Safe and Effective with Limited Efficacy in Patients with Leptomeningeal Disease

Brown, S. R.

1984 - Belantamab Mafodotin Plus Cyclophosphamide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Interim Results from the UK Myeloma Research Alliance Prommise Clinical Trial
3354 - Extended Intensified Consolidation and Maintenance Improve Ultra High-Risk Multiple Myeloma Patient Outcome – Long-Term Follow-up of the Ukmra Optimum/Muknine Trial

Brown, T. R.

5065 - Trends of Opioid Prescribing and Vaso-Occlusive Crises in Sickle Cell Disease in the U.S. (2011-2023)

Brown, T.

4999 - Exploring the Patient Perspective of Gene Therapy for Sickle Cell Disease

Brown, T.

2808.1 - A Children’s Oncology Group Clinical Trial of Long-Term Outcomes in Survivors of Down Syndrome-Associated Acute Leukemia (ALTE22C1): Clinical Trial in Progress

Brown, V.

64 - Deciphering the AML Niche: RNA Sequencing and Spatial Transcriptomics Reveal Diverse Transcriptomic Landscapes in Responders Vs. Non-Responders
754 - Engrafted JAK2V617F Clone Hijacks Resident Non-Mutated Hematopoietic System to Drive Myeloproliferative Neoplasm
- Investigating the Role of Long Interspersed Element-1 (LINE-1) in Age-Related Clonal Hematopoiesis of Indeterminate Potential (CHIP) Driven By JAK2 V617F Mutation

Brown Wadé, N.

1655 - Real-World Characteristics and Survival Outcomes of Patients with Mantle Cell Lymphoma Treated with Covalent Bruton's Tyrosine Kinase Inhibitors in First-Line
3719 - A Real-World (RW) Analysis of the Relationship between Epstein-Barr Virus (EBV) Positivity and Baseline Characteristics, Treatment Patterns and Clinical Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL)

Browne, L.

1352 - Oncogenic Potential and Sensitivity to Menin Inhibitors of a Novel Fusion KAT6B::NUTM2B in Congenital Myeloid Sarcoma with Bone Marrow Involvement

Browne, R.

3067 - Promising Safety and Efficacy Data for Peginterferon Alfa-2a (PEG-IFN) and Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy) in a North American Adult T-Cell Leukemia Lymphoma (NA-ATLL) Cohort of Patients

Browne, S.

1715 - Real World Evidence of Second Line Therapy in Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geltamo Study

Browning, A.

2170 - Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
4241 - Omission of Venetoclax Ramp-up Dosing during Induction Therapy for Acute Myeloid Leukemia in Combination with DNA Hypomethylating Agents Is Safe and Well-Tolerated
4921 - Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States

Bruat, V.

4053 - Mosaic Chromosomal Alterations Driving Clonal Hematopoiesis Show Shared and Divergent Patterns of Accumulation Among Humans of Diverse Ancestries

Bruce, A.

1081 - The G6PD a- Variant Does Not Modulate Pulmonary Hypertension Phenotypes in Mice

Bruch, P. M.

4383 - Immune Cell Infiltration Impacts Chemotherapy Efficacy in B-NHL

Brück, O. E.

329 - Genomic Subtypes of AML Define Sensitivity to NK Cell Cytotoxicity
1476 - Deep Learning Models for Predicting Overall Survival of Acute Myeloid Leukemia Using Short-Term Longitudinal Blood Measurements and the Omop Common Data Model
1529 - Comparison of Anti-PD1, Anti-CTLA4 and Anti-TIM3 in Treatment of AML Patients with Single-Cell Transcriptomics Displays Different Effects on Immune Subtypes
1780 - Computational Cytomorphological Analyses Identifies Bone Marrow Erythroblast Proportion As a Biomarker of Treatment-Free Remission in CML
3596 - Predicting Antigen-Specific T Cell Immunity Against Wilms Tumor 1 in Hematologic Cancer
3612 - Enabling Population-Scale Screening of Myeloid Neoplasms Using Blood Cell Count Dynamics
4320 - Integrating Computational Cytomorphological Analysis of Bone Marrow Smears and Clinical Data for Predicting Response to Venetoclax and Hypomethylating Agents in AML

Bruckman, M. A.

3931 - Post-Injury Treatment with Rapid Intraosseous Injection of Lyophilized Synthetic Platelets Enhances Survival, Hemostasis, and Hemodynamics in a Rat Model of Liver Laceration

Brudno, J. N.

- Moderator Introduction (Malignant Hematology Perspective)

Brueckner, M.

2094 - Cellular Composition and Clinical Factors Influencing Manufacturing Outcomes for Anti-BCMA CAR T Cell Therapy in a Large Real-World Cohort of Relapsed/Refractory Multiple Myeloma

Bruedigam, C.

52 - Overcoming Ven/Aza Resistance through Imetelstat-Mediated Lipophagy in Acute Myeloid Leukemia

Bruedigam, C.

1347 - Dnmt3a Mutation Promotes Expansion of a Quiescent Myeloid Progenitor Population in Npm1^c-Flt3^ITD Acute Myeloid Leukemia

Brueggemann, M.

840 - Update on GMALL Trial 08/2013 Shows Durable Favorable Outcome of Newly Diagnosed Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) with Imatinib, Dose-Reduced Induction Followed By Stem Cell Transplantation

Bruelle, M.

4903 - Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe

Bruenker, P.

918 - CSF1R Targeting T Cell Engaging Bispecific Antibodies Enable Safe and Efficient Immunotherapies in Acute Myeloid Leukemia

Brüggemann, M.

2832 - Recurrent Molecular Variants, Clonal Evolution and Clinical Relevance in T-Cell Lymphoblastic Neoplasia Comparing Lymphoma and Leukemia Samples Derived from Children and Adults

Brüggemann, M.

318 - Drug Sensitivity and Treatment Response Are Modulated By the Cell of Origin, the Underlying Gene Fusion, and Patient Age in KMT2A-Rearranged BCP-ALL
631 - IDH2 Mutations from Clonal Hematopoiesis and Acquired IKZF1 Deletions Define a Novel B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma
636 - CD127-Directed Immunotherapy with Lusvertikimab Outperforms Imatinib in Preclinical ABL-Class-Fusion-Positive BCP-ALL
914 - A Novel Platform Technology for the Development of NK Cell-Based Cellular Immunotherapies
961 - Chemotherapy or Stem Cell Transplantation in Adult High Risk Ph/BCR::ABL1-Negative ALL Patients with Early MRD Negativity: Results of the Randomized GMALL Trial 08/2013
1436 - Outcome of Patients with Hematologic or Molecular Relapsed/Refractory (R/R) Acute T- Lymphoblastic Leukemia - Data from the GMALL Study Group
1458 - C/EBP Family Member Gene Fusions and Cooperating Genomic Events Define Two Distinct Molecular Sub-Groups in Adult B Precursor ALL
1460 - Data-Informed, Refined Immunophenotypic Classification of Adult T-Lineage Acute Lymphoblastic Leukemia
2959 - Circulating Tumor DNA Kinetics at Day 14 after CAR T-Cell Therapy Identifies Patients with B-Cell Lymphoma at Risk for Early Treatment Failure
4173 - Preclinical Development of a Novel Humanized and Fc-Engineered Antibody-Drug Conjugate for the Therapy of T-Cell Acute Lymphoblastic Leukemia
4213 - Integrateall, a Machine Learning Pipeline for Multi-Level Data Extraction from RNA-Seq Profiles Unravels Novel Drivers and Systematic Subtype Classification in B-Cell Precursor ALL

Brüggemann, M.

4218 - A Novel 12-Color 2-Tube Next Generation Flow Approach Enables Sensitive Detection of Measurable Residual Disease in Virtually All T-Cell Acute Lymphoblastic Leukemia Patients

Brugger, R.

519 - Clinical Management Bundle for Patients with Sickle Cell Disease: Improving Completion of Age-Specific Screening Tests and Disease-Modifying Therapy Use

Brugger, W.

963 - Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes
3458 - Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in the Open-Label, Multi-Center, Global, Single-Arm, Phase Ib/II FELIX Study: The Impact of Bridging Therapies on CAR T-Cell Expansion and Persistence
4837 - Healthcare Resource Utilization and Costs Associated with Managing CRS and ICANS in Patients with Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia Receiving Obecabtagene autoleucel (obe-cel)
4845 - Risk Factors Associated with Sub-Optimal Outcomes Following Obecabtagene autoleucel (obe-cel) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): What We Have Learned from the FELIX Trial

Brugières, L.

3108 - Brigatinib Monotherapy in Children with R/R ALK+ ALCL, IMT, or Other Solid Tumors: Updated Results from the Brigaped (ITCC-098) Phase 1 Dose-Escalation Study

Brugnara, C.

1105 - Single Cell Hemoglobin Quantification Reveals HbF and HbS Increases in Sickle Erythrocytes from Patients Treated with Hydroxyurea

Bruins, L. A.

3269 - A Proteogenomic Approach to Identify Potential Drivers of Hyperdiploid Multiple Myeloma
4616 - Serum Immunoglobulins Are an Independent Prognostic Marker of Time to First Therapy in Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) and Monoclonal B-Cell Lymphocytosis (MBL)

Bruketa, E.

1091 - Iron and B12 Deficiency Has Rarely Been Considered in Studies Defining Hemoglobin Concentration Reference Intervals in Pregnancy: A Systematic Review

Brulc, E. B.

5161 - Multiple Lines of Therapy and Progression to Next Lines in Multiple Myeloma Patients: Real-World Studies in Argentina (TOTEMM-A) and Brazil (TOTEMM-B)

Brummendorf, T. H. H.

406 - Intraindividual Comparison of Recognition of Symptom Burden in MPN between Patient- and Physician-Reported Assessment and Its Impact on Survival – an Analysis By the German Study Group for MPN (GSG-MPN)
1327 - Application of Machine Learning in the Diagnostic Work-up of Telomere Biology Disorders
1348 - CSF3R^T618I Is Stabilized By Calnexin and Induces Unfolded Protein Response (UPR) and ER-Phagy: A Pro-Survival Pathway for Oncogenic Misfolded CSF3R Proteins in Chronic Neutrophilic Leukemia (CNL)
1766 - Second-Line Bosutinib Is Effective and Feasible in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) – an Analysis of a Subcohort of the Bodo Trial (CML-VII-study of the German CML Study Group)
1774 - The Combination of Asciminib with ATP Competing Tyrosine Kinase Inhibitors Might Overcome the Negative Impact of ASXL1 Mutations on Molecular Response in Newly Diagnosed CML Patients
2329 - Incidence, Time to Diagnosis, and Therapeutic Landscape of Aplastic Anemia: Results from a Large United States Claims Database
2934 - The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients
3250 - Venetoclax May Overcome the Prognostic Disadvantage of Short Telomeres Regarding Progression Free Survival in Previously Untreated CLL Patients with Coexisting Conditions: A Study By the German CLL Study Group (GCLLSG)
4082 - The Impact of Body Mass Index (BMI) in Patients with Aplastic Anemia Receiving Weight-Adjusted Horse Anti-Thymocyte Globulin (hATG) on Outcome, Response and Relapse Rate

Brummer, T.

3392 - FLT3-ITD Driven CMTM6 Expression Contributes to Immune Escape of Acute Myeloid Leukemia

Brummet, M. E.

1074 - RBC eNOS Regulates O₂ Delivery Phenotype during Circulatory Transit Via Control of Intracellular pH
2453 - Oxygen Responsive Myosin Activation Governs Oscillatory Piezo1 Signaling in RBCs during Circulatory Transit

Bruna, R.

1577 - TP53, CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial
2980 - Integration of [¹⁸f]FDG-PET Radiomics with Liquid Biopsy Improves Outcome Prediction in Newly Diagnosed DLBCL Patients

Bruna, R.

1580 - Longitudinal Monitoring of Circulating Tumor DNA to Predict Survival in Newly Diagnosed Peripheral T-Cell Lymphoma Patients

Brunaldi, L.

5166 - Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee

Brundige, K.

441 - Outcomes of Hematopoietic Stem Cell Transplantation for High-Risk Marrow Features without Malignancy in Shwachman-Diamond Syndrome
2703 - Incidence of Myeloid Malignancy in Shwachman-Diamond Syndrome: An International Cohort Study

Brune, L.

808 - Serine Threonine Protein Kinase 25 (STK25) Is a New Mediator of Myelopoiesis and Myeloid Cell Effector Function(s) during Injury and Inflammation

Brune, P.

2876 - ICT01, an Investigational γ9δ2 T Cell Activator, Added to Azacitidine-Venetoclax Achieves Frequent and Early Complete Remissions in Adults with AML Unfit for Intensive Induction Chemotherapy: Interim Results from the Ongoing Open-Label, Randomized Phase 1 Study Eviction

Brunello, L.

3131 - Outcomes of CAR T-Cells Therapy in High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas: A Weighted Comparison Analysis from CAR-T SIE Study

Brunette, M.

265 - CLAG-M or FLAG-Ida Followed Immediately By Allogeneic Hematopoietic Cell Transplantation for Adults with Relapsed/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasm

Brunner, A. M.

117 - Multi-Site Randomized Trial of a Collaborative Palliative and Oncology Care Model for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Receiving Non-Intensive Therapy
662 - Results from a Phase 1 Open-Label Dose Escalation and Expansion Trial of Oral Azacitidine + Cedazuridine (ASTX030) in Patients with Myelodysplastic Syndromes (MDS) and MDS/Myeloproliferative Neoplasms (MPN)
664 - Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database
1833 - Clinical Activity and Safety of the Oral ATR Inhibitor Ceralasertib (AZD6738) in Patients with MDS or CMML after Prior HMA Therapy
3219 - Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database
4282 - Real-World Treatment Patterns and Effectiveness of Midostaurin Versus Quizartinib in FLT3-ITD Mutated Acute Myeloid Leukemia Undergoing Intensive Induction
4541 - A Novel BCR::ABL1 Rearrangement Harboring the Gatekeeper Mutation Drives Hyper-Kinase Activity Conferring Resistance to Ponatinib and Asciminib Combination Therapy

Brunner, F.

4498 - Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Bruno, A.

2863 - Venetoclax and Hypomethylating Agents Confirmed to be Standard Therapy in De Novo and ELN17 Not Adverse Acute Myeloid Leukemia Patients, Unfit for Chemotherapy According to SIE/Sies/GITMO Criteria. a Multicentric Real-Life Study on 379 Patients, By the Hematological Network Rete Ematologica Lombarda (REL)

Bruno, B.

898 - Early Relapse in Patients with Newly-Diagnosed Multiple Myeloma: A European Myeloma Network/Harmony Alliance Analysis Including 10843 Patients
1854 - Treatment with Venetoclax Positively Modulates Immunological Parameters and T-Cell Features in Patients with Chronic Lymphocytic Leukemia
2226 - Development and Validation of Novel Machine Learning-Based Risk Scores for Multiple Myeloma: Insights from the Harmony Alliance Big Data Platform
3297 - Exploring the Cell-Free Transcriptome As Biomarker Source in IgM Gammopathies: New Insights from the Fondazione Italiana Linfomi “BIO-WM” Trial
4390 - Determining Outcome in IgM Gammopathies: Integration of Molecular, Flow Cytometry and Clinical Factors in an International, Multicenter Series (the SAL-TO Study)

Bruno, B.

310 - Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and Outcomes
596 - Long-Term Outcome of Unrelated Cord Blood Transplantation in Patients with Idiopathic Refractory Severe Aplastic Anemia: A Nationwide Phase 2 Study
1314 - Recursive Partitioning As a Tool for Differential Diagnosis between Acquired and Inherited Bone Marrow Failure Syndromes (BMF)
4075 - Upfront HSCT with an Alemtuzumab Based Conditioning Regimen in Children with Acquired Aplastic Anemia: A Retrospective Study from the SFGM-TC
4859 - Up-Front Matched Unrelated Donor Transplantation in Pediatric Patients with Idiopathic Aplastic Anemia: A Phase II Feasibility Study, on Behalf of Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC) and French Reference National Center of Severe Aplastic Anemia

Bruno, B.

4946 - Allogeneic Stem-Cell Transplantation for Relapsed/Refractory ALK–Positive Anaplastic Large-Cell Lymphoma: A Study from the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)

Bruno, S.

2916 - T/NK Cell-Associated Transcriptomic Profile Informs Response to FLT3 Inhibitors in Acute Myeloid Leukemia
3158 - ASXL1 Mutations at Diagnosis Did Not Impact on the Depth of Molecular Response (MR) and on Treatment-Free Remission (TFR) Eligibility in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Receiving either Nilotinib (NIL) First-Line or Imatinib (IM) with Early Switch to NIL in Case of No Optimal Response in the SUSTRENIM Clinical Trial

Brunori, M.

4699 - Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Bruns, C.

5037 - Estimating the Impact on Survival of Not Receiving CAR T Therapy Despite Being Eligible in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Patients in Germany

Bruns, D.

5011 - Contemporary Screening and Treatment Practices for Iron Deficiency in Pregnancy

Bruns, H.

1153 - Deciphering Inflammasome Activation in Gaucher Macrophages and Its Role in the Development of Multiple Myeloma
2023 - CD47 Upregulation Inhibits Phagocytic Clearance of Alloreactive Donor T Cells after Allo-HCT
4835 - Distinct Safety and Toxicity Profile of CD19-Directed CAR T-Cell Therapy in Systemic Lupus Erythematosus Versus B-Cell Lymphoma – a Single-Center Experience

Brunson, A.

1127 - Identification of Clinical Sub-Phenotypes of Sickle Cell Disease Using Latent Class Analysis
2360 - Identifying Disparities in Autologous Hematopoietic Cell Transplantation (autoHCT) Utilization for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in California

Brunstein, C.

695 - Likelihood of finding an 8/8 HLA-matched unrelated donor (Donor Search Prognosis) is not associated with survival: Primary results from BMT CTN 1702
2145 - Prevalence and Outcomes of Opportunistic Infections in Steroid Refractory Graft Versus Host Disease Patients Treated with Ruxolitinib, Ibrutinib, and Belumosudil
3488 - Factors Associated with Platelet Engraftment Following Allogeneic Hematopoietic Cell Transplantation

Brunsting Hoffmann, G.

335 - SEC62 Regulates HLA-E Expression in Diffuse Large B-Cell Lymphoma to Function As a Mechanism of Immune Evasion
758 - Impaired Response to Oxidative DNA Damage Underlies Genomic Instability in B-Cell Leukemia Driven By RPS15 Mutation
761 - Polyfunctional Effector PD-1⁺ CD8⁺ T Cells and M1 Macrophages Promote Immune Checkpoint Blockade Response in Richter Syndrome Mouse Models

Bruntz, R.

154 - Large-Scale In Vivo Zebrafish Drug Screen Uncovers Novel Insights into Leukemia Stem Cell Biology

Bruscaggin, A.

73 - Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated By Epigenetic Plasticity of Residual Disease and By-Pass Signaling Via MAPK Pathway
854 - A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Ctdna
1367 - Mouse Model of Splenic Marginal Zone Lymphoma to Decipher the Pathogenetic Implications of NOTCH2 and KLF2 Mutations
1578 - Clonal Hematopoiesis in Diffuse Large B-Cell Lymphoma: Clinical and Molecular Correlations
2960 - Non-Coding Mutations of BCL6 in Classical Hodgkin Lymphoma
2980 - Integration of [¹⁸f]FDG-PET Radiomics with Liquid Biopsy Improves Outcome Prediction in Newly Diagnosed DLBCL Patients
4354 - Circulating Tumor DNA for Primary Mediastinal B-Cell Lymphoma Genotyping: A Prospective Multicenter Study
4356 - Early Assessment of Circulating Tumor (ct)DNA and Analysis of TP53 mutations in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma Treated with Glofitamab Monotherapy

Brutus, J.

1010 - Minimal Residual Disease (MRD)-Adapted Duration of Front-Line Venetoclax and Obinutuzumab Treatment for Fit Patients with Chronic Lymphocytic Leukemia (CLL)

Bruun Kristensen, I. B.

1988 - Selinexor with Alternating Bortezomib or Lenalidomide Plus Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients (SABLe), Nordic Myeloma Study Group 29/21

Bruun-Rasmussen, P.

1124 - Large Scale Analysis of the Real-World Association between Fetal Hemoglobin and Vaso-Occlusive Crises in Sickle Cell Disease

Bruxvoort, K. J.

403 - Self-Rated Health Is an Independent Predictor of Subsequent Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Myeloid Malignancies: A BMTSS Report
2338 - Self-Rated Health Is an Independent Predictor of Subsequent Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Lymphoid Malignancies: A BMTSS Report
5036 - Predictors of Risky Health Behaviors Among Blood or Marrow Transplant (BMT) Survivors of Lymphoid Malignancies – a BMT Survivor Study (BMTSS)
5053 - Predictors of Risky Health Behaviors Among Blood or Marrow Transplant (BMT) Survivors of Myeloid Malignancies – a BMT Survivor Study (BMTSS)
5146 - Self-Rated Health Is an Independent Predictor of Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Plasma Cell Disorders: A BMTSS Report

Bruzek, S.

1234 - Plasma Hypercoagulability and Hypofibrinolysis Are Associated with Increased Markers of Inflammation in Pediatric VTE: Findings from the Kids-DOTT Trial Biobank

Bruzzese, A.

4699 - Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Bryan, L. J.

3160 - Clinical Assessment of Cumulative Stress Via Allostatic Load in Chronic Myeloid Leukemia Patients: Implications for Treatment Outcomes
3132.1 - ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after Response to Standard Therapy

Bryant, A.

772 - Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial
1951 - Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry

Bryant, B.

984 - Romidepsin, Azacitidine, Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-Cell Lymphoma
2958 - Circulating Tumor DNA Predicts Time to First Treatment in Previously Untreated Follicular Lymphoma: Analysis from a Prospective Clonal Evolution Study

Bryant, D.

1544 - Karyotype AI for Precision Oncology

Brysland, S.

3939 - Patient-Specific Platelet Phenotypes in Patients with Immune Thrombocytopenia

Bryson, E.

3509 - Terminal Complement Activation in Children with Sinusoidal Obstructive Syndrome after Hematopoietic Cell Transplantation

Brysting, J. J.

1339 - Specific U6 Small Nucleolar RNAs Are Present on the Surface of Primary AML Specimens and Are Accompanied By Short Fragments of Longer RNAs

Brzezniakiewicz-Janus, K.

4268 - The Experience of Commercially Available CPX-351 Use As First-Line Treatment for Patients with Acute Myeloid Leukemia – a Report of Polish Adult Leukemia Group (PALG)

Brzoska, T.

2607 - αIIbβ3-Dependent Platelet Procoagulant Activity Promotes Pulmonary Arterial Thrombosis Triggered By Blood-Borne Tissue Factor

Bseiso, A. W.

2115 - A Retrospective Study of C5b-9 and MASP2 Deposition in Skin Microvasculature As a Prognostic and Diagnostic Tool for Transplant-Associated Thrombotic Microangiopathy

Bu, D.

149 - Prolonged Persistence and Functional Activity of Anti-BCMA CAR-T Durcabtagene Autoleucel (PHE885) Manufactured Using the T-Charge™ Platform

Bu, J.

3022 - Comparing Antihistamine Premedication Regimens for Preventing Rituximab-Associated Infusion Reactions in Hemato-Oncology Patients: A Retrospective Analysis

Bu, X.

379 - Heterogeneity of PD-1⁺regulatory T Cells after Low-Dose IL-2 Therapy for Patients with Chronic Graft-Versus-Host Disease
761 - Polyfunctional Effector PD-1⁺ CD8⁺ T Cells and M1 Macrophages Promote Immune Checkpoint Blockade Response in Richter Syndrome Mouse Models

Buadi, F.

83 - Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma
1880 - Single-Cell Spatial Proteomic Characterization of Clonal Plasma Cell and Immune Cell Metabolism within the Bone Marrow Microenvironment in High-Risk Smoldering Multiple Myeloma and Its Association with Progression to Multiple Myeloma
1981 - Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience
2400 - Improved Survival with Daratumumab-Cybord Compared to Cybord As Frontline Therapy in Immunoglobulin Light Chain (AL) Amyloidosis
3308 - Predictors of Liver Response in Light Chain (AL) Amyloidosis: A Study with 130 Patients
3315 - Impact of Multiple High-Risk Cytogenetic Abnormalities on the Survival Outcomes of Patients with Primary Plasma Cell Leukemia
4681 - Model for Predicting Day-100 Stem Cell Transplant-Related Mortality in AL Amyloidosis
4695 - Frailty-Based Outcomes with Bispecific Antibodies in Older Patients with Multiple Myeloma
4704 - Flow Cytometry-Based Assessment of the Proportion of Monoclonal Plasma Cells in Synthetic Phase (S-phase) Is an Independent Marker of Adverse Prognosis in Patients with Newly Diagnosed Multiple Myeloma
4711 - Radiomics-Based Biomarkers for Risk Stratification in Newly Diagnosed Multiple Myeloma
4716 - Evaluating the Interaction between Baseline Risk Stratification, Post-Transplant Measurable Residual Disease, and Long-Term Outcomes in Multiple Myeloma
4728 - Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes
5149 - Characteristics and Outcomes of Patients with Second Hematological Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
4685.1 - Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)

Buatois, S.

1323 - Phase III COMMODORE 2 and 1 Trials: Characterization of Breakthrough Hemolysis Events in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Crovalimab or Eculizumab

Bubalo, J.

3760 - Real-World Characteristics and Treatment Patterns of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) As Front-Line Treatment: Results from a Multicenter Chart Review Study

Bubb, Q.

- Development of Multivalent Cell Therapies for Treatment of Hematologic Malignancies

Bubis, L.

3635 - Patient Decision Aid for Extended Duration Thromboprophylaxis for Major Abdominopelvic Cancer Surgery: A Usability Study

Buccheri, V.

2348 - Real-World Analysis of Patients with CLL Treated with Ibrutinib: A Retrospective Analysis of the Brazilian Registry of CLL

Bucci, L.

684 - Update on Monocentric CD19-CAR T-Cell Therapy in 30 Patients with Autoimmune Disease

Bucciarelli, G.

4117 - Unraveling the Drivers of the Stress Granule Signature in Splicing Factor-Mutant Myeloid Malignancies

Buccisano, F.

2893 - Venetoclax and Azacitidine for Relapse Prevention in NPM1-Mutated Acute Myeloid Leukemia in Molecular Failure: Results from the Ongoing Gimema AML2521 Phase 2 Trial
4252 - Clinical Implications of Central Nervous System Involvement in Acute Myeloid Leukemia
4329 - Leukemic Phenotype Determines Prognostic Relevance of Limit of Quantification for Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia

Bucelli, C.

1772 - Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50 – 60 Years: A “Campus CML” Study
4532 - Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact Project, a CML Campus Study
4550 - Prognostic Insights on PRE-Fibrotic Primary Myelofibrosis: A Clinical-Pathological Perspective in 762 Patients

Buch, A.

657 - A Phase 1b Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia

Buchan, C. A.

286 - COVID-19 Humoral Immunity Improves with Third and Subsequent Vaccine Doses in Patients with Plasma Cell Dyscrasias, Particularly in Those Receiving antiCD38 Therapy
2114 - Assessing Risk of Infectious Episodes in Patients Post Hematopoietic Stem Cell Transplantation Using Pre-Transplant Baseline Colonization Screening

Buchanan, F. B.

919 - CD30.CAR-T Cells Co-Expressing the CCR4 Chemokine Receptor in Relapsed/Refractory Hodgkin Lymphoma
3468 - Phase 1 Trial of CD30-Directed, CCR4 Co-Expressing Chimeric Antigen Receptor T-Cells in Patients with CD30⁺ Cutaneous T-Cell Lymphomas Refractory to Brentuximab Vedotin

Buchbinder, N.

2182 - Analysis of Outcomes after Second Allogeneic Stem Cell Transplant in Relapsed Acute Myeloid Leukaemia in Children: A Study from the EBMT Pediatric Diseases Working Party
4075 - Upfront HSCT with an Alemtuzumab Based Conditioning Regimen in Children with Acquired Aplastic Anemia: A Retrospective Study from the SFGM-TC
4859 - Up-Front Matched Unrelated Donor Transplantation in Pediatric Patients with Idiopathic Aplastic Anemia: A Phase II Feasibility Study, on Behalf of Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC) and French Reference National Center of Severe Aplastic Anemia

Buchman, N.

3189 - DNMT3A, TET2, and ASXL1 (DTA) Mutations Are Associated with Thrombosis and Bleeding in Patients with Myeloproliferative Neoplasms

Büchner, J.

310 - Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and Outcomes
2827 - Rescuing of the Chemotherapy Sensitivity in Relapsed/Refractory, Pediatric Acute Lymphoblastic Leukemia (r/r ALL) through the Combination of Navitoclax (NAV) and Venetoclax (VEN): Results of Compassionate Use across Four European Countries

Buck, K.

3672 - Addressing Patient Representation in Hematopoietic Cell Transplant Clinical Trials: Insights Gained through the Access Trial

Buck, M. C.

2666 - Single Cell Multiomic Analysis of Bone Marrow Hematopoietic Stem/Progenitor Cells from Individuals with Clonal Hematopoiesis Reveals Potential Mechanisms of Anemia Development
2676 - Single-Cell Transcriptomics of Bone Marrow Mesenchymal Stromal Cells Identifies Altered CLCF1 Signaling in DNMT3A-Mutated Clonal Hematopoiesis

Buck, S.

2768 - Combined Use of Ziftomenib and Selinexor Is Effective in NPM1 Mutant Acute Myeloid Leukemia

Buck, T. T.

4757.2 - Trial in Progress: Phase 2 Study of Subcutaneous Isatuximab, Administered By an on-Body Delivery System, in Combination with Weekly Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (SubQSA)

Buckland, G.

3223 - Clinical Response to Azacitidine in Myelodysplastic Neoplasms Is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor Cells In Vivo

Buckle, I.

4004 - Caplacizumab Resistance in Immune Thrombotic Thrombocytopenic Purpura (TTP) Mediated By VWF A1 Domain Missense Mutation

Buckley, E.

3885 - OEF Measured with Diffuse Optical Spectroscopies As a Biomarker of Silent Stroke in Pediatric Sickle Cell Anemia

Buckley, L.

2645 - Characterization and Stability of Spray Dried Plasma Manufactured with the Frontlineodp™ System

Buckley, P. R.

4382 - Highly Heterogeneous Cellular Composition and Neighborhood Architecture within the Follicular Lymphoma Tumor Microenvironment

Buckley, S.

3191 - Improvement in Serum Albumin As a Measure of Improved Metabolic Profile in Pacritinib-Treated Patients: A Retrospective Analysis of Patients Treated across Three Clinical Trials

Buckley, S. M.

4112 - HMGB3: A Novel Regulator of Leukemia Proliferation

Buckner, T. W.

3972 - Pain Reduction Following Treatment of Bleeding Episodes with Eptacog Beta in Adults and Adolescents with Hemophilia A or B Complicated By Inhibitors
5133 - Modeling Longitudinal Quality of Life Changes in Patients Diagnosed with Lymphomas: Heatmap Analysis of Electronic Patient-Reported Outcomes (ePRO) Data from the Bison-PRO Quality of Life Study

Buckstein, R.

352 - Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes
1825 - Improvements in Hematological Parameters and Quality of Life (QOL) with Elritercept (KER-050): Results from an Ongoing Phase 2 Trial in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS)
4583 - Improvement in Quality of Life in MDS Patients Who Become Transfusion Independent after Treatment
4598 - Impact of Frailty in a Prospective Cohort of Patients with MDS Treated with Hypomethylating Agents
3228.1 - Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)

Buda, Sr., G.

4699 - Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Budak, Y.

1094 - A New Diagnostic Method for Premarital Screening of Thalassemia and Hemoglobinopathies: Microchip Electrophoresis (Gazelle) Method

Budano, N. S.

1647 - Two-Year Follow-up after Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia
3011 - A Phase II Study of Pirtobrutinib and Venetoclax in Previously Treated Patients with Waldenström Macroglobulinemia: An Interim Analysis
4404 - A Phase II Trial of Loncastuximab Tesirine in Patients with Previously Treated Waldenström Macroglobulinemia

Budde, E.

1742.1 - A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Budde, L. E.

458 - PET-Directed Therapy with ABVD Vs. Bv+AVD Followed By Nivolumab in Patients with Early Stage Hodgkin Lymphoma: A Propensity Score Matched Analysis of CALGB50604 and ACCRULY1601
524 - Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma
989 - A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
1645 - Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II
1646 - Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma
2278 - Outpatient Administration of Brexucabtagene Autoleucel (brexu-cel) for Acute Lymphoblastic Leukemia (ALL) and Mantle Cell Lymphoma (MCL) Is Safe and Feasible
2289 - Demystifying the Delivery and Adverse Event Management of Bispecific Antibodies in the Community Setting
2373 - Characterizing the US Patient Population Receiving Rituximab with Gemcitabine and Oxaliplatin (R-GemOx) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Using Real-World Data
3008 - Fixed-Duration Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Updated Results from the Phase II Morningsun Study
3127 - Favorable Safety Profile and Durable Responses to Pmb-CT01 (BAFFR-CAR T Cell) Therapy in Patients with B-Cell Lymphomas Ineligible for or Who Failed CD19-Targeted Therapy, Including CD19-Negative Disease
3534 - Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Vs-Host Disease and Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation: A Case-Control Propensity Matching Analysis
4407 - Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study

Budhathoki, A.

878 - TGF-β1-SMAD2 Axis Regulates Hematopoiesis and β-Globin Gene Expression Via Super-Enhancer Associated Chromatin Reorganization

Budka, J.

2031 - Early MRD Detection after CAR-T Associated with Poor Outcome in Patients with Large B-Cell Lymphoma
4368 - Impact of Inflammation, Tumor and Product Attributes on Clinical Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Axicabtagene Ciloleucel

Budnik, B.

1354 - AML Stem Cell Clearance By Inhibiting Selenoprotein Biosynthesis That Causes Cgas-Sting Activation and Ferroptosis

Budnik, I.

551 - Impaired Platelet Function in Ehlers–Danlos Syndrome: Insights from Human Subjects and a Murine Model

Budziszewska, B. K.

2854 - The Premature Reduction of Venetoclax in an Initial Cycle of Ven-AZA Regimen for Unfit AML Patients Leads to Shortened Overall Survival - a Retrospective Study of Polish Adult Leukemia Group (PALG)

Buechner, J.

4864 - Comparative Results of Pediatric Patients with ALL Receiving Either of Two Different Types of Human Anti-T Lymphocyte Globulin Prior to Hematopoietic Stem Cell Transplantation: Findings from the International Prospective Forum Study

Buecklein, V. L.

961 - Chemotherapy or Stem Cell Transplantation in Adult High Risk Ph/BCR::ABL1-Negative ALL Patients with Early MRD Negativity: Results of the Randomized GMALL Trial 08/2013
1714 - Inflammation-Based Scores Predict Survival after CD3xCD20 Bispecific T Cell Engagers in R/R LBCL
3425 - Divergent Population Dynamics and Gene Signaling in Monocytes Distinctly Influence Responses to CD19-Targeted CAR T-Cells in Relapsed/Refractory B-NHL
3818 - Outcomes of Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Multicenter Real-World Analysis
5037 - Estimating the Impact on Survival of Not Receiving CAR T Therapy Despite Being Eligible in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Patients in Germany
1527.1 - Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1-Mutated AML – the SAL/AMLCG Vincent Trial
2883.1 - A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of Cln‑049 for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease

Buehler, P.

1116 - Circulating Peripheral Blood Mononuclear Cells from Adults with Sickle Cell Disease (SCD)- Associated Pulmonary Hypertension (PH) Patients Have Increased Iron Content and a Unique Multi-Omic Signature
1143 - Peripheral Blood Macrophages (PBMCs) from Adults with Sickle Cell Disease Have a Unique Phenotype
3874 - Low Dose Clodronate Improves Exercise Tolerance, Right Ventricular Function, and Alters Resident Lung Macrophage Phenotypes

Bueno, D.

3463 - Alloreactive Vs IL15 Ex Vivo Stimulated Natural Killer Cells As Adoptive Cell Therapy in Haploidentical Transplantation for Pediatric Acute Leukemia: A Phase I/II Clinical Trial

Bueno, J.

2487 - Placental Abnormalities in the Humanized Mouse Model of Sickle Cell Disease
3863 - Pharmacological Inhibition of TMPRSS6 Decreases Hemoglobin Concentration and Red Blood Cell (RBC) Hemolysis in a Mouse Model of Sickle Cell Disease

Bueno, M. L.

3589 - PIM447, a Pan-PIM Kinase Inhibitor, in Combination with Venetoclax Exerts a Potent Anti-Tumor Activity in the Bone Marrow Niche
4968 - Novel MET Inhibitors Provide a Therapeutic Opportunity for AML By Overcoming the Protective Action of the Bone Marrow Niche

Bueno, O.

496 - ABBV-383 Plus Daratumumab-Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Dose-Escalation and Safety Expansion Study
3731 - Patient Experience with Venetoclax+Rituximab and BTK Inhibitors in Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL): A Qualitative Interview Study in the UK (ELECTRIC)

Bueren, J.

3583.1 - RP-L301, a Lentiviral-Mediated Gene Therapy for Pyruvate Kinase Deficiency (PKD): A Phase 2 Clinical Trial Design

Bueso-Ramos, C. E.

346 - Clonal Origin of Therapy-Related Myeloid Neoplasms after Autologous Stem Cell Transplant
2681 - Multimodal Spatial Profiling in Acute Myeloid Leukemia
4224 - Genomic Profiling of T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL) for Identification of Driver Aberrations Using Combined Next Generation Sequencing and Optical Genome Mapping in Clinical Diagnostic Laboratory

Buettner, F.

229 - Pathogenesis and Clinical Relevance of Diffuse Large B-Cell Lymphoma Proteogenotypes

Buettner-Herold, M.

2023 - CD47 Upregulation Inhibits Phagocytic Clearance of Alloreactive Donor T Cells after Allo-HCT

Buffardi, S.

3055 - Pembrolizumab in Children, Adolescents, and Young Adults with High-Risk Classic Hodgkin Lymphoma (cHL) with Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study

Buffet, P.

3839 - Protein S Enhances the Phagocytosis of Phosphatidylserine-Positive Erythrocyte: Implications for the Erythrocytes Turnover

Buffet, R.

4311 - IL-1RAP Is a Targetable Surface Antigen in Relapsed/Refractoy AML

Buffet, R.

2424 - Treatments and Outcomes of Adult Patients with AML in the Real-Life – First Report of the French Observational ALFA-PPP Study

Bug, G.

776 - Follow-up of the Randomized ASAP Trial Shows No Survival Advantage for Patients with Poor Responsive or Relapsed AML Who Received Intensive Salvage Chemotherapy for Remission Induction Prior to Allogeneic Transplantation Compared to Immediate Allogeneic Transplantation
4942 - Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party

Bug, G.

3554 - Impact of Allogeneic Hematopoietic Cell Transplantation Post-Sars-Cov-2 Infection: A Retrospective Analysis By the German Cooperative Transplant Study Group

Bugarin, C.

2526 - Investigating Neutropenia in FNIP1 Deficiency: A CRISPR/Cas9 Model in HL-60 Cells
2834 - CD19 CAR T Cells Drive a Remodeling of the Immune Microenvironment Associated with T-Cell Dysfunction in Acute Lymphoblastic Leukemia
4218 - A Novel 12-Color 2-Tube Next Generation Flow Approach Enables Sensitive Detection of Measurable Residual Disease in Virtually All T-Cell Acute Lymphoblastic Leukemia Patients

Bugarin-Estrada, E.

1930 - Prognostic Factors for Survival in Multiple Myeloma Patients That Receive Bispecific Antibodies: Does Relative Dose Intensity Matters?
1942 - Evaluating the Kinetics of Absolute Lymphocyte Counts Following Bispecific T-Cell Engager Therapy to Predict Clinical Outcomes in Relapsed/Refractory Multiple Myeloma

Bugatti, M.

453 - B Cell Receptor Silencing Reveals Origin and Impacts Treatment of High-Grade B Cell Lymphomas with MYC and BCL2 Rearrangements

Buhl, I. K.

586 - Mutations in BCOR, CCND2, NRAS and XPO1 Predict Clinical Outcomes upon MRD-Guided Venetoclax Plus Ibrutinib in Relapsed and Refractory Chronic Lymphocytic Leukemia

Buhl, S.

74 - Eradication of the CLECL1+ CLL Subset That Is Prone to Carrying Novel Genomic Mutations and Promoting a Pro-Tumor Microenvironment By a Series of New Monoclonal Antibodies Reactive with Distinct Target Epitopes

Buhlinger, K. M.

1481 - Azacitidine and Venetoclax with or without Donor Lymphocyte Infusion in Relapsed AML Post Allo-HSCT: A Single-Institution Retrospective Study

Bühnen, I.

3050 - Patterns of Disease in Early Stage Favorable Hodgkins Lymphoma
4428 - Abscopal Effect of Radiotherapy and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Results of the International GHSG Phase II Aern Trial

Buhrlage, S. J.

834 - Development and Characterization of Novel Dual HCK/BTK Bifunctional Protacs That Potently Inhibit Kinase Function and Demonstrate Robust in Vitro and In Vivo Degradation of Targets for the Treatment of MYD88-Mutated B-Cell Malignancies
4359 - Development and Characterization of a Novel Bifunctional Protac Jh-XIII-05-1 That Shows Potent IRAK1 and IRAK4 Kinase Inhibition and Target Degradation and Is Highly Active in MYD88 Mutated B-Cell Lymphoma Cells Alone and in Combination with BTK- and BCL2- Inhibitors

Bui, A.

3429 - The Role of Gut Microbiota in Modulating Efficacy and Adverse Effects of CAR T-Cell Therapy in the Pediatric Population

Bui, T.

4687 - Clearance of Circulating Multiple Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

Bui, T.

3403 - Enforced Expression of Mitochondrial Calcium Uniporter in Donor T Cells Abolishes Gvhd Progression
3430 - Inhibiting Tumor Cell CDK9 Reprograms Cell Death Pathways to Enhance Efficacy of CAR T Cell Therapy

Buiakova, O.

2784 - Sky-1214, a Small Molecule Splicing Modulator Targeting FANCL and Fanci, Provides a New Mechanism of Action Targeting Multiple Myeloma and Non-Hodgkin’s Lymphoma

Buijs, A.

1459 - Challenging Conventional Diagnostic Methods By Comprehensive Molecular Diagnostics: Results of a Nationwide Prospective Comparison in Children with Acute Lymphoblastic Leukemia

Buissereth, T.

547 - Critical Bleeding in Adults and Children with Immune Thrombocytopenia: A Multicentre Cohort Study

Buisson, R.

954 - A Protein-Coding Circular RNA That Regulates DNA Damage Response in BCR::ABL-Positive Leukemias

Buitrago, L.

1943 - Prognostic Impact of Measurable Residual Disease Evaluated By Next Generation Flow and PET-CT in Clinical Practice at Fundación Santa Fe De Bogotá Hospital, Colombia

Buizza, A.

104 - Clinical Relevance of the Integrative Analysis of Gut Microbiome and Metabolomics in Myeloid Neoplasms: Correlations with Genomic Profiles, Treatment Response/Complications and Clinical Outcome
105 - Enhancing Personalized Prognostic Assessment of Myelodysplastic Syndromes through a Multimodal and Explainable Deep Data Fusion Approach (MAGAERA)
665 - Landscape of Immune Cell States and Ecosystems in Patients with Myelodysplastic Syndrome to Refine Prognostic Assessment and Predict Treatment Response. a Study By i4MDS Consortium
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
2221 - A Comprehensive, Artificial Intelligence, Digital Twin Platform Based on Multimodal Real-World Data Integration for Personalized Medicine in Hematology
3194 - Single-Cell Multi-Omics Reveals Anticipated Erythroid Differentiation and Transcriptional Regulation in Differentiation Trajectories of SF3B1 - JAK2/MPL Mutated Cells in MDS/MPN-RS-T
3198 - Large-Scale Transcriptome Analysis Supports Genomic Taxonomy and Predicts Response to Hypomethylating Agents in Myelodysplastic Neoplasms
3597 - The “David Vs Goliath” Study: Application of Large Language Models (LLM) for Automatic Medical Information Retrieval from Multiple Data Sources to Accelerate Clinical and Translational Research in Hematology
3598 - Artificial Intelligence-Powered Digital Pathology to Improve Diagnosis and Personalized Prognostic Assessment in Patient with Myeloid Neoplasms
4052 - Clonal Hematopoiesis and the Risk of Dementia: The Monzino 80-Plus Population-Based Study
4981 - Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology

Bujko, K.

4034 - The Pro-Mobilizing Effects of UDP-Glucose—P2Y14 Purinergic Receptor Signaling Are Explained By Promoting Membrane Lipid Raft Formation to Optimize Hspcs' Responsiveness to Chemoattractants—a Potential Strategy to Optimize Hematopoietic Transplantation and Improve Transplant Outcomes

Bujko-Wasiak, N.

4268 - The Experience of Commercially Available CPX-351 Use As First-Line Treatment for Patients with Acute Myeloid Leukemia – a Report of Polish Adult Leukemia Group (PALG)

Buka, R. J.

2637 - Rapido: Results from a UK-Wide Audit of 2477 Patients Who Received a Reversal Agent for a Direct Oral Anticoagulant

Bukhari, S. N.

2122 - Sociodemographic and Patient-Related Determinants of Outcomes after Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
3503 - Impact of CD34+ Graft Cell Dose on Outcomes after Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis
3524 - Sociodemographic and Patient-Related Determinants of Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis

Bukhari, Y.

1142 - Steroid Pre-Busulfan Based Reduced-Intensity Conditioning in Matched Related Hematopoietic Stem Cell Transplantation: Outcomes in Young and Adult Sickle Cell Disease Patients

Bukstein, F.

2086 - Standardization Protocol to Mitigate Progression of Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) in Elderly Patients Treated with CD28 Co-Stimulatory Anti-CD19 CAR-T Cells – a Pilot Study

Bukumiric, Z.

650 - Identifying Trial-Eligible High- and High-Intermediate Risk Patients with Diffuse Large B-Cell Lymphoma Using Prognostic Models: A Real-Life Comparative Analysis of IPI, aaIPI and NCCN-IPI from Danish Study Group

Bulabois, C. É.

505 - Non-T-Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation from Unrelated and Matched Sibling Donors in Patients with Secondary Acute Myeloid Leukemia in First Complete Remission: A Study from the ALWP/EBMT
693 - No Differences in Transplant Outcomes with Post-Transplant Cyclophosphamide in One Antigen Mismatched Unrelated Donor Compared to Matched Unrelated Donor Recipients Receiving Antithymocyte Globulin in Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
3483 - Sequential Intensified Conditioning Regimen Allogeneic Transplantation in Younger Adult Patients with Adverse-Risk Acute Myeloid Leukemia: A Multi-Center Prospective Study from the Acute Leukemia French Intergroup on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
4909 - Cyclosporine Versus Cyclosporine Plus Mycophenolate Mofetil in Reduced Intensity Allogeneic Stem Cell Transplantation for Intermediate-Risk AML: A Multi-Center Randomized Study from the Acute Leukemia French Intergroup, on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
4946 - Allogeneic Stem-Cell Transplantation for Relapsed/Refractory ALK–Positive Anaplastic Large-Cell Lymphoma: A Study from the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)

Bulanova, E.

2783 - Development of ZE66-0205, a Novel MALT1 Degrader for Treatment of B-Cell Malignancies

Bulatao, I.

1829 - Response Rate, Event-Free Survival (EFS), and Overall Survival in Higher-Risk Myelodysplastic Syndromes (MDS): U.S. Food and Drug Administration (FDA) Trial-Level and Patient-Level Analyses

Buldini, B.

730 - Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy
2910 - Novel Promising Therapeutic Strategies for Advancing the Treatment of KMT2A-Rearranged AML
3086 - CD20-Negative Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphomas and Mature B-Cell Leukemia in Children, Adolescent and Young Adults: A Retrospective Review
4217 - Frequency and Early Prognostic Significance of Gene-Class Fusions Identified By RNA-Seq in Children and Adolescent with T-Cell Acute Lymphoblastic Leukemia Enrolled on AIEOP-BFM ALL 2017 Study

Bulgin, D.

5061 - Understanding Facilitators and Barriers to Disease Self-Management for Men Living with Sickle Cell Disease

Bulian, P.

75 - High IGHV Intraclonal Diversification Identifies CLL with Good Prognosis, Features of Anergy and Specific T-Cell Profiles
854 - A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Ctdna
2960 - Non-Coding Mutations of BCL6 in Classical Hodgkin Lymphoma

Bulkley, A.

118 - The Burden of Transfusion Dependence on Caregivers of Patients with Lower-Risk Myelodysplastic Syndromes in North America and Europe

Bull, J.

822 - Spatial Transcriptomics Identifies Aberrant Communication between Dendritic Cells and Leukemia Stem Cells As a Therapeutically Targetable Axis in Juvenile Myelomonocytic Leukemia

Bull-Linderman, D.

4277 - Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First Remission

Büller, H.

1246 - Imaging Predictors of Intracerebral Hemorrhage in Patients with Brain Tumors Treated with Anticoagulation

Buller, S.

2276 - The Clinical Impact and Cost-Effectiveness of PET-Based and Ctdna-Based Evaluation at End-of-Therapy after Frontline Treatment of DLBCL

Bullinger, L.

44 - Tracing Clonal Hematopoiesis and Tumor-Specific Mutations in Hematopoietic Progenitors of B Cell Non-Hodgkin Lymphoma (NHL) Patients
844 - The Prognostic Impact of Myelodysplasia-Related Gene Mutations in Acute Myeloid Leukemia with FLT3-ITD Mutations
926 - Leukemia Evolution and Resistance to Graft-Versus-Leukemia Responses Revealed By Mitochondrial DNA Mutations
1341 - Mutant Idh1 Blocks Neutrophil Maturation By Repressing Myeloid Progenitor Programs
1830 - Genetic Diversity Drives Differing Morphological and Clinical Presentation and Survival in Myelodysplastic-Type CMML with a Low Absolute Monocyte Count
2027 - Utilization of Therapy-Naïve T Cells to Enhance the Efficacy of CAR-T Cells in the Treatment of B-NHL Patients
2711 - The LMO2-LDB1-TAL1 Complex Regulates Transcription Networks in AML Relapse
2934 - The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients
2956 - Intra-Tumor Heterogeneity in Core-Binding Factor Acute Myeloid Leukemia
4613 - Clonal Hematopoiesis in Patients with Chronic Lymphocytic Leukemia Treated with Fixed-Duration Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Insights from the Randomized CLL14 Trial
- Medical Informatics & AI

Bullo, M.

3013 - Ibrutinib or Chemo-Immunotherapy As Second Line Treatment in Waldenstrom Macroglobulinaemia? a Real-Life Multicentre Study

Bullock, C.

88 - A Versatile B Cell Engineering Platform Enables Development of B Cell Medicines for Sustained Delivery of Therapeutic Biologics

Bullock, K.

4060 - Loss of Negative Metabolic Feedback Drives TET2 Mutant Inflammation

Bult, J. A.

2984 - Unveiling Transformation Mechanisms of Nodal Marginal Zone Lymphoma Using a Multi-Omics Approach

Bumgarner, K.

4751 - Final Results of Phase 1 Clinical Trial of Belantamab Mafodotin Combined with Carfilzomib, Lenalidomide, and Dexamethasone for Multiple Myeloma after One to Three Prior Lines of Therapy

Bumma, N.

285 - Lovesick: Examining Couples Health during Myeloma Transplant
891 - Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study
1919 - Diagnostic Test Accuracy of Cardiac Imaging for AL Amyloidosis: A Systematic Review and Meta-Analysis
1920 - Diagnostic Test Accuracy of Bone Scintigraphy in the Diagnosis of Attr Amyloidosis: A Systematic Review and Meta-Analysis
1925 - Diagnostic Test Accuracy of Serum and Urine Immunofixation and Free Light Chains in the Diagnosis of Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
1926 - Diagnostic Test Accuracy of Cardiac Biomarkers for Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
3365 - Combination Regimens in MM Post Autologous Hematopoietic Cell Transplantation (AHCT) to Eliminate MRD Utilizing Iberdomide (COMMANDER): Results of Dose-Finding Component of a Phase 1b/2 Trial
3369 - Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study
4717 - Cytomegalovirus Reactivation in Patients with Multiple Myeloma Treated with Teclistamab: Risk Factors and Clinical Impact
2000.1 - MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial
- Congo Red Stain Bone Marrow Screening for AL Amyloidosis
- Adult BMT/Cellular Therapy
- Diversity, Equity, and Inclusion

Bumroonkit, C.

2331 - Clinical Characteristic Outcomes and Mortality Among Cancer and Non-Cancer Patients Presented with Incidental Pulmonary Embolism

Bunce, M. W.

1198 - Human Lymphatic Fluid Supports Coagulation Driven Primarily By the Extrinsic Pathway

Bundalo, A.

2235 - Systematic Identification of Gene-Drug Interactions Using an Advanced CRISPR Screening Platform to Predict Therapy Response across Cancer Types

Bundalo, M.

3402 - Allogeneic Hematopoietic Cell Transplantation Promotes Atherosclerosis in Mice Driven By Donor CD8+ T Cells

Bundy, A.

2246 - Pain Management in Patients with Sickle Cell Disease through an Inpatient Sickle Cell Disease Consult Service

Bunjes, D. W.

2153 - The Impact of CMV-Prophylaxis with Letermovir on Immune Reconstitution after Allogeneic Stem Cell Transplantation: Single-Center Analysis of 363 Transplanted Patients

Buño, I.

2044 - Molecular Tumor Burden and Clonal Evolution As Factors Associated with Early Progression in Large B-Cell Lymphomas Treated with CAR-T Therapy

Bunod, L.

3358 - The Impact of Patient-Reported Adverse Events on Quality of Life: An Analysis of the Dreamm-7 and Dreamm-8 Randomized Controlled Trials

Bunworasate, U.

1636 - Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry
3251 - Acalabrutinib Versus Chlorambucil Plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia: A Randomized, Multicenter, Open-Label, Phase 3 Study

Buon, L.

1947 - Full Spectrum Multi-Parameter Single-Tube Flow Cytometry Analysis for Cross-Sectional Immune-Profiling of Natural Killer Cells in Multiple Myeloma Clinical Samples
4133 - Deciphering Drivers of Functional and Phenotypic Changes through Genome-Wide Screen (DRIVE-Genome) to Identify Genes Inducing Genomic Instability in Myeloma

Buonamici, S.

826 - REM-422, a Small Molecule MYB mRNA Degrader, Demonstrates Anti-Leukemic Activity As Monotherapy and in Combination with Standards of Care in Preclinical Models of AML

Buono, R.

2789 - A Novel Approach Combining Type II JAK Inhibitor Chz-868 with Nutrient Restriction to Augment Cell Death in Philadelphia like Acute Lymphoblastic Leukemia

Buonomo, E.

924 - TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial

Bupp, C.

3672 - Addressing Patient Representation in Hematopoietic Cell Transplant Clinical Trials: Insights Gained through the Access Trial

Buracchi, C.

2834 - CD19 CAR T Cells Drive a Remodeling of the Immune Microenvironment Associated with T-Cell Dysfunction in Acute Lymphoblastic Leukemia

Burack, R.

1629 - Subsets of Follicular Lymphoma (FL) 3B Have Divergent Biological Behavior and Clinical Outcome: Results from the Prospective Multicenter MER and LEO Cohorts
1652 - Outcomes in Early Relapse of Follicular Lymphoma Versus Early Histologic Transformation Following Firstline Immunochemotherapy in Follicular Lymphoma
2838 - Immunoglobulin Sequencing Biologically Distinguishes B-Lymphoblastic Lymphoma from Acute Lymphoblastic Leukemia and Reveals a Spectrum of Disease Dissemination across Clinical Stages
3007 - Frontline R-CHOP and BR Have Similar Outcomes By SUV_max in Follicular Lymphoma

Burack, R.

3000 - Comparative Analysis of T Cell Profiles in Splenic Small B-Cell Malignancies
3002 - Distinct Signaling Profiles in Primary Splenic Small B-Cell Lymphomas

Burch, R.

2047 - Enabling Potent T Cell Delivery and Mitigating Key Off-Target Concerns of In Vivo

CAR T Lentiviral Vectors with the Targeted Paramyxovirus Fusogen System
2196 - Relieving Restriction in Resting CD8+ T Cells Increases Gene Transfer and Improves Tumor Killing after Transduction with CD8-Targeted CD19CAR Fusosome

Burchert, A.

1766 - Second-Line Bosutinib Is Effective and Feasible in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) – an Analysis of a Subcohort of the Bodo Trial (CML-VII-study of the German CML Study Group)
1774 - The Combination of Asciminib with ATP Competing Tyrosine Kinase Inhibitors Might Overcome the Negative Impact of ASXL1 Mutations on Molecular Response in Newly Diagnosed CML Patients
2211 - Age-Stratified Game-Theory-Informed Machine Learning of Molecular Alterations Unveils Prognostic Divergence in 3062 Pediatric and Adult Acute Myeloid Leukemia Patients
2934 - The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients
3560 - Impact of FLT3 Inhibitor Maintenance Therapy on Post-Transplant Outcomes in FLT3-Mutated AML Patients: A Real World Analysis from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)
1527.1 - Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1-Mutated AML – the SAL/AMLCG Vincent Trial

Burd, A.

1564 - Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with NPM1 Mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial
4324 - Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age
4325 - IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy
2883.4 - A Phase 1, Open-Label, Dose Escalation and Dose Expansion, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Lomonitinib (ZE46-0134) in Adults with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia
2907.2 - A Randomized Phase 2 Trial of 28-Day (Arm A) Versus 14-Day (Arm B) Schedule of Venetoclax + Azacitidine in Newly Diagnosed Acute Myeloid Leukemia Patients ≥ 60 Years

Burd, A.

1396 - A Randomized Placebo-Controlled Phase 1 Trial in Healthy Volunteers Investigating the Safety, Pharmacokinetics and Pharmacodynamics of a Novel FLT3/IRAK4 Inhibitor, Lomonitinib (ZE46-0134)
2783 - Development of ZE66-0205, a Novel MALT1 Degrader for Treatment of B-Cell Malignancies

Burd, C. E.

- Geroscience and Geri-Omics in Hematologic Malignancies

Burdeau, J. A.

2613 - Real-World Effectiveness of Ravulizumab Among Adults with Atypical Hemolytic Uremic Syndrome (aHUS) Who Switched to Ravulizumab within 3 Months of Eculizumab Treatment: A Physician Panel-Based Chart Review Study (aHUS IMPACT)

Burel, L.

4354 - Circulating Tumor DNA for Primary Mediastinal B-Cell Lymphoma Genotyping: A Prospective Multicenter Study

Burgdorf, N.

3480 - FAS Ablation Confers Resistance to Allogeneic CAR-T Rejection By T Cells in Absence of NK Cell Sensitization

Burger, J. A.

1011 - Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
1014 - Atezolizumab Combined with Venetoclax and Obinutuzumab for Frontline CLL
1855 - Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10^-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL
1868 - A Phase II Study of Time-Limited Treatment with Acalabrutinib Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
2901 - A Phase II Study of Cladribine, Idarubicin, and Cytarabine (CLIA) in Combination with Gilteritinib for Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia
3246 - Predictors for Time-to-First-Treatment in Patients with Del(17p) and/or TP53-Mutated Chronic Lymphocytic Leukemia
3255 - Deep and Sustained Responses in Patients with CLL Treated with Zanubrutinib or Zanubrutinib + Obinutuzumab in Phase 1/2 AU-003 and Phase 1b GA-101 Studies: A Report from the Zanubrutinib Extension Study
4194 - Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia: 3-Year Update
4610 - Topic Modeling of Genotyping of Transcriptomes Reveals Collaboration between BTK^C481S-Mutant and Wild Type Cells in Btki-Resistant Chronic Lymphocytic Leukemia
4615 - Treatment with First-Line Ibrutinib Improves Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) and High-Risk Genomic Features to Rates Approximating an Age-Matched US Population: Pooled Analysis of Phase 3 Trials with 10 Years of Follow-up
4631 - Time-Limited Therapy with Zanubrutinib Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia: Early Results of an Ongoing Phase II Trial

Burger, M. T.

1381 - S227928: A Novel Anti-CD74 ADC with MCL-1 Inhibitor Payload for the Treatment of Acute Myeloid Leukemia (AML) and Other Hematologic Malignancies

Burgess, M.

3006 - Multiomics Analysis of Paired Diagnosis and Relapse DLBCL Biopsies Shows a Reduction in T Cell Infiltration and Function at Relapse

Burgess, M. R.

922 - Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM)
2069 - BMS-986393, a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1–3 Prior Regimens: Updated Phase 1 Safety and Efficacy Results

Bürgi, J.

557 - Post Partum Haemorrhage (PPH): Time to Change Perception of Pathophysiology and Approach to Therapy? Uterine Atony in Developing PPH Is Rare with Disturbances of Coagulation Being Early and Frequent

Bürgisser, P. E.

431 - A Novel Cause of Type 1 VWD: Impaired Exocytosis of Weibel-Palade Bodies Due to Biallelic Mutations in Madd

Burgos da Silva, M.

259 - Increased Fiber Intake Results in Better Overall Survival and Lower GI-aGVHD in Allo-HCT Recipients and Pre-Clinical Gvhd Models

Burgos, L.

4328 - Single-Cell Multiomics Data-Driven Measurable Residual Disease (MRD) Assessment Using Multidimensional Flow Cytometry (MFC) in Acute Myeloid Leukemia (AML)
4798 - Molecular Mechanisms Promoting Long-Term Cytopenia after BCMA CAR-T Therapy in Multiple Myeloma

Burguener, V.

1172 - Molecular Delineation and Targeting of a Megakaryocyte Ontogenic Switch for Therapeutic Applications

Buri, M.

4078 - Phase III COMMODORE 1 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Ravulizumab

Burkard, P.

186 - Platelets-Derived Integrin and Tetraspanin-Rich Tethers (PITTs) Drive Pulmonary Inflammation

Burkart, M.

1787 - Outcomes of Patients with IDH1/2 Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Era of IDH Inhibitors
3794 - Assessing Disparities in a Chicagoland Cohort of Patients with Myelofibrosis

Burkart, M.

2858 - The Impact of Weight Loss Grading Scale, a Measure of Cancer Cachexia, on Clinical Outcomes in Patients with Acute Myeloid Leukemia
2867 - Assessing Role of Comorbidities in Treatment Selection for Older Patients with Acute Myeloid Leukemia

Burkart, M.

1385 - Identifying the Impact of ADAR1 Inhibition on LSC Niche Remodeling in 3D Nanobioreactors

Burke, A.

4434.1 - CD38-SADA Pretargeted Radioimmunotherapy (PRIT) with Lutetium 177 (Lu177)-DOTA in Adult Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: A First-in-Human Phase 1 Trial

Burke, J. M.

460 - Updated Analysis of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Nonbulky, Early-Stage Classical Hodgkin Lymphoma
469 - Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes
886 - BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
2268 - Best Practices to Overcoming Challenges in Initiating Venetoclax for Patients with Chronic Lymphocytic Leukemia: Results from a United States Community-Based Healthcare Practitioner Survey
3008 - Fixed-Duration Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Updated Results from the Phase II Morningsun Study
4632 - Zanubrutinib is Well Tolerated and Effective in Acalabrutinib-Intolerant Patients with B-cell Malignancies
3132.1 - ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after Response to Standard Therapy
3257.2 - BRAVE: A Phase 2 Trial Evaluating the Efficacy and Safety of Venetoclax in Combination with Bruton’s Tyrosine Kinase Inhibitors in Patients with First-Line Chronic Lymphocytic Leukemia

Burke, L. M.

658 - Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study

Burke, L.

1238 - Patient Reported Outcomes during Long-Term Follow-up of Atypical Hemolytic Uremic Syndrome in the Era of Terminal Complement Inhibition

Burke, M. M.

1067 - Acceptability and Feasibility of Salivary Stress Research with Adolescents and Young Adults with Sickle Cell Disease
3693 - Prospective Biopsychosocial Impacts of Stress and Disease Stigma Among Adolescents and Young Adults with Sickle Cell Disease

Burke, M. J.

315 - Prognostic Impact of t(1;19) in Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Treated on Contemporary Children’s Oncology Group (COG) Protocols
2813 - Utility of a Second Interim Maintenance Phase to Improve Outcomes for Pediatric Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
4195 - Additional Induction Intrathecal Cytarabine for Patients with CNS2 Disease at Diagnosis Is Not Beneficial for Patients with B-ALL Treated on Children's Oncology Group Protocols AALL0932 and AALL1131

Burke, P. W.

2800 - Ph-like ALL Is Associated with Unfavorable Outcomes in Hispanics and Native Americans: A Multicenter Analysis

Burkhardt, B.

2832 - Recurrent Molecular Variants, Clonal Evolution and Clinical Relevance in T-Cell Lymphoblastic Neoplasia Comparing Lymphoma and Leukemia Samples Derived from Children and Adults
3548 - Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia: Results of the AML BFM Study Group
3563 - Addition of Anti-T-Lymphocyte-Globuline As Graft Versus Host Disease Prophylaxis for Matched Unrelated Donors Equalizes Outcomes with Matched Sibling Donors: Results from the AML SCT-BFM 2007 Trial
- Age-Related Molecular Changes in Burkitt Lymphoma

Burkhart, C.

552 - Ianalumab, an ADCC-Enhanced Anti-BAFF-Receptor Antibody, Has Beneficial Effects in an Active Mouse Model of Immune Thrombocytopenia (ITP)

Burkhart, M.

2423 - Association of Neighborhood Crime with AML Molecular Subtypes and Survival

Burks, J. K.

1301 - Spatial Analysis of Human p53 Mutated AML Bone Marrow Reveals Novel MRD Clusters and Spatial Microenvironmental Features of p53 Mutated AML
2681 - Multimodal Spatial Profiling in Acute Myeloid Leukemia

Burman, S. S.

4060 - Loss of Negative Metabolic Feedback Drives TET2 Mutant Inflammation

Burmeister, T.

318 - Drug Sensitivity and Treatment Response Are Modulated By the Cell of Origin, the Underlying Gene Fusion, and Patient Age in KMT2A-Rearranged BCP-ALL
840 - Update on GMALL Trial 08/2013 Shows Durable Favorable Outcome of Newly Diagnosed Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) with Imatinib, Dose-Reduced Induction Followed By Stem Cell Transplantation
1460 - Data-Informed, Refined Immunophenotypic Classification of Adult T-Lineage Acute Lymphoblastic Leukemia

Burnap, B.

1326 - Natural History and Predictors of Survival in Adult Patients with Telomere Biology Disorders

Burnett, A. K.

845 - Impact of Cytogenetics, Induction Chemotherapy and MRD on Outcomes of Intensively Treated AML with KMT2A Rearrangements – Experience from UK NCRI AML17 and AML19

Burney, Z. A.

1911 - Assessing the Efficacy and Safety of Reduced Dexamethasone Duration in Newly Diagnosed AL Amyloidosis Versus Standard Therapy

Burns, C.

2785 - LY4152199, a First-in-Class BAFF-RxCD3 Bispecific Antibody for the Treatment of B Cell Malignancies

Burns, D.

4315 - In AML Patients Allografted in First Remission, DNMT3A Mutations Differentially Affect Post-Transplant Outcomes According to Karyotype, NPM1 and FLT3-ITD Mutation Status - from the EBMT-ALWP

Burns, E. R.

371 - Development of CAR T Cells Targeting U5 snRNP200 for the Treatment of Acute Myeloid and B-Lymphoid Leukemias
950 - Systematic Evaluation of GAPs and Gefs Identifies ARHGAP45 As a Targetable Leukemia-Specific Dependency
2070 - CD371-Targeted CAR T-Cells Secreting Interleukin-18 Exhibit Robust Expansion and Disease Clearance in Patients with Refractory Acute Myeloid Leukemia
3406 - Developing an Optimal Fully-Human CD371-Targeting IL-18 Secreting CAR T Cell for the Treatment of Acute Myeloid Leukemia
4802 - Enhancing CAR T Cell Efficacy By Modulating PI3K Signaling Via a Synthetic CD28 Rheostat

Burns, E. A.

1673 - Beyond Classical Hodgkin Lymphoma: Long-Term Risks and Secondary Cancers-Insights from the Texas Cancer Registry
1716 - Primary Vitreoretinal Lymphoma with or without Intracranial Involvement: A Single Center Experience
5131 - Statins May Improve Outcomes and Toxicities in Patients Undergoing CD19-Specific CAR T-Cell Therapy for Aggressive B-Cell Lymphomas

Burns, F.

4815 - Characterizing the Role of Interferon-γ Signaling in Natural Killer Cell Dysfunction in Venetoclax-Resistant Acute Myeloid Leukemia

Burns, K.

848 - Correlation of Baseline Gene Mutations With Quizartinib Efficacy in Patients With FLT3-ITD–Positive Newly Diagnosed Acute Myeloid Leukemia in the Phase 3 QuANTUM-First Trial
1509 - Anchored Matching Adjusted Indirect Treatment Comparison of Quizartinib Vs Midostaurin in Newly Diagnosed Patients with FLT3-ITD-Positive Acute Myeloid Leukaemia
2890 - Quantum-First: Effects of Quizartinib (Q) on RFS, OS, CIR, and MRD in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication–Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML) Who Received Continuation (CONT) Therapy (tx)
1504.3 - Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, FLT3-ITD–Negative Acute Myeloid Leukemia

Burns, L.

4911 - Long Term Outcomes of a Randomized Trial of Anti-T Lymphocyte Globulin to Improve Moderate-Severe Chronic Gvhd Free Survival after Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Analysis

Burns, M.

5051 - To Treat or Not to Treat: Factors Associated with Receipt of Allogeneic Hematopoietic Cell Transplant

Burns, M. A.

307 - Efficacy and Toxicity of Fixed Dose Versus Reduced/PK-Adjusted Dose Pegaspargase in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia: Results of DFCI ALL Consortium Protocol 16-001
311 - Feasibility of Adjusting Risk Group and Risk Group-Based Therapy during Induction in the Treatment of B-Cell Acute Lymphoblastic Leukemia: Results from DFCI ALL Consortium Protocol 16-001

Burns, M.

4453.1 - First-in-Human Phase 1a Clinical Trial of the Investigational New Drug ST-001, a Novel Nano-Phospholipid Dispersion Formulation of Fenretinide, in Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

Burny, C.

4097 - Deciphering EZH2 Non-Canonical Activities in AML Resistance

Burridge, S.

4206 - Bridging Pediatric B-Cell Acute Lymphoblastic Leukemia (ALL) Patients to CAR-T Cell Therapy: A National Perspective

Burroni, B.

745 - Ibrutinib, Venetoclax Plus CD20 Monoclonal Ab Provides Very High MRD Negativity in Previously Untreated MCL Patients, Initial Results of OASIS II, a Randomized Phase 2 Trial
1596 - Predictive Power of Early, Sequential Minimal Residual Disease and Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Monitoring in Young Patients with Mantle Cell Lymphoma in the Lyma Trial: A Lysa Study
4360 - Aberrant Cytoplasmic Expression of p16 Is a New Strong Prognostic Marker in Young MCL Patients Treated By Frontline Cytarabine-Based Immunochemotherapy, a Study from the Lysa Group, Nordic Lymphoma Group and the European MCL Network
4516 - Spatial Transcriptomic Profiling of Bone Marrow Vascular Niches Unveils an Endothelial Stress Signature in Myeloproliferative Neoplasms

Burrowes, S. A.

3617 - SNAP: Supportive Non-Invasive Ventilation for Acute Chest Syndrome Prevention in Hospitalized Children with Sickle Cell Disease: Facilitators, Barriers, and Contextual Factors Related to Implementation

Burrows, F.

1452 - Targeting Menin in T-Lineage Acute Lymphoblastic Leukemia
2768 - Combined Use of Ziftomenib and Selinexor Is Effective in NPM1 Mutant Acute Myeloid Leukemia

Burrows, K.

4741 - Hyperbaric Oxygen (HBO) Effects on Blood Count Recovery and Post Transplant Outcomes Following High-Dose Therapy and Autologous HSPC Transplantation for Multiple Myeloma: Final Analysis of the Multicenter Phase II Randomized Clinical Trial

Burslem, G. M.

1391 - The Arginine Methyltransferase PRMT5 Regulates Maintenance and TKI Resistance of Self-Renewing FLT3-ITD AML LSC

Burt, J.

5011 - Contemporary Screening and Treatment Practices for Iron Deficiency in Pregnancy

Burt, R.

1454 - The Role of the Bone Marrow Immune Niche in Preventing Relapse in Adult B-ALL Following Reduced Intensity Conditioning Allogeneic HSCT
2823 - A UK Intention to Treat Analysis of Brexucabtagene Autoleucel for Relapsed or Refractory Adult Acute Lymphoblastic Leukaemia Following 1 Year of Therapy Access
4152 - Specific Bone Marrow Niche Components Determine Degree of Protection from Gilteritinib Induced Differentiation Response in FLT3-ITD AML

Burtness, B.

2705 - PLK1 Acts in Homologous Recombinatorial Repair and in Mitosis As Synthetically Lethal with the Fanconi Anemia/BRCA Pathway

Burton, A.

2238 - Case Management Time in SCD Adults Is Correlated with ED and Ambulatory Utilization and with Behavioral Health Diagnoses, but Not with Hospitalization and Costs

Burton, B. J.

1983 - Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma (SMM)

Burton, C.

229 - Pathogenesis and Clinical Relevance of Diffuse Large B-Cell Lymphoma Proteogenotypes
235 - Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich

Burton, H.

445 - Outpatient Vs Inpatient Hidac Consolidation for AML: The MSKCC Experience

Burton, T.

224 - Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial

Burzinski, R.

4132 - Activating STAT3 Mutations Drive CD38 Expression in T-Large Granular Lymphocytic Leukemia

Busarello, E.

4117 - Unraveling the Drivers of the Stress Granule Signature in Splicing Factor-Mutant Myeloid Malignancies

Busca, A.

505 - Non-T-Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation from Unrelated and Matched Sibling Donors in Patients with Secondary Acute Myeloid Leukemia in First Complete Remission: A Study from the ALWP/EBMT
2190 - Peripheral Blood Stem Cell Versus Bone Marrow Graft for Non-T-Depleted Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Patients with Secondary Acute Myeloid Leukemia in First Complete Remission: A Study from the ALWP/EBMT

Buscarini, E.

553 - A Randomized, Placebo-Controlled, Multicenter Proof-of-Concept (POC) Study to Assess the Safety and Efficacy of the Novel Allosteric AKT Inhibitor, VAD044, in Adults with Hereditary Hemorrhagic Telangiectasia (HHT)

Buscetta, A.

1068 - A Holistic Approach to Sickle Cell Disease Severity Using Patient-Reported Outcomes

Busch, C.

148 - A Synthetic Receptor Enables Breakthrough Scale Manufacturing of iPSC-Derived CD19-CAR Cell Therapies for Hematologic and Autoimmune Diseases

Busch, D.

2027 - Utilization of Therapy-Naïve T Cells to Enhance the Efficacy of CAR-T Cells in the Treatment of B-NHL Patients

Busch, D. H.

4904 - Loss of Microbiota-Derived Metabolites Is Associated with Mucosal-Barrier-Injury Bloodstream Infection in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Busch, G.

3425 - Divergent Population Dynamics and Gene Signaling in Monocytes Distinctly Influence Responses to CD19-Targeted CAR T-Cells in Relapsed/Refractory B-NHL

Busch, H.

631 - IDH2 Mutations from Clonal Hematopoiesis and Acquired IKZF1 Deletions Define a Novel B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma
1348 - CSF3R^T618I Is Stabilized By Calnexin and Induces Unfolded Protein Response (UPR) and ER-Phagy: A Pro-Survival Pathway for Oncogenic Misfolded CSF3R Proteins in Chronic Neutrophilic Leukemia (CNL)
1458 - C/EBP Family Member Gene Fusions and Cooperating Genomic Events Define Two Distinct Molecular Sub-Groups in Adult B Precursor ALL

Busch, M. P.

3835 - Arginine Metabolism Is a Biomarker of Red Blood Cell and Human Aging

Busch, S.

1293 - iPSC Reprogramming Identifies the Role of Cryptic Drivers in Preleukemic Clonal Evolution

Buser, M.

2666 - Single Cell Multiomic Analysis of Bone Marrow Hematopoietic Stem/Progenitor Cells from Individuals with Clonal Hematopoiesis Reveals Potential Mechanisms of Anemia Development
2676 - Single-Cell Transcriptomics of Bone Marrow Mesenchymal Stromal Cells Identifies Altered CLCF1 Signaling in DNMT3A-Mutated Clonal Hematopoiesis

Bush, S.

1150 - Transcriptomic Analysis of the Functions of CSF1R-Dependent Macrophages in Postnatal Development in the Rat

Bushman, F.

501 - Dual-Vector-Transduction with Single-Step Magnetic Selection (Zip-sort) Increases Transgenic Payloads to Enhance CAR T Cell Activity

Bushnell, K.

4853 - Early Leukapheresis in Patients with B-ALL Yields an Activated, Early Memory T-Cell Phenotype Associated with Response to CAR T-Cell Therapy

Buske, C.

859 - Bortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First – Line Treatment for Waldenström’s Macroglobulinemia: Results of the Multicenter Phase II trial (ECWM-2) of the European Consortium for Waldenström’s Macroglobulinemia
4114 - An Aberrantly Overexpressed Short Isoform of TET1 Lacking a DNA Binding Domain Drives Aberrant 5-Hydroxymethylation Marks, Oncogenic Pathways, and Growth in Acute Myeloid Leukemia
4352 - Determining the Mutational Landscape of Waldenström’s Macroglobulinemia By Liquid Biopsy: Results of the Prospective Ecwm-2 Trial of the European Consortium for Waldenström’s Macroglobulinemia
4394 - Real World Patient Diagnostic and Treatment Patterns in Marginal Zone Lymphoma (MZL): First Results of the Prospective National MZL Registry of the German Lymphoma Alliance
4412 - Long-Term Impact of Dose Interruptions (DIs) of Bruton Tyrosine Kinase Inhibitors (BTKis) on Change in IgM Levels and Clinical Outcomes in Waldenström Macroglobulinemia (WM)
4498 - Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Busnego Barreto, M. T.

3109 - Real-World Management Patterns of Acute Toxicity Following Bispecific Antibody Therapy for Patients with B-Cell Lymphoma - the Geltamo (Spanish Lymphoma Group) Experience

Buson, E.

4132 - Activating STAT3 Mutations Drive CD38 Expression in T-Large Granular Lymphocytic Leukemia

Busque, L.

408 - Understanding the Lived Experience of Fatigue in Adolescents and Young Adults with Myeloproliferative Neoplasms: A Mixed Methods Study

Buss, J.

2921 - BRAF-Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML
4304 - Characterization of Sole Loss of the Y Chromosome and Associated Effects on Adaptive Immunity in Adult Male Patients with Acute Myeloid Leukemia (AML)

Buss, J. L.

5065 - Trends of Opioid Prescribing and Vaso-Occlusive Crises in Sickle Cell Disease in the U.S. (2011-2023)

Bussel, J. B.

1175 - Correlation of Low Variant Allele Frequency STAT3 Gain-of-Function Mutations and T-Cell Clonality with Cyclic Thrombocytopenia
1176 - Medical Problems of Mothers of Children with Fetal-Neonatal Alloimmune Thrombocytopenia (FNAIT): Autoimmunity and Psychological Symptoms
1178 - Analysis of Screening for Autism Spectrum Disorders in Children Affected By Fnait with and without Intra-Cranial Hemorrhage
1179 - Fetal and Neonatal Alloimmune Thrombocytopenia: Risk of ICH in Second Pregnancy and Treatments to Maintain an Adequate Platelet Count
2556 - Patients with Immune Thrombocytopenia Have Higher Proportion of Ultra Large VWF Multimers and Lower ADAMTS13 Activity Than Healthy Controls
1193.1 - Design of a Phase 3, Multicenter, Randomized, Open-Label Study of Nipocalimab or IVIG in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia (FREESIA-3)

Busser, F.

3897 - Heavy Menstrual Bleeding in Adult Women with Sickle Cell Disease

Bussi, Y.

4813 - A Spatial Atlas of Human Gastro-Intestinal Acute Gvhd Reveals Epithelial and Immune Dynamics Underlying Disease Pathophysiology

Busto Medina, M. J.

1957 - Unraveling Long-Term Survival of Multiple Myeloma Patients, the GEM2000 Experience

Bustoros, M.

1928 - Tumor-Intrinsic and Immune Predictors of Response to Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
1936 - Abnormal Serum Fixation Patterns Are a Common Event Following BCMA CAR-T Therapy in Relapsed Refractory Multiple Myeloma and Are Often Preceded By Immunological Events

Butcher, B. E.

1721 - Interim Safety Analysis of ALLG-Pacific (NHL35): An Open Label Phase II Study of Pembrolizumab and Chemo-Immunotherapy As First-Line Therapy for Primary Mediastinal B-Cell Lymphoma
4502.2 - Australasian Leukaemia & Lymphoma Group NHL32 Block PCNSL: An Open Label Phase II Study of Pembrolizumab Following Chemoimmunotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma - Trial in Progress
4605.1 - Targeting the Myelodysplasia (MDS) Inflammasome with the Oral Wnt/β-Catenin Pathway Inhibitor, ES-3000 in Combination with Oral Decitabine/Cedazuridine (ASTX727) an Australasian Leukaemia and Lymphoma Group Trial (ALLG MDS05/D1)

Butera, D.

2578 - Disulfide Bond Heterogeneity in Factor VIII: Implications for Protein Function and Haemophilia a Therapy

Butler, B. J.

3514.1 - OPTIMIZE: A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide As GVHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Butler, H.

5005 - Assessing Social Media Preferences and Developing Digital Health Care Transition Education Materials for Emerging Adults with Sickle Cell Disease: A Mixed Method Pilot Study

Butler, J.

582 - A Randomized Phase 2, Investigator-Led Trial of Glofitamab-R-CHOP or Glofitamab-Polatuzumab Vedotin-R-CHP (COALITION) in Younger Patients with High Burden, High-Risk Large B-Cell Lymphoma Demonstrates Safety, Uncompromised Chemotherapy Intensity, a High Rate of Durable Remissions, and Unique FDG-PET Response Characteristics
3034 - Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update

Butler, J. M.

2021 - CCR2 Cooperatively Regulates Hematopoietic Stem Cell Homing to the Bone Marrow

Butler, M.

2100 - Preclinical Proof of Concept for Decentralized Manufacturing of a MAGE-A4/CD8alpha-Expressing Autologous T-Cell Therapy for Solid Tumors

Butman, J.

4507 - Steroid Prophylaxis in Patients Receiving CAR T-Cell Therapy for Relapsed and Refractory Non-Hodgkin Lymphoma

Butman, J. A.

3122 - Phase 1 Study of Escalating Doses of Ibrutinib in Teddi-R with Isavuconazole for Relapsed and Refractory Primary DLBCL of the CNS

Butrym, A.

2854 - The Premature Reduction of Venetoclax in an Initial Cycle of Ven-AZA Regimen for Unfit AML Patients Leads to Shortened Overall Survival - a Retrospective Study of Polish Adult Leukemia Group (PALG)

Butt, A.

3947 - Trends and Disparities in Idiopathic Thrombocytopenic Purpura-Related Mortality in the United States: A Retrospective Study over Two Decades

Butt, A.

601 - Deciding between Multiple Curative Options in Sickle Cell Disease: Cost-Effectiveness of Non-Myeloablative/Reduced Intensity Conditioning Haploidentical Allo-HSCT Vs Gene Therapy Vs Standard of Care in Adult Patients with Sickle Cell Disease

Butt, H.

516 - CD117 Antibody Conditioning and Multiplex Base Editing Enable Rapid and Robust Fetal Hemoglobin Reactivation in a Rhesus Autologous Transplantation Model
4997 - Identifying Pediatric Patients with Sickle Cell Disease at High Risk of Experiencing Chronic Pain after HSCT

Butta, N.

2569 - B-Cell Distribution in Immune Thrombocytopenia and Its Relation to Ageing
3977 - Concizumab As a Possible Treatment for Bleeding Disordersof Unknown Cause

Butte, A.

390 - AI Predicts Early Relapse Post-Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma Patients in a Multi-Center Real-World Study

Butter, F.

152 - The Transcriptional Activators p300/Crebbp Are Context-Dependent Functional Repressors of Interferon Genes, Offering Therapeutic Promise in AML

Butterfield, R. J.

243 - TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms

Buttigieg, M. M.

1287 - Inflammatory Reprogramming of the Tumor Microenvironment By Clonal Hematopoiesis Is Associated with Clinical Outcomes in Solid Cancer
2662 - Clonal Hematopoiesis Is Associated with Changes to T Cell Contexture in Solid Tumours
4059 - Transcriptomic Analysis of Clonal Hematopoiesis in Non-Small Cell Lung Carcinoma Unveils a Tumorigenic and Dysregulated Immune Profile

Buttkereit, U.

4857 - Analysis of Early Apheresis Immunophenotype, Batch Data Variables and Clinical Outcomes for Optimization of CAR-T-Cell Therapy in Aggressive B-Cell Lymphomas

Büttner, R.

367 - Targeting Lymphoma Associated Myeloid-Monocytic Cells through CSF1R Blockade Enhances CAR-T Cell Response in Aggressive B Cell Lymphoma

Büttner- Herold, M.

3402 - Allogeneic Hematopoietic Cell Transplantation Promotes Atherosclerosis in Mice Driven By Donor CD8+ T Cells

Büttner-Herold, M.

3147 - Chronic Kidney Dysfunction Induced By Jak2V617F-Mediated Mesangiolysis

Button, P.

1445 - Health-Related Quality of Life in Adolescents and Young Adults Treated with Blinatumomab Consolidation for CD19+ Ph-Negative Acute Lymphoblastic Leukemia in the Australasian Lymphoma and Leukaemia Group (ALLG) ALL09 "Sublime” Study

Buxman, L.

5080 - Real-World Experience with Combination Therapy of Fostamatinib and Thrombopoetin Receptor Agonists (TPO-RAs) for Treatment of Immune Thrombocytopenia (ITP): Patient-Reported Outcomes

Buxton, R.

2828.1 - Trial in Progress: Update on the TACL T2020-003 Randomized Phase 2 Trial to Improve Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL-2)

Buzaglo, J.

2437 - Perceptions of Treatment Tolerability and Its Relationship to Income in Patients with Hematologic Malignancy: Findings from the Cancer Experience Registry

Buzele, R.

1917 - Characteristics of Autoimmune Hemolytic Anemia Associated with Khsv/HHV-8 Multicentric Castleman Disease

Buzzatti, E.

2440 - Clinician’s Knowledge and Awareness of Patient-Reported Outcomes in Immune Thrombocytopenia: Results of a National Survey (ITP NET, GIMEMA Working Group Anemia and Thrombocytopenia)
4252 - Clinical Implications of Central Nervous System Involvement in Acute Myeloid Leukemia

By, K.

860 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenström Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study
885 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study
1649 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory (R/R) Indolent NHL: Results from the Phase 1 CaDAnCe-101 Study

Byard, N.

4755 - Initial Results from the Frailty-Stratified, Randomised Controlled Bayesian Adaptive Trial of Bortezomib Versus Lenalidomide in Transplant Ineligible Myeloma (TI-NDMM) – the FRAIL-M Study (AMaRC 19-01; ALLG MM22)

Bye, M.

71 - Real World Comparison of Efficacy and Safety of Fludarabine-Versus Bendamustine-Based Lymphodepleting Chemotherapy for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Relapse/Refractory (r/r) Large B-Cell Lymphoma (LBCL)
526 - Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
2178 - Single-Agent Ibrutinib Versus Allogeneic Hematopoietic Cell Transplantation for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and del(17p)
5092 - Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR^® Registry

Byers, III, J. S.

2035 - CRG-023 Is a Novel Tri-Specific CAR T Product Candidate Engineered to Prevent Antigen Escape and Sustain Durable Anti-Tumor Functionality Against B-Cell Malignancies

Byersdorfer, C.

906 - IL-33⁺ Stromal Cells in the Lymphoid Tissues Program Donor CD4⁺ T Cell Exhaustion That Blunts Subsequent IL-33⁺ Target Tissue-Driven Pathology but Not Graft Vs. Lymphoma Responses
2016 - Investigating the Role of PPAR Delta in Alloreactive T Cells
2020 - Deletion of AMPK in Human T Cells Decreases Glycolytic Compensation and Severity of Xenogeneic Gvhd without Impairing GVL Potential

Byfield, K.

3894 - Impact of Malnutrition on Patients with Sickle Cell Anemia Hospitalized with Vaso-Occlusive Crisis: A US Collaborative Network Cohort Study
3951 - Protein Energy Malnutrition and in-Hospital Outcomes Among Hospitalized Patients with Immune Thrombocytopenia: A United States Collaborative Network Cohort Study
5106 - Impact of Protein Energy Malnutrition on Hospitalized Patients with Hodgkin’s Lymphoma: A United States Population-Based Cohort Study

Bygrave, C.

1023 - Tolerability and Clinical Activity of Novel First-in-Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
1984 - Belantamab Mafodotin Plus Cyclophosphamide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Interim Results from the UK Myeloma Research Alliance Prommise Clinical Trial
2388 - Evolution of Treatment Patterns and Survival Outcomes in European Patients with Multiple Myeloma from 2012-2023 through the Honeur Federated Data Network
3300 - A Novel Approach to Lower Risk Monoclonal Gammopathy of Undetermined Significance (MGUS) Follow-up Based on Isotype-Specific Annualised Progression Risk: A Retrospective Real World Evidence Single Centre UK Study
3333 - Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial
4744 - Increased Rates of MRD Conversion from Positive (+ve) to Negative (-ve) Following ASCT Compared to Chemotherapy Consolidation in Newly Diagnosed Multiple Myeloma Is Prognostic for Improved Progression Free Survival: Dynamic MRD Assessment in the UK-MRA Cardamon Trial

Bykova, A.

4539 - Results of the Molecular Response Evaluation and TKI Dose Adjustment in Chronic Myeloid Leukemia Patients in Prospective Study of Reduction and Discontinuation Treatment of TKI (READIT)

Byrd, J. C.

884 - Efficacy and Safety of the Bruton’s Tyrosine Kinase (BTK) Degrader NX-5948 in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Updated Results from an Ongoing Phase 1a/b Study
909 - BTK Inhibition Prevents the Induction of Myeloid-Derived Suppressor Cells in Malignancy and Improves CART Function
1396 - A Randomized Placebo-Controlled Phase 1 Trial in Healthy Volunteers Investigating the Safety, Pharmacokinetics and Pharmacodynamics of a Novel FLT3/IRAK4 Inhibitor, Lomonitinib (ZE46-0134)
1564 - Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with NPM1 Mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial
1875 - Clinical Characteristics and Outcome in a Cohort of CLL Patients with BTK T474 Gatekeeper Mutation
2663 - MYD88 Is Mutated in Clonal Hematopoiesis and Drives Altered Immune Cell Populations
2783 - Development of ZE66-0205, a Novel MALT1 Degrader for Treatment of B-Cell Malignancies
2921 - BRAF-Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML
3233 - The Impact of Therapeutic Selective Pressure on the Evolutionary Landscape of Chronic Lymphocytic Leukemia
3245 - A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL
4304 - Characterization of Sole Loss of the Y Chromosome and Associated Effects on Adaptive Immunity in Adult Male Patients with Acute Myeloid Leukemia (AML)
4324 - Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age
4325 - IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy
4622 - LP-168 (Rocbrutinib), a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton’s Tyrosine Kinase: Updates on the Phase 1 Trial and Initial Results of the CLL Gatekeeper Mutation Cohort
4629 - Outcomes of Patients with Chronic Lymphocytic Leukemia Discontinuing Bruton Tyrosine Kinase Inhibitors Due to Adverse Effects
5099 - Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy
2883.4 - A Phase 1, Open-Label, Dose Escalation and Dose Expansion, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Lomonitinib (ZE46-0134) in Adults with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia
2907.2 - A Randomized Phase 2 Trial of 28-Day (Arm A) Versus 14-Day (Arm B) Schedule of Venetoclax + Azacitidine in Newly Diagnosed Acute Myeloid Leukemia Patients ≥ 60 Years
3147.1 - A Multicenter, Open-Label, Phase 1 Clinical Trial of AJ1-11095 Administered As Oral Monotherapy in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed By a Type I JAK2 Inhibitor (JAK2i)
- Malignant Hematology

Byrd, K. P.

736 - Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2)

Byrne, J.

59 - A Randomised Comparison of CPX-351 Versus Standard Daunorubicin and Cytarabine Plus Fractionated Gemtuzumab Ozogamicin in Older Adults with AML without Adverse Risk Cytogenetics: Results of the NCRI AML18 Trial
3146 - RUX-AZA Response in AP/BP-MPN Is Driven By Release of the Differentiation Block in Mutant HSPCs: A Single-Cell Multi-Omic Analysis of Responders on the Phase Ib Phazar Study
3562 - Similar Transplant Outcomes for Haplo and MUD Allo-Hcts in AML Patients Achieving CR2: A Study Analyzing 4030 Allo-HCT Recipients from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Byrne, M.

3958 - Whole Genome Sequencing to Elucidate Genetic Modifiers of FVIII Clearance Heterogeneity in Patients with Hemophilia a

Byrne, R.

1150 - Transcriptomic Analysis of the Functions of CSF1R-Dependent Macrophages in Postnatal Development in the Rat

Bystrická, L.

719 - Association between Hemophilia Joint Health Score and Quality of Life Using Results from the Xtend-1 Efanesoctocog Alfa Phase 3 Trial

Bystrom, R. P.

1508 - Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed By Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid Leukemia
2947 - The Prognostic and Predictive Value of RUNX1 Mutations in Newly Diagnosed Acute Myeloid Leukemia – an International Multicenter Cohort Study
4267 - Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics
4281 - Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients with Chromosome 5 and 7 Abnormalities
5171 - Impact of Social Determinants of Health on Overall Survival in Patients with AML By European Leukemianet Risk Group
5175 - Impact of Molecular Ontogeny on Hematological Recovery in AML Patients Treated with Hypomethylating Agent Plus Venetoclax Therapy

Byun, J. M.

1375 - ATR Inhibitor Elimusertib Suppresses Drug Persister Clones in TP53-Mutated Acute Myeloid Leukemia Via CGAS-Sting-Mediated Cell Death
3369 - Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study
4028 - Rh Antigens Immunogenicity Prediction Using in silico analysis of HLA Binding
4698 - Prognostic Impact of Response Kinetics and Influencing Factors in Multiple Myeloma Patients Treated with Carfilzomib- or Ixazomib-Based Treatment
4707 - Efficacy and Safety of T-Cell Engagers Compared to Standard of Care for Relapsed/Refractory Multiple Myeloma Treatment: A Real-World RCT Mimicking Analyses

Bywater, M.

1346 - Single Cell Genotype-Phenotype Analysis Demonstrates That Post-MPN AML Is Driven By Clonal Evolution and Loss of Transcriptional Heterogeneity within Stem Cell Compartments
1347 - Dnmt3a Mutation Promotes Expansion of a Quiescent Myeloid Progenitor Population in Npm1^c-Flt3^ITD Acute Myeloid Leukemia

Author Index: B